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1 Introduction 
 
1.1 Nicotinic Acetylcholine Receptors  
 
1.1.1 The Structure of nAChRs 
 
Nicotinic acetylcholine receptors (nAChRs) are members of the pentametric “cys-loop” 
superfamily of ligand-gated ion channels that also includes e.g. glycine, GABAA and 5-HT3 
receptors.1,2 The nAChR macromolecule is an ion-channel complex that is composed of five 
subunits assembled like the staves of a barrel around a central water-filled pore (Figure 1-
1).3 nAChRs can be divided into two groups: muscle receptors, located at the skeletal 
neuromuscular junction where they mediate neuromuscular transmission, and neuronal 
receptors, which are found throughout the peripheral and central nervous systems.1 
Seventeen genes coding for five muscle and twelve neuronal nAChRs subunits have so far 
been cloned and they encode for peptides possessing sequence homology, sharing a 
general linear structure and having similar topologies.4,5  Each receptor subunit is a three 
domain protein that divides the receptor channel into three parts (ligand-binding, membrane- 
 
 
Figure 1-1 Ribbon diagrams of the whole receptor (muscle type), as viewed (a) from the synaptic 
cleft and (b) parallel with membrane plane. In the picture (a) only the ligand-binding 
domain is highlighted and in the picture (b) only the two front subunits are highlighted 
(α in red, β in green, γ in blue and δ in light blue). [Ref. 6] 
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spinning and intracellular part). Figure 1-2 illustrates the structure of a single subunit.6 The 
amino and carboxy termini are located extracellularly. The N-terminal is built around a β-
sandwich core consisting of ten β-strands (red and blue sheets) and one α-helix. The 
extracellular portion contains several loops that are critical for the receptor function (e.g. the 
Cys loop, the β1-β2 loop or the loops A, B and C). The membrane-spinning portion is 
composed of α-helical segments (M1 – M4) and their functionally important loops (M1-M2 
and M2-M3). The intracellular portion is composed mainly of the extension of the sequence 
between M3 and M4 and a curved α-helix, termed MA.6  
 
 
Figure 1-2 Ribbon diagrams of the α-subunit viewed parallel with the membrane plane, in 
orientations such that the channel axis (vertical line) is at the back (a) and to the side 
(b). The α-helices are in yellow, the β-strands composing the β sandwich are in blue 
(inner) and red (counter). [Ref. 6] 
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The most well characterised nAChRs are those found at the mammalian neuromuscular 
junction. The muscle nAChR shares many similarities with acetylcholine-binding sites found 
in the (muscle-derived) electric organ of Torpedo californica and this fish has provided for 
decades an extremely rich source of nAChRs for physiological and biochemical studies.7 The 
muscle subtype is composed of two α1 subunits, one of each β1, δ and either γ or ε. During 
the development of the neuromuscular junctions, the γ subunit (embryonic form) is present, 
but after the synaptogenesis is complete, the ε subunit (adult form) replaces it.8      
Neuronal nAChRs are much more diverse than the muscle type because many subunit 
combinations are possible. The assembly of the subunits in the neuronal nAChR is less 
tightly constrained than that of the muscle receptor. To date, nine neuronal subunits with the 
homology of muscle α1 (α2 – α10) and three non-α subunits (β2 – β4) have been identified.9 
In CNS these subunits form either heteromeric or homomeric complexes. The majority of the 
heteromeric receptor complexes identified are believed to contain a single type of α and a 
single type β subunit in (α)2(β)3 stochiometry, e.g. (α4)2(β2)3.10 However, heteromeric 
receptors involving three types of subunits can be formed as well, e.g. the α3 and α5 
subunits have been shown to form “triplet” receptors when co-expressed with other α or β 
subunits in the Xenopus expression system.11 The properties of these triple receptors were 
distinct from those containing a single type of α and β subunit. The functional homomeric 
nAChR pentamers can be composed only of α7 – α10 subunits12 (e.g. (α7)5, the homomeric 
subtype widely distributed in mammalian CNS).  
A number of different approaches (e.g. photoaffinity labelling experiments13, modelling of the 
putative three-dimensional structure of nAChRs14, investigations with ligand probes and 
mutation of residues believed to be involved in ACh binding15) allowed elucidation of the 
structure of the ACh-binding site. It has been shown that the binding site in the heteromeric 
receptors is located on the interface between α and adjacent non-α (γ/ε or β) subunit, i.e. 
heteromeric receptors possess two binding sites. In the homomeric receptors, the binding 
site is placed on each interface between two α subunits. Therefore, five binding sites must 
be present in e.g. (α7)5 subtype. While α subunit contributes the principal component, the 
neighbouring subunit (γ, δ or ε for the muscle and β or α for the neuronal) builds the 
complementary component of the binding site.  
Brejc et al16 published the crystal structure of an acetylcholine-binding protein (AChBP), 
isolated from the fresh water snail, Lymnaea stagnalis.  The soluble, homopentameric 
AChBP is 210 residues long and resembles the extracellular binding domain of nAChRs. X-
ray diffraction analysis of this protein has provided valuable information about the nature of 
the binding pocket and confirmed its position on the interface between two subunits. The key 
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region of the nAChR binding domain is the convergence of three tyrosine and two tryptophan 
side chains, framing a ‘box’ of electron-rich aromatic rings. It is established that the cationic 
moiety of acetylcholine (or other nicotinic ligands) binds in this hydrophobic box with the α- 
subunit of the nAChR protein via strong pi-cation interaction. Thus, the pi-cation interactions, 
previously predicted in the binding of nicotinic agonists17, are indeed decisive in high affinity 
binding.  The other “bridge” in the binding mode is believed to be a hydrogen bond between 
a hydrogen bond donor (HBD) in the receptor and hydrogen bond acceptor (HBA) in the 
ligand. 
 
1.1.2 nAChRs in Human Pathology  
 
Nicotinic acetylcholine receptors have been implicated with a number of disorders affecting 
the nervous system (e.g. Tourette’s syndrome, schizophrenia, epilepsy, depression, anxiety) 
as well as pathologies in non-neuronal tissues and cells (e.g. small-cell lung carcinoma or 
inflammatory bowel disease). However, the main focus in the field of these ligand-gated ion 
channels is on their involvement in neurodegenerative diseases such as Alzheimer’s or 
Parkinson’s and in antinociception.  
Tourette’s syndrome, characterised by uncontrolled obsessive behaviour as well as 
spontaneous motor and verbal tics, is usually treated with neuroleptics like haloperidol, 
however with little success. (-)-Nicotine in the form of chewing gum and patches improves 
the motor and verbal tics symptoms18 and potentiates the behavioural effects of haloperidol 
in animals19, suggesting that nAChR may play a role in the etiology of this neuropsychiatric 
disorder. The mechanism of the beneficial effect of nicotine remains unclear. 
Schizophrenia, a chronically deteriorating psychosis (hallucination, disturbance of thought, 
self-awareness and perception) has been linked with nAChRs because of the high 
percentage of smokers among schizophrenics, 90% as compared to 33% in the general 
population.20 This high nicotine intake in the schizophrenic population is accepted as a form 
of self-medication to compensate for a deficit in nicotinic neurotransmission.21 It was 
observed that the density of α7 receptors has been reduced in the CA3 region of 
hippocampus in the brain of schizophrenics.22 Using genome-wide analysis, a connection 
between schizophrenia and dinucleotide polymorphism at chromosome 15q13-14, a site of 
the α7-subunit gene CHRNA7 has been found.20a 
Epilepsy, in particular Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE, 
epileptic seizures occurring mainly during the sleep) is associated with mutation in the gene 
coding for either the α4 or β2 nAChR subunit.23 These mutations have been reported to be 
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responsible only for some factors leading to the clinical manifestation of the disease, 
however not for all the symptoms of ADNFLE.24 There are experimental indications that also 
α7 subunits are involved in seizure control.25 
Depression/anxiety are also believed to be related to nAChR dysfunction. Direct evidence 
of altered nAChR function in individuals suffering from these disorders is missing, but genetic 
studies showed a positive correlation between tobacco dependence and major depression.26 
In addition, smoking is more prevalent in patients suffering from depression than in general 
population.27 
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by a progressive 
loss of short-term memory and higher cognitive functions. The most marked changes in the 
neurotransmitter system of patients are the degeneration of the cholinergic innervation28 and 
the reduction of the choline acetyl transferase activity29 in the hippocampus and cerebral 
cortex. There is accumulating evidence that the function and density of neuronal nAChRs 
(especially α4β2 subtype) is reduced in the AD brains.30  In addition, β-amyloid peptides 
which are part of the neuritic plaques found in AD brains, have been shown to bind to α7 
nAChRs and are neurotoxic.31 Thus, drugs targeted for treatment of AD through modulation 
of nAChRs should either target α4β2 subtype and cause receptor activation or activate α7 
and improve cell survival. 
Patients with Parkinson’s disease (PD) suffer from motor dysfunction resulting in muscular 
rigidity, tremor and uncoordinated movement. PD is a neurodegenerative disease manifested 
by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta 
accompanied by parallel loss of high affinity nicotine binding in these regions.32a Nicotine 
improves the symptoms of PD patients and the beneficial effects of the tobacco alkaloid are 
consequences of increased dopamine levels in the substantia nigra32b and mesolimbic 
system33, as well as of possible inhibition of monoamine oxidase B34. Once more, the risk of 
developing PD is inversely correlated with the number of cigarettes smoked.35 
Pain and nAChRs are linked since the discovery of antinociceptive properties of the nicotinic 
agonist epibatidine, which possesses 200-fold higher analgesic effect than morphine in the 
hot-plate test.36  The initial euphoria of this discovery disappeared because of the highly toxic 
effects of epibatidine mediated by peripheral nAChRs.37 On the other hand, ABT-594, a 
selective nicotinic agonist for neuronal subtypes has been reported to be in clinical trials for 
the treatment of neuropathic pain38, even if the side-effect profile of this compound is not 
improved compared to epibatidine39.   
Tobacco smoking, despite its positive effect in etiology of diseases such as Alzheimer’s or 
Parkinson’s, is the leading cause of preventable death worldwide.40 Nicotine mediates its 
action through nAChRs in CNS, especially via dopamine release in the nucleus accumbens 
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or prefrontal cortex.41 These brain regions are connected to the ventral tegmental area that is 
a part of the reward system in the human brain.42 Nicotine administration in a form of gum, 
transdermal patch, nasal spray and inhaler or the non-nicotine based antidepressant 
bupropion is used for the treatment of nicotine addiction.43 Administration of nicotine by any 
form is statistically more effective than placebos, but the long-term relapse rates are as high 
as 80%.43 Thus, improving the long-term efficacy is a key component of novel 
pharmacotherapies for smoking cessation.  
The existence of multiple nAChR subtypes and their connection to numerous human 
pathologies understandably requests development of suitably selective nAChRs ligands in 
order to target one receptor subtype mediating one certain therapeutically beneficial function, 
while eliminating undesired side effects. Subunit specific ligands would have wide-ranging 
effects in the laboratory as experimental tools and in the clinic as therapeutic agents. Thus, 
targeting nAChRs still remains an interesting opportunity to identify new potential drugs and 
this has led to a vast variety of compounds from different chemical classes.44   
 
1.2 Nicotinic Acetylcholine Receptors Ligands  
 
A great deal of synthetic effort has been applied towards the synthesis of potent, selective 
ligands for the nicotinic acetylcholine receptor45 and the non-peptidic nAChRs ligands have 
been divided by Schmitt46 into five classes. This classification is based on the structure, 
taking into account principal features of the endogenous ligand acetylcholine 1, which are the 
cationic centre and HBA/pi moiety (Figure 1-3). The binding affinity of the simplest nAChR 
agonist - tetramethylammonium ion (Ki = 480 nM, radioligand: [
3H]nicotine, tissue: rat brain; 
Ki = 2.3 µM, radioligand: [3H]α-Bgt, tissue: rat brain)47 reveals the importance of the 
ammonium head for recognition of nAChRs. 
 
N
+
CH3
CH3
O CH3
O
CH3
cationic center
HBA/pi moietyacetylcholine 1
 
Figure 1-3  Structure of the nAChR endogenous ligand acetylcholine 1. The pharmacophoric 
elements – cationic centre and HBA/pi moiety – are pointed out. 
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1.2.1 Class A: Acyclic HBA/pi and Acyclic Cation 
 
Nicotinic ligands with acyclic HBA/pi and cationic moieties belong to the Class A of Schmitt’s 
classification.46 These compounds are in general the most flexible nAChR ligands due to the 
missing ring constrain.  
The prototype is acetylcholine 1, which binds with high affinity to α4β2 receptor subtype (Ki = 
3-10 nM) but with lower affinity to [125I]α-Bgt binding sites (Ki = 4,000 nM)
48. However, ACh 1 
lacks selectivity between nAChRs and mAChRs and the quaternised amino group of ACh 1 
is associated with poor penetration through the blood-brain barrier. Carbacholine, an ACh 
analogue, in which the ester moiety of ACh is replaced by a carbamate group, is a mixed 
muscarinic-nicotinic acetylcholine receptor agonist (Ki = 750 nM for α4β2 rat brain nicotinic 
binding site, Ki = 5 nM for [
3H]oxotremorine binding site)49, but N-methylcarbamoylcholine 2 
(MCC) displays nanomolar binding affinity to nAChRs (Ki = 23 nM)
49 with certain selectivity 
for neuronal receptors versus the muscarinic AChRs (Ki = 150 nM)
49 (Figure 1-4). MCC 2 
was extensively studied at the beginning of the “nAChRs era” 50 and the tritium labelled MCC 
2 was used as a radioligand for investigating the nicotinic recognition sites in brain tissue.51 
Introduction of another methyl group at the carbamate nitrogen of MCC 2 yields N,N-
dimethyl-carbamoylcholine DMCC, which shows higher selectivity for nAChR (Ki = 20 nM, rat 
brain α4β2 binding)49 versus mAChR (Ki = 1,200 nM)
49 compared to MCC 2.  
Choline 3 (Figure 1-4), a precursor and a metabolite of acetylcholine 1, is an effective agonist 
of α7 nAChRs even if it presents very low affinity for this receptor subtype (Ki = 2,380 µM).52 
Choline 3 possesses higher affinity towards α4β2 nACh receptor (Ki = 112 µM) and has been 
shown to protect neural cells from cytotoxicity induced by growth factor deprivation.53  
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Figure 1-4  Chemical structure and affinities of MCC 2 and choline 3 [Ref. 49, 52] 
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1.2.2 Class B: Cyclic HBA/pi and Acyclic Cation 
 
Ligands in the Class B hold a cyclic HBA/pi system and an open-chain cationic moiety.46  
The first series of ligands in this group are choline derivatives.  Radioligand binding studies 
of phenylether of choline 4, a potent ganglion stimulant54, revealed a high affinity of 4 for the 
central nAChRs, i.e. Ki = 22.3 nM for α4β2* and Ki = 196 nM for α7* binding (Figure 1-5).
55 
Introduction of an amide moiety to the structure of phenylether of choline 4 yields a 
carbamate 5 that shows higher affinity for the α7* (Ki = 38.9 nM) than for the α4β2 nAChR 
subtype (Ki = 835 nM) (Figure1-5).
55 
Dukat et al studied a series of pyrrolidine ring-opened analogues of nicotine possessing a (3-
pyridyl)-C-N+ motif.56 Although none of these analogues exhibited higher binding affinity than 
(-)-nicotine (Ki = 2.3 nM)
56, 3-(N-methyl-N-ethylaminomethyl)pyridine 6 (Figure 1-5) binds 
with significant affinity (Ki = 28 nM). Substitution of the 6-position of 6 with methyl or halogen 
was well tolerated (Ki = 41 nM for 6-chloro; Ki = 93 nM for 6-fluoro and Ki = 66 nM for 6-
methyl analogues), but methyl substitution in the position 2 or 4 caused a loss of the binding 
affinity (Ki = 4,614 and 1,745 nM, respectively).
56 
trans-Metanicotine 7 (also known as RJR-2403, [E]-N-methyl-4-[3-pyridinyl]-3-butene-1-
amine monofumarate) is another ring-opened isomer of nicotine (Figure 1-5). RJR-2403 7 
binds with similar high affinity to both [3H]nicotine binding nAChR subtypes expressed in rat 
brain and α4β2 expressed in transfected clonal cell line M10 (Ki = 26 nM). Despite its 6-fold 
lower affinity than the affinity of nicotine for the α4β2 nAChR, trans-metanicotine 7 is only 
slightly less potent and nearly as efficacious toward activation of the receptor.57 Several 
modifications of trans-metanicotine 7 (e.g. methylation of the terminal amino group) resulted 
in lower binding affinity (Ki = 4,500 nM for N-methyl analogue of 7) compared to the parent 
structure58. On the other hand, some structural modification led to an improved 
pharmacological profile and Targacept has recently identified a pyridine-substituted and α-
branched analogue of trans-metanicotine TC-1734 8 ((S)-(E)-N-methyl-5-[3-(5-
isopropoxypyridinyl)]-4-penten-2-amine), an orally active novel neuronal nicotinic agonist with 
high selectivity for α4β2 nicotinic receptors (Figure 1-5).59 TC-1734 binds with high affinity (Ki 
= 11 nM) to α4β2 nAChR labelled with [3H]nicotine in membranes from rat cerebral cortex, 
but was not able to displace [125I]α-Bgt binding (α7 nAChRs) in rat hippocampal membranes. 
Furthermore, phase I clinical trials demonstrated TC-1734’s favourable pharmacokinetic and 
safety profile by acute oral administration.59 
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Figure 1-5 Class B ligands: structure and binding affinities for central nAChRs  [Ref. 54 - 57, 59]                          
 
 
1.2.3 Class C: Cyclic HBA/pi and Cyclic Cation 
 
The Class C of nAChR ligands involves structures in which both the cationic centre and 
HBA/pi moiety are cyclic.46 Class C consists of ligands such as DMPP, nicotine, epibatidine 
and their analogues as well as highly potent group of 3-pyridylether derivatives. 
The structure of N,N-dimethylphenylpiperazine 9 (DMPP, N1-dimethyl-N4-phenylpiperazinium 
iodide) (Figure 1-6) represents an unique pharmacophore for nAChRs binding due to its 
short internitrogen distance (see 1.3 nAChR Pharmacophore Models). DMPP 9 binds with 
high affinity to the α4β2 (Ki = 31 – 57 nM)
60 and α7 (Ki = 7.6 µM)61 receptors. On the contrary, 
the research group of Varani reported for DMPP 8 a Ki value of 250 nM (assays were 
completed with rat brain tissue labelled by [3H]cytisine).62 The same research group focused 
on the modification of the structure of DMPP 9 in order to improve its properties, since it is 
unlikely that quaternary compounds will cross the blood-brain barrier and distribute 
effectively into the CNS.62 The variation of the lead 9 afforded several nonquaternary agents 
with improved affinity for central α4β2 receptor subtype (e.g. for 1-methyl-4-pyridin-3-yl 
piperazine with Ki = 90 nM). 
(-)-Nicotine 10 ((S)-3-(1-methyl-2-pyrrolidinyl)-pyridine) (Figure 1-6), the prototypical nAChR 
ligand, possesses a structure that appears to be well optimised for activity at the α4β2 
nAChR, since the simplest modifications lead to less potent analogues. The N-methyl 
pyrrolidine moiety and (S)-stereochemistry are critical features that contribute to the high 
α4β2 affinity (Ki = 1 – 5 nM).
63  
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The pyrrolidine ring expansion of nornicotine leads to anabasine 11 (Figure 1-6), an alkaloid 
also present in tobacco. In an assay published by Kem et al64, anabasine 11 together with its 
dehydro analogue anabaseine 12 (an alkaloid isolated from a marine worm) (Figure 1-6) 
have substantially weaker affinity (Ki = 260 and 32 nM, respectively) than nicotine 10 (Ki = 
4.1 nM) at α4β2 receptors but actually exhibit somewhat improved potency at the α7 subtype 
(Ki = 58 nM for anabasine 11 and anabaseine 12) compared to nicotine 10 (Ki = 400 nM).
64 
Anabaseine 12 has been used as a template for construction of α7-selective compounds as it 
is substantially more efficacious than either (-)-nicotine 10 or acetylcholine 1 at rat α7 
receptors expressed in oocytes.65 The 3-(2,4-dimethoxybenzylidine)-anabaseine derivative 
GTS-21 13 has emerged as an important compound for characterisation of the α7 function in 
vivo, even despite its weak potency (Ki = 650 nM) and low maximal efficacy (50% of ACh 
response).66 
While substitution on the pyrrolidine ring causes loss of the binding affinity, the substitution 
on the pyridine ring of (-)-nicotine 10 is better tolerated, occasionally affording compounds 
with higher affinity. For example, the 5-ethynyl analogue of nicotine SIB-1508Y 14 ((S)-(-)-5-
ethynyl-3-(1-methyl-2-pyrrolidinyl)-pyridine) (Figure 1-6), displaces [3H]nicotine from rat 
cortical membranes with affinity equivalent to that of nicotine 10 (IC50 = 3 and 4 nM, 
respectively).67 Since SIB-1508Y 14 is particularly efficacious in stimulating the release of 
dopamine, it was evaluated in an animal model of Parkinson’s disease and selected for 
preclinical and clinical trials.68  
With regard to the substitution of the position 6 in (-)-nicotine 10, it was shown that the 
lipophilicity and bulkiness of the substituents influence the ligand’s binding affinity for α4β2 
nAChR.69 While 6-phenyl-nicotine exhibits very low binding affinity (Ki = 9,440 nM)
69, 
6-(2-phenylethyl)-nicotine was found to bind at α4β2 nicotinic receptor with high affinity (Ki = 
15 nM) and antagonise the antinociceptive effects of (-)-nicotine 10 in mouse tail-flick assays 
in a dose-dependent fashion when administered via an intrathecal route.70 
A series of nicotine analogues, in which the pyridine ring is replaced by isoxazole, isothiazole 
or pyrazole moieties, has been synthesized and claimed by Abbott Laboratories. 
Replacement of pyridine ring by 3-methyl-5-isoxazole moiety led to a structure known as 
ABT-418 15 (Figure 1-6; Ki = 4.2 nM for [
3H]cytisine binding sites)71, which has been shown 
to possess cognitive-enhancing and anxiolytic like activities in animal models with an 
improved safety profile compared to that of nicotine.72 Unfortunately, ABT-418 15 did not 
succeed in the clinical trials.73   
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Figure 1-6  nAChR ligands of the Class C (cyclic cation centre, cyclic HBA/pi system)  
  [Ref. 60, 61, 63, 64 - 67, 71, 74, 76, 78] 
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Incorporation of an ether link between the pyrrolidine and pyridine rings of nicotine results in 
a potent ligand A-84543 16 (3-((1-methyl-2-(S)-pyrrolidinyl)-methoxy)-pyridine) (Figure 1-6), 
which binds to rodent α4β2 nAChRs with 7-fold higher affinity than nicotine (Ki = 0.15 nM).
74  
The exploration of the 3-pyridyl ether motif combined with pyrrolidine ring contraction to 
azetidine led to the discovery of A-85380 17 (3-(2-(S)-azetidinylmethoxy)-pyridine) (Figure 1-
6), an exceptionally potent and selective ligand for the human α4β2 (Ki = 0.05 nM) over α7 
(Ki = 148 nM) and neuromuscular (Ki = 314 nM) nAChR subtypes.
75 In functional studies, A-
85380 17 was shown to be significantly more potent than (-)-nicotine 10 to activate ion flux 
through a number of nAChRs, to activate human α7 nAChR channel currents and to facilitate 
the dopamine release.75 The 6-halogen substitution improves in vivo activity and ABT-594 18 
(5-(2-(R)-azetidinylmethoxy)-2-chloropyridine) (Figure 1-6) possessing chlorine in the 
position 6 was identified as a potent nicotinic agonist with broad spectrum analgesic 
activity.76 ABT-594 18 is a potent inhibitor of [3H]cytisine binding to α4β2 nAChRs (Ki = 37 
pM, rat brain; Ki = 55 pM, transfected human receptor) that displaces [
125I]α-bungarotoxin 
from the (α1)2β1δγ neuromuscular nAChR with low affinity (Ki = 10,000 nM). Functionally, 
ABT-594 18 is an agonist and pharmacologically, it has an in vitro profile distinct from that of 
the prototypic nicotinic analgesic epibatidine.77 With the reduced side-effects (as a 
consequence of the very low binding to the muscle type nAChR), this compound represents 
a novel alternative for pain management. 
Last, but by no means least, representative of Class C is epibatidine 19 (exo-2-(6-chloro-3-
pyridyl)-7-azabicyclo-[2.2.1]heptane) (Figure 1-6), among the naturally occurring alkaloids 
the most potent nAChR ligand. Both enantiomers of epibatidine, (+)-19 (the 1S,2S,4R-
stereoisomer) and (-)-19 (the 1R,2R,4S-stereoisomer) possess nearly equal affinity for the 
α4β2 nAChR subtype (Ki = 26 and 18 pM, respectively).
78 Epibatidine 19 had proved to be 
200-fold more potent than morphine as an analgetic79, but also exhibited high potency and 
efficacy for activation of peripheral nAChRs which is the reason of its high toxicity. Numerous 
series of epibatidine derivatives have been synthesized so far, including changes in 
stereochemistry80, alkylation of the NH group81, changes in the 2’-chloropyridine ring82, 
replacement of the 2’-chloropyridine ring with bioisosteric rings (e.g. by 3’-methylisoxazolyl 
ring resulting in compound named epiboxidine 20 (Figure 1-6)83 or by substituted pyrimidine 
rings84), changes in the 7-azabicyclo[2.2.1]heptane ring system85 or synthesis of 
conformationally-constrained analogues86. Many of the analogues retain the picomolar 
affinity, but the small therapeutic window has not been greatly improved.  
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1.2.4 Class D: Acyclic HBA/pi and Cyclic Cation 
 
Members of Class D contain an acyclic HBA/pi moiety and a cationic site that is cyclic.46  
(+)-Anatoxin-a 21 (the 1R,6S-stereoisomer) (Figure 1-7), an alkaloidal toxin produced by the 
freshwater cyanobacterium Anabaena flos-aquae, is a potent and stereoselective agonist at 
nAChRs in the periphery as well as in CNS.87 The naturally occurring (+)-anatoxin-a 21 binds 
with high affinity to α4β2 (Ki = 3.5 nM) receptors and with 100-fold lower affinity to α7 (Ki = 
380 nM) receptors.88 Gündisch et al. reported even higher binding affinity of 21 for both α4β2 
(Ki = 1.1 nM) and α7 (Ki = 90 nM) nicotinic receptor subtypes.
89  (+)-Anatoxin-a 21 is a potent 
agonist stimulating the 86Rb+ influx into M10 cells, which express the nicotinic receptor 
subtype comprising α4 and β2 subunits, with EC50 value of 48 nM.
90 The semi-rigid structure 
of the azabicyclononene ring of (+)-anatoxin-a 21, its stereoselectivity and functional group 
chemistry make the alkaloid an interesting template for SAR studies. However, no 
modification reported in the literature results in an increased affinity at either receptor 
subtype.88,91  
Ferruginines are a group of 8-azabicyclo[3.2.1]oct-2-enes closely related to (+)-anatoxin-a 
21. In the natural (+)-ferruginine 22 (the 1R,5S-stereoisomer; potent neurotoxin from the 
arboreal species Darlingia ferruginea and darlingiana) as well as in the unnatural (-)-
enantiomer 22 (Figure 1-7) the acetyl moiety is a pharmacophoric element. Although (-)-
ferruginine 22 and its demethylated analogue (-)-norferuginine display lower affinity for α4β2 
(Ki = 120 and 94 nM, respectively) and α7 protein (Ki = 330 and 110,000 nM, respectively) 
than (+)-anatoxin-a 21, they served as templates for design of novel ferruginine-type nAChR 
ligands.89,92 Replacement of the acetyl group in (-)-norferruginine 22 with 1,3-diazine (the 
structure then belongs to the Class C of Schmitt’s classification46) resulted in 30-fold 
improvement in the affinity for the α4β2 subtype (Ki = 3.7 nM) combined with significant 
selectivity ratio between the α4β2 and α7 subtypes (Ki (α4β2) / Ki (α7) = 1,351).
89   
(-)-Lobeline 23 (the 2R,6S,10S-stereoisomer) (2-[6-((S)-2-hydroxy-2-phenylethyl)-1-methyl-
piperidin-2-yl]-1-phenylethanone) (Figure 1-7), a major alkaloidal constituent of Indian 
tobacco (Lobelia inflata), is a unique nicotinic alkaloid bearing a 2,5-disustitued piperidine. 
(-)-Lobeline 23 binds to the α4β2 nAChR subtype with a similarly high affinity like (-)-nicotine 
10 (Ki = 4 nM)
96b and produces some, but not all pharmacological effects of (-)-nicotine 10 
(e.g. nausea, tachycardia, anxiolytic activity).93 Interestingly, the behavioural effects of (-)-
lobeline 23 cannot be blocked by pre-treatment with nAChR antagonist mecamylamine, 
suggesting that the Indian tobacco alkaloid 23 might be binding to different, 
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Figure 1-7 Naturally occurring alkaloids as members of the Class D [Ref. 88, 89, 96b, 99] 
 
mecamylamine-insensitive subpopulations of nicotinic receptors than (-)-nicotine 10.94 
Furthermore, lobeline-evoked overflow from [3H]dopamine-preloaded striatal slices and 
synaptosomes is also mecamylamine-insensitive, indicating that this response is not 
mediated by nicotinic receptors.95 The same authors declare, that (-)-lobeline 23 is a nAChR 
antagonist, as it inhibits the effects of (-)-nicotine 10 in several in vitro experiments. 
Structurally, (-)-lobeline 23 and (-)-nicotine 10 share very little similarities and (-)-lobeline 23 
does not fit the classical nicotinic pharmacophore. However, SAR studies confirmed that the 
piperidine-ring nitrogen represents the onium feature and the carbonyl group rather than 
hydroxyl group represents the HBA/pi feature.96 All lobeline analogues that have been 
reported96b,97 bind with lower affinity than the parent alkaloid. Only recently, (-)-lobeline 23 
and especially lobelane (defunctionalised saturated lobeline analogue) were identified as 
weak vesicular monoamine transporter-2 (VMAT-2) ligands (Ki = 2.76 and 0.97 µM, 
respectively). A series of lobelane derivatives was evaluated for their affinity and selectivity 
for VMAT-2, through which psychostimulant drugs (e.g. amphetamine and metamphetamine) 
promote dopamine release responsible for the rewarding effects of the abused drugs. The 
most potent analogues display nanomolar affinities (Ki = 430 – 580 nM).
98 
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Another plant-derived alkaloid of the Class D is methyllycaconitine 24 (MLA) (Figure 1-7), a 
competitive antagonist of nAChRs, with a significant preference for neuronal [125I]-
bungarotoxin binding sites (Ki = 1.4 nM).
99 This norditerpenoid alkaloid is present in 
Delphinium brownii seeds and possesses insecticidal properties.100 Hydrolysis of the ester 
bond in MLA 24 to produce lycoctonine diminishes affinity for rat brain [125I]Bgt binding sites 
2500-fold, indicating that the ester linked 2-(methylsuccinimido)benzoyl group is necessary 
for the α7 subtype recognition, although the selectivity for α7-type nAChR resides in the 
norditerpenoid core.101 High affinity, rapid binding kinetics and selectivity for α7 nAChR make 
[3H]MLA 24 a suitable radioligand for pharmacological studies of α-Bgt sensitive nicotinic 
acetylcholine receptors.102   
 
1.2.5 Class E: HBA/pi and Cation in Fused Ring System 
 
The nAChR ligands of the final Class E have both their HBA/pi and cationic moieties fused in 
the same polycyclic or spiro system.46  
Dihydro-β-erythroidine 25 (Figure 1-8) is a nAChR ligand that has HBA/pi and cationic 
moieties locked in a nearly coplanar configuration. Dihydro-β-erythroidine 25, an alkaloid 
present in the seeds of genus Erythrina, is a nicotinic receptor antagonist that binds to α4β2 
protein with high affinity (Ki = 35 nM).
103 
Astra researchers synthesized and evaluated a quinuclidine-based nAChR ligand, 
designated as AR-R17779 26 ((-)-spiro[1-azabicyclo[2.2.2]octane-3,5’-oxazolidin-2’-one]) 
(Figure 1-8).104 This compound is a potent full agonist (efficacy = 96%) at the rat α7 nicotinic 
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Figure 1-8 Nicotinic ligands of the Class E (HBA/pi and cationic moieties fused in the same 
polycyclic or spiro system). [Ref. 103, 104, 118] 
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receptor subtype and exhibits remarkable selectivity for α7 (Ki = 92 nM) receptor over α4β2 
(Ki = 16,000 nM). AR-R17779 26 has been reported to enhance learning and memory 
function in rats105, but it failed to improve the performance in rat’s model of attention.106 SAR 
of this restricted analogue of acetylcholine displayed that there is little space for change in its 
rigid molecule. The interaction of AR-R17779 26 is stereosensitive and the (-)-enantiomer 
binds to the [125I]α-Bgt nicotinic sites more tightly than the (+)-antipode (Ki = 9,400 nM). 
Changing the carbamate bond to a carbonate, ester or amide led to dramatic loss in α7 
receptor affinity. 
(-)-Cytisine 27 also belongs to this class. This alkaloid is described in detail in Chapter 3. 
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1.3 nAChR Pharmacophore Models 
 
Consideration of the structures of acetylcholine 1 and (-)-nicotine 10 reveals two fundamental 
nAChR pharmacophore elements – a quaternised or protonated/protonable nitrogen (N+) and 
a hydrogen bond acceptor (HBA) (the carbonyl oxygen of ACh 1 and the pyridine’s nitrogen 
in (-)-nicotine 10). These basic elements were involved in the first useful pharmacophore 
model developed by Beers and Reich.107 Sheridan et al. refined this model using a distance 
geometry approach and formulated a three-point pharmacophore.108 They defined a third 
element, so-called dummy point (C), responsible for the spatial orientation of the HBA 
functionality. The distances of the triangle were proposed as follows: N+---HBA 4.8 Å, HBA---
dummy point (C) 1.2 Å and N+---dummy point (C) 4.0 Å (Figure 1-9).  
 
Figure 1-9  Pharmacophore model proposed by Sheridan et al. [Ref. 108] 
 
Holladay et al.109 developed a “four-point” model, in which numbers (1) and (2) mark the 
nitrogen functionalities (onium head and HBA) and numbers (3) and (4) represent locations 
on the nAChR protein with which they interact (Figure 1-10). The optimal internitrogen 
distance was proposed to be 4.85 Å.  
 
 
 
 
 
 
 
 
 
Figure 1-10 Pharmacophore model proposed by Holladay et al. [Ref. 109] 
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In the new vector model developed by Tønder et al.,110 the authors suggested that the 
distance between the points a and b (i.e. points at the receptor where ligand’s 
pharmacophores bind) define the binding better than the direct N---N distance. Point a is a 
site selected to be 2.9 Å in length from the onium group and b is a site selected to be 2.9 Å 
from a hydrogen bond acceptor. The a---b distance of approximately 7.3 – 8.0 Å was 
suggested to be optimal for high affinity. The same authors improved the vector model in an 
attempt to define three-point pharmacophore and included the dummy-point (C) (Figure 1-
11).111,112  
 
Figure 1-11 The improved vector model proposed by Tønder et al. [Ref. 111-112]  
 
However, none of the proposed pharmacophore models seems to be “perfectly ideal” as they 
all fail to explain some of the available data. For example, the internitrogen distance of 4.8 Å 
proposed by Sheridan et al. as optimal for high binding affinity is not applicable to all nAChR 
ligands. In the Table 1-1 are listed several nAChR ligands that fit into the “distance model”, 
but also several compounds in which the suggested internitrogen distance cannot be 
achieved. The N---N distance in epibatidine 19, the most potent α4β2 ligand, was first 
reported to be 5.5 Å.113 Later, with the discovery of azetidinylmethoxypyridine A-85380 17, it 
was shown that other low-energy conformers of epibatidine 19 were possible and these 
conformers possessed calculated internitrogen distance between 4.6 Å and 5.6 Å, but A-
85380 17 which is almost equipotent to epibatidine 19, was reported to have an internitrogen 
distance of 6.1 Å (Table 1-1).74a Koren et al showed afterward that A-85380 17 is a rather 
flexible molecule and has stable conformation with a internitrogen distance of 4.39 Å.114 
Thus, the Sheridan distance model108 can be applied to the picomolar binding of epibatidine 
19 and A-85380 17, however there are compounds which cannot achieve the short 
internitrogen distance and still display good affinity for nAChR, e.g. 30 and 31 (Table 1-
1).62b,115  
7.3 – 8.0 Å 
Site Point b 
Site Point a 
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Table 1-1 Internitrogen distances and α4β2 binding affinities of representative nAChR ligands or 
ligands that do not fit into the Sheridan “distance model”. The ligands are listed with 
regard to the increasing N---N distance. 
 
 
Ligand 
    N --- N distance 
      [Å] 
Ki @ α4β2 
[nM] 
Reference 
 
NN
+CH3
CH3       DMPP 9 
 
2.5 – 2.9 
 
57 
 
[62b] 
N
O
N
H
  A – 85380 17* 
 
3.39 
 
0.017 
 
[114] 
   
N
CH3
N            nicotine  10 
 
4.8 
 
1-10 
 
[108] 
 
    
N
N
ClH
  epibatidine 19 
 
4.6 – 5.6 
5.5 
 
0.043 
0.050 
 
[74a] 
[113] 
 
   
N
H
N
N
                      28 
 
5.67 – 5.69 
 
3.7 
 
[89] 
  N
O
N
H
 A – 85380 17* 
 
6.1 
 
0.052 
 
[74a] 
 
NNH
NN
Cl
              29 
 
6.26 
 
32 
 
[116] 
 
 N
N
H
CH3
                     30 
 
> 8 
 
58 
 
[115] 
 
NN
+CH3
CH3
CN
                31 
 
8.37 
 
300 
 
[62b] 
*) A-85380 is positioned twice, as two different distance values are reported in literature 
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Compound 29 (Table 1-1) also gives support to the hypothesis that a longer  
internitrogen distance (~ 6.0 Å) than in the Sheridan model is still compatible with an affinity 
 for the α4β2 receptor in the nanomolar range.116  However, Gündisch et al89 suggested that 
the internitrogen distance crucial for high affinity binding to nAChR should be closer to that 
found for the lowest-energy conformation of epibatidine (5.5 Å)113, as they measured for high 
affinity compound 28 (Ki = 3.7 nM) an internitrogen distance of 5.67 – 5.69 Å (Table 1-1). In 
summary, the internitrogen distance itself cannot be used for prediction and/or rationalisation 
of binding affinity and activity of diverse sets of nicotinic agents.  
The vector models fail e.g. to explain the very different affinity of aminoethoxypyridine (AXP) 
analogues, which were accounted by the vector model.117 While N,N-dimethyl AXP 32 shows 
nanomolar α4β2 affinity (Ki = 21 nM), replacement of the ether oxygen by a methylene group 
affords compound 33 that lacks affinity (Ki > 10, 000 nM) (Figure 1-12). 
 
 
N
X
N
CH3
CH3
32   X = O      Ki = 21 nM
33   X = CH2   Ki > 10,000 nM
 
Figure 1-12 Examples of AXP-analogues which do not fit the vector pharmacophore model 
[Ref.117] 
 
 
Recently, the “water-extension” concept has arisen among the nAChR community.115 The 
idea is that a molecule of water might hydrogen bond to the ‘short’ ligands and converts them 
to ‘long’ ligands, meaning that the ligand’s HBA or onium head hydrogen bonds to water, 
which in turn, hydrogen bonds with the receptor (Figure 1-13). Some unexpected results 
obtained in the laboratories have been rationalised with this concept, but it still requires 
further investigation.  
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Figure 1-13 “Water-extension” concept applied to nicotine 10 [Ref. 115]  
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2 Objectives 
 
 
The neuronal nAChRs have been associated with a great variety of pathological conditions, 
which results in a therapeutic potential of nAChR ligands. The nAChR pharmacopoeia is 
increasing and several agonists have entered clinical trials for the treatment of Alzheimer’s 
(ABT-418, GTS-21, RJR-2403) or Parkinson’s disease (SIB-1508Y). Unfortunately, the 
therapeutic use of compounds interacting with central nAChRs (i.e. α4β2 and α7 subtypes) is 
often associated with unwanted side effects. The side effects result from the interaction of 
the compound with the nAChRs in the peripheral nervous system (e.g. α3β4 and (α1)2β1γδ 
subtype). Thus, the medicinal chemistry research of nAChR ligands has to focus not only on 
development of ligands with high affinity, but also on development of agents that exhibit 
sufficient selectivity for central nAChRs over the muscle and ganglionic receptors. 
The main goal of the presented thesis was to develop novel nAChR ligands based on (-)-
cytisine 27 (Project I, main project) and choline 3 (Project II). Analogue design and biological 
evaluation of the novel compounds should help to understand which structure elements 
contribute to the compound’s affinity and selectivity profile. 
Project I 
(-)-Cytisine 27, a toxic alkaloid found in many plants of the Fabaceae family, displays 
picomolar affinity for α4β2 nAChR (Ki = 0.122 nM)
118 and is a partial agonist with weak 
efficacy at this nAChR subtype.119 The partial agonistic activity of (-)-cytisine 27 provides 
desired pharmacological effect for the treatment of smoking cessation. In this regard, the 
pure alkaloid (TABEX®)120 is used in Bulgaria and varenicline (Pfizer), an azatricyclic 
compound imitating the structure of (-)-cytisine 27 is in Phase III clinical trials for the 
treatment of tobacco dependence.121 
Structure-activity studies have concentrated on substitution of the secondary amine and 
halogenation of the pyridone ring.118,122,123 While modification of the secondary amine 
decreased the affinity to a lesser or greater degree123, the halogenation of the pyridone ring 
provided a series of analogues with generally high α4β2 affinity118. Heterocyclic and 
(hetero)aryl cytisine derivatives have also been reported (Figure 2-1), but no binding affinity 
data has been published for these compounds, with one exception.124 Roger et al. reported Ki 
values of 24 and 3,462 nM for 3-(2-fluoropyridinyl)-cytisine at α4β2 and α7 receptor 
subtypes.125 In other words, very little is known about the impact of bulkier substituents at the 
pyridone fragment on the affinity and subtype selectivity for nAChRs. 
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       2-tienyl, 3-tienyl, benzyl
phenyl  
Figure 2-1 Structures of known (-)-cytisine analogues with unknown binding affinities 
 
The target compounds should therefore feature bulkier substituents, i.e. substituted phenyl 
and heterocyclic moieties in the position 3 or 5 of the cytisine structure (Figure 2-2).  
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Figure 2-2 Structure of target compounds 
 
The synthetic protocols reported for the incorporation of phenyl or aryl moieties into the 
cytisine backbone did not appear to be efficient for rapid synthesis of numerous derivatives 
required for SAR study, as they were complicated and lengthy, often using highly toxic 
stannane reagents. Thus, the work was focused on the development of rapid and more 
effective synthetic route to (hetero)aryl cytisine derivatives. 
The assignment of the carbon and proton signals of cytisine 27 is poorly documented in the 
literature126,127,128 and no publication deals with comprehensive NMR analysis of (-)-cytisine 
27. Moreover, no detailed study for distinguishing 3- and 5-substituted isomers has been 
reported. In order to correctly differentiate the isomeric 3- and 5-(hetero)aryl cytisine 
derivatives, a complete and correct set of 1H and 13C chemical shifts assignment for the 
unsubstituted alkaloid 27 was required. For that reason, another goal was to perform 
extensive NMR study of the parent alkaloid as well as of its several analogues. This study 
should provide information regarding the assignment of the 1H and 13C chemical shift to the 
cytisine skeleton and establish “diagnostical tools” for the differentiation of 3- and 5-isomers.  
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Although the cytisine analogues were aimed as potent α4β2 ligands, they were tested in 
radioligand binding studies not only for the affinity on the target receptor subtype, but also for 
their affinity towards different subtypes, i.e. α7*, α3β4* and (α1)2β1γδ nAChRs. The 
determination of binding affinities will bring great impact on the current knowledge of 
structure-activity relationship, which is restricted due to the moderately big group of cytisine 
derivatives synthesized to date and very limited number of disclosed binding affinities. At the 
same time, the comparison of the binding profiles at different nAChRs subtype may help to 
understand the requests of each receptor for a selective ligand. 
Project II 
The nicotinic pharmacopoeia has expanded in the last decade with a number of novel 
synthetic ligands, however, the vast majority of these compounds is selective for α4β2 
subtype and only a very limited number of potent α7-ligands is known to this point in time 
(e.g. α-bungarotoxin, MLA, anabaseine, GTS-21 or AR-R17779). 
Choline 3, a precursor and a metabolite of acetylcholine 1, is an effective agonist of α7 
nAChRs even if it presents very low affinity for the α7 nAChR (Ki = 2,380 µM).52 Choline 3 
has been shown to protect neural cells from cytotoxicity induced by growth factor 
deprivation53 and it was suggested that the choline structure may serve as a template for the 
development of novel agents with both α7-nicotinic agonist activity and potential 
neuroprotective ability.53 Nevertheless, the structure of choline 3 has attracted limited interest 
as a lead compound in the search for nAChR ligands and it was rationale to revisit this 
structure as a lead for development of novel nAChR ligands, with potential α7 selectivity.  
The main goal of this project was to explore structural requirements of the nAChRs for a 
selective ligand based on choline. Our research group has shown, that phenylether of 
choline 4, which shows nanomolar affinities for neuronal nAChRs and prevalence for α4β2* 
subtype is converted into an α7*-selective ligand 5 by an addition of amide moiety.55 Thus, 
the question is: Does carbamate moiety between the pharmacophoric elements always result 
into α7-selective ligands?  
In the target phenylcarbamate derivatives of 5, the quaternary nitrogen will be incorporated 
into various azacyclic systems (N-methylpyrrolidine, N-methylpiperidine and quinuclidine), as 
compounds with tertiary amine groups have a higher probability to cross the blood-brain 
barrier. Additional substitution at the phenyl moiety should give deeper insight into the 
structure-activity relationships. Since the ortho and para position of the phenyl moiety in 
carbamates have been proved to strongly increase the affinity for muscarinic receptors as 
well as increase the anaesthetic effects, the meta position of the phenyl ring was selected for 
the introduction of various substituents (Br, CH3, Ph and styryl). 
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Figure 2-3 Development of nAChR ligands based on choline: project and structure of target 
compounds 
 
The novel structures will be investigated in radioligand binding studies for their affinity 
towards nicotinic acetylcholine receptors, whereas the affinity for four subtypes, i.e. α4β2*, 
α7*, α3β4* and (α1)2β1γδ will be tested. This extensive pharmacological in vitro evaluation 
should provide valuable knowledge for the future development of nAChR ligands based on a 
phenylcarbamate template.    
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3 Project I: Development of Novel nAChR Ligands based 
on Cytisine 
 
3.1 Cytisine as a Lead Compound 
 
3.1.1 Introduction 
 
(-)-Cytisine 27 was discovered in 1863 by Husemann and Marmé129, as one of the poisonous 
alkaloids present in the seeds of Laburnum anagyroides (syn. Cytisus laburnum, Fabaceae). 
The physicochemical properties were for the 19th century extensively studied by Partheil130 
and he also established (-)-cytisine 27 to be identical with ulexin131, discovered by Gerrard132 
in the seeds of Ulex europeus. More recently, Gorter proved its identity with baptitoxine, the 
alkaloid of the root of Baptisia tinctoria.133 The structure of (-)-cytisine 27 was successfully 
established in the 1930s by H.R. Ing.134 
(-)-Cytisine 27 ((7R,9S)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one) 
is a chiral quinolizidine alkaloid composed of an unsymmetrical, partially aromatic, bridged 
tricyclic skeleton (Figure 3-1). Quinolizidine alkaloids are derived from lysine and have two 
fused 6-membered rings that share nitrogen. At least 570 are known, but (-)-cytisine 27 and 
sparteine are the two most widely distributed quinolizidine alkaloids.135 In the structure of (-)-
cytisine 27 rings A and B form a bispidine framework that is fused to a 2-pyridone moiety 
(ring C) (Figure 3-1). The absolute configuration of the two chiral centres in the natural (-)-
cytisine 27 was established to be 7R and 9S.136 The absolute configuration of the unnatural 
(+)-enantiomer is 7S,9R. In the following work the signature “cytisine 27” refers to the 
naturally occurring 7R,9S-cytisine, in cases of unnatural and racemic cytisine configurations, 
signs (+) and (±) will be used. The alternative numbering mostly used in the literature and in 
this thesis is not consistent with IUPAC numbering (Figure 3-1).  
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Figure 3-1  Structure of cytisine 27. The rings A and B form a bispidine framework that is fused to 
a 2-pyridone moiety (C). The absolute configuration is 7R, 9S. Note: The alternative 
numbering mostly used in literature and in this thesis is not consistent with IUPAC 
numbering. 
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The lupin alkaloid cytisine 27 is present in many plants of the family Fabaceae. The isolation 
from e.g. Euchresta japonica137, Maakkia tashiroi138, Sophora exigua139, Ormosia emarginata 
etc.140, Echinosophora koreensis141, Agryrolobium uniflorum142 have been described in the 
literature. 
In Europe, cytisine 27 can be easily isolated from seeds of Laburnum, a genus of two 
species, L. anagyroides and L. alpinum. Both species are bushy plants or small trees, 
cultivated throughout the Europe for their flowers, which appear early in the spring in rich, 
pendent, yellow clusters (Picture 3-1). However, most garden trees are the hybrid of the two 
species (termed Laburnum x watereri) which have the “benefit” of low seed production as 
Laburnum seed toxicity (i.e. cytisine toxicity) is a common cause of children’s poisoning.143 
Symptoms of cytisine 27 poisoning are intense sleepiness, vomiting, convulsive movements 
and eventually death by respiratory failure. However, recovery from these symptoms occurs 
more or less speedily and only few cases were recorded in which death was the result.144 
  
Picture 3-1 “Goldregen” tree (Laburnum anagyroides) in the spring and autumn 
 
3.1.2 Pharmacological Characterisation of Cytisine 
 
Compared to (-)-nicotine 10, naturally occurring cytisine 27 is a more potent nAChR ligand 
with higher selectivity and subnanomolar affinity towards the α4β2 subtype (Table 3-1). In the 
radioligand binding studies using rat brain membranes, Gündisch et al report for cytisine 27 
Ki = 0.120 – 0.124 nM
118,145 while others report lower binding, i.e. Ki = 0.45 nM
146 and Ki = 3 
nM.123 To the α4β2 receptor expressed in Xenopus laevis oocytes cytisine 27 binds with Ki 
values of 1.03 nM.146 Similar binding of cytisine 27 to α4β2 protein was found in assays 
performed with SH-EP1-hα4β2 clonal cell lines that express human α4β2 nACh receptors (Ki 
= 1.2 nM147  and Ki = 1.07 nM
148). 
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Table 3-1 Ki values of cytisine at various nAChR subtypes 
 α4β2 [nM] Tissue Reference 
Ki  = 0.120 rat brain [145b] 
 0.122 rat brain [118] 
 0.124 rat brain [145a] 
 0.17 rat brain [121] 
 0.23 HEK 293 cell line [185] 
 0.45 rat brain [146] 
 1.03 Xenopus laevis oocytes [146] 
 1.2 SH-EP1-hα4β2 cell line [147] 
 1.5 rat brain [122] 
 3 rat brain [123] 
 α7 [nM] Tissue Reference 
Ki  = 8,000 SH-SY5Y-hα7 cell line [147] 
 4,200 IMR 32 cell line [121, 185] 
 261 rat brain [118] 
 α3β4 [nM] Tissue Reference 
Ki  = 18 pig adrenal [183] 
 54 rat adrenal [183] 
 56 Xenopus laevis oocytes [146] 
 81 rat ganglia [122] 
 220 KXα3β4R2 cell line [150] 
 840 IMR 32 cell line [121, 185] 
 (α1)2β1γδ [nM] Tissue Reference 
Ki  = 250 cells electroplax [121, 185] 
 1,300 Torpedo californica electroplax [183] 
 
The Ki for cytisine 27 at other nACh receptor subtypes are listed in the Table 3-1. Cytisine 27 
displaces [3H]MLA from rat brain binding sites (i.e. α7 subtype) with Ki value of 261 nM
118 and 
α-[125I]Bgt from SH-SY5Y-hα7 neuroblastoma clonal cell line with Ki value of 8.0 µM.147 In the 
binding studies using Xenopus laevis oocytes Ki value of 8.36 µM was obtained.148 Cytisine 
27 has been shown to be a potent ligand also for α3β4 subtypes (Ki = 18 – 220 
nM).121,122,146,150,183,185 The Ki value of 27 for the (α1)2β1γδ nAChR subtype at the 
neuromuscular junction is in the micromolar range (Ki = 1,300 nM).
183 Coe et al just recently 
reported a Ki value of 250 nM for cytisine affinity towards [
125I]-α-bungarotoxin binding sites 
expresed in cells electroplax.121,185 
Functional data performed on known pairwise combinations of α and β subunits expressed in 
Xenopus oocytes showed that the effects of cytisine 27 on nAChRs are sensitive to receptor 
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subunit composition and the major factor in determining its efficacy is the nature of thee β 
subunit. Cytisine 27 was reported to be able to differentiate between receptors containing β4 
and receptors containing β2 subunits. While nAChRs composed of α2, α3 or α4 in 
combination with β2 were insensitive to cytisine 27 compared to ACh 1, and nAChRs 
composed of α2, α3 or α4 in combination with β4 were 3- to 17-fold more sensitive to cytisine 
27 than to ACh 1.149  
Cytisine 27 acts as a true partial agonist for β2-containing nAChRs and can inhibit in the low 
concentration (20 nM) 50% of the α4β2 response to its endogenous neurotransmitter ACh 1 
(1 µM) through a competitive mechanism. In the case of α4β2 receptors, cytisine 27 binds 
with high apparent affinity and low efficacy (the responses of α4β2-injected oocytes to the 
application of 1 mM cytisine 27 being only 14.7% of the response to 1 mM ACh 1).119 
Functional studies103 with recombinant human nAChRs expressed in Xenopus oocytes 
exposed the same result, i.e. cytisine 27 displayed very low efficacy at β2-containing 
hnAChRs (hα2β2, hα3β2 and hα4β2) in contrast to its efficacy shown on β4-containing 
receptors (hα2β4, hα3β4 and hα4β4). In the same study, cytisine 27 was shown to possess a 
full agonist profile only on hα7 nAChRs.103 
Partial agonist activity of cytisine 27 (59% efficacy compared to (±)-epibatidine 19) was 
established also in K-177 cells expressing human α4β2 nAChR and in cultured cells 
expressing α3β4 receptors (62% efficacy compared to (±)-epibatidine 19).150 
The nicotine-like properties of cytisine 27 were first described by Dale and Laidlaw.151 
Although cytisine 27 is about 10-times more potent than (-)-nicotine 10 in binding 
experiments, it is less potent in producing the nicotine-like pharmacological effects.152 Reavill 
et al confirmed that cytisine 27 has nicotine-like discriminative effect, but in much lesser 
extent than (-)-nicotine 10.153 The unimpressive behavioural effects of 27 were accounted at 
this point for its poor penetration to CNS due to the low lipophilicity (log kw = 0.21 at pH 7.4, 
for comparison, (-)-nicotine 10 showed in the same experiment log kw = 1.24).
153 Currently, 
the modern understanding of cytisine 27 being a partial agonist explains its pharmacological 
behaviour.  
 
3.1.3 Radioligand [3H]Cytisine 
 
High affinity and selectivity of cytisine 27 for α4β2 nAChRs understandably led to the 
evaluation of tritium labelled [3H]cytisine 27 in radioligand binding studies. In the pilot study, 
[3H]cytisine 27 was found to bind with high affinity to α4β2 nAChRs (Kd = 0.96 nM, rat brain 
Project I: Cytisine as a lead compound29 
 
tissues) and specific binding represented 60% – 90% of total binding at all concentrations 
examined (up to 15 nM).154 Anderson and Arneric reported for [3H]cytisine 27 binding in rat 
brain membrane fractions Kd value of 0.15 nM
155 and Khan et al. examined [3H]cytisine 27 
binding to membranes isolated from regions of the rat spinal cord. In their study, radioligand 
[3H]cytisine 27 showed saturable, noncooperative binding to a single class of nAChRs with a 
Kd of 0.44 nM.
156 Gündisch et al reported for [3H]cytisine 27 a Kd value of 0.120 nM.
145a 
Currently, the tritium labelled cytisine 27 is being used in the radioligand binding experiments 
for the determination of affinities of various nAChR ligands. 
Evaluation of the radioligand 27 in post mortem human brain revealed binding of [3H]cytisine 
27 to be of high affinity (Kd = 0.245 nM), saturable, reversible and labelling a single class of 
nAChRs. 157 The authors suggested that these characteristics make the radioligand useful for 
the quantisation of nicotinic cholinergic receptors in the human brain or in the tissues with 
low receptor density. Ex vivo labelling experiments using mouse brain and [3H]cytisine 27 
demonstrated that this radioligand is capable to label nAChRs.158 However, a positron 
emission tomography (PET) attempt to visualise nicotinic cholinergic receptors in baboon 
brain with N-[11C]methyl-cytisine failed.159 The authors believed that the N-[11C]methyl-
cytisine crossed the blood-brain barrier very slowly and therefore the brain uptake of the 
radioligand was not different from blood radioactivity. However, the authors were mistaken 
with the affinity of caulophylline (N-methyl-cytisine) as they reported that caulophylline has a 
ten-fold higher potency than cytisine 27 in displacing [3H]nicotine at brain nACh receptors. 
The real affinity of caulophylline (Ki = 5.7 nM)
118 is the reason why N-[11C]methyl-cytisine is 
not a suitable tracer for PET studies of nAChR in primate brains, as PET methodology 
requires ligands with picomolar affinity, when monitoring neuroreceptors with low density.  
3.1.4 Cytisine in Human Medicine 
 
Nicotinic acetylcholine receptors are thoroughly investigated as potential drug targets in 
many therapeutic areas. nAChR ligands, including cytisine 27 and its derivatives, are claimed 
in the patent literature for the treatment of an endless list of pathologies, e.g. Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, Tourette’s syndrome, mania, 
depression, anxiety, pain, jet-lag, glaucoma etc. The lists go up to thirty CNS- and non CNS-
related disorders.160 Cytisine 27 is mostly associated with the treatment of smoking and 
nicotine addiction.124 
The first human smoking cessation study with cytisine 27 was performed in the 1960s. The 
study failed due to the poor effectivity resulting from poor bioavailability.161 Several decades 
later, combination of nicotine replacement therapy with nAChR antagonist mecamylamine 34 
(Figure 3-2) was found to be more effective than either treatment alone.162 This discovery 
initiated a new therapeutical approach to smoking cessation using partial agonists. Sanofi-
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Synthelabo developed a nAChR partial agonist SSR591813 35 (Figure 3-2) that displays 
antiaddictive-like activity in animal models and reduces the dopamine-releasing and 
discriminating effects of nicotine.163 
Cytisine 27 is currently on the market in Bulgaria as the main compound of Tabex® intended 
for treatment of tobacco dependence.120 Even if Tabex brought some positive results, the 
pure alkaloid has not found an application in the medicine outside of Bulgaria, most likely due 
to the small therapeutic window and the above mentioned poor bioavailability.  
Pfizer recently described a novel series of compounds exhibiting a partial agonist profile and 
identified varenicline 36 (Figure 3-2), an azatricyclic compound imitating the structure of 
cytisine 27, as the most suitable compound for the treatment of tobacco dependence.121,164 
The in vivo properties of varenicline 36 demonstrated its ability to attenuate the central 
dopaminergic response to smoking while simultaneously providing relief from withdrawal 
syndromes that accompany cessations attempts.121 
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Figure 3-2  Chemical structures of nAChRs antagonist 34 and partial agonists 35 & 36 intended 
for the treatment of smoking cessation [Ref. 121, 162, 163] 
 
 
3.1.5 Total Synthesis of Cytisine 
 
The complex tricyclic structure of cytisine 27 has been an interesting chemical challenge for 
organic chemists over the decades. Several total syntheses of racemic cytisine 27 were 
described in the 1950s by van Tamelen165, Bohlman166 and Govindachari167 and served to 
confirm its structure. However, these lengthy and low-yields resulting syntheses were not 
improved for nearly 50 years and only the identification of cytisine 27 as a potent nAChR 
ligand awoke new interest into the total synthesis of this alkaloid.     
The first “new century” total syntheses of (±)-cytisine 27 were published by the Pfizer group 
in 2000. In the paper of O’Neill168 the alkaloid (±)-27 was prepared in five steps featuring an  
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Scheme 3-1 First “new century” total synthesis of (±)-cytisine 27, Stille cross-coupling reaction as a 
key step in the synthesis of the functionalised biaryl pyridine system 37 [Ref.168] 
 
“in situ” Stille or Suzuki to provide the desired biaryl pyridine system 37 (Scheme 3-1). The 
utility of this procedure was established via synthesis of novel derivative 9-methoxycytisine 
38 using similar sequence (Figure 3-1). At the same time, Coe described a concise 6-step 
synthesis of racemic (±)-cytisine 27 from cyclopent-3-enylmethanol.169  This strategy featured 
the intramolecular Heck cyclization of glutarimide-derived ketene aminals to construct the 
tricyclic carbon skeleton of (±)-cytisine 27, which was obtained in 16% overall yield. The 
crucial bipyridine 37 of the synthetic route published by O’Neill et al168 was later synthesized 
by a French group via Negishi cross-coupling reaction.170 Recently published novel strategy 
for the synthesis of racemic cytisine 27, which was achieved in a total of 8 steps from 
commercially available starting materials, promises potential for more general application to 
the assembly of other lupine alkaloids.171  
The first total enantioselective synthesis of (-)-cytisine 27 and its (+)-enantiomer was 
reported a few years later. The authors established 12-steps, 9%-overall yield synthesis of 
the enantiopure alkaloid 27 with ruthenium-catalysed ring closing metathesis representing 
the key step.172  Enantiopure synthesis of (+)-cytisine 27 has been published together with 
synthetic routes of (+)-kuraramine and (+)-jussiaeiine, the oxidative metabolites of N-
methylcytisine. These alkaloids were synthesized via samarium diiodide-promoted reductive 
deamination.173 
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3.1.6 Modification of the Cytisine Scaffold 
 
Nevertheless, the above described routes still present a very complicated organic challenge 
and all novel analogues disclosed to date have been synthesized via modification of cytisine 
27 obtained from natural sources and have been limited – with a few exceptions  –  to 
halogenation on the pyridone moiety and substitution of the secondary amine group. This 
chapter will discuss the chemistry of the cytisine derivatives, while the following Chapter 
3.1.7 will focus on the biological data of these derivatives.    
First halogenated derivative of cytisine 27 – 3,5-dibromo-cytisine 46 – was synthesized 
several decades ago. The alkaloid 27 was treated with excess of bromine in the aqueous 
acetic acid.174 Imming et al118 developed an effective one-step syntheses of halogenated 
derivatives of cytisine featuring a halogen substituent in the position 3 (39/40/41), in the 
position 5 (42/43/44) or both 3 and 5 (45/46/47) of the 2-pyridone fragment. The key step in 
syntheses was halogenation of N-12 protonated (-)-cytisinium acetate 48 (Scheme 3-2), 
prepared in situ by employing aqueous acetic acid as the solvent and utilising N-chloro, N-
bromosuccinimide or iodine chloride as halogen transfer reagents (Scheme 3-2)118.  
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Scheme 3-2 Effective one-step syntheses of mono- and dihalogenated cytisine derivatives  
[Ref. 118] 
 
Halogenated analogues of cytisine 39 – 47 were also disclosed in some Pfizer patents124 and 
were prepared in a similar way, using halogenated succinimides as halogenation agents, but 
the bispidine nitrogen was tBOC-protected before the halogenation. The protecting group 
was subsequently removed with trifluoroacetic acid. 
Several papers describe modification of the cytisine 27 structure by reactions at the 
secondary amino group. Substitution of the basic nitrogen with isocyanates and 
isothiocyanates afforded urea- and N-arylthiocarbamylderivatives of cytisine.175,176 In the ex-
Soviet Union, cytisine 27 deserved much attention in the 1970s due to its utilisation as a 
respiratory stimulant.177 Recently, the remaining interest has produced many analogues, all 
of them presenting structural variation on the secondary amino group. N-alkyl- and 
sulfonamide derivatives of cytisine 27 were reported178,179, as well as analogues of 
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cytisylmethylbarbituric acids180. Acylation of the alkaloid 27 with the benzocrown-ether 
carboxylic acid chlorides allowed incorporation of the benzocrown-ether fragment into the 
structure of cytisine 27.181  
A large group of N-substituted derivatives of cytisine 27 possessing an aliphatic, arylaliphatic 
or heteroaromatic substituent (Scheme 3-3, 49 representing a general structure) was 
synthesized together with compounds bearing a second cytisine unit, linked through an 
aliphatic or xylene chain (Scheme 3-3, 50 representing a general structure).122,123 
 
NH
N
O
N
N
N
O
N
R
O
RX
X-R-X
N
N
O
R
27
R = alkyl e.g. ethyl, isopropyl, pentyl
R = aralkyl e.g. benzyl, ethyl-2-phenyl
R = heteroaryl e.g. 2-pyridinyl
R = e.g. methyl, ethyl, 2-butyne
49
50
X = Br, Cl, I
 
Scheme 3-3 Structural variation of the secondary amino group of cytisine 27 [Ref. 122, 123] 
 
Oxygen-sulphur exchange with Lawesson’s reagent under microwave irradiation allowed 
synthesis of bioisosteric thiocytisine 51 and via hydrogenation of double bonds 
tetrahydrocytisine 52 was synthesized (Figure 3-3).118,182 N-methylation of cytisine 27 leads to 
an alkaloid known as caulophylline 53 (Figure 3-3). Several analogues featuring 2 or 3 
modifications were also prepared, e.g. tetrahydrothiocytisine 54, 3,5-dibromo-N-
methylcytisine 55, N-methyl-tetrahydrothiocytisine 56 (Figure 3-3).118,182,183 
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Figure 3-3 Structures of cytisine analogues. 51 – 53 possess one modification, while 54 – 56 
feature two or three modifications compared to cytisine 27 [Ref. 118, 182, 183] 
 
 
A series of cytisine derivatives with bulkier (hetero)cyclic substituents in the position 3 or 5 
were disclosed in several Pfizer patents.124 In order to develop PET ligands based on 
cytisine, 3-(4’-fluorophenyl)-cytisine184 and (-)-3-(2-fluoropyridin-5-yl)-cytisine125 were 
prepared via Stille cross-coupling reaction. These synthetic routes and structures are 
described in detail in Chapter 3.2. 
Partial agonist properties of cytisine 27 and the involvement of α4β2 nAChRs in mesolimbic 
dopaminergic system responsible for drug abuse as a pathway to treat smoking cessation 
led Pfizer to the development of racemic all-carbon-containing cytisine analogues 57 
(Scheme 3-4), in which the pyridone ring was replaced by a substituted phenyl ring.185 These 
analogues were generated via Heck cyclization protocol and followed the synthetic strategy 
for the total synthesis of racemic (±)-cytisine 27169 (Scheme 3-4). 
Br
OMe
R
NH
R2
R3
R4R5
9 steps
e.g. R2 = OH,  R3 = R4 = R5 = H
       R2 = F,     R3 = R4 = R5 = H
       R3 = F,     R2 = R4 = R5 = H
       R3 = NO2, R2 = R4 = R5 = H 
       R4 = NO2, R2 = R3 = R5 = H
57
 
Scheme 3-4 Structure of all-carbon-containing cytisine analogues 57 [Ref.185] 
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3.1.7 Structure-Activity Relationship of Cytisine Derivatives  
 
The knowledge of the structure-activity relationship for the lead compound 27 is very limited, 
since the binding affinity or the pharmacological activity data of the analogues disclosed in 
patent literature is not provided. Thus, the SAR for cytisine 27 as a lead compound is to date 
based on information obtained from research groups of Gündisch (University of Bonn, 
Germany), Cassels & Bermúdez (University of Chile & Oxford Brookes University, England), 
Sparatore (University of Genoa, Italy), Lasne (University of Caen-Basse-Normandie, France) 
and the most recent Pfizer publication185. 
 
SAR for α4β2 nAChR subtype 
Cytisine 27 exhibits high affinity towards α4β2 nAChRs (Ki = 0.120 – 3 nM, Table 3-2).
121-
123,145-147,185 The introduction of the substituent on the amine nitrogen always caused a 
dramatic loss in affinity dropping into the nanomolar range. This reduction of affinity was 
observed with a simple N-methylation of cytisine 27 to caulophylline 53 (Ki = 5.7 nM)
118, as 
well as with the introduction of a longer aliphatic, an arylaliphatic or a bulkier aryl moieties (Ki 
= 1.2 – 4,850 nM for compounds of general structure 49 in the Scheme 1-3)123. The 
compounds consisting of two cytisine units joined through an aliphatic or arylaliphatic moiety 
(50, Scheme 1-3) also showed a decrease in affinity. When the link between the bispidine’s 
nitrogens involved 3-4 carbon atoms, the deterioration of affinity was smaller (Ki = 25 – 30 
nM) than that observed with a chain of 2 or 6 carbon atoms (Ki = 96 and 313 nM).
123 
The introduction of halogen substituent into position 3 (39 - 41) resulted in an increase of the 
binding affinity to the rat brain α4β2 nAChRs (Ki = 0.010 – 0.022 nM).
118 3-Bromocytisine 40 
shows the highest affinity for α4β2 subtype (Ki = 10 pM), exceeding that of the parent alkaloid  
27 by approximately one order of magnitude and comparable to the affinity of epibatidine 19 
(Ki = 0.018 nM)
78.  The binding to α4β2 protein was reduced with halogenation of the position 
5 (Ki = 0.23 – 2.5 nM for 42 - 44) and dihalogenation of the positions 3 and 5 of the pyridone 
ring (Ki = 0.52 – 10.8 nM for 45 - 47).
118  
Brominated cytisine analogues 40, 43 and 47 have been also tested in the cell lines 
expressing hα4β2 receptor.147,148 The rank of order of potency for blockade of [3H]cytisine 
was 5-Br-cyt 43 (Ki = 1.54 µM) < 3,5-diBr-cyt 46 (Ki = 0.42 µM) < cytisine 27 (Ki = 1.07 nM) < 
3-Br-cyt 40 (Ki = 0.082 nM). 3-Iodo-cytisine 41 was found to be less potent than 40, but still 
showed a higher binding to the hα4β2 nAChR (Ki = 0.7 nM) than the parent alkaloid 27.
148 5-
Iodo-cytisine 44 (Ki = 10 nM) was less potent than cytisine 27, but possesses a higher affinity 
than the 5-bromo analogue 43.147 
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The introduction of the nitro group into position 3 slightly decreases the binding affinity of the 
lead 27 (Ki = 0.42 nM for 3-nitrocytisine 58). The 5-nitro counterpart 59 possesses 
approximately 150-fold lower affinity for α4β2 nACh receptor (Ki = 65.6 nM).
183 
The divalent bioisosteric replacement of the lactam oxygen of cytisine 27 by sulphur yielded 
thiocytisine 51 and 7-fold affinity reduction (Ki = 0.832 nM) compared to cytisine 27 (Ki = 
0.122 nM).118 However, the thiolactam 51 showed the best affinity-selectivity profile for α4β2 
vs α7 nAChR subtypes (Ki = 0.832/4000 nM, respectively).
118,182,183 The combination of two or 
three modifications of the cytisine 27 scaffold (e.g. bioisosteric replacement and 
halogenation) led to decrease of the α4β2 binding affinities (Table 3-2).183  
 
Table 3-2 Affinities of cytisine analogues with two or three modifications at α4β2 nAChRs  
[Ref. 183] 
N
N
X
R1
R2
R3  
 
R1 
 
R2 
 
R3 
 
X 
 
Ki [nM] 
H H H O 0.122 
CH3 Br H O 1.37 
CH3 Br Br O 485 
CH3 I H O 1.0 
CH3 I I O 656 
CH3 H H S 6,000 
H Br H S 0.6 
H H Br S 8.1 
H Cl H S 1.48 
H H Cl S 55 
-CO-CH3 H H S 857 
 
The impact of the bulky substitution in the position 3 or 5 cannot be evaluated, as biological 
data of the phenyl and aryl derivatives of cytisine 27 have not been disclosed124, with one 
exception. Roger et al reported a Ki value of 24 nM for 3-(2-fluoropyridin-5-yl)-cytisine at 
α4β2 receptor subtype.125   
The structure-activity relationships for all-carbon derivatives of cytisine 57 exposed similar 
findings regarding the structure requirements for high affinity nAChRs ligands (Table 3-3)  
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Table 3-3 Structures and affinities of all-carbon analogues of cytisine 57 for hα4β2 nAChRs in 
HEK 293 cells [Ref.185] 
NH
R1
R2
R3R4  
 
 
Compound 
 
 
R1 
 
R2 
 
R3 
 
R4 Ki [nM] 
cytisine 27 --- --- --- --- 0.23 
57a H H H H 34 
57b OH H H H 2.9 
57c F H H H 6.5 
57d H F H H 2.0 
57e H OMe H H 1.4 
57f H NO2 H H 4.9 
57g H H NO2 H 6.5 
57h H H H NO2 14 
57i F F H H 0.44 
57j H Ph H H > 500 
 
and controversial results regarding the α4β2 pharmacophore model.185 High-affinity 
compounds (57b - 57i) share a common substitution pattern of possessing electron-
withdrawing group (OH, OMe, F, NO2), preferably in the position that equals the position 3 in 
cytisine 27 (e.g. comparison of 57c and 57d). These groups are poor hydrogen bond 
acceptor (HBA) or are devoid of H-bond acceptor capability, which is believed to be crucial 
for receptor binding. The most potent compound 57i combines two neighbouring fluorine 
atoms and shows affinity (Ki = 0.44 nM) comparable to the affinity of cytisine 27 (Ki = 0.23 
nM).185 
The SARs for cytisine 27 analogues is summarized in Figure 3-3.  
 
NH
N
O
3-substitution improves the affinity
              Br ~ I ~ Cl >>>NO2
5-substitution offers no obvious
            affinity advantage
N-substitution causes 
dramatic loss of affinity
oxygen-sulphur exchange tolerated
 AND thiocysine shows the best
          affinity-selectivity profile 
hydrogenation of double
bonds poorly tolerated 
 
Figure 3-3 SARs for cytisine 27 analogues at α4β2 nAChR 
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SAR for α7 nAChR subtype 
Cytisine 27 displays moderate binding to α7 nAChR (Ki = 261 nM)
118,183 and the structure-
affinity relationship for this receptor subtype mostly follows the trend observed for SAR at 
α4β2 nicotinic acetylcholine binding sites.  
The N-substitution greatly reduces affinity and the introduction of a methyl or dimethyl moiety 
at the secondary amine function yielded Ki values in micromolar range (Ki = 15,000 and 
1,100 nM, respectively).118 
The introduction of halogen atom into position 3 resulted in improved affinity (Ki = 1.5 – 2.5 
nM), the rank of order for α7 affinity being 3-Cl 39 (Ki = 2.5 nM) < 3-Br 40 (Ki = 2.0 nM) < 3-I 
41 (Ki = 1.5 nM).
118 While all 5-halogen derivatives of cytisine 42 – 44 showed reduced 
affinity for α4β2 receptor compared to the lead 27; in the case of α7 nAChR, only 5-
chlorocytisine 42 binds with lower affinity (Ki = 1,000 nM).
118 The introduction of bromine or 
iodine atoms into the position 5 of the pyridone moiety is favourable for the recognition of α7 
receptor subtype and 5-bromo- and 5-iodo-cytisine 43 and 44 show approximately 10-fold 
higher affinity (Ki = 28 and 21 nM, respectively)
118 compared to the parent alkaloid 27. 
Substitution of both positions with chlorine and bromine (45 and 46) afforded less potent 
ligands (Ki = 1,500 and 1,000 nM), but the same modification with iodine resulted in potent 
α7 ligand 47 (Ki = 41 nM).
118 
Houlihan et al tested brominated and iodinated analogues of cytisine in binding assays with 
SH-SY5Y-hα7 clonal cell lines, which overexpress the human α7 nAChR.148 For the bromo 
analogues 40, 43 and 46, the following rank order of α7 affinities was obtained: 3,5-diBr-cyt 
46 (Ki = 13.50 µM) < 5-Br-cyt 43 (Ki = 10.10 µM) < cyt 27 (Ki = 8.36 µM) < 3-Br-cyt 40 (Ki = 
16 nM).148  3-Iodocytisine 41 (Ki = 7 nM) in the same test system showed a higher affinity 
than cytisine 27, while 5-iodo analogue 44 exhibited the α7 affinity of cytisine 27 (Ki = 8 
µM).147 
Nitro analogues of cytisine showed different affinities for α7 receptor. While 3-nitrocytisine 58 
inhibited the binding of [3H]MLA with Ki of 40.7 nM, 5-nitrocytisine 59 showed affinity in 
micromolar range (Ki = 12,000 nM).
183 
Hydrogenation of double bonds and oxygen-sulphur exchange are detrimental for binding to 
α7 nAChR. However, the micromolar affinity of thiocytisine 51 for α7 (Ki = 4,000 nM) makes 
the bioisosteric lactam 51 the most α4β2/α7 selective ligand.118  Halogenation of thiocytisine 
51 in position 3 significantly improves the affinity for [3H]MLA binding sites (Ki = 48 and 50 
nM for 3-bromothiocytisine and 3-chlorothiocytisine, respectively) not only compared to 
thiocytisine 51 (Ki = 4,000 nM) but also to cytisine 27 (Ki = 261 nM).
183 The introduction of a 
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bulky 4-fluorophenyl moiety into the position 3 resulted in a ligand with low α7 binding affinity 
(Ki = 3,462 nM).
125 
In the series of all-carbon cytisine derivatives 57, the compounds bearing fluorine 57c (R1 = 
F), 57d (R2 = F) as well as difluoro analogue 57i (R1 = R2 = F) displaced [125I]-αBgt with a 
significantly higher affinity (Ki = 350 – 830 nM) than cytisine 27 did in the same test system 
(Ki = 4,200 nM).
185 Other analogues (e.g. 57e, R2 = OMe) tested for their α7 affinity also 
showed a higher binding to the α7 nAChR subtype (Ki = 2,400 nM) than the lead 27.
185 
The SAR of cytisine 27 analogues for the α7 subtype is summarized in the Figure 3-4. 
 
NH
N
O
5-substitution (Cl, NO2)  decreases affinity
N-substitution causes 
dramatic loss of affinity
oxygen-sulphur exchange not tolerated
  
hydrogenation of double
bonds poorly tolerated 
substitution with substituted pyridine moiety
                reduces affinity
5-substitution (I > Br) increases affinity
3-halogenation increases affinity
              Cl ~ Br ~ I
 NO2 group decreases affinity
 
 
Figure 3-4 SARs for cytisine 27 analogues at α7 nAChR 
 
 
SAR for α3β4 nAChR subtype  
 
Cytisine 27 binds to [3H]epibatidine labelled binding sites in pig adrenals with Ki = 19 nM.
183 
The rate of the decreased α3β4 affinity via N-substitution depends on the bulkiness of the 
substitutent, e.g. Ki = 1,500 nM for caulophylline 53 vs. Ki = 5,500 nM for N-benzylcytisine.
183  
Halogenation of position 3 leads to an increase of binding affinity, the rank of order being 
cytisine 27 (Ki = 19 nM) < 3-Cl-cyt 39 (Ki = 1.1 nM) < 3-Br-cyt 40 (Ki = 0.61 nM) < 3-I-cyt 41 
(Ki = 0.35 nM).
183 Identical rank was obtained for 5-halogenated analogues 42 – 44 {cyt 27 
(Ki = 19 nM) < 5-Cl-cyt 42 (Ki = 14.3 nM) < 5-Br-cyt 43 (Ki = 5.0 nM) < 5-I-cyt 44 (Ki = 3.25 
nM)}.183 
Introduction of the nitro group into position 3 yields ligand 58 with affinity (Ki = 12 nM) nearly 
identical to the affinity of the parent alkaloid 27. Nitro group in the position 5 significantly 
reduces binding to the α3β4 protein (Ki = 1,000 nM for 59) compared to the affinity of cytisine 
27 (Ki = 19 nM).
183 
40Project I: Cytisine as a lead compound 
 
Hydrogenation of the double bond in the pyridone moiety (compound 52) as well as 
bioisosteric replacement of oxygen by sulphur (compound 51) leads to compounds with 
lower α3β4 affinity (Ki = 385 nM and 632 nM, respectively) than that of the parent alkaloid 
27.183 
Selected all-carbon cytisine derivatives 57 (for structure see Table 3-3) have been tested for 
their affinity to the α3β4 nACh receptor expressed in IMR32 cells.185 In this assay, cytisine 27 
displaced [3H]epibatidine with Ki value of 840 nM and only two compounds showed lower 
binding affinity (Ki = 340 and 710 nM for  57f (R2 = NO2) and 57d (R2 = F), respectively). 
Derivatives 57e (R2 = OMe) and 57i (R1 = R2 = F) bind to α3β4 nAChR with the same 
affinity as cytisine 27 (Ki = 810 nM).
185 
The structure-activity relationship of cytisine 27 analogues for the α4β3 nAChR subtype is 
summarized in Figure 3-5. 
NH
N
O
N-substitution causes 
dramatic loss of affinity
oxygen-sulphur exchange not tolerated
  
hydrogenation of double
bonds not tolerated substitution with NO2 group reduces affinity
  5-substitution increases affinity
                  Cl < Br < I
3-substitution increases affinity
              Cl < Br < I
substitution with NO2 group reduces affinity  
Figure 3-5 SARs for cytisine 27 analogues at α3β4 nAChR 
 
 
SAR for (α1)2β1γδ nAChRs 
 
Cytisine 27 possesses micromolar affinity to the nAChRs at the neuromuscular junction (Ki = 
1,300 nM).183 All modifications introduced into the structure of 27 led to ligands with reduced 
affinity (Ki > 1,300 nM), except for halogenation of position 3. While 3-chlorocytisine 39 
shows affinity (Ki = 1,332 nM) identical with the affinity of cytisine 27, 3-bromo- and 3-iodo- 
analogue 40 - 41 with Ki = 627 and 413 nM, respectively, are more potent ligands for muscle 
nACh receptors than the parent alkaloid 27.183  
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3.2 Syntheses of Novel nAChRs based on Cytisine  
 
The method of choice for the synthesis of novel nAChRs ligands was the Suzuki cross-
coupling reaction carried out under microwave accelerated conditions. This choice can be 
rationalised firstly with the fact that the Suzuki reaction (palladium-catalysed cross-coupling 
of arylhalides and organoboron compounds in the presence of a base) is one of the most 
versatile cross-coupling reactions used in modern organic synthesis for creating C-C bonds. 
Secondly, heating and driving chemical reactions by microwave energy has recently been 
reported to dramatically reduce the reaction time (from days and hours to minutes and 
seconds) of various chemical reactions, including the Suzuki cross-coupling reaction. 
 
3.2.1 Suzuki Cross-Coupling Reaction  
 
Suzuki reaction186 together with Grignard187, Stille188, Hiyama189 or Sonogashira190 reactions 
(named after the pioneers in the field) build a group of reactions termed as “cross-couplings” 
(Scheme 3-5). These reactions are based on transmetallation of organometallic nucleophiles 
and share many mechanistic aspects, although some differences exist in the activation of the 
organometallic nucleophile. The Suzuki (or Suzuki-Miyaura) coupling of organoboron 
compounds has been recognised after more than three decades of intensive research (first 
papers describing these reactions appeared at the end of the 1970s and at the beginning of  
the 1980s) as the most general and selective palladium-catalysed cross-coupling reaction.191 
Heck reaction192 or “coupling process” differs from the family of “coupling reactions” as the 
transmetallation step is absent in the Heck reaction. In the arylation/alkenylation of olefins, 
the C-C bond is formed by an addition-elimination mechanism, i.e. the addition of ArPdX (X = 
halogen or triflate) is followed by the elimination of HPdX to form the substituted alkene 
product.193  
In 1979, Suzuki reported that cross-coupling reactions between alkenylboranes and 1-alkenyl 
halides are effectively catalysed by tetrakis(triphenylphosphine)-palladium [Pd(PPh3)4] in the 
presence of a base and water.186a,b This publication started the historical period of “Suzuki 
reaction” which attracts as much attention today as it did at the beginning. Nowadays, the 
Suzuki cross-coupling reaction is not limited only to the formation of C(sp2)-C(sp2) bonds but 
also C(sp3)-C(sp3), C(sp2)-C(sp3) or C(sp)-C(sp2) bonds can be formed using the Suzuki 
protocol under carefully selected reaction conditions. The need of a base due to the 
activation of the low nucleophilicity possessing organoborane is the most noteworthy 
difference between Suzuki cross-coupling and all other cross-coupling reactions.191c  
 
42Project I: Suzuki cross-coupling reaction 
 
X
X = Hal, triflate
+ Pd(0)
R
R
R
R
R
R Mg Br
R H
R Sn(n-Bu)3
R SiMe3
R
R
R B(OH)2
Grignard
Stille
Sonogashira
Hiyama
Suzuki
Heck
 
Scheme 3-5 Cross-coupling reactions [Ref. 186 – 192] 
 
3.2.1.1 Mechanism 
 
A catalytic cycle for the cross-coupling reaction of organoboron compounds with organic 
halides  (iodides, bromides and electron deficient chlorides) and organic triflates follows a 
general catalytic cycle of organometallics, involving: (A) oxidative addition of organic halides 
or other electrophiles to a palladium(0) complex yielding R1-Pd(II)-X 60; (B) transmetallation 
between R1-Pd-X and R2-B(OH)2 with the aid of bases affording R1-Pd(II)-R2 61; and (C) 
reductive elimination of R1-R2 62 to regenerate the palladium(0) complex (Scheme 3-6).
191  
The oxidative addition of organic electrophiles R1X to Pd(0) complex affords a stable trans-
palladium(II) complex 60. The first step of the cross-coupling reaction takes place usually by 
aromatic nucleophilic substitution (SN2 reaction). Oxidative addition is reported to be the rate-
determining step in the catalytic cycle and the order of reactivity of electrophilic partners has 
been established as I >> OTf ~ Br >> Cl. Electron-withdrawing substituents on aryl and 1-
alkenyl halides lead to rate acceleration.191 
The transmetallation involves nucleophilic displacement of R1-Pd(II)-X 60 with the borate 
complex [R2B(OH)3]M 63, yielding R1-Pd(II)-R2 61, B(OH)3 and MX.
191c 
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Pd(0) R1X
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R1-Pd(II)-X  60
R2-B(OH)2 + baseB(OH)3
R1-Pd(II)-R2  61
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(B) transmetallation
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Scheme 3-6 Catalytic cycle of Suzuki cross-coupling reaction [Ref. 191] 
 
Due to the low nucleophilicity of the borane reagents (compared with organostannanes, for 
example) the Suzuki reaction requires the use of a base in order to take place. The essential 
role of the base is to generate a more reactive borate complex by coordination of the 
hydroxide ion to the boron. The quarterization of the boron atom with a negatively charged 
base enhances the nucleophilicity of the organic group on the boron atom, and the 
corresponding “ate” complex easily undergoes the coupling reaction with R1-Pd(II)-X 60.
191c 
Reductive elimination of organic partners from R1-Pd(II)-R2 61 yields the desired product R1-
R2 62 and reproduces the palladium(0) complex.
194 The reaction takes place directly from cis-
isomer, the trans-isomers react after their trans-cis isomerization to the corresponding cis-
complex.191a  
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3.2.1.2 Reaction Conditions 
 
The nature of the organoborane, the aryl, vinyl or alkyl halide, the palladium catalyst and the 
base significantly influence the yields of products and formation of byproducts. 
 
3.2.1.2.1 Palladium Catalyst  
 
The most commonly used catalyst is [Pd(PPh3)]4. Freshly synthesized, this catalyst is a 
bright-yellow crystalline powder, which darkens over time and with exposure to air and 
temperatures above 0°C, leading to a decreased activity of the catalyst.195 [Pd(PPh3)]4 is 
commercially available and some chemical suppliers provide this catalyst in good quality. 
Another catalyst employed in Suzuki cross-coupling reaction is PdCl2(PPh3)2, which is 
reduced in situ to the reactive palladium(0) species.196 Although this catalyst is air and 
temperature stable and less expensive than [Pd(PPh3)]4, it has been used in smaller extents.  
The addition of a phosphine ligand to [Pd2(dba)3], [Pd(dba)2] or Pd(OAc)2 is an alternative 
method for preparing analogous palladium(0)/phosphine catalyst.191c  
 
3.2.1.2.2 Base 
 
A carefully selected base is essential for a successful Suzuki cross-coupling. The “standard” 
Na2CO3 is effective for a variety of coupling reactions, but it is not suitable for alkyl and 
alkynyl coupling or for reactants that are sterically hindered. For example, the reaction of 
mesitylboronic acid with iodobenzene shows the following rate of reactivity: TlOH > Ba(OH)2, 
Tl2CO3 > NaOH > Cs2CO3, K3PO4 > Na2CO3 > NaHCO3.
197 Thallium salts have been 
successfully used also in the alkyl-aryl or alkyl-vinyl coupling reactions.198 It is acknowledged 
that Cs2CO3 in the presence of water accelerates the coupling reaction carried out at room 
temperature.199 Stronger bases such as NaOH, TlOH and NaOMe were shown to perform 
well in THF/H2O solvent systems, whereas weaker bases such K2CO3 and K3PO4 were more 
successful in DMF.200,209  
The different effect of a base can be explained with different stability constant of counter 
cations for halide and hydroxide anions.  The base has been proposed to be involved in 
several steps of the catalytic cycle, but most notably in the transmetallation process, whereas 
the most essential role of the base is the conversion of the boronic acid into the more 
reactive borate species 63 (Scheme 3-7).210a 
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R2B(OH)2 + MOH
R1-Pd(II)-X R1-Pd(II)-R2 + B(OH)3 + MX
[R2B(OH)3]M  6360 61
 
Scheme 3-7 The role of a base in the transmetallation process [Ref. 201] 
 
The concentration of the hydroxyborate complex [R2B(OH)3]M 63 exists in an alkaline 
solution in equilibrium with a free boronic acid and increases by increasing the basic strength 
(OH- > MPO4
- > MCO3
- > HCO3
-).201 Furthermore, the stability constant of cations for OH- 
becomes smaller when moving down the periodic table (Cs+ < K+ < Na+ < Li+).201 Thus, 
cesium bases yield a higher concentration of [R2B(OH)3]Cs than do the smaller alkali. 
Additionally, the transmetallation step is faster when bases with counter cations of a high 
stability constant for halide anions (Ag+ > Tl+ >> Ba2+ > Cs+ > K+) are employed. 202 
As the presence of water greatly accelerates the reaction203, aqueous solutions of bases 
(e.g. 2 M Na2CO3) or hydrated bases (e.g. K3PO4*3H2O) are employed in the Suzuki cross-
coupling reaction.  
 
3.2.1.2.3 Organoboron Coupling Partner 
 
The advantages of organoboron reagents are their high selectivity in cross-coupling 
reactions and the tolerance of functional groups on either coupling partners (hydroxy, amino, 
nitro, phenyl, ester, ketone, cyanide, aldehyde groups).191,210a In addition, they are in general 
thermally stable and inert to water and oxygen, thus allowing handling without special 
precautions.191 The great variability of commercially available organoboron reagents makes 
the Suzuki reaction very attractive for the lead modification. 
It has been confirmed that all kinds of carbon-boron bonds, i.e. (sp3)C-B, (sp2)C-B and (sp)C-
B, can be employed as cross-coupling partners in coupling reactions. However, (sp2)C-B 
derivatives remain the most used boron coupling partners.  
Preparation and Coupling of Aryl- and Alkenylboron Derivatives 
The classical synthesis of aryl- and 1-alkenylboronic acids or esters is the transmetallation of 
Grignard or lithium reagents to alkoxyborates. Subsequent treatment of the alkoxyborates 
with aqueous acid provides arylboronic acids (Scheme 3-8/A).204 Arylboronic esters can be  
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Scheme 3-8 Synthesis of (sp2)C-B organoboron reagents [Ref. 204 – 206] 
 
directly synthesized via cross-coupling of aryl halides/triflates with (alkoxy)diboron 
compounds (Scheme 3-8/B).205 Hydroboration of a terminal alkyne with catecholborane 
produces 1-alkenylboronic ester (Scheme 3-8/C).206 
 
Preparation and Coupling of Alkynylborane Derivatives 
Sonderquist et al. reported that alkynyl(methoxy)borates 64 prepared in situ from an 
alkynyllithium and the B-methoxy-9-borabicyclo[3.3.1]nonane 65 (B-methoxy-9-BBN) are 
stable complexes that couple with 1-alkenyl (R2-X) and aryl halides (ArX) (Scheme 3-9/A).207 
An analogous reaction of an allylboronate complex 66 with arylhalides (ArX) affords 
allylarenes in high yields (Scheme 3-9/B).208 
 
B OMe R1 R2
R1 Li
B Ar
CH2
R2-X or ArX
PdCl2(dppf)
THF, reflux
ArX
PdCl2(dppf)
THF, reflux
NaOMe B
OMe
-
B R1
OMe
-
A
B
65
64
66  
Scheme 3-9 Preparation and cross-coupling reaction of alkynyl 64 and allyl boron reagent 66  
[Ref. 207, 208] 
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Preparation and Coupling of Alkylboron Derivatives 
Hydroboration of terminal alkenes with 9-borabicyclo[3.3.1]nonane 67 (9-BBN) is the most 
convenient method to furnish the desired alkylboron reagents 68209, which are highly 
sensitive to air, but they can be used directly for subsequent coupling reaction without 
isolation (Scheme 3-10). 
R BH B
R
ArX
Pd catalyst 
    base
R
Ar
+
67 68  
Scheme 3-10 Preparation and coupling of C(sp3) organoboron reagent 68 [Ref. 209] 
 
The tendency of the alkyl-palladium complex to undergo β-hydride elimination instead of 
reductive elimination can be prevented with the right choice of the catalyst, base and solvent. 
The most used ligand for alkyl-alkenyl, alkyl-aryl and alkyl-alkyl coupling is [PdCl2(dppf)] or 
[PdCl2(dppf)]/AsPh3 and the use of aqueous base or hydrated inorganic bases (e.g. 
K3PO4*nH2O) is recommended.
199 Solvents such as THF, DMF, dioxane or toluene are 
usually employed. 
The connection of two fragments via the hydroboronation-cross-coupling sequence has 
found a wide range of applications in the synthesis of natural products.210a Danishefsky et al. 
have reported a total synthesis of the promising anticancer agent (-)-epothilone B using B-
alkyl Suzuki-Miyaura coupling method as shown in Scheme 3-11 and a sister compound 
epothilone A was synthesized by a similar procedure.210b-e The key step is the 
hydroboronation of terminal alkene 69 which is directly followed by cross-coupling with 
iodoalkene 70 to furnish the desired cis-alkene 71. 
Me
OTBS
Me
OTPS
OMe
MeO
R
OAc
H
Me
OTBS
Me
OTPS
OMe
MeO
S
N
R I
OAc
S
N
H
epothilone A
epothilone B
9-BBN
THF
RT, 5 h
PdCl2(dppf) / AsPh3
DMF / H2O, RT, 3 h
69
70
71
 
Scheme 3-11 Hydroboronation-cross-coupling sequence in the synthesis of the cytotoxic agents 
epothilone A and epothilone B [Ref. 210a-e] 
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3.2.1.2.4 Organic Halides / Pseudohalides as Coupling 
Partners 
 
Aryl and alkenyl halides or triflates are mostly employed in the Suzuki coupling. Alkyl halides 
are not common substrates for the Suzuki reaction due to their slow rate of oxidative addition 
and their fast β-hydride elimination from the derived palladium intermediate. However, under 
the right conditions, alkyl halides will also react with organoboron coupling partners (see 
below).   
Coupling of Aryl Halides 
Aryl halides often used in the Suzuki reaction are bromides and iodides. Arylchlorides do not 
participate in the coupling reaction, except when used in conjugation with electron-deficient 
groups.191a  
The first observed method to prepare biaryls is shown in Scheme 3-12.186c Various 
modifications (base, catalyst, solvent) of Suzuki protocol have been reported, but it can be 
concluded that the “standard” Suzuki conditions (Pd(PPh3)4/aq.Na2CO3/DME) work 
satisfactorily in most cases. The reaction is successful for aryl triflates, iodo- and 
bromoarenes and some of pi-deficient heteroaryl chlorides.191a 
 
B
OH
OH
Br
CH3 CH3
Pd(PPh3)4
aq. Na2CO3
benzene, reflux
+
 
 
Scheme 3-12 First biaryl Suzuki cross-coupling reaction [Ref. 186a] 
 
Noteworthy improvements of biaryl coupling during the years of investigation are e.g. Suzuki 
coupling of extremely sterically bulky boronic acid with halopyridines in non-aqueous solvent 
with potassium t-butoxide giving the best result among the bases examined211, ambient 
temperature Suzuki-type biaryl coupling212, “ligandless” Pd(OAc)2-catalysed biaryl formation 
in water in the presence of tetrabutylammoniumbromide (TBAB)213 or synthesis of axially 
chiral biaryls.214 
Coupling of Alkenyl Halides 
Cross-coupling reactions of 1-alkenylboron compounds with 1-alkenyl halides afford 
stereodefined dienes, trienes and further conjugated polyenes. 1-alkenylboronic acids couple 
with iodoalkenes when relatively strong base (TlOH > NaOH > K3PO4 > Na2CO3 > NaOAc)
215 
and a phosphine-based Pd-catalyst (Pd(PPh3)4 or PdCl2(PPh3)2) are employed.
216 Thallium 
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hydroxide is an excellent base that enables completion of the alkenyl-alkenyl coupling within 
few hours even at room temperature.217 The protocol has been successfully used for a 
number of syntheses of natural products, including (-)-bafilomycin A.218  
Coupling of Alkyl Halides 
Iodoalkanes were reported to react with alkyl boranes in the presence of K3PO4 and catalytic 
amounts of tetrakis(triphenylphosphine)palladium. The reaction was performed in dioxane 
and generated corresponding coupling products in moderate to good yields (45% – 71%). 
PdCl2(dppf) did not act as an efficient catalyst in this protocol.
210a  
Coupling of Triflates 
Triflates (trifluoromethanesulphonates) have been discovered to undergo cross-coupling with 
organoboron compounds in the same way as coupling with organostannanes, aluminium or 
zinc compounds.219 The triflates are easily accessed from phenols or carbonyl enolates.220 
Catalysts such as PdCl2(dppf) or Pd(PPh3)4 and powdered K3PO4 suspended in THF or 
dioxane result in successful coupling of triflates with arylboronic acids.191  
 
3.2.2 Suzuki vs. Stille Cross-Coupling Reaction 
 
Palladium-catalysed cross-coupling of organotin reagents with organic electrophiles, alias 
Stille reaction221, is shown in the Scheme 3-13. This reaction is very similar to the Suzuki 
cross-coupling, but alkyltin reagents are used instead of boronic acids. 
 
Sn
R1R
R
R
R2
X
R1
R2
Sn
XR
R
R
Pd0
+
R2 = aryl, vinyl
R   = Me, n-Bu
R1 = alkyl, aryl
+
product unwanted byproduct
 
Scheme 3-13 Stille cross-coupling reaction [Ref. 221] 
 
Catalytic cycle of Stille coupling follows the one of the Suzuki coupling, i.e. the first step is 
oxidative addition of R2-X to the active palladium species (PdL2) to give R2-PdL2-X, followed 
by transmetallation to give R1-PdL2-R2 and finally reductive elimination to give R1-R2.
222 
This catalytic cycle performs well in THF, HMPA223, NMP222 or in ionic liquids224. Pd(PPh3)4 is 
referred to as “traditional favourite”, while PdCl2(PPh3)2 is the “traditional” catalyst.
222 Addition 
of CuCl or LiCl to Pd(PPh3)4 or ZnCl2 to PdCl2(PPh3)4 was reported to increase yields of the 
coupling reactions.225  
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Stille cross-coupling is a very flexible and versatile chemical reaction as organotin coupling 
partners can be synthesized from any bromine involving organic compound. Recently, this 
reaction has attracted many chemists working on the total synthesis of natural products.226 
For example, a stannylpyridine 72 was used in the key step of the synthesis of (±)-
epibatidine 19 (Scheme 3-14).227  
N
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1. n-BuLi, -78°C, THF
2. n-Bu3SnCl, -78°C
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I
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PdCl2[P(o-tolyl)3]2
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Scheme 3-14 Stille cross-coupling in the total synthesis of (±)-epibatidine 19 [Ref. 227] 
 
However, it is important to point out, that the organotin compounds are highly toxic and the 
presence of the organotin residue (“unwanted byproduct”) hampers the purification of the 
desired product, since the separation of tin compounds present in the reaction mixture is 
rather difficult. An ideal reaction system would be one in which the product can be obtained 
free from byproducts, but such a system has not been reported so far.   
On the other hand, organoboron reagents employed in the Suzuki reaction are non-toxic, 
commercially available and coupling products can be obtained in very high purity, given that 
the right purification methods are applied (e.g. high performance liquid chromatography). 
 
3.2.3 Suzuki Reaction in Microwave Assisted Organic 
Synthesis 
 
Traditionally, organic synthesis is carried out by conductive heating with an external heat 
source (oil bath). This is a comparatively slow and inefficient method for transferring energy 
into the system since it depends on the thermal conductivity of various materials that must be 
penetrated. In 1986, two independent groups reported accelerating effects of microwaves in 
the organic synthesis228, but the research in this field had not boomed until the late 1990s. 
The use of domestic microwave appliances was lacking the control of temperature and 
pressure, meaning that the risk of flammability of organic solvents was high. Besides, results 
obtained in “kitchen” microwave ovens had very low reproducibility. The introduction of 
microwave reactors designed for organic synthesis with efficient temperature and pressure 
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control system did not only increase the safety of microwave synthesis in the laboratories, 
but also led to reproducible synthetic conditions. As expected, this resulted in a real 
“microwave boom” and microwave assisted organic synthesis (MAOS) has attracted a great 
amount of attention in last 5 years, which is documented in several reviews229  and books230. 
Several research groups, e.g. of Hallberg and Larhed (Uppsala University), Leadbeater 
(Kings College, London) or Kappe (Karl-Franzens University, Graz) have demonstrated over 
the past decade that the microwave heating greatly accelerates transition-metal-catalysed 
carbon-carbon bond forming, including the Suzuki cross-coupling reaction. 
 
3.2.3.1 Microwave 
 
A microwave is a form of electromagnetic energy in the frequency range of 0.3 to 300 GHz. 
All domestic “kitchen” microwaves and all microwave reactors used for industrial, scientific or 
medical applications operate at a frequency of 2.45 GHz (which corresponds to a wavelength 
of 12.24 cm) to avoid interference with telecommunication and cellular phone frequencies. 
Microwaves move at the speed of light (300,000 km/sec) and the energy of microwave 
photon in this frequency region is 0.037 kcal/mole.229,230  This energy is very low compared to 
the typical energy required to break chemical bonds (80-120 kcal/mole), thus it is clear that 
microwaves cannot affect the structure of an organic molecule and induce a chemical 
reaction.231,232  
 
3.2.3.2 Microwaves as a Heating Source in Organic Synthesis 
 
Although some chemical reactions proceed under ambient conditions, in most cases the 
organic synthesis is carried out at high temperature and the definition from the chemistry 
dictionary233 of N. Macquer edited in 1775 “All the chemistry operations could be reduced to 
decomposition and combination; hence, the fire appears as an universal agent in chemistry 
as in nature” is still valid.  
The conventional heating source - the oil bath - produces slow conductive heating, i.e. the 
heat is driven into the substance passing through the walls of the vessel in order to reach the 
solvents and reactants and it is dependent on the thermal conductivity of materials that have 
to be penetrated. Until the thermal equilibrium is achieved, the temperature of the vessels is 
higher than the temperature of the reaction mixture and overall, the control of the chemical 
reaction is rather difficult.230a   
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Figure 3-6 Schematic presentation of heating the reaction mixture with microwaves [Ref. 230a] 
 
In contrast, microwave irradiation generates efficient internal heating by direct coupling of 
microwave energy with the molecules (solvents, reagents, catalysts) that are present in 
reaction mixture. Because this process does not depend on the thermal conductivity of the 
vessel materials, the result is an instantaneous localised superheating of any molecule that 
couples with microwaves (Figure 3-6). 234   
The electric component of the electromagnetic field of the microwave causes heating by two 
main mechanisms – dipole rotation (dipolar molecules rotate to align themselves with the 
fluctuating electric field of the microwave) and ionic conduction (migration of dissolved ions 
with the oscillating electric field).229,230 
The ability of a particular substance to heat under microwave irradiation conditions is 
dependent upon two factors. The first one is the efficiency with which the substance absorbs 
the microwave energy, described by dielectric constant ε´, also known as the relative 
permittivity, a value dependent on both temperature and frequency. The second factor is the 
efficiency with which the absorbed energy can be converted to heat, described by the loss 
factor ε´´.  The ability of a specific substance to convert electromagnetic energy into heat at a 
given frequency and temperature is determined by loss tangent or tangent delta (tan δ). It is 
expressed as the tangent of the ratio of the loss factor and the dielectric properties (Eq. 1).235 
tan δ = ε´´ / ε´     (Eq. 1) 
 
Solvents with a high tan δ value efficiently absorb the microwave energy and will, therefore, 
provide rapid heating. The loss factors for some common organic solvents are summarised 
  
Reactants-solvent mixture  
(absorbs microwave energy) 
  
Vessel wall is transparent to 
microwave energy 
Localised  
superheating 
Microwave energy 
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Table 3-4 Loss tangent (tan δ) of different solvents, measured at 2.45 GHz and 20°C*  
 
Solvent tan δ Solvent tan δ 
high absorbing  > 0.5 DMF 0.161 
ethylene glycol 1.350 1,2-dichloroethane 0.127 
ethanol 0.941 water 0.123 
DMSO 0.825 chlorobenzene 0.101 
2-propanol 0.799 low absorbing < 0.1 
formic acid 0.722 chloroform 0.091 
methanol 0.659 acetonitrile 0.062 
nitrobenzene 0.589 ethyl acetate 0.059 
1-butanol 0.571 acetone 0.054 
medium absorbing 0.5 – 0.1 tetrahydrofuran 0.047 
2-butanol 0.447 dichloromethane 0.042 
1,2-dichlorobenzene 0.280 toluene 0.040 
NMP 0.275 hexane 0.020 
acetic acid 0.174   
 *) Data from Ref. 230a 
 
in Table 3-4. In general, solvents can be divided into three groups: high (tan δ > 0.5), 
medium (tan δ 0.1 – 0.5) and low microwave absorbing (tan δ < 0.1). Less polar or non-polar 
solvents, such as carbon tetrachloride, benzene and dioxane, are more or less microwave 
transparent. However, the addition of polar substances/mediums (e.g. fluid salts or ionic 
liquids) significantly increases the absorbance level of the reaction environment.230a  
Some microwave-enhanced reactions have produced different products than the 
conventionally heated counterpart synthesis carried out at the same temperature.  These 
findings have led to speculation on existence of “specific” or “non-thermal” microwave 
effects.236 Although this topic has been intensely discussed237, there is a general agreement 
that rate enhancement observed in MAOS is merely due to the superheating effect of 
microwave irradiation. The unique microwave dielectric heating mechanism can rapidly 
superheat solvents at atmospheric pressure above their boiling points (up to 26°C above the 
conventional boiling point) and this cannot be achieved with any conventional heating.229c  
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3.2.3.3 Microwaves in Suzuki Cross-coupling Reaction 
 
High-speed Suzuki coupling carried out under controlled microwave conditions has been 
known for several years. In 1996, Larhed and coworkers238 coupled 4-methylphenyl bromide 
73 and phenyl boronic acid 74 in less than 4 min, showing that microwave irradiation indeed 
shortens reaction times from hours to minutes (Scheme 3-15).  More interestingly, the 
reaction worked smoothly on solid support affording high yields of products.239 
 
 
CH3 Br B
OH
OH
CH3+
73 74
2.8 min 55 W
Pd(PPh3)4, EtOH
DME, H2O
 
Scheme 3-15 First microwave promoted Suzuki reaction [Ref. 238] 
 
A significant advance in Suzuki chemistry has been the observation that the coupling 
reaction can be carried out using water as the solvent in conjunction with microwave heating.  
Water is cheap, readily available nontoxic solvent with a high loss tangent (tan δ) making it 
an excellent solvent for microwave-mediated synthesis. Water as a solvent has been used in 
the synthesis of poly(ethyleneglycol)-esterified biaryls via Suzuki cross-coupling under  the 
“ligandless” (i.e. no ligands such as PPh3 present in the reaction mixture) palladium acetate-
catalysed condition.240 Also Leadbeater and Marco described very rapid, ligand-free 
palladium-catalysed aqueous Suzuki couplings of aryl halides (including chlorides) with aryl 
boronic acids.241 The common drawback of using water as a solvent (limited solubility of 
substrates and stability of metal catalyst in aqueous medium) has been overcome by the use 
of 1.0 equivalent of tetrabutylammonium bromide (TBAB) as a phase-transfer catalyst. The 
addition of TBAB facilitates the solubility of organic substrates and activates the boronic acid 
by formation of [R4N]
+[ArB(OH)3]
-. Under these optimised reaction condition various aryl 
halides were coupled with aryl boronic acids within 5 min (Scheme 3-16).241   
 
R2R1
X
R1
B
OH
OH
R2
+
Pd(OAc)2, TBAB, 
Na2CO3, H2O
MW, 150 - 175°C
     5 min
 
Scheme 3-16 Ligand-free Suzuki reaction with TBAB as an additive [Ref. 241] 
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Deactivated, non-activated and activated aryl chlorides (normally not efficient coupling 
partners) were shown in another study to undergo coupling with boronic acids, when 
microwave energy is used for heating. The reactions were performed in 1,4-dioxane in the 
presence of 2 equivalents of K3PO4.
242 However, microwaves brought the most unexpected 
development in the Suzuki chemistry via a breakthrough discovery by Leadbeater and Marco 
indicating that the “Suzuki reaction takes a naked hot bath”.244 They reported a successful 
coupling of aryl bromides (e.g. 75) and iodides with electron-poor or electron-neutral boronic 
acids (e.g. 74) in the water without a palladium catalyst (Scheme 3-17). The transition-metal-
free aqueous Suzuki-type coupling again utilised 1.0 equivalent of TBAB as an additive, 3.8 
equivalents of Na2CO3 as a base and 1.3 equivalent of corresponding boronic acid.
243 This 
astonishing finding denies the long understanding of the mechanism of aryl-aryl couplings of 
aryl halides in which a transition metal is required to break the strong C(sp2)-X bond. The 
exact mechanism of this novel transformation remains unknown, but there are various 
speculations. One possibility is that the reaction occurred through a radical mechanism.244 
 
Br
COMe B
OH
OH
COMe+
 TBAB, Na2CO3, H2O
MW, 150°C, 5 min
75 74  
Scheme 3-17 Transition-metal-free Suzuki-type coupling [Ref. 243] 
 
In summary, the beneficial impact of microwave irradiation on Suzuki coupling (shorter 
reaction time, higher yield and cleaner reaction environment) has been well established and 
the use of microwaves in the organic synthesis is limited only to the high equipment costs. 
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3.2.4 Isolation of Cytisine 
3.2.4.1 Introduction 
 
In Europe cytisine 27 may be easily isolated from seeds of Laburnum anagyroides medicus 
(Fabaceae)182,184,245 known as “Goldregen” in Germany. This bushy plant or small tree 
contains the highly toxic alkaloid 27 with the greatest amount found in black seeds.  
Protocols describing the extraction of cytisine 27 from the seeds of L. anagyroides follow the 
general method of alkaloids isolation and vary basically only in the type of solvent or 
acid/base used (Table 3-5). The yields of the isolation alter (0.1% to 1.8% reported in the 
literature)182,184,245 and cannot be taken as a consequence of the chosen method of isolation. 
The content of cytisine 27 is believed to be influenced by the age of the plant and climatic 
conditions. Additionally, L. anagyroides has been often replaced by hybrid Laburnum x 
watereri, with a significantly lower amount of the main alkaloid 27, in order to prevent 
intoxication by cytisine 27.143 
Table 3-5 Selected procedures used for cytisine 27 extraction from Laburnum anagyroides as 
reported in the literature [Ref. 182, 184, 245] 
 
Bojadshiewa et 
al.245 
Marriére et al.184 Klaperski182 
seeds dissolved in perchlorethylene CH2Cl2 /MeOH CHCl3 
 
alkalization 
 
10% NH4OH 25% NH4OH 10% KOH 
 
acidification 
 
5% H2SO4 0.5 N HCl 1% HCl 
 
alkalization 
 
25% NH4OH 25% NH4OH 10% KOH 
 
extraction 
 
CHCl3 CH2Cl2 CH2Cl2 
 
flash chromatography 
 
--- 
CH2Cl2/MeOH/NH4OH 
85 : 15 : 1 
CHCl3/MeOH 
5 : 1 
recrystallization 
 
perchlorethylene 
 
 
--- --- 
 
3.2.4.2 Method / Results 
 
The enantiopure cytisine 27 needed for further synthesis was isolated from the seeds of 
Laburnum anagyroides and watereri, collected in the Köln/Bonn area during September and 
October. Air-dried plant materials were extracted with a mixture of dichloromethane, 
methanol and 25% ammonia through Ultra-turrax homogenization. The extracts were 
concentrated under reduced pressure and extracted with 1M hydrochloric acid. The aqueous 
acid solution was made alkaline with ammonium hydroxide and extracted at least 10 times 
with dichloromethane. The organic solvent was evaporated in vacuo and the brown thick 
                                                                                           Project I: Syntheses of novel ligands57 
 
 
residue was chromatographed on a silica gel column using mixture of chloroform and 
methanol as a mobile phase. Recrystallization from perchlorethylene afforded cytisine 27 as 
light yellow crystals (0.11% – 0.48%), which was used for spectroscopic analysis and further 
synthesis.  
3.2.4.3 Discussion 
 
This isolation protocol was based on the procedure published by Marriére et al184, however it 
was modified at few steps. The time of ultra-turrax homogenization and subsequent 
maceration was extended from 1 hour to 8 hours and 1 M hydrochloric acid was used for 
acidification. For the flash chromatography a mixture of CHCl3/MeOH was used. However, in 
this way obtained cytisine 27 did not possess satisfying purity and more purification steps 
were required. Recrystallization from perchloroethylene afforded cytisine 27 as light yellow 
crystals in 0.11% – 0.18% yields. Much higher yields were achieved when seeds were 
separated from their pouches before the actual extraction (0.27% – 0.48%). Seeing that 
perchlorethylene is a highly toxic solvent, circumvention of its usage was necessary. 
Therefore, the recrystallization was replaced by high performance liquid chromatography 
(HPLC) purification of the N-protected cytisine, i.e. cytisine 27 obtained after flash 
chromatography was directly used in the next step (the protection of the bispidine nitrogen) 
and purified with HPLC (see Chapter 3.2.5).  
 
3.2.5 Protection of the Secondary Amino Group of Cytisine  
3.2.5.1 Introduction  
 
The lone electrons pair on the amino group may be easily protonated and is generally 
reactive towards electrophiles. In order to decrease the reactivity of this functional group, it is 
usually converted to an amide or a carbamate, since the carbonyl group effectively withdraws 
electron density from the nitrogen and renders it unreactive.246  
Many amine protecting groups of the carbamate (-NCOOR) or of the amide (-NCOR) type 
have been developed.  tert-Butoxycarbonyl (tBOC) protective group is an example of 
protecting groups of carbamate type and is widely used for protection of secondary amines. 
tert-Butoxycarbonyl group is introduced with reagents such as di-tert-butoxycarbonate247 or t-
BOC-azide248. tBOC protective group is not hydrolysed under basic conditions and is inert to 
many nucleophilic reagents.249 These characteristics make t-butyl carbamate a perfect 
protective group of the secondary amine in cytisine 27, which is later employed in the Suzuki 
reaction, carried out in the presence of a base and with nucleophilic organoboron coupling 
partners.  
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The synthesis of N-tBOC-cytisine 76 had been reported and provided useful information for 
fast and efficient synthesis of the N-protected alkaloid 76.124,125 The protection was performed 
with di-tert-butoxycarbonate in a presence of aqueous sodium carbonate solution, THF or 
dichloromethane were used as solvents. The reaction times differ extremely – the protection 
was quantitative after 48 hrs, when THF was employed125 and after 90 min, when 
dichloromethane was used124. Other protecting groups (-NO, -COOMe) for the secondary 
amine of cytisine 27 were reported as well.184  
3.2.5.2 Method / Results 
 
N-tBOC-protected alkaloid 76 from crystalline cytisine 27 was easily prepared by employing 
1.2 eq of di-tert-butylcarbonate and sodium carbonate (Scheme 3-18). The product was 
recrystallised from petroleum ether and obtained in high yields (77% – 90%).  
    Na2CO3, CH2Cl2, H2O
             60°C, 2h
             77 - 90 %
di-tert-butylcarbonate
NH
N
O
27
N
N
O
O
CH3
CH3
CH3
O
76
 
Scheme 3-18 Synthesis of  tBOC-protecting cytisine 76 
 
In the second method, the introduction of the protecting group was part of the 
isolation/purification process. Herein, cytisine 27 obtained after flash chromatography was 
dissolved in dichloromethane and treated with an excess of aqueous sodium carbonate and 
di-tert-butyldicarbonate at reflux temperature. The reaction was monitored by TLC in order to 
achieve quantitative substitution. The N-protected alkaloid 76 was purified with HPLC using 
isocratic methanol/water mixture (60:40 v/v) on a reverse phase C18 (RP-C18) column (tr = 
6.9 min). The combined aqueous fractions of product were concentrated under reduced 
pressure and the remaining solvent (i.e. water) was removed by lyophilization for at least 24 
hours. The amount of isolated alkaloid 27 was calculated from the quantity of N-tBOC-
cytisine 76. Yields represent ratio of cytisine 27 amount to the quantity of plant material 
(1,000 g) and are listed in the Table 3-6. 
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Table 3-6 Amount of cytisine 27 calculated from the amount of N-tBOC-cytisine 76.  Yields 
calculated as the ratio of cytisine 27 quantity to the amount of plant material (1,000 g) 
 
Experiment N-tBOC-cytisine 76 Cytisine 27 Yields 
1 1.80 g ~ 1.18 g 0.12% 
2 1.76 g ~ 1.15 g 0.11% 
3 2.70 g ~ 1.77 g 0.17% 
4 2.30 g ~ 1.51 g 0.15% 
5 2.06 g ~ 1.35 g 0.13% 
 
3.2.5.3 Discussion 
 
Using crystalline cytisine 27, the reaction was performed in dichloromethane with 1.2 eq of 
di-tert-butoxycarbonate and sodium carbonate as a base. The product 76 was recrystallised 
from petroleum ether and obtained in high yields (77% – 90%).  
In order to avoid the use of perchloroethylene (in the isolation step), the brownish cytisine 27 
obtained after flash chromatography was dissolved in dichloromethane and treated with an 
excess of aqueous sodium carbonate and di-tert-butoxycarbonate. The reaction was stopped 
when the quantitative substitution was achieved (monitored by TLC). The N-protected 
alkaloid 76 was purified with HPLC and obtained as white crystalline powder. The yields of 
this isolation/purification process were ranging from 0.11% to 0.17% and were identical to the 
yields of extraction, when perchlorethylene was used for recrystallization (0.11% – 0.18%).  
The results demonstrate that protection of the N-12 as a part of the isolation process 
improved the known conventional methods of cytisine 27 purification. The alkaloid 27 (in the 
N-tBOC- protected form 76) was obtained in the same yields, but in higher purity and without 
using highly toxic solvent.  
 
3.2.6 2-Pyridone Scaffold 
 
Since all of the following chemistry includes modification of the 2-pyridone moiety of the 
cytisine 27, a short review of this structure is given here. Many naturally occurring and 
synthetic compounds contain a 2-pyridone ring and its chemistry is well documented.250-267 
Among the naturally occurring substances which incorporate the 2-pyridone nucleus are e.g. 
ricinine250, fredericamycin A251 and tenellin.252 Camptothecin 77 (Figure 3-7), isolated from 
the tree Camptotheca acuminata Decne (Nyssaceae) possesses antileukemic activity253 and 
its decarboxylated E-ring analogue, mappicine ketone (MPK) was shown to possess potent 
activity against the herpesviruses HSV-1, HSV-2 and human cytomegalovirus.254 The 2-
pyridone ring can be also found in the structure of paraensidimerins 78 (Figure 3-7) and 
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vepridimerins, a large group of dimeric quinoline alkaloids.255 Additional members of this 
group are quinolizidine alkaloids cytisine 27 and anagyrine. 
2-Pyridone scaffold is further present in a specific non-nucleoside reverse transcriptase 
inhibitor of human immunodeficiency virus-1 L-697,661 (Figure 3-7)256 or in the structure of 
cardiotonic agents Milrinone 79 and Amrinone 80 displaying selective PDE-3 inhibitor activity 
(Figure 3-7).257 Some 2-pyridones are also reported to be human rhinovirus (HRV) 3C 
protease (3CP) inhibitors.258  3-Aryl-2-pyridone derivatives were designed and tested as 
selective kappa opioid receptor agonists.259 
However, the vast majority of papers discuss synthetic approaches to 2-pyridones253-255,258,260 
and only very few papers involve the Suzuki coupling performed on the pyridone 
moiety.259,262,263,266,267 The latter reactions are discussed together with the coupling reactions 
on the cytisine backbone and are divided into Chapters 3.2.8 and 3.2.9, concerning the 
position of the substitution.  
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Figure 3-7 Structure of pharmacologically interesting compounds possessing 2-pyridone scaffold 
(in red) [Ref. 253, 255 - 257]  
 
 
                                                                                           Project I: Syntheses of novel ligands61 
 
 
3.2.7 Bromination of Cytisine 
3.2.7.1 Introduction 
 
The target molecules - (hetero)aryl analogues of cytisine – were planned to be synthesized 
via a palladium-catalysed Suzuki reaction. In a cross-coupling reaction one coupling partner 
possesses a halide or a pseudohalide while the other coupling partner is an organoboron 
reagent. As the arylboronic acids are commercially available in great variety, only the type of 
halide/pseudohalide that should be introduced into the molecule of N-tBOC-cytisine 76 was 
considered. The synthesis of a triflate derivative requires hydroxyl or carbonyl group193 and 
the introduction of any of them into the structure of cytisine 27 could be a multistep chemical 
challenge.  
Halogenation, e.g. bromination of cytisine 27 offers a simpler, faster route for the preparation 
of a cytisine-derived coupling partner. Bromination can be done with elementary bromine, 
which has an advantage of an easy control of the dosage and the high selectivity.261 
However, elementary bromine is too expensive for technical purposes and has been 
replaced by other bromination agents, such as bromotrichloromethane, t-butylhypobromit or 
N-bromosuccinimide (NBS). NBS is widely used in free radical, allylic or benzylic 
brominations and also for the electrophilic substitution of aromatic rings.261  
Semple et al259a prepared 3-bromopyridone by treatment of 2-pyridone with bromine in KBr 
solution, however in low yields (22%). For the halogenation of the position 5 of 2-pyridone 
scaffold N-bromosuccinimide was employed and the desired product was obtained in 55% 
yields. 3-Bromo and 5-bromopyridone were successfully coupled with a wide range of 
boronic acids under Suzuki conditions.259a 
Bromination of cytisine 27 has been previously reported.118,124,174,182,184 Excess of bromine in 
acetic acid afforded 3,5-dibromocytisine 46.174 Similarly, avoiding the introduction of 
protecting groups, monobrominated cytisine derivatives 40 and 43 were prepared by 
treatment of cytisine 27 in aqueous acetic acid with one equivalent of NBS.118,182 Using a 
manifold excess of bromine transfer reagent, 3,5-dibromocytisine 46 predominated.118,182  
Other studies124,184 performed bromination after protecting the secondary amine group of 
cytisine 27. N-protected alkaloid 76 was treated with NBS in different solvents (CH2Cl2, DMF, 
MeCN, H2O/H
+) and the influence of the solvent on the 3-bromo/5-bromocytisine ratio was 
studied. The substitution time was 30 – 90 minutes.  
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3.2.7.2 Method / Results 
 
Bromination of the pyridone ring was carried out with N-bromosuccinimide in 
dichloromethane. Adding one equivalent of NBS, a mixture of two monosubstituted isomers, 
namely 3-bromo-N-tBOC-cytisine 81 and 5-bromo-N-tBOC-cytisine 82 was obtained 
(Scheme 3-19).   
 
N
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N
O
tBOC
Br
 NBS (1 eq)
CH2Cl2, 60°C, 2h
76
81 82
+
38.0 - 51.4 % 28.1 - 42.2 %  
Scheme 3-19 Synthesis of monobrominated analogues of cytisine 81 and 82 
 
The separation of the two regioisomers 81 and 82 was successfully performed with HPLC 
using isocratic MeOH/H2O mixture as a mobile phase. The compounds 81 (38.0% – 51.4%) 
and 82 (28.1% – 42.2%) were obtained as white crystalline powders that were further used 
for the coupling reaction.  
Bromine transfer reagent in a twofold excess afforded a third product, 3,5-dibromo-N-tBOC-
cytisine 83, next to the small quantity of monobrominated isomers 81 and 82. The reaction 
products were easily separated on a RP-C18 column with methanol/water mixture as a 
mobile phase and dried via evaporation and lyophilization of the solvents. The yields of this 
reaction are listed in Table 3-7. 
 
Table 3-7 Yields of monobrominated and dibrominated cytisine derivatives 81 – 83 when 2 eq of 
NBS were applied 
 
 
N
N
O
R1
R2
tBOC
 
 
Cpd. R1 R2 Yields 
81 Br H 19.8% 
82 H Br 13.2% 
83 Br Br 42% 
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3.2.7.3 Discussion 
 
When one molar equivalent of NBS was used, the reaction afforded two monosubstituted 
regioisomers, 3-bromo-N-tBOC-cytisine 81 (43%) and 5-bromo-N-tBOC-cytisine 82 (32%). 
The resulting mixture was successfully separated with preparative high performance liquid 
chromatography (HPLC). This method showed a clear advantage over the purification and 
separation of the products on silica gel (CH2Cl2/MeOH 99:1), which had been performed 
before the HPLC method was established. The similar lipophilicity of isomers 81 and 82 
resulted in close RF values (RF = 0.21 and 0.33 for 81 and 82, respectively, CH2Cl2/MeOH 
99:1), thus complicating the separation of the isomers. The 3-bromo isomer 81 contained 5-
bromo isomer 82 and vice versa. On the other hand, RP-C18 phase and automatization 
yielded each isomer in a high purity. 
3-Bromo analogue 81 has been obtained in higher yields than the corresponding 5-
substituted derivative 82, which is in agreement with literature.124,184 The ratio of 3- and 5-
regioisomers seems to be dependent not only on the solvent used for the reaction,184 but 
also on the nature of the protecting group (Table 3-8). Bromination of the N-12 protonated 
cytisinium acetate gave the isomers in the same yields (27%, Table 3-8)118, while protection 
of the nitrogen with -tBOC or –COOMe yielded 3-bromo isomer in higher yields compared to 
its 5-halogenated counterpart (Table 3-8).184 However, using tBOC as a protecting group and 
CH2Cl2 as a solvent showed the advantage of obtaining smaller 3-/5-isomer ratio (1.34) 
compared to the 2.10 ratio, when the bromination was performed in dichloromethane on the 
–COOMe-protected cytisine (Table 3-8).184 Thus, the conditions described herein offer so far 
the best protocol for the synthesis of 5-bromo-N-tBOC-protected cytisine derivative 82. 
 
Table 3-8 Yields of monobrominated regioisomers in different solvents and with different N-
protecting groups, using 1 eq of NBS 
 
Solvent 
Protecting 
group 
3-bromo  
isomer 
[%] 
5-bromo 
isomer 
[%] 
3,5-dibromo  
analogue 
[%] 
3- / 5- 
ratio 
CH2Cl2 -tBOC 43
a 32a 0 1.34 
60% CH3COOH
b none 27 27 5 1.00 
CH2Cl2
c -COOMe 65 31 4 2.10 
MeCNc -COOMe 72 19 9 3.79 
DMFc -COOMe 73 23 2 3.17 
H3O
+c -COOMe 75 18 5 4.16 
THFc -COOMe 85 15 0 5.66 
a) average of 8 experiments, SEM = ± 5.2 for the 3-isomer; SEM = ± 5.9 for the 5-isomer  
b) taken from Ref. 118 
c) taken from Ref. 184 
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Adding two molar equivalents of the halogenating agent, the product 83 predominates, but 
the monobrominated isomers were obtained as well (81/82/83 20%/13%/42%). Imming et al. 
reported nearly quantitative substitution of both positions (3 and 5) when manifold excess of 
the NBS was employed.118 The yield of 3,5-dibromo-N-tBOC-cytisine 83 did not increase with 
an extended reaction time (up to 5 hrs) or an addition of N-bromosuccinimide (up to 4 mmol). 
 
3.2.8 3-Phenyl Analogues of Cytisine  
3.2.8.1 Introduction 
 
Pfizer claimed synthesis of 3-phenyl-cytisine and a series of 3-aryl analogues of cytisine via 
Suzuki cross-coupling reaction.124 In this route, firstly N-tBOC-cytisine-3-boronic acid 84 was 
prepared from bromine counterpart 81 via n-BuLi promoted transmetallation with 
triisopropylborate 85 (Scheme 3-20). The boronic acid of the alkaloid was subsequently 
coupled with (hetero)arylbromides (e.g. 86) using the standard Suzuki conditions 
Pd(PPh3)4/Na2CO3 in ethanol/water solution. The protecting group was removed by treatment 
with trifluoroacetic acid in methylene chloride and the final products were obtained as 
hydrochlorides.124 A synthesis of 3-(2,6-difluorophenyl)cytisine hydrochloride 87 shown in the 
Scheme 3-20 is an example of this method. Although the patent literature disclose a large 
number of cytisine derivatives, only limited NMR analysis data are available and the 
information about yields is missing. The structures of the analogues were confirmed merely 
with high-resolution mass spectrometry (HRMS). Therefore, it is difficult to evaluate the 
success of this protocol. 
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Scheme 3-20 Synthesis of 87 as an example of synthetic protocol developed for the synthesis of 3-
phenylsubstituted cytisine analogues [Ref. 124] 
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Marriére et al.184 synthesized 3-(4’-fluorophenyl)-cytisine by coupling stannylcytisine with 4-
fluorobromobenzene (Stille reaction) using two types of catalyst systems (Pd2(dba)3/AsPh3 
and PdCl2(PPh3)2/LiCl) and different protecting groups. The yields of these two 
transformations are satisfying (37% – 72%), but the long reaction times (12 to 60 hours) and 
the need of synthesizing the stannane coupling partners hamper the use of this protocol for 
the rapid synthesis of numerous derivatives required for a SAR study. 
Suzuki coupling on 2-pyridone moiety was successfully applied in the total synthesis of 
indoloquinoline alkaloid cryptotackieine 88 (syn. neocryptolepine).262 Coupling of 89 with N-
pivaloylamino phenylboronic acid in the presence of a palladium catalyst afforded the biaryl 
90, which is considered to be the key intermediate for preparation of the alkaloid 88 (Scheme 
3-21).  
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CH3
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Scheme 3-21 Suzuki coupling in the position 3 of the pyridone moiety in the total synthesis of 
cryptotackieine [Ref. 262] 
 
Similar approach to 3-arylsubstituted 2-pyridones has been published by Semple et al. as a 
part of synthesis of kappa opioid receptor agonists.259 Herein, N-substituted 3-bromo-2-
pyridone was coupled with various boronic acid under the catalysis of Pd(OAc)2. Dioxane 
was employed as a solvent, NaHCO3 as a base and the reaction time was 4 hours. Yields of 
40% – 90% were reported. 
Collins and Castro prepared 3-trifluoromethanesulfonyloxy-2-pyridone 91 (Scheme 3-22) by 
Vilsmeier formylation and cyclisation of acyl enamine.263 The triflate 91 was then found to 
undergo a range of palladium-catalysed cross-coupling reactions (one of them being Suzuki 
coupling) giving a synthetic sequence of general use for the preparation of substituted 2-
pyridones 92 (Scheme 3-22). Unfortunately, these results do not provide any helpful 
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information for the scope of this investigation, as the addition of a triflate moiety to the 
structure of cytisine 27 would be more lengthy and complicated than bromination. 
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Scheme 3-22 Palladium-catalysed coupling of 2-pyridone 91 and various boronic acids [Ref. 263] 
 
3.2.8.2 Method / Results 
 
A series of known∗ and novel cytisine analogues was synthesized via Suzuki cross-coupling 
reaction. All coupling reactions were performed in a single mode microwave cavity using 
power of no more than 30 W. Pd(PPh3)4 catalysed coupling reaction of 81 with phenylboronic 
acid 74 or differently m-substituted phenylboronic acids provided in the presence of sodium 
carbonate tBOC-protected phenyl analogues of cytisine 93 – 100 in less than 30 minutes 
(Scheme 3-23). Dimethoxyethane (DME) and water were employed as solvents. After solid 
phase extraction of lipophilic catalyst residues the coupling products were isolated with 
preparative HPLC system, using methanol/water mixture as a mobile phase and RP C-18 
column. The composition of the mobile phase was chosen with regard to the lipophilicity of 
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          OCF3 97   Cl 98   F 99    Ph  100
81
 Scheme 3-23 Suzuki cross-coupling between 3-bromo-N-tBOC-cytisine 81 and different boronic 
acids 
                                                 
∗ 3-phenyl-N-tBOC-cyt 93 and 3-(3’-fluorophenyl)-N-tBOC-cyt 99 have been synthesized previously124 
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the substituent in order to achieve retention time of the product between 10-20 min. The 
concentrated aqueous solution of the coupling product was directly used for the removal of 
the protecting groups.  
 
 
3.2.8.3 Discussion 
 
The key step in the addition of phenyl group as well as differently m-substituted phenyl 
moieties into the structure of cytisine 27 is the Suzuki cross-coupling reaction under 
microwave accelerated conditions. All coupling reactions of 3-bromo-N-tBOC-cytisine 81 and 
various boronic acids were performed in a single mode microwave cavity using power of no 
more than 30 W to avoid the decomposition of the catalytic system. In addition, hydrolysis of 
the carbamate bond was observed within the first experiments, when a higher energy (50 – 
100 W) was used. This is very beneficial for the deprotection chemistry, as it offers a new, 
convenient and fast removal of the tBOC protecting group. However, in order to avoid the 
decomposition of the catalyst and the use of buffered aqueous solutions for preparative 
HPLC purification of the coupling product as a free base, the microwave energy was kept 
under 30 W.  
Application of the standard Suzuki protocol (Pd(PPh3)4, Na2CO3, DME/H2O) and microwave 
irradiation as a heating source afforded known and novel cytisine analogues 93 – 100 in less 
than 30 minutes in moderate to excellent yields (36% – 83%). Compared to conventional 
heating, microwave dielectric heating shortened the reaction time from the 4 hours reported 
for coupling of 3-bromo-2-pyridones259 and 16 hours reported for the coupling of cytisine-3-
boronic acid 84124 to 30 min. 
All syntheses were performed on a milligram scale. From the medicinal chemistry point of 
view, it is more efficient at the lead modification/optimization stage to use chromatography for 
purification than to search for more efficient, higher-yielding, alternative synthetic routes and 
crystallization techniques.264 Chromatography on silica gel was found not to separate the 
coupling product from bromine reactant, which was mostly present in a small quantity in the 
reaction mixture. However, high performance liquid chromatography on a reverse phase C-
18 column allowed excellent separation and purification of the wanted coupling product. 
Isocratic mixture of methanol/water in composition with regard to the lipophilic nature of the 
substituent yielded the coupling product in high purity.  
Microwave-assisted Suzuki coupling was “discovered” nearly a decade ago238 and since 
then, numerous papers report the advantage of microwave on the coupling process.229,230 
Yet, the vast majority of the published microwave-enhanced Suzuki reaction employed 
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simple coupling partners, which were very similar to those used in the first microwave 
promoted Suzuki reaction, i.e. 1-bromo-4-methyl-benzene 73 and phenylboronic acid 74.238 
Thus, the efficient coupling of 3-bromo-N-tBOC-cytisine 81 with various boronic acids 
enlarges the limited number of papers reporting the use of Suzuki cross-coupling reaction for 
the high-speed modification of various heterocyclic scaffolds of pharmacological or biological 
interest. 265   
 
3.2.9 5-Phenyl Analogues of Cytisine 
3.2.9.1 Introduction 
In the patent literature orientated on the diversification of the cytisine scaffold124, three 5-
substituted analogues of cytisine were claimed. 5-Methyl-, 5-vinyl- and 5-phenyl-cytisines 
were synthesized via Stille cross-coupling reaction (Scheme 3-24). Of particular interest is up 
to date the only one analogue of cytisine with aryl substituent in position 5. 5-Phenyl-N-
tBOC-cytisine was synthesized via coupling of 5-bromo-N-tBOC-cytisine 82 and 
tributylphenyltin under PdBnCl(PPh3)2 catalysis.
 The reaction time of this substitution was 48 
hours (Scheme 3-24).124  
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Scheme 3-24 Stille cross-coupling reactions of 5-bromo-N-tBOC-cytisine 82 [Ref. 124] 
 
Arylation of the position 5 of the pyridone moiety is documented also by a single report. 
Nadin266 coupled tricyclic 5-triflate-pyridone 101 with o-, m- and p-methoxyphenyl-boronic 
acid under common Suzuki condition (Pd(PPh3)4, Na2CO3, DME/H2O). The coupling products 
102 were isolated in high yields (76% – 93%) (Scheme 3-25). 
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Scheme 3-25 Introduction of aryl moiety into the position 5 of a pyridone ring in 101 via Suzuki 
cross-coupling reaction [Ref. 266] 
 
3.2.9.2 Method / Results  
 
Microwave irradiation (30 W) allowed incorporation of unsubstituted or substituted phenyl 
moieties into position 5 of the pyridone ring in less than 30 minutes. 5-phenyl analogues of 
cytisine 103 – 100 (except for 108) were synthesized under standard Suzuki conditions - 
Pd(PPh3)4, Na2CO3, DME/H2O in 27% – 81% yields (Scheme 3-26). Solid phase extraction 
(RP-C18) followed by HPLC purification afforded separation of the products from the 
reagents and side products. The concentrated aqueous solutions of coupling products were 
directly used in the deprotection step. The reaction products were always identified via NMR 
and HRMS analysis of the final deprotected ligands. For the synthesis of 5-(3’-chlorophenyl)-
N-tBOC-cytisine 108, potassium phosphate was used as a base and the reaction time was 
extended to 60 min. The desired product, however, was obtained in low yield (23%).  
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Scheme 3-26 Suzuki cross-coupling of 5-bromo-N-tBOC-cytisine 82 and 3-substituted phenylboronic 
acids 
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3.2.9.3 Discussion 
 
Triflates have been shown to be efficient leaving groups for Suzuki couplings on the 
pyridones in the position 3263, 4267 and 5266.  However, the introduction of a triflate moiety into 
any position of the cytisine’s pyridone ring would require several steps. The better 
documented bromination of pyridone moiety in the cytisine structure118,124,174,182,184  yielded 
efficient N-protected 3-bromocytisine coupling partner 81 and it was somehow expected that 
bromine in the position 5 will also be an efficient leaving group for Suzuki cross-coupling.  
Indeed, microwave irradiation (30 W) and standard Suzuki conditions [Pd(PPh3)4, Na2CO3, 
DME/H2O] allowed phenyl substitution in the position 5 of the pyridone ring within 30 min 
(Scheme 3-26), compared to 48 hours when the Stille protocol was applied.124 Moreover, the 
method described herein afforded a successful cross-coupling of 5-bromo-N-tBOC-cytisine 
82 with various m-substituted phenyl boronic acid (Table 3-9). The method was changed for 
the synthesis of 5-(-3’-chlorophenyl)-N-tBOC-cytisine 108. Sodium carbonate as a base did 
not provide the coupling product in yields higher than 5%, even if the reaction time was 
extended from 30 min to 60 min. Replacing sodium carbonate by a stronger base - 
potassium phosphate - gave at the reaction time of 60 min the desired product (23%). 
Table 3-9 Retention times and yields of coupling products synthesized via Suzuki reaction 
N
N
O R
tBOC
                                                         
N
N
O
R
tBOC
 
Compound 
tr*  
[min] 
Yields** 
[%] 
R Compound 
tr*  
[min] 
Yields** 
[%] 
93 16.73A 58 H 103 17.32A 39 
94 17.18A 83 NO2 104 16.70
A 62 
95 16.27B 65 CH3 105 16.17
B 58 
96 19.28B 52 CF3 106 17.05
B 64 
97 21.28B 64 OCF3 107 21.12
B 27 
98 20.39B 47 Cl 108 20.52B 23 
99 13.70B 46 F 109 12.32B 81 
100 27.29 36 Ph 110 27.65C 62 
*) A, B, C stand for methods used by the HPLC purification 
A) MeOH/H2O 60:40 v/v 
B) MeOH/H2O 65:35 v/v 
C) MeOH/H2O 65:35 v/v for 15 min, the gradient to MeOH/H2O 80:20 v/v in 15 min 
**) yields calculated over two steps – coupling reaction and deprotection, however, as the deprotection 
     was quantitative, the final yields can be considered as the yields of the coupling reaction 
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5-Phenyl analogues were like their 3-phenyl counterparts purified with isocratic 
methanol/water mixture on a RP-C18 phase, using preparative HPLC. The retention times of 
the corresponding 3- and 5-derivatives differentiate slightly, indicating very similar lipophilic 
properties of the counterparts (Table 3-9). For example, the retention times of 3- and 5-(m-
tolyl)-N-tBOC-cytisine 95 and 105 are 16.27 min and 16.17 min, respectively (Table 3-6). It 
should be noted that the preparative HPLC does not focus on the peak profile monitoring for 
quantitative estimation and elution time measurement. The aim of the preparative HPLC is 
an actual collection of an eluted component, i.e. the separation and purification of synthetic 
products. In addition, mass overload leads to changed retention times and as a 
consequence, the retention times obtained from the preparative HPLC cannot be taken as 
identification parameters.268 Indeed, it was observed that the retention time depended on the 
quantity on the coupling product. While in the analytical HPLC exact concentration of a 
substance is loaded on the column (e.g. 1 µg/1 mL), in the preparative HPLC, reaction 
mixture with unknown concentration of the reaction product is used. The concentration of the 
sample mixture can be only estimated from the masses of applied reactants.  
The expectation of position 5 being less reactive than the position 3 was confirmed in most 
syntheses (Table 3-9). An exception to the rule is the yield of 5-(3’-fluorophenyl)-derivative 
109 (81%), which highly exceeds the yield of 3-(3’-fluorophenyl)-N-tBOC-cytisine 99 (46%).  
Suzuki coupling can be accompanied with several side reactions. A phenyl-coupling product 
derived from triphenylphosphine is an important side-product in the cross-coupling reaction 
of electron-rich haloarenes having no steric hindrance of an ortho substituent.269 However, 
the pyridone moiety of cytisine 27 is rather electron-deficient and both positions (3 and 5) 
have ortho-substituents (2-oxo and bulky bispidine moiety, respectively). Another side 
reaction is oxygen-induced homocoupling of arylboronic acids, which occurs when the 
reaction mixture is exposed to air. The homocoupling is very slow under neutral conditions, 
but is very rapid in the presence of an aqueous base.270 Therefore, the coupling reactions 
were performed under argon atmosphere and with an excess of boronic acid (1.5 eq). 
Nevertheless, the complete absence of oxygen cannot be achieved and the use of an 
aqueous Na2CO3 solution could lead to an undesired homocoupling of employed arylboronic 
acids. As the side products of the coupling reaction were not identified, also the participation 
of phophine-bound phenyl in the coupling cycle of cytisine 27 cannot be excluded. These, 
and maybe some other unknown side reactions together with the lower reactivity of the 
position 5 can rationalise the varying yields of the coupling reactions.  
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3.2.10 Heterocyclic Derivatives of Cytisine 
3.2.10.1 Introduction 
Up to date, all heterocyclic analogues of cytisine possess heterocycle only in the position 3. 
In the Pfizer patent124 they have been synthesized either via the Suzuki coupling of N-tBOC-
cytisine-3-boronic acid 84 and corresponding heteroaryl bromides (analogous synthesis to 
Scheme 3-20) or via Pd-catalysed Buchwald-Hartwig reaction. Coupling of 3-bromo-N-tBOC-
cytisine 81 and morpholine, using bis[1,2-bis(diphenylphosphino)ethane]-palladium(0) as a 
catalyst and sodium tert-butoxide as a base yielded N-protected 3-morpholino-cytisine 111 
(Scheme 3-27). Also 3-pyrrolidino-cytisine was prepared through this procedure.124  
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Scheme 3-27 Buchwald-Hartwig coupling as key step for synthesis of heterocyclic analogue of 
cytisine 111 [Ref. 124] 
 
In the development of 3-(2-[18F]fluoropyridinyl)-cytisine125, intended as a suitable radiotracer 
for use in PET, the synthesis of the N-protected “cold” counterpart 112 has been described. 
The key step was Stille cross-coupling reaction of N-protected 3-iodocytisine 113 or N-
protected 3-trimethylstannylcytisine 114 derivative with corresponding coupling partners 115 
and 116 (Scheme 3-28).125  
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113
114
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5
116
112
112  
Scheme 3-28 Stille coupling as a key step in the synthesis of 3-(2-fluoropyridine)-N-tBOC-cytisine 
112 [Ref. 125] 
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Suzuki cross-coupling reaction with heteroaryl boronic acids has been performed on the 
pyridone scaffold.263 3-Triflate-2-pyridone undergoes coupling with 3-thienyl and 4-pyridinyl 
boronic acid under standard Suzuki conditions (Pd(PPh3)4/Na2CO3/DME-H2O).
263 The 
coupling reaction of 4-triflate-2-pyridone and 2-thienyl boronic acid proceeds greatly at room 
temperature in the presence of Pd(PPh3)4/K2CO3/THF-DMA 1:1 (96% yields).
267   
 
3.2.10.2 Method / Results 
 
The introduction of heterocyclic scaffolds of biological interest into the position 3 or 5 of the 
cytisine structure is shown in Schemes 3-29 and 3-30. While coupling of 5-indolylboronic 
acid with both 81 or 82 performed well under “standard” condition (entry 117 and 123), the 
same condition afforded incorporation of 3,4-methylenedioxyphenyl group only into the more 
reactive position 3 of the pyridone moiety (entry 118). For the same coupling with 5-bromo-N-
tBOC-cytisine 82 sodium carbonate had to be replaced by Ba(OH)2 and the reaction time 
extended to 60 min (entry 124).  The application of K3PO4 as a base afforded synthesis of  3-
(3’-pyridyl)-N-tBOC-cytisine 119 within 60 min, but the stronger base Ba(OH)2 had to be 
employed for the synthesis of the corresponding 5-substituted counterpart (entry 125). The 
same observation was made for incorporation of 1-methyl-1H-pyrazol-4-yl moiety. Whereas 
the coupling reaction in the presence of K3PO4 as a base gave the desired coupling product 
122 in 30 min, the corresponding 5-substituted analogue (entry 126) was synthesized only 
when Ba(OH)2 was employed and the reaction time extended to 60 min. Potassium 
phosphate also allowed incorporation of 4-pyridyl and quinolin-8-yl into the position 3 of the 
pyridone moiety (entry 120 and 121), however, the introduction of these substituents into 
position 5 was not successful. All attempts to synthesize 5-(4’-pyridyl)- and 5-(quinolin-8’-yl) 
analogue failed. The syntheses were carried out under a variety of conditions with regard to 
the base (Na2CO3, K2CO3,, Cs2CO3 or Ba(OH)2), solvent (DME or DMF) and reaction time. 
The microwave heating was stopped after 60 or 90 minutes. However, no combination 
allowed incorporation of quinolin-8-yl and 4-pyridyl moieties into position 5. For every Suzuki 
cross-coupling of 81 or 82 with heterocyclic boronic acids, Pd(PPh3)4 was employed as a 
catalyst and DME/H2O as solvents. Since the unsuccessful syntheses were performed with 
the same catalyst (Pd(PPh3)4), employing different catalyst systems (e.g. PdBnCl(PPh3)2 or 
Pd(OAc)2/PPh3) could allow incorporation of 4-pyridyl and quinolin-8-yl moieties into position 
5. 
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Scheme 3-29 Introduction of heterocyclic or heteroaryl moieties into the position 3 of cytisine 
The purification of all N-protected reaction products 117 – 126 consisted of a solid phase 
extraction of the highly lipophilic catalyst and a separation of the reaction products from 
reactants and side products, which was performed with HPLC using isocratic methanol/water 
mixture.  
The coupling reactions with heterocyclic boronic acids confirmed the higher reactivity of 
position 3. 5-Substituted coupling products were always achieved in lower yields (Table 3-10) 
and all attempts to introduce quinol-8-yl and 4-pyridyl moieties into the position 5 failed. 
Similarly, coupling reactions of 3- or 5-bromo-N-tBOC-cytisine 81 – 82 with 2-chloro-5-  
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Scheme 3-30 Modification of position 5 via the introduction of heterocyclic moieties 
 
pyridylboronic acid yielded the desired coupling product in trace. This could be explained 
with the fact that boronic acids containing heteroatoms easily undergo in aqueous milieu 
hydrolytic B-C bond cleavage.271 This side reaction is accelerated in electron-deficient 
boronic acids272 and 2-pyridylboronic acid was reported not to give coupling products 
because of its very rapid deprotonation.168,191c Electron-withdrawing effect of the chlorine in 
the 2-chloro-5-pyridyl boronic acid is probably responsible for the hydrolytic cleavage of the 
B-C bond.  
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Table 3-10 Retention times and yields of heterocyclic cytisine derivatives 117 – 126 prepared via 
Suzuki reaction 
N
N
O
R
tBOC
                                                   
N
N
O
R
tBOC
   
*) A and B stand for methods used for the HPLC purification 
A) MeOH/H2O 60:40 v/v 
B) MeOH/H2O 50:50 v/v 
**) yields calculated over two steps – coupling reaction and deprotection, however, as the deprotection 
     was quantitative, the yields can be considered as the yields of the coupling reaction 
 
 
3.2.10.3 Discussion 
The results of Suzuki cross-coupling with heteroaryl boronic acids extend the original 
observation from the synthesis of aryl analogues. Microwave activation as an unconventional 
energy source demonstrated beneficial impact also with the introduction of a heterocyclic unit 
of pharmacological interest into the structure of cytisine 27. A new strategy for the 
straightforward and fast synthesis of heterocyclic cytisine analogues yielded ten novel 
derivatives 117 – 126 featuring bulky heterocycle in the position 3 or 5.  
However, the reaction condition described for phenyl derivatives (Chapters 3.2.8 and 3.2.9) 
had to be modified in some protocols, as using the “standard microwave conditions” 
[Pd(PPh3)4, Na2CO3, DME/H2O, 30 W, 30 min], gave only very fair yields. The syntheses of 
117 – 126 were carried out under a variety of conditions regarding the base (Na2CO3, K2CO3, 
Compound 
tr* 
[min] 
 
Yields** 
[%] 
R Compound 
tr* 
[min] 
Yields** 
[%] 
117 16.12A 37 
N
H  
123 15.55A 26 
118 18.99A 36 
O
O
 
124 18.69A 25 
119 16.05B 66 
N
 
125 14.52B 32 
120 17.80B 62 N
 
not purified 
 
< 5  
121 18.43A 44 
N
 
not purified 
 
< 5 
122 15.32B 70 N
N
CH3
 
126 12.65B 19 
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K3PO4, Cs2CO3 or Ba(OH)2), solvent (DME or DMF) and reaction time. Replacement of DME 
by DMF did not increase yields while the addition of K3PO4 or Ba(OH)2 exerted a remarkable 
affect on the acceleration of the coupling rate.  
The rate and yield enhancing effect of a base is a result of the increasing basic strength of 
counter anions (HCO3
- < MCO3
- < MPO4
- < OH-). Furthermore, counter cations possess 
different stability constant for halides (Na+ < K+ < Cs+ < Ba2+ << Tl+ < Ag+) and for hydroxide 
anions (Cs+ < K+ < Na+ < Li+).191c, 201  Thus, in the example of the synthesis of 3-(4’-pyridyl)-N-
tBOC-cytisine 120 (Scheme 3-27), a stronger base K2PO4
- yields in the transmetallation step 
a higher concentration of 4-pyridylboronate complex 127 than NaCO3
- does (Scheme 3-31).  
 
N
N
O
Pd(II)
tBOC
Br
N
N
O
Pd(II)
tBOC
N
B
OHOH
OH
K3PO4
KBr+ +
MOH
[4-pyridyl-B(OH)3]
- K+ + K2HPO4
4-pyridylB(OH)2+ + H2O
127
Scheme 3-31 Hypothetical transmetallation process in the synthesis of 3-(4’-pyridyl) derivative 120 
 
Moreover, K+ supports a higher concentration of the boronate 127 because it possesses a 
lower stability constant for hydroxide anion than Na+. On the other hand, potassium cation 
has a higher stability constant for bromide than Na+, meaning that the transmetallation is 
faster with potassium salts (e.g. K2CO3, K3PO4) than with sodium salts (e.g. Na2CO3).  
 
3.2.11   3,5-Disubstituted Analogues of Cytisine 
3.2.11.1 Introduction 
The published 3,5-dihalogenated cytisine analogues possess either the same or different 
halogen atoms in positions 3 and 5, e.g. 3,5-dichlorocytisine 45 and 3-bromo-5-
chlorocytisine.118,182 The mixed dihalogenated cytisine analogues were synthesized via “step 
by step” halogenation with common halogen transfer reagents such as N-bromo- or N-
chlorosuccinimide.182 A twofold excess of halogen transfer reagent (e.g. N-
chlorosuccinimide) yielded derivatives with the same halogen in positions 3 and 5, e.g. 3,5-
dichlorocytisine 45.118  
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The introduction of methyl-, ethyl-, vinyl- and phenyl moieties into positions 3 and 5 has been 
claimed, but synthetic protocol only for the synthesis of 3,5-dimethylcytisine was disclosed.124 
The target derivative was synthesized once more via the Stille cross-coupling reaction of 3,5-
dibromo-N-tBOC-cytisine 83 and a 10-fold excess of tetramethyltin under the catalysis of 
trans-benzylchloro-bis(triphenylphosphine)palladium in HMPA. The reaction was completed 
after 12 hours.124 
3.2.11.2 Method / Results 
 
The synthetic routes to disubstituted cytisine analogues 128 and 129 started with 3,5-
dibromo-N-tBOC-cytisine 83 (Scheme 3-32). The Suzuki-cross coupling reaction with 
phenylboronic acid 74 was selectively performed with the bromine in position 3. When 
Na2CO3 was used as a base, only the bromine in the position 3 of the pyridone moiety 
coupled with phenylboronic acid. Using 3-pyridylboronic acid and potassium phosphate led to 
an addition of the 3-pyridyl substituent again only to position 3. For both reactions Pd(PPh3)4 
was applied as a catalyst and DME/H2O as solvents. The microwave irradiation of the 
maximum 30 W was stopped after 30 or 60 min. The purification procedure of the coupling 
products followed the protocol described for phenyl and heterocyclic derivatives (SPE and 
HPLC separation).  
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Scheme 3-32 Selective cross-coupling in the position 3 of 3,5-dibromo-N-tBOC-cytisine 83 
 
3.2.11.3 Discussion 
 
The conditions used in the selective Suzuki cross-coupling reaction were chosen due to 
previous experience revealing that the more reactive position 3 of the pyridone moiety 
undergoes coupling with the boronic acid easier and faster. Thus, employing bases such as 
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Na2CO3 or K3PO4 afforded coupling reaction only in position 3, while the bromine in position 
5 was not attacked. In this way obtained 3-phenyl-5-bromo- and 3-(3’-pyridyl)-5-bromo 
analogues 128 and 129 are novel disubstituted cytisine derivatives.   
Selective coupling has been previously reported, but selective only by the means of different 
reactivity of iodine and bromine towards the Suzuki reaction (Scheme 3-33). The coupling of 
4-boronic acid of anisole and bromo-iodo-phenanthroline 130 affords coupling product 131. 
The results of this study demonstrate that positions with leaving groups of different reactivity 
can selectively undergo the coupling reaction under carefully chosen conditions.191b 
N N
Br
I
B
OH
OH
OMe
N N
Br
MeO
Pd(PPh3)4
Ba(OH)2
DME/H2O
+
130 131
  
Scheme 3-33 Selective Suzuki cross-coupling reaction [Ref. 191b] 
 
3.2.12     Removal of the tBOC Protecting Group 
3.2.12.1 Introduction 
Traditionally, the tBOC group is cleaved by acidic hydrolysis using hydrochloric acid in 
ethylacetate273 or trifluoroacetic acid (TFA) in dichloromethane124. 10% Sulphuric acid in 
dioxane has been used as well.274 The tBOC group can be also removed thermally, either 
neat275,276 or in diphenyl ether277. 
Microwave irradiation has been shown to be effective in the deprotection methods, especially 
in protocols requiring harsh conventional conditions. Extensive research on microwave-
accelerated deprotection278 yielded new protocols for alternative cleavage reactions. For 
example, the use of irritating and corrosive TFA can be eliminated with microwave irradiation. 
A solvent-free deprotection of N-tBOC group occurs upon exposure to microwaves in the 
presence of neutral alumina with aluminium chloride.279 Cleavage of tBOC can be achieved 
by coupling microwave irradiation and silica gel.280 Recently, an absolute deprotection of 
tBOC protected amino acid and peptide esters employing p-TsOH in toluene under 
microwave irradiation was found to be completed in 30 second. The method worked well also 
in methanol and acetonitrile.281 
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3.2.12.2 Method/Results 
Hydrochloric acid quantitatively (reaction time > 24 hours) removed the tBOC group and after 
extraction of a free base into chloroform, final products 93e – 100e and 103e – 110e were 
obtained as off-white crystalline powders (Scheme 3-34, Method A).  
However, it was observed that heating the Suzuki reaction with microwave irradiation 
quantitatively removed the tBOC protecting group. Therefore, after the HPLC purification, the 
aqueous fraction containing the N-protected product was concentrated to approximately 80 
mL and the removal of the carbamate was achieved by thermal fission (150°C) of CO2 and 
isobutene using microwave irradiation of 150 W for 30 minutes (Scheme 3-34, Method B). As 
the reaction was quantitative, no purification was required and lyophilization of water for at 
least 24 h afforded ligands 117e – 126e as white or yellowish crystalline powders.  
N
N
O
tBOC
R1
R2
NH
N
O
R1
R2
   93e - 100e    R1 = aryl, R2 = H
 103e - 110e    R1 = H,  R2 = aryl
 117e - 122e    R1 = heterocycle, R2 = H
 123e - 126e    R1 = H, R2 = heterocycle
      128e         R1 = phenyl,    R2 = Br
      129e         R1 = 3-pyridyl, R2 = Br
A: 1 M HCl, reflux, 24 h
or B: H2O, 150 W, 30 min
           "thermal fission"
 
Scheme 3-34 Removal of the tBOC-protecting group by acidic hydrolysis (A) or thermal fission 
promoted with microwave irradiation (B) 
 
3.2.12.3 Discussion 
 
The removal of the tBOC-protecting group was performed directly in the concentrated 
aqueous solution of the coupling product, obtained from HPLC purification.  
Trifluoroacetic acid caused too many side products that had to be removed by flash 
chromatography, which resulted in a significant loss of the little quantity of the coupling 
product. Therefore, hydrochloric acid was used for the hydrolysis of the carbamate bond. The 
reaction was monitored by TLC in order to achieve quantitative yields. Free base was 
extracted into chloroform and after evaporation of the solvent under reduced pressure the 
ligands 93e – 100e and 103e – 110e were obtained as off-white crystalline powders. 
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A great improvement was the discovery that the tBOC protecting group can be quantitatively 
removed with the microwave heating. Quantitative thermal fission of carbon dioxide and 
isobutene was achieved with microwave-enhanced fast heating within 30 min. The final 
products 117e – 126e (free bases) were obtained after lyophilization of solvent (i.e. water) as 
white or yellowish crystalline powders.  
This protocol offers a high-speed, efficient and quantitative cleavage of the tBOC-protecting 
group. Microwave irradiation of the aqueous solution of the N-tBOC protected amine 
improves previously reported similar approaches.279-281 While the thermal fission of tBOC 
group with conventional heating required two hours276, alternative dielectric heating 
completed the same reaction within 30 minutes. Microwaves were shown to enhance 
deprotection of secondary amines, however in the presence of organic solvents (e.g. 
toluene) or reactants (e.g. silica gel). The method presented herein requires water as a 
solvent and no reagents. 
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3.3 1H and 13C NMR Chemical Shifts Assignment for the 
Novel nAChRs Ligands 
 
3.3.1 Overview of used NMR Spectroscopy Methods 
 
The aim of the standard 1H NMR experiment is to record a routine proton NMR spectrum in 
order to obtain structure-related information for the protons of the sample, i.e. chemical 
shifts, spin-spin couplings and intensities.282 The aim of the standard 13C NMR experiment is 
to record a 13C spectrum with proton broad-band decoupling and data accumulation so as to 
acquire chemical shift information for the compound’s carbon skeleton.283  
Well separated resonances in the 1H NMR spectrum can be selectively irradiated by relevant 
decoupler frequencies, this method is called Single-Frequency Decoupling (SFD). In the 
13C NMR spectrum, the signal of the carbon atom adjacent to the irradiated proton will be 
detected as a singlet, the other carbon resonances are off-resonance decoupled, with 
splitting dependent on the frequency distance from the decoupler frequency applied. 
Although time consuming, this procedure affords plentiful information about the C,H coupling 
behaviour of the spin system in question.283 
Distortionless Enhancement by Polarization Transfer (DEPT) produces subspectra for 
distinguishing the CH, CH2 and CH3 carbons. In the DEPT-135 spectrum, CH and CH3 
carbon are presented by positive signals and CH2 by negative signals, whereas signals of 
quaternary carbons are missing.285 
While conventional NMR spectra (1D NMR) are plots of intensity vs. frequency, in two-
dimensional spectroscopy (2D NMR) intensity is plotted as a mutual correlation of two 
resonance frequencies. 2D NMR spectrum means a spectrum in which both axes show 
chemical shifts, with the intensity of the correlation peaks constituting a third dimension. 
From a practical point of view, the most useful 2D spectra are those that show either 
homonuclear 1H- 1H or heteronuclear 1H-13C correlations.284  
The 2D hydrogen Correlated Spectroscopy (COSY) is a valuable source of information 
regarding the coupling partners. The one-dimensional 1H NMR spectrum can be found along 
the top and left sides of the 2D COSY spectrum. Cross peaks exist in the 2D COSY 
spectrum where there is a spin-spin coupling between hydrogens.285  
2D-Incredible Natural Abundance Double Quantum Transfer Experiment 
(INADEQUATE) detects the 13C nuclei connected to another 13C nucleus and reveals 
connectivities of neighbouring carbons. This experiment is relatively insensitive, thus time-
consuming and a large sample of the analysed structure is necessary.285    
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One particularly useful experiment is to record a two-dimensional spectrum in which the co-
ordinate of a peak in one dimension is the chemical shift of one type nucleus (e.g. proton) 
and the co-ordinate in the other dimension is the chemical shift of another nucleus (e.g. 
carbon) which is bound to the first nucleus (heteronuclear correlation experiments).286 
Heteronuclear Single Quantum Coherence (HSQC) shows correlations between directly 
bonded atoms, e.g. 13C-1H. The 2D data set reveals cross peaks corresponding to the carbon 
atoms and protons attached to them. Such spectra are very useful as aids to signal 
assignment, e.g. if the proton spectrum has already been assigned, the HSQC spectrum will 
give the assignment of all carbons linked to the protons.287 
Another 2D NMR onset is called Heteronuclear Multiple Bond Correlation (HMBC) which 
provides 2- and 3-bond coupling correlation information (2/3JC,H coupling).  The purpose of 
HMBC is to suppress correlations via 1JC,H. Since this suppression is not perfect, 
1JC,H are still 
observable, but those arising from 2/3JC,H are predominant. 
 
3.3.2 Project 
 
The assignment of the carbon and proton signals of cytisine 27 is poorly documented in the 
literature. The absolute configuration and stereochemistry of some quinolizidine alkaloids 
(e.g. sparteine or anagyrine) have been extensively studied with NMR experiments288, but no 
publication deals with comprehensive structural analysis of cytisine 27.  
The structure of the alkaloid 27 was established in the 1930s by Ing.134 In the 1950s three 
independent groups described the total syntheses of racemic cytisine 27, which served to 
confirm its structure.165-167 A first assignment of 13C chemical shifts of cytisine 27 was 
performed by Bohlmann126 (Table 3-11), however the author did not provide any 
argumentation of the assignment. The assignments of 13C chemical shifts of cytisine 27 
reported afterwards are in agreement with the first assignment127,128,142 (Table 3-11), but one 
has to take into consideration that the assignment published by Bohlman126 always served as 
a primary work for the identification of cytisine 27. Publications168-173 describing the total 
synthesis of enantiopure or racemic cytisine 27 provide 1H and 13C chemical shift data, 
however no assignment of the chemical shifts is reported.  
Furthermore, no detailed study for distinguishing 3- and 5-substituted isomers has been 
reported. In the Pfizer patent124 the 3- and 5-bromo isomers 81 and 82 were differentiated by 
NMR techniques with regard to the 1H chemical shifts of H3 (δ 6.38 ppm) and H5 (δ 5.99 
ppm). Similarly, the thesis focusing on structural modification of the cytisine scaffold182 does 
not offer any additional experiments required for a correct assignment of 1H and 13C chemical  
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Table 3-11 13C chemical shifts of cytisine 25 [Ref. 126-128,142] 
NH
N
O
2
3
45
67
8
9 10
11
13
1
12
 
                    
 
                                                                                                             
 13C chemical shifts [ppm] as reported by 
             Bohlmann126     Takamatsu127          Asres128      El-Shazly142 
                       (CDCl3)            (CD3OD)          (CDCl3)          (CDCl3) 
C2 163.6 166.6 163.6 163.6 
C3 116.5 117.8 116.5 116.7 
C4 138.7 142.1 138.5 138.7 
C5 104.9 108.9 104.6 104.9 
C6 151.2 153.4 151.4 151.0 
C7 35.5 36.9 35.3 35.6 
C8 26.2 27.3 25.3 26.3 
C9 27.7 29.5 27.8 27.8 
C10 49.7 51.8 49.9 49.7 
C11 52.9 53.6 62.1 52.9 
C13 53.9 54.6 46.1 53.9 
 
shifts for positions 3 and 5, although numerous 3- and 5-haloderivatives of cytisine have 
been reported in this thesis.  
In order to differentiate the isomeric 3- and 5-(hetero)aryl cytisine derivatives, a correct and 
complete set of 1H and 13C chemical shift assignment for the unsubstituted alkaloid 27 was 
required. The details regarding assignment of the 1H chemical shifts for cytisine 27 were not 
found in the literature. Similarly, the publication of Bohlmann126 did not provide any 
rationalisation for the assignment of 13C chemical shifts. Therefore not only the standard 1H 
and 13C spectra, but also the 2D correlation maps (COSY, HSQC, HMBC, INADEQUATE) of 
cytisine 27 were measured in two different solvents - deuterated chloroform (CDCl3) and 
methanol (CD3OD).  
Detailed 2D NMR COSY, HSQC and HMBC spectra were performed also for the phenyl 
substituted analogues 93e and 103e in order to establish “diagnostical tools” for their 
differentiation. For the heteroaryl cytisine derivatives 117e, 119e, 121e, 124e 2D COSY as 
well as HSQC spectra were measured, as those would facilitate an assignment of 1H and 13C 
chemical shifts of the heteroaryl moieties.   
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3.3.3 Spectral Assignments of 1H and 13C Chemical Shifts  
 
3.3.3.1 Cytisine 27 
 
The 1H NMR, 13C NMR and DEPT-135 spectra of cytisine 27 in CDCl3 are pictured in Figure 
3-8. Cytisine 27 possesses sp2 and sp3 carbons. Three sp3 carbons (C11, C13 and C10) are 
connected to the nitrogen atom. The sp2 carbons are part of a pseudoaromatic pyridone 
moiety. In the 1H spectra the protons H3, H4 and H5 arise in the aromatic downfield region (δ 
5.5 – 7.5 ppm), while the aliphatic protons of the bispidine ring appear in the upfield part (δ 
1.5 – 4.0 ppm). 
Starting with the aliphatic region of the 1H NMR spectrum (Figure 3-8/A), the most upfield 
shifted peak (δ 1.70 ppm) which integrates for 2 protons was identified as H8. This signal 
provided the starting point for assignments of the remaining bispidine protons. In the 2D 
COSY spectrum of cytisine 27 (Figure 3-9), H8 displayed cross peaks with singlets at δ 2.08 
and δ 2.69 ppm and with a multiplet at δ 2.73 – 2.83 ppm. The two singlets at δ 2.08 ppm 
and δ 2.69 ppm may be assigned only to H7 and H9, concerning the information obtained in 
the COSY map. The δ 2.08 ppm peak was correlated firstly to a doublet at δ 3.85 ppm and 
secondly to a doublet of doublet (“dd”) at δ 3.63 ppm, both being signals of protons H10β and 
H10α, respectively (shifted downfield as they are linked to a carbon with a nitrogen 
attachment). Therefore, the δ 2.08 ppm singlet was assigned to H9 and the singlet at δ 2.69 
ppm to H7. To conclude, the multiplet δ 2.73 – 2.83 was assigned to protons H11 and H13. 
The geminal coupling of the protons H10α and H10β was recognised as 
2J = 15.6 Hz and the 
vicinal coupling of one of them (dd at δ 3.63 ppm) to H9 as 3J = 6.6 Hz.  
The dd at δ 7.05 ppm correlated with two doublet signals at δ 6.17 ppm and δ 5.77 ppm, 
respectively. Coupling constants of 3J = 6.9 Hz and 3J = 9.1 Hz were observed and the signal 
at δ 7.05 was attributed to H4.  Another two doublets at δ 5.77 ppm (3J = 6.9 Hz) and at δ 
6.17 ppm (3J = 9.1 Hz), representing the olefinic protons H3 and H5, could not be 
unambiguously assigned at this point.  
After completing the assignments of the cytisine’s 1H chemical shifts (except for H3 and H5), 
13C spectra were recorded and analysed along with the HSQC and HMBC 1H – 13C 2D shift 
correlation experiments.  In the DEPT-135 spectrum (Figure 3-8/C) four methine carbons 
were found (δ 25.6; 49.1; 52.3 and 53.3 ppm). HSQC correlations (Figure 3-10) allowed 
straightforward assignment of signals at δ 25.6 ppm and δ 49.1 ppm to C8 and C10. In order 
to assign the signals at δ 52.3 and 53.3 ppm to either carbon C11 or C13, it was necessary 
86Cytisine: NMR spectroscopy of novel ligands  
 
 
Figure 3-8 1H NMR (A), 13C NMR (B) and DEPT-135 (C) spectra of cytisine 27 [CDCl3, 125 MHz 
(13C NMR) and 500 MHz (1H NMR)] 
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Figure 3-9 2D COSY contour plot of cytisine 27 (CDCl3, 500 MHz) 
 
to examine their two- and three bond 1H and 13C correlations in the HMBC spectrum (Figure 
3-11). Of particular interest was the long-range coupling of both H10 protons to the signal at 
δ 52.3 ppm, whereas a correlation to the signal at δ 53.3 ppm is missing (Figure 3-11). This 
cross peak must arise from a coupling of C11 to H10 over three bonds. Therefore, the δ 52.3 
ppm chemical shift was assigned to carbon C11 and the signal at δ 53.3 ppm corresponds to 
C13. Two positive signals of the DEPT-135 spectrum at δ 27.0 ppm and δ 34.9 ppm were 
identified as aliphatic CH groups and the HSQC correlation map (Figure 4-3) was used to 
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assign the respective protons (H9 and H7). Thus, the chemical shift of C9 was located at δ 
25.6 ppm and the carbon C7 possesses a chemical shift of δ 34.9 ppm. 
In the aromatic part of the 13C NMR spectrum, the most downfield shifted signal (δ 162.8 
ppm) was attributed to the carbonyl group (C2). The one-bond 1H-13C correlation detected in 
the HSQC spectrum identified the signal at δ 138.1 ppm as C4 (Figure 3-10). The same 
spectrum allowed the attribution of the proton at δ 5.77 ppm to the carbon at δ 104.2 ppm 
and the proton at δ 6.17 ppm to the carbon at δ 115.7 ppm. Thus, the remaining signal at δ 
150.7 ppm belongs to C6 (Figure 3-10). 
However, the major problem in analysing the cytisine’s NMR spectra was the identification of 
C3/H3 and C5/H5 (δ 6.17/115.7 ppm vs. δ 5.77/104.2 ppm). In the HMBC experiment, two 
and three bond correlations emerged from the carbon C2 to the doublet at δ 6.17 ppm and, 
furthermore, from the carbon C7 towards the doublet at δ 5.77 ppm (Figure 3-11). Since the 
detection of 5J correlation in the HMBC spectrum is unlikely and may be excluded (i.e. C7 to 
H3), the doublet at δ 5.77 ppm was assigned to H5. Thus, with these findings in mind, signals 
at δ 6.17/115.7 ppm were attributed to H3/C3 and the set of signals at δ 5.77/104.2 ppm to 
H5/C5, respectively.  
An INADEQUATE experiment was performed in order to obtain the connectivity pattern of 
the skeleton atoms. Unfortunately, the connectivity between C6 and C5 was not detected 
and the carbonyl C2 was found to couple with the signal at δ 104.2 ppm (Figure 3-12). Both 
one-bond couplings 1J(C,C) and long-range couplings nJ(C,C) (n = 2 or 3) have been 
described by INADEQUATE measurements.285  Since the cross-signal of C2 - C(δ 104.2 
ppm) had a lower intensity when compared to other correlations and more cross-signals of 
that intensity were found in the INADEQUATE map (Figure 3-12, red circles), this cross-
signal was attributed to the long-range coupling over three bonds, i.e. carbonyl C2 to C5. The 
INADEQUATE conclusions about the carbon-carbon connectivity of the bispidine moiety 
confirmed the 13C assignment which had been obtained through HSQC and HMBC 
experiments.   
In order to verify the 1H and 13C signals assignment to positions 3 and 5, a natural proton-
coupled 13C NMR spectrum was measured (Figure 3-13/B). The signal at δ 104.2 ppm was 
obtained as a doublet of doublet of doublet (DDD; 1JC5/H5 = 166.3 Hz; 
3JC5/H3 = 7.5 Hz; 
3JC5/H7 
= 3.3 Hz) and the signal at δ 115.71 ppm appeared as a doublet of doublet (DD, 1JC3/H3 = 
167.1 Hz; 3JC3/H5 = 7.3 Hz). Single-frequency decoupling (SFD) via selective irradiation at δ 
2.69 ppm (H7) (Figure 3-13/C) revealed the signal at δ 104.2 ppm as a doublet of doublet 
(DD; 1JC5/H5 = 162.2 Hz; 
3JC5/H3 = 8.2 Hz), whereas the 
3J coupling of C5 to H7 was missing.  
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Figure 3-10 2D HSQC contour plot of cytisine 27 [CDCl3, 125 MHz (
13C NMR) and 500 MHz (1H 
NMR)] 
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Figure 3-11 2D HMBC contour plot of cytisine 27.  Cross-peaks of particular interest are 
highlighted in blue. [CDCl3, 125 MHz (
13C NMR) and 500 MHz (1H NMR)] 
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Figure 3-12 2D INADEQUATE spectrum of cytisine 27 (CDCl3, 125 MHz). Red circles pointing out 
correlations over two or three bonds.  
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Figure 3-13 Part of decoupled 13C spectrum (A), coupled 13C spectrum (B) and single frequency 
decoupled (δ 2.69 ppm) 13C spectrum (C) of cytisine 27 (CDCl3, 125 MHz)  
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The signal at δ 115.7 ppm remained unchanged (DD, 1JC3/H3 = 163.5 Hz 
1JC3/H5 = 7.0 Hz) 
(Figure 3-13/C). Therefore, this signal was unequivocally assigned to C3 and the signal at δ 
104.2 ppm was assigned to C5. Consequently, H3 appeared at δ 6.17 ppm and proton H5 
was located to δ 5.77 ppm.  
Except for SFD, all experiments were repeated in deuterated methanol (CD3OD). There are 
some subtle differences in the 1H and 13C NMR spectra measured in deuterated chloroform 
and methanol (Table 3-12). In CD3OD (compared to CDCl3), the proton H5 is shifted 
downfield (∆ δ 0.53 ppm) more than the proton H3 (∆ δ 0.27 ppm). Therefore, these two 
questionable protons (H3 and H5) appear much closer to each other in CD3OD (δ 6.44 and 
6.30 ppm) than they appear in CDCl3 (δ 6.17 and 5.77 ppm). The signals of both H3 and H5 
are doublets of doublets with ortho couplings to H4 (3JH4,H5 = 6.9 Hz;  
3JH3,H4 = 9.1 Hz) and a 
mutual meta coupling (4JH3,H5 = 1.4 Hz). All aliphatic protons are shifted downfield in CD3OD 
by 0.3 ppm, as compared to the chemical shifts in CDCl3.  
The 13C chemical shifts of cytisine 27 in CD3OD were slightly shifted downfield (app. ∆ δ 1-4 
ppm) when compared to results from experiments performed in CDCl3 (Table 4-2). The most 
pronounced downfield shift was observed for C5 and the smallest shift for C3. As in the 1H 
NMR spectrum, also in the 13C NMR chemical shift map, the signals of C3 and C5 
approximated each other. Results from the 2D NMR experiments (HSQC, HMBC, 
INADEQUATE) performed in CD3OD allowed unambiguous assignments of all 
1H and 13C 
signals in the cytisine 27 skeleton and confirmed the assignments of the signals obtained 
from CDCl3 – experiments (Table 3-12).  
 
Table 3-12 1H and 13C chemical shifts of cytisine 27  
                                                1H NMR (500 MHz) 
                        CDCl3                     CD3OD 
                      δ [ppm]                     δ [ppm] 
                    13C NMR (125 MHz) 
                       CDCl3                CD3OD 
                        δ [ppm]                δ [ppm] 
H3 6.17 6.44 C2 162.8 165.8 
H4 7.05 7.49 C3 115.7 117.0 
H5 5.77 6.30 C4 138.1 141.3 
H7 2.69 2.99 – 3.11 C5 104.2 108.0 
H8A 1.70 2.04  C6 150.7 153.3 
H8B 1.70 1.98 C7 34.9 36.6 
H9 2.08 2.39 C8 25.6 26.9 
H10α 3.63   3.92  C9 27.0 29.0 
H10β 3.85 4.09 C10 49.1 51.3 
H11 2.73 – 2.83 2.99 – 3.11 C11 52.3 53.4 
H13 2.73 – 2.83 2.99 – 3.11 C13 53.3 54.4 
94Cytisine: NMR spectroscopy of novel ligands  
 
 Thus, the extensive NMR study of the cytisine 27 approved the 13C chemical shift’s 
assignment of Bohlmann et al126 and provided a detailed assignment of the 1H chemical 
shifts for the first time. The final 1H and 13C signal assignment (CDCl3) is shown in Figure 3-
14. 
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Figure 3-14 Complete assignment of 1H (in green, CDCl3, 500 MHz) and 
13C (in blue, CDCl3, 125 
MHz) chemical shifts (δ, ppm) for cytisine 27  
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3.3.3.2 3-Phenyl- and 5-Phenyl-cytisine 93e & 103e 
 
1H and 13C NMR chemical shifts of 3-phenyl-cytisine 93e and 5-phenyl-cytisine 103e are 
listed in Table 3-13. An introduction of a phenyl moiety into position 3 or 5 leads to downfield 
shifts of all 1H signals (∆ δ 0.27 – 0.46 ppm) when compared to cytisine 27.  
Significant differences between the isomers 93e and 103e might be seen in the 1H NMR 
spectrum of the bispidine ring moiety. Bispidine as such is a symmetrical molecule (Figure 3-
15/A) and the protons herein designated as H8 are chemically and magnetically equivalent, 
thus they appear in the 1H spectrum as a singlet (δ 1.42 ppm)289. The annelation of a 
pyridone moiety to the bispidine ring system resulting into the structure of cytisine 27 disturbs 
the symmetry of the bispidine moiety and the H8 protons become magnetically different. In 
the 1H NMR spectra the protons H8A and H8B are expected to arise as separated peaks. 
However, the used experimental conditions were not able to detect these two protons 
separately and the H8 protons gave a sharp singlet in the 1H NMR spectrum of cytisine 27  
 
Table 3-13 1H and 13C chemical shifts of cytisine 27, 3-phenyl-cytisine 93e and 5-phenyl-cytisine 
103e (CDCl3, 500 MHz) 
 
cytisine 
 27 
δ [ppm] 
3-Ph-cyt 
93e 
δ [ppm] 
5-Ph-cyt 
103e 
δ [ppm] 
 
cytisine 
 27 
δ [ppm] 
3-Ph-cyt 
93e 
δ [ppm] 
5-Ph-cyt 
103e 
δ [ppm] 
H3 6.10 --- 6.49 C2 162.8 162.1 163.1 
H4 7.00 7.46 7.21 C3 115.7 127.4 116.1 
H5 5.72 6.09 --- C4 138.1 137.4 141.4 
H7 2.62 2.91 3.04 C5 104.2 105.0 119.3 
H8A 1.84 C6 150.7 150.3 147.5 
H8B 
1.65 1.96 
1.92 C7 34.9 35.7 31.6 
H9 2.03 2.34 2.30 C8 25.6 26.3 26.4 
H10α 3.57 3.96 4.19 C9 27.0 27.9 27.4 
H10β 3.77 4.19 3.95 C10 49.1 50.2 50.4 
H11A 3.12 C11 52.3 53.0 52.2 
H11B 
2.70 – 2.75 3.02 – 3.07 
2.92 C13 53.3 54.0 53.0 
H13A 2.81 C1’ --- 137.0 138.5 
H13B 
2.70 – 2.75 3.02 – 3.07 
2.69 C2’ --- 128.6 129.8 
H2’ --- 7.69 7.19 C3’ --- 128.0 128.6 
H3’ --- 7.38 7.37 C4’ --- 127.2 127.4 
H4’ --- 7.29 7.31 C5’ --- 128.0 128.6 
H5’ --- 7.38 7.37 C6’ --- 128.6 129.8 
H6’ --- 7.69 7.19     
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(Figure 3-15/B).  The H8 signal simplicity remained the same in 3-phenyl-cytisine 93e (Figure 
3-15/C). Only in the spectrum of 5-phenyl-cytisine 103e the protons attached to the C8 
appear as expected separated doublets at δ 1.84 ppm and δ 1.92 ppm with a geminal 
coupling of 2J = 13 Hz (Figure 3-15/D).  
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Figure 3-15 Bispidine moiety as a symmetrical molecule (A). H8 protons appear as singlets in 
cytisine 27 (B) and 3-phenyl-cytisine 93e (C). In the spectrum of 5-phenyl-cytisine 
103e the H8 protons give two separated doublets (D). 
 
Furthermore, in the spectrum of 103e each proton of the methylene groups in the position 11 
and 13 showed separated doublet instead of overlapping doublets as seen in cytisine 27 (δ 
2.73 – 2.83 ppm, Figure 3-8/A) and 3-phenyl-cytisine 93e (δ 3.02 – 3.07 ppm, Figure 3-16). 
The COSY spectrum of 103e (Figure 3-17) revealed cross peaks between the doublet at δ 
2.81 ppm and the doublet of doublet at δ 2.69 ppm. These cross peaks emerged from the 
geminal coupling (2J = 12 Hz) of the H13 protons, which showed a “roof effect”. Additionally, 
both H13 protons gave cross signals to H7, but only one of them was detected as a doublet 
of doublet (3J = 2.5 Hz, 2J = 12 Hz). The doublets at δ 3.12 ppm and δ 2.92 ppm showed a 
lone mutual cross peak (2J = 12 Hz) and were assigned to the methylene group in the 
position 11.  
Differences between the 1H NMR spectrum of 3-phenyl- and 5-phenyl-cytisine 93e and 103e 
were also observed in the chemical shifts of the phenyl substituent. In the 1H NMR spectrum 
of 93e, the “ortho” protons (H2’ and H6’) are shifted downfield (δ 7.69 ppm) as compared to 
the chemical shift of the same protons in the spectrum of 103e (δ 7.19 ppm) (Table 3-13). 
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Figure 3-16 2D COSY contour plot of 3-phenyl-cytisine 93e (CDCl3, 500 MHz) 
 
This relative downfield shift of “ortho” protons in 93e may be explained by an inductive effect 
of the 2-carbonyl group or through an anisotropic effect mediated thereby.  
In the 3-phenyl- and 5-phenyl-cytisine 93e and 103e the pyridone protons H4/H5 and H3/H4 
each represent an AB system. Similarly to the data obtained from the analysis of cytisine’s 1H 
chemical shifts, the coupling constant of H3/H4 was bigger (3JH3,H4 = 9.5 Hz) than that of 
H4/H5 (3JH4,H5 = 7.2 Hz). 
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Figure 3-17 2D COSY contour plot of 5-phenyl-cytisine 103e (CDCl3, 500 MHz) 
 
The substitutions in position 3 or 5 led to a downfield shift of 13C signals, ∆ δ 11.7 ppm for the 
substituted C3 and ∆ δ 15.1 ppm for the substituted C5, when compared with the chemical 
shifts found in cytisine 27 (Table 3-13). Simultaneously, a phenyl substitution in position 5 
caused an upfield shift of C6 (∆ δ 3.2 ppm) and C7 (∆ δ 3.3 ppm). In 3-phenyl-cytisine 93e,  
the carbons C6 and C7 retained the 13C chemical shift values measured in cytisine 27. 
HSQC correlation maps assigned 13C signals to all secondary and tertiary carbons of 3-
phenyl and 5-phenyl-cytisine 93e and 103e (Figure 3-18 and 3-19).  
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Figure 3-18 2D HSQC contour plot of 3-phenyl-cytisine 93e [CDCl3, 125 MHz (
13C NMR) and 500 
MHz (1H NMR)] 
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Figure 3-19 2D HSQC contour plot of 5-phenyl-cytisine 103e [CDCl3, 125 MHz (
13C NMR) and 500 
MHz (1H NMR)] 
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Figure 3-20 2D HMBC contour plot of 3-phenylcytisine 93e. Decisive correlation C7/H5 highlighted 
in blue.  [CDCl3, 125 MHz (
13C NMR) and 500 MHz (1H NMR)] 
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Figure 3-21 2D HMBC contour plot of 5-phenyl-cytisine 103e. Decisive correlations highlighted in 
blue.  [CDCl3, 125 MHz (
13C NMR) and 500 MHz (1H NMR)] 
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Examinations of the long-range 1H-13C correlations in the HMBC spectra of 3-phenyl-cytisine 
93e (Figure 3-20) and 5-phenyl-cytisine 103e (Figure 3-21) confirmed the structure of these 
two isomers. While in the HMBC spectrum of 103e the carbon C6 is long range coupled over 
four bonds to the “ortho” protons H2’ and H6’ (Figure 3-21), in the HMBC of its 3-phenyl 
counterpart 93e a cross peak between C6 and H2’/H6’ is not observed (Figure 3-20). On the 
other hand, in the HMBC chemical shift map of 93e, a correlation peak between C7 and H5 
is present (Figure 3-20). 
In summary, the most important differences between the two phenyl isomers 93e and 103e 
are: 
1. H8 protons appear in 5-phenyl-cytisine 103e as the two most upfield shifted doublets. 
These protons give in 3-phenyl-cytisine 93e, like in cytisine 27, a singlet peak. 
2. Protons H2’ and H6’ (“ortho” protons of the phenyl substituent) experience a stronger 
deshielding (δ 7.69 ppm) in the 3-phenyl-cytisine 93e than in 5-phenylcytisine 103e (δ 
7.19 ppm). 
3. The 13C shifts of C6 in 3-phenyl-cytisine 93e remain similar to the corresponding 
cytisine 27 carbon (δ 150.3/150.7 ppm, respectively). Likewise, the 13C chemical shifts 
of C7 do not significantly differ (δ 35.7/34.9 ppm, respectively). In the 13C NMR 
spectrum of 5-phenyl-cytisine 103e, the chemical shifts of C6 and C7 are shifted 
upfield by approximately ∆ δ 3 ppm (δ 147.5 and 31.6 ppm, respectively).  
4. The coupling constant 3J between H3 and H4 is bigger (3JH3,H4 = 9.5 Hz) than that of 
the coupling between H4 and H5 (3JH4,H5 = 7.2 Hz). 
These differences are shown in the Figure 3-22 and may be used as “diagnostical” tools to 
distinguish a 3- and a 5-aryl substitution in the cytisine skeleton. 
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Figure 3-22 1H and 13C NMR spectrum differences between 3-phenyl- and 5-phenylcytisine 93e 
and 103e [CDCl3, 125 MHz (
13C NMR) and 500 MHz (1H NMR)] 
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3.3.3.3 3-Aryl Analogues of Cytisine 
 
All 1H chemical shifts of the 3-aryl substituted cytisine analogues 94e – 100e were easily 
assigned with the help of the complete assignment of 1H NMR signals for 3-phenyl-cytisine 
93e (Table 3-14).  
Methyl-substitution of the phenyl ring in the structures 94e – 100e did not display any 
significant effect on the 1H chemical shifts of the bispidine and pyridone moieties. The 
alteration of 1H chemical shifts of the “cytisine part” in the aryl substituted analogues 94e – 
100e remain within ∆ δ ± 0.03 ppm, compared to the 1H chemical shift of 3-phenyl-cytisine 
93e (Table 3-14). In the phenyl moiety of 94e – 100e, the H3’ chemical shifts are missing and 
the resulting protons H2’, H4’, H5’ and H6’ show expected multiplicities and chemical shifts, 
depending on the nature of the meta substitution (Table 3-14).  
All data obtained from 1H NMR spectra are in agreement with the “diagnostical” tools 
suggested in the previous chapter (3.3.3.2 3-Phenyl and 5-Phenyl-cytisine 93e and 103e). 
The coupling constant of the AB system (H4 and H5) in 94e – 100e is δ 7.00 – 7.30 Hz, the 
protons H8 always appear as broad singlets around δ 1.96 ppm and the magnitude of the 
downfield shift of H2’ is always bigger than that observed in 5-aryl analogues. 
13C chemical shifts of 3-aryl derivatives of cytisine 94e – 100e are listed in the Table 3-15.  
The 13C chemical shifts of the cytisine moiety in the structures 94e – 100e were largely 
unaffected by the introduction of the meta substituent (Table 3-15). Except for the carbon C3, 
which reflected the differences in various aromatic ring substituents, the cytisine part of the 
molecules retained the chemical shifts observed in 3-phenyl-cytisine 93e. The 13C chemical 
shifts of C3 in the structures 94e – 100e were shifted slightly (δ 124.7 – 129.1 ppm) when 
compared to the chemical shift of C3 in 3-phenyl-cytisine 93e (δ 127.4 ppm) (Table 3-15).  
The analysis and assignment of the 13C NMR signals for the aryl moieties in 94e – 100e had 
been performed mainly on the basis of the additivity rule, known as substituent–induced 
chemical shift “SCS”.283,286 All phenyl ring substituents caused downfield shifts of the α-
carbon (C3’, δ 128.0 ppm), their magnitudes being correlated with their electronegativity. 
Increasing electronegativity of the substituent increased the downfield shift of the α-carbon 
(Table 3-15). Therefore, a strong inductive effect of fluorine in 99e led to the most 
pronounced deshielding of the α-carbon (∆ δ 35.6 ppm); nitro (entry 94e) and 
trifluoromethoxy (entry 97e) substituents caused lower, yet significant, downfield shifts (∆ δ 
20.2 and 21.0 ppm, respectively). The lower electronegativity of chlorine resulted only in a 
moderate downfield shift (∆ δ 5.9 ppm, entry 98e). Methyl substitution of C3’ (entry 95e) or a 
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phenyl attachment (entry 100e) both caused downfield shifts (∆ δ 9.3 and 13.4 ppm, 
respectively), owing to the rule δ(Ctert) < δ(Cquart). 
The large deshielding effect observed on the 13C shift of a carbon atom directly attached to a 
halogen atom (e.g. fluorine) or to a substituent with negative inductive effect (e.g. nitro or 
trifluoromethoxy group) does not apply to the chemical shifts of the β- and γ-carbons. In the 
cases of the electronegative substitution, the 13C chemical shifts of the corresponding γ-
carbons are reported to move upfield.286 Indeed, the 13C chemical shift of C5’ in 3-(3’-
fluorophenyl)-cytisine 99e showed an upfield shift of ∆ δ 1.4 ppm. The SCSs (i.e. the 
additivity increments) of various groups for the 13C chemical shifts of the phenyl carbons in 
the series of 3-aryl-cytisine 93e – 99e are given in Table 3-16. The data found are in 
agreement with the literature SCSs data.286 The additivity increments for OCF3 substitution 
(97e) are not listed, since the literature data for SCSs of a trifluoromethoxy group are still not 
available.  
Table 3-16 Additivity increments [ppm] of various groups for the 13C chemical shifts of the phenyl 
carbons in the series of 3-aryl cytisine derivatives (94e – 96e and 98e – 99e), literature 
SCSs values shown in parentheses
286  
NH
N
O R
1'
2' 3'
4'
5'6'  
                      
                                                                                                                                Additivity Increments [ppm] 
         R =  H  93e      NO2  94e        CH3 95e          CF3 96e       Cl  98e            F  99e 
                  [δ,ppm] 
C1’ 137.00 2.0 (0.8) 0.5 (0.0) 1.1 (-0.3) 2.1 (1.0) 2.4 (0.9) 
C2’ 128.6 -5.3 (-5.3) 0.7 (0.6) -4.8 (-2.6) 0.0 (0.2) -14.6( -14.3) 
C3’ 128.0 20.2 (19.6) 9.3 (9.3) 2.4 (2.6) 5.9 (6.4) 35.6 (35.1) 
C4’ 127.2 -5.3 (-5.3) 0.9 (0.6) -1.9 (-2.6) 0.0 (0.2) -11.6 (-14.3) 
C5’ 128.0 0.9 (0.6) 0.0 (0.0) 0.4 (-0.3) 1.2 (1.0) 1.4 (0.9) 
C6’ 128.6 6.1 (6.0) -2.9 (-3.1) 3.3 (-3.2) -1.9 (-2.0) -4.5 (-4.4) 
 
The 13C chemical shift assignment of the biphenyl substituent in 100e remains incomplete, as 
nine tertiary carbons of the biphenyl moiety possess nearly identical chemical shifts in the 
range δ 125.5 ppm to δ 127.6 ppm. Only the assignments of the quaternary carbons C1’ (δ 
137.8 ppm), C3’ (δ 141.4 ppm) and C1’’ (δ 141.0 ppm) could be estimated, however, they 
might be reversed. Due to the small amount of the substance, detailed 2D NMR correlation 
experiments (e.g. HSQC or HMBC) required for a complete and final assignment were not 
measured.  
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In the 13C NMR spectrum of 3-(3’-fluorophenyl)-cytisine 99e a doublet was observed at δ 
163.6 ppm, corresponding to an aromatic C-F coupling, with a 1JC,F = 244.1 Hz. Generally, 
the long range coupling of fluorine with their neighbouring aromatic carbons greatly facilitate 
the assignment of the remaining 13C chemical shifts. The fluorine-carbon couplings observed 
here ranged over two bonds to C2’ (2JC,F = 21.2 Hz) and C4’ (
2JC,F = 22.4 Hz), over three 
bonds to C1’ (3JC,F = 8.2 Hz) and to C5’ (
3JC,F = 8.5 Hz) as well as over four bonds to C6’ 
(4JC,F = 2.7 Hz) and C3 (
4JC,F = 2.3 Hz) and all of them agreed with literature citation
286 (Table 
3-17). 
Table 3-17 13C -19F Coupling constants in 3-(3’-fluorophenyl)-cytisine 99e, the respective coupling 
carbon atom given in parentheses 
   
 
 
NH
N
O F
1'
2' 3'
4'
5'6'
99e
 
 
 
Also in the 13C NMR spectra of 3-(3’-trifluoromethyl-phenyl)-cytisine 96e and 3-(3’-
trifluomethoxy-phenyl)-cytisine 97e, the 13C-19F couplings were apparent and raised several 
quartets. The characteristic coupling constants (1JC,F = 272.5 Hz; 
2JC,F = 31.7 Hz; 
3JC,F = 3.7 
Hz) found in the spectrum of 96e originate from the direct and the long range couplings 
between fluorine and its adjacent carbons. The constants are nearly identical with the 
literature values reported (Table 3-18). The quartet at δ 121.2 ppm in the 13C chemical shifts 
spectrum of 3-(3’-trifluoromethoxyphenyl)-cytisine 97e with coupling constant of 1JC,F = 257 
Hz was assigned to the carbon of the trifluoromethoxy group. Additionally, in the spectrum of 
97e a long range 13C3’-19F coupling was observed (3J = 1.5 Hz). 
Table 3-18 13C -19F Coupling constants in 3-(3’-trifluoromethyl-phenyl)-cytisine 96e  
NH
N
O CF3
96e
1'
2' 3'
4'
5'6'
 
 
13
C
 -19
F Coupling constant [Hz] 
literature
286
          found 
1JC,F 245 244.1    (C3’) 
 
2JC,F 21 21.2      (C2’) 
  22.4      (C4’) 
 
3JC,F 8 8.2        (C1’) 
  8.5        (C5’) 
 
4JC,F 3 2.3        (C3) 
  2.7        (C6’) 
 
 
13
C
 -19
F Coupling constant [Hz] 
literature
286
            found 
1JC,F 272 272.5      (CF3) 
 
2JC,F 32 31.7        (C3’) 
 
3JC,F 4 3.7          (C2’) 
  3.7          (C4’) 
                                                                             Cytisine: NMR spectroscopy of novel ligands109 
 
3.3.3.4 5-Aryl Analogues of Cytisine 
 
The 1H and 13C chemical shifts of the 5-aryl derivatives of cytisine 103e – 110e are listed in 
Tables 3-20 and 3-21. Assignment of 1H and 13C signals was carried out by comparison with 
the assignments for 5-phenyl-cytisine 103e as well as through the increment additivity rules. 
The 1H chemical shifts of the cytisine moiety of the 5-aryl derivatives 104e – 110e compare 
greatly to those of the cytisine part in the 5-phenyl analogue 103e (Table 3-20). Protons H8 
(assigned to a sharp methylene singlet in the 1H spectra of the 3-aryl derivatives 93e – 100e) 
appeared in the spectra of the 5-aryl derivatives as two separated broad singlets (104e, 107e 
and 108e) or as two broad doublets with geminal couplings 2JH8α/H8β between 12.6 and 13 Hz 
(105e, 106e and 109e). The A and B doublets of the 11 and 13 methylene AB systems are 
all well separated and may be correlated to their geminal partners with the aid of their “roof” 
effect.  
The protons H3 and H4 of the 5-substituted pyridone moiety in the series of 5-aryl derivatives 
103e – 110e, always representing an AB system, display cis coupling constants 3JH3,H4 = 9.1 
– 9.3 Hz. The respective vicinal coupling constants 3JH3,H4 = 9.1 and 9.5 Hz were established 
in the 1H spectrum of cytisine 27 and 5-phenyl-cytisine 103e. These results suggest that the 
meta-substitution on the phenyl ring does not particularly influence the vicinal coupling of the 
H3 and H4 protons.  
However, the meta-substituent changed the 1H chemical shifts of phenyl moiety in 104e – 
110e when compared to the chemical shifts of 5-phenyl-cytisine 103e (Table 3-20). The 
assignment of the four protons H2’, H4’, H5’ and H6’ was feasible through their multiplicities 
and substituent chemical shifts. Significant differences between the chemical shifts of H2’ in 
5-aryl and 3-aryl analogues were observed. The H2’ protons of 3-aryl substituted cytisines 
94e – 100e were deshielded by the neighbouring carbonyl group while in the 5-aryl 
derivatives 103e – 110e this neighbour effect was lacking (Table 3-19).  
Table 3-19 
1
H chemical shifts of H2’ protons in 3- and 5-aryl derivatives of cytisine (signed as 3-
H2’ and 5-H2’) (CDCl3, 500 MHz) 
 
 
1H chemical shifts of H2’ [ppm] 
                         R =    H             CH3            Cl             NO2            CF3           F            OCF3 
3-H2’ 7.69 7.52 7.69 8.53 7.95 7.43 7.58 
5-H2’     7.21 7.00 7.32 8.10 7.46 6.90 7.08 
∆ δ 0.48 0.52 0.37 0.43 0.49 0.53 0.50 
                        ∆ δ = 0.47 ± 0.06 ppm 
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13C chemical shifts of the phenyl moieties in 103e – 110e are in agreement with 13C chemical 
shifts of the corresponding carbons in their 3-aryl counterparts 93e – 100e as well as with the 
predicted values (i.e. 13C chemical shifts of the phenyl ring in 103e ± SCS of the substitutent 
with regard to the position286). Thus, the additivity increments calculated from the 
experimental data are in good accordance with literature SCSs data286 (Table 3-22). 
 
Table 3-22 Additivity increments [ppm] of various groups for the 13C chemical shifts of the phenyl 
carbons in the series of 5-aryl cytisine derivatives (104e – 106e and 109e), literature 
SCSs values shown in parentheses
286
 
NH
N
O
R
1'
2'
3'
4' 5'
6'
 
 
                                  Substituent chemical shifts [ppm] 
        R =  H  103e          NO2 104e        CH3 105e        CF3 106e            F 109e 
                    [δ, ppm] 
C1’ 138.5 1.5 (0.8) -0.1 (0.0) 0.8 (-0.3) 2.1 (0.9) 
C2’ 129.8 -5.6 (-5.3) 0.6 (0.6) -3.3 (-2.6) -13.0 ( -14.3) 
C3’ 128.6 19.8 (19.6) 9.7 (9.3) 2.3 (2.6) 35.0 (35.1) 
C4’ 127.4 -5.5 (-5.3) 0.7 (0.6) -3.1 (-2.6) -13.0 (-14.3) 
C5’ 128.6 0.6 (0.6) -0.2 (0.0) 0.6 (-0.3) 1.5 (0.9) 
C6’ 129.8 5.7 (6.0) -3.0 (-3.1) 3.4 (-3.2) -4.2 (-4.4) 
 
One of the “diagnostical tools” to distinguish the 3- and 5-substituted counterparts is the 
chemical shift difference of approximately δ 3 ppm between the carbons C6 and C7 in the 3-
substituted 93e – 100e and 5-substituted analogues 103e – 110e. While in the 13C NMR 
spectra of cytisine 27 and the 3-phenyl derivatives 93e – 100e the carbons C6 and C7 
display signals around δ 150 ppm and δ 35 ppm, respectively (Table 3-15), the same 
carbons are shifted upfield in the 13C spectra of the 5-substituted analogues 103e – 110e 
(Table 3-21).  Hence, their carbons C6 are located between δ 147.4 – 148.1 ppm and their 
C7 between δ 30.5 – 32.1 ppm. Similar shift mutation, however in the opposite direction, was 
observed for C4 of the 5-substituted derivatives. While 3-substitution did not alter the 13C 
chemical shift of C4 compared with cytisine 27 (δ 137.0 – 137.6 ppm) (Table 3-15), a 5-
substitution resulted in a medium downfield shift of ∆ δ 2.27 ± 0.23 ppm (n=6) and thereby, 
the C4 signals were found between δ 140.8 and 141.4 ppm (Table 3-21). The 13C chemical 
shifts of the remaining carbons in the bispidine and pyridone ring maintained the values 
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found in the spectra of the unsubstituted alkaloid 27 and the 3-substituted analogues 93e – 
100e. 
In the 13C spectra of the compounds 106e, 107e and 109e containing fluorine, characteristic 
13C-19F couplings were observed (Table 3-23). C-F doublets in the 5-(3’-fluoro)-phenyl 
analogue 109e and C-F3 quartets in the spectrum of 106e supported the carbon assignment 
when literature data286 were considered.  The C-F doublet in 109e was found at δ 163.6 ppm 
(literature: δ 163.6 ppm)286 and the chemical shift of the CF3 – quartet in 106e (δ 124.9 ppm) 
also definitely agreed with the value published (δ 124.5 ppm)286. The presence of a CF3-
group gave hints towards the C3’, C2’ and C4’ signals (δ 130.9; 126.5 and 124.3 ppm, 
respectively) which were split into quartets, their shifts matching the literature ppm values (δ 
130.8 ppm for C3’ and δ 125.4 ppm for ortho C2’ and C4’).286 
Table 3-23 13C-19F Coupling constants in 5-(3’-trifluoromethylphenyl)-cytisine 106e (A) and 5-(3’-
fluorophenyl)-cytisine 109e (B), coupling carbon given in parentheses 
  
       
NH
N
O
CF
3
1'2'
3'
4' 5'
6'
106e
A
 
 
          
NH
N
O
F
1'2'
3'
4' 5'
6'
109e
B
   
 
 
 
 
 
 
13
C
 -19
F Coupling constant [Hz]  
literature
286
         found 
1JC,F 272 272.5   (CF3) 
 
2JC,F 32 32.3     (C3’) 
 
3JC,F 4 3.8       (C2’) 
  3.8       (C4’) 
 
13
C
 -19
F Coupling constant [Hz] 
literature
286
          found 
1JC,F 245 247.6   (C3’) 
 
2JC,F 21 21.0     (C2’) 
  21.0     (C4’) 
 
3JC,F 8 7.7       (C1’) 
  8.5       (C5’) 
4JC,F 3 2.7       (C6’) 
  1.7       (C5) 
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3.3.3.5 Heterocyclic Analogues of Cytisine 
 
1H and 13C chemical shifts of the cytisine derivatives 117e – 126e, substituted in 3- and 5-
position with heterocycle are listed in the Tables 3-24, 3-25 and 3-26.  
In general it may be concluded that a 3-substitution with a heterocyclic moiety moved all the 
1H chemical shifts of the cytisine moiety downfield when compared to the unsubstituted 
alkaloid 27 (Table 3-24). The examination of the 13C data obtained from cytisine 27 and its 3-
heterocyclic derivatives 117e – 122e revealed only a difference in the chemical shift of C3, 
whereas the chemical shifts of other cytisine carbons (C2-C13) were largely unaffected 
(Table 3-25).  
The substitution of the position 5 with a heterocycle (123e – 126e) also caused a downfield 
shift of all 1H signals for cytisine moiety (Table 3-26). The 13C chemical shifts of the bispidine 
and pyridone moieties in the structures of the 5-substituted analogues 123e – 126e were 
consistent with the trends reported for 5-aryl derivatives 103e – 110e (i.e. upfield shift of C6 
and C7 signals) (Table 3-26). 
Structures and assignment of NMR signals of the heterocyclic analogues 117e – 126e is 
discussed separately for each set of corresponding 3- and 5-isomer.  
 
3.3.3.5.1 3- and 5-(5’-Indolyl)-cytisine 117e & 123e 
 
The 1H chemical shifts of 3-(5’-indolyl)-cytisine 117e are listed in Table 3-24. The doublet at δ 
6.06 ppm (3J = 7.0 Hz) was assigned to H5. This signal provided the starting point for 
assignments of the remaining aromatic protons located in the region δ 8.3 – 6.0 ppm. In the 
COSY 2D spectrum of 117e (Figure 3-24), H5 displayed a cross peak to a doublet at δ 7.47 
ppm (3J = 7.0 Hz), which therefore was assigned to H4. A broad singlet at δ 8.28 ppm 
appeared as the most downfield shifted signal, it was assigned to the indolic NH group. 
Another singlet at δ 7.92 ppm was recognised as H2’ and it showed only one correlation 
towards the doublet at δ 7.52 ppm. This doublet had an additional cross peak with the 
doublet at δ 7.38 ppm, therefore these two signals were identified as H7’ (coupling with H2’ 
and H6’) and H6’ (coupling with H7’). A pseudotriplet at δ 7.16 ppm produced a cross peak 
with the NH group at δ 8.28 ppm, thus it was assigned to the proton H4’. Finally, the cross 
signal between δ 7.16 ppm and δ 6.54 ppm could only arise from a coupling between H4’ (δ 
7.16 ppm) and H3’ (δ 6.54 ppm).   
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Table 3-26  1H and 13C chemical shifts of 5-heterocyclic derivatives of cytisine 123e – 126e [CDCl3, 
                          500 MHz for 1H NMR; 125 MHz for 13C NMR]  
NH
N
O
R
45
67
8
9 10
11
13
3
2
 
R 
H 
cytisine 27 N
H6'
1'
2' 3'
4'
5'
7'
2'a
5'a
 
123e 
O
CH2
O
6'
1'
2'
3'
4'
5'  
124e 
N
1'
2' 3'
4'
5'6'  
125e 
N
N
CH3
1'
2' 3'
4'
5'  
126e 
H3 6.10 6.49 6.45 6.52 6.46 
H4 7.00 7.28 7.17 7.18 7.22 
H7 2.62 3.14 3.08 2.97 3.13 
H8A 1.81 1.84 1.86 
H8B 
1.65 
1.93 1.91 1.94 
1.88 
H9 2.03 2.30 2.30 2.35 2.31 
H10α 3.57 3.97 3.93 3.95 3.95 
H10β 3.77 4.23 4.18 4.21 4.17 
H11A 3.08 2.82 3.14 3.08 
H11B 
2.70 – 2.75 
2.93 2.72 2.93 2.98 
H13A 2.87 3.08 2.79 2.93 
H13B 
2.70 – 2.75 
2.64 2.92 2.71 2.87 
H2’ --- 7.44 6.65 8.49 7.26 
H3’ --- 6.53 --- --- --- 
H4’ --- 7.26 --- 8.58 --- 
H5’ --- 8.53 (NH) 6.80 7.33 7.38 
H6’ --- 6.98 6.63 7.55 --- 
 5.72 (H5) 7.39 (H7’) 5.97 (CH2) --- 3.91 (CH3) 
C2 163.7 163.2 163.1 163.0 163.1 
C3 116.8 115.7 116.0 116.7 116.3 
C4 138.8 142.2 141.5 141.0 142.0 
C5 105.1 120.5 118.8 115.3 109.4 
C6 150.9 147.6 147.8 148.1 148.2 
C7 35.5 31.6 31.6 31.6 31.8 
C8 26.2 26.4 26.4 26.2 26.3 
C9 27.7 27.4 27.4 27.2 27.3 
C10 49.7 50.4 50.4 50.4 50.4 
C11 53.8 52.2 52.1 51.8 52.4 
C13 52.8 52.9 52.9 52.7 52.9 
C1’ --- 129.8 132.0 134.3 118.5 
C2’ --- 121.7 110.2 148.8 139.1 
C3’ --- 102.6 147.7 --- --- 
C4’ --- 125.1 146.9 150.5 --- 
C5’ --- 135.0 (C5’a) 108.4 123.5 129.1 
C6’ --- 111.1 123.1 137.2 --- 
C7’ --- 123.9 --- --- --- 
 --- 128.0 (C2’a) 101.2 (CH2) --- 39.1 (CH3) 
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In the HSQC experiment of 127e (Figure 3-25), the carbons C2’a and C5’a were identified by 
comparison with literature data286 for the corresponding carbons in the unsubstituted indole 
(Figure 3-23/A). Assignments of C1’ (δ 129.13 ppm) and C3 (δ 128.90 ppm) were achieved 
when 13C chemical shifts for 117e and its 5-counterpart 123e were compared. In both 
spectra, quaternary carbon signals at δ 129.1 (C1’ in 117e) and 129.8 ppm (C1’ in 123e) 
were present, whereas the signal at δ 128.9 ppm (substituted C3 of 117e) was replaced in 
the spectrum of 5-(5’-indolyl)-cytisine 123e in favour of a signal at δ 115.7 ppm 
(unsubstituted C3 of 123e). Vice versa, in the spectrum of 117e the 13C chemical shift of the 
methine carbon C5 was located at δ 105.1 ppm, while in the spectrum of 123e the 
substituted C5 signal was at δ 120.5 ppm.  This comparison, as well as the complete 
assignment of 1H and 13C chemical shifts for 117e allowed a straightforward assignment of all 
1H and 13C chemical shifts for 5-(5’-indolyl)-cytisine 123e. 
The assignment of 13C chemical shifts of the indolyl moieties of both isomers were verified by 
the literature286 comparison (Figure 3-23). Shift differences in the spectra of 117e and 123e 
agree well with the above mentioned diagnostical tools for differentiating the 3- and 5-
isomers (Figure 3-22).  
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Figure 3-23 Comparison of 13C chemical shifts of unsubstituted indole (A, Ref. 286) and indole 
moiety bound to cytisine in positions 3 (B) and 5 (C). Also the diagnostical tools to 
distinguish the isomers 117e and 123e are pictured. 
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Figure 3-24 2D COSY contour plot of 3-(5’-indolyl)-cytisine 117e (CDCl3, 500 MHz) 
H8 
H9      NH12   H7 
H11/H13 
  H10α 
H10β 
H5 
 H3’ 
H4’ 
H6’ 
     H4 
 H7’ 
H2’ 
NH5’ 
NH12 
H8 
H9 
H7 
H11B+H13 
H11A 
H10α 
H10β 
H5 
H3’ 
H4’ 
 
H6’ 
H4 
H7’ 
 
H2’ 
 
  NH5’ 
NH
N
O
NH
6 '
1 '
2 '
3 '
4 '
5 '
7 '
2 'a
5 'a
45
67
8
9 1 0
1 1
1 3
3
2
1 2
 
120Cytisine: NMR spectroscopy of novel ligands  
 
 
Figure 3-25 2D HSQC contour plot of 3-(5’-indolyl)-cytisine 117e [CDCl3, 500 MHz for 
1H NMR; 
125 MHz for 13C NMR]  
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3.3.3.5.2 3- and 5-(3’,4’-Methylenedioxyphenyl)-cytisine 118e & 
124e 
 
In the set of the 3’,4’-methylenedioxyphenyl-cytisines 118e and 124e, the 1H and 13C 
chemical shift assignments were first completed for the 5-isomer 124e. Herein, the cytisine 
moiety could be easily assigned by comparison with previous assignments, since the 5-
substituent of any type was found not to influence the chemical shifts of the cytisine moiety 
(Table 3-26). The aromatic protons of 124e were assigned with the aid of the 2D COSY 
spectrum (Figure 3-26). The proton at δ 6.45 ppm was assigned to H3. H3 displayed a cross 
signal to the doublet at δ 7.17 ppm, this was therefore assigned to H4. The doublet at δ 6.65 
ppm except of its meta coupling (4J = 1.8 Hz) showed no cross signal and was assigned to 
H2’. The doublet of doublet at δ 6.63 ppm was assigned to H6’, due to its meta coupling (4J = 
1.8 Hz towards H2’). The significant cross peak for H6’ and a doublet at δ 6.80 ppm proved 
this signal to be H5’.  
The HSQC spectrum of 124e assigned peaks to the carbons bonded with protons (Figure 3-
27). The quaternary carbons C3’ and C4’ had nearly identical chemical shifts (δ 146.9 and 
147.7 ppm) and could not be unambiguously assigned. The substitution of C5 caused a 
downfield shift of ∆ δ 14.6 ppm compared to the 13C chemical shift of an unsubstituted C5 in 
the cytisine spectrum (δ 104.2 ppm). The remaining 13C chemical shift at δ 132.0 ppm was 
assigned to the quaternary carbon C1’. 
The assignment of 1H and 13C chemical shifts of 3-(3’,4’-methylenedioxy-phenyl) derivative 
118e (Table 3-24 and 3-25) was completed with the information obtained from the 
assignment of 124e and the known NMR spectral differences between the 3- and 5 isomers. 
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Figure 3-26 2D COSY contour plot of 5-(3’,4’-methylenedioxyphenyl)-cytisine 124e (CDCl3, 500 
MHz) 
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Figure 3-27 2D HSQC contour plot of 5-(3’,4’-methylenedioxyphenyl)-cytisine 124e [CDCl3, 500 
MHz (1H NMR); 125 MHz (13C NMR)] 
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3.3.3.5.3 3- and 5-(3’-Pyridyl)-cytisine 119e & 125e 
 
The protons’ chemical shifts for the cytisine moiety of the 3-(3’-pyridyl)-cytisine 119e (Table 
3-24) were feasible by comparing them with those of 3-phenyl derivative 93e and the 
assignment was verified with further information obtained from the COSY experiment (Figure 
3-28). A comparison of 1H signals of the cytisine partial structures of 93e and 119e revealed 
no significant differences (Table 3-13 and 3-24).  The pyridyl moiety in 119e was easily 
assigned from the COSY mapping (Figure 3-28). Proton H2’ and H4’ both are attached to a 
carbon with nitrogen as a neighbour and were expected to be shifted downfield. Therefore, 
the doublet at δ 8.78 ppm with a vicinal coupling constant of 4J = 1.6 Hz was assigned to H2’. 
This proton correlated to the doublet of doublet of doublet (ddd) at δ 8.16 ppm, which also 
showed a coupling of 4J = 1.6 Hz and was identified as H6’. The H6’ proton showed one 
further coupling to the more upfield shifted “ddd” signal at δ 7.29 ppm, which was assigned to 
H5’. The H4’ proton was recognised as a doublet of doublet at δ 8.49 ppm, due to its cross 
signals to H5’ and H6’ and its respective coupling constants of 3J = 4.7 Hz (to H5’) and 4J = 
1.6 Hz (to H6’).  
Thus, the COSY spectrum revealed a complete 1H shift data set and the HSQC spectrum 
(Figure 3-29) identified the 13C chemical shifts of carbons attached to protons. The signals at 
δ 161.9 and 151.5 ppm were assigned to the carbonyl C2 and the quaternary C6. The two 
remaining signals at δ 133.2 and 123.9 ppm were attributed to C1’ and C3, respectively.  The 
13C chemical shift for carbon 3 in pyridine (equivalent to C1’) is reported to be δ 123.6 
ppm.286  As the deshielding of the carbon nucleus by aryl substitution causes a downfield 
shift, the signal at δ 133.2 ppm had to be assigned to C1’. The remaining signal at δ 123.9 
ppm was then attributed to C3. Hence, the C3 suffered downfield shifting by ∆ δ 7.1 ppm 
through the introduction of the pyridyl moiety. 
The complete assignment of the 1H and 13C chemical shifts of 119e, additivity rules and the 
estimated chemical shifts allowed a fast assignment of the 1H and 13C NMR spectral data for 
5-(3’-pyridyl)-cytisine 125e (Table 3-26). 
 
3.3.3.5.4 3-(4’-Pyridyl)-cytisine 120e 
 
The 1H chemical shifts of the cytisine moiety in 120e (Table 3-24) were clearly assigned 
through an analogy with 3-(3’-pyridyl)-cytisine 119e. The 4-pyridyl moiety is a symmetrical 
residue that possesses two sets of equivalent protons – “ortho” (H3’ and H5’) and “meta” (H2’ 
and H6’) protons with regard to the nitrogen. The most shifted downfield doublet of doublet  
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Figure 3-28 2D COSY contour plot of 3-(3’-pyridyl)-cytisine 119e (CDCl3, 500 MHz) 
 
was assigned to the pair of “ortho” protons (δ 8.57 ppm). This signal displayed a cross peak 
to the doublet of doublet at δ 7.67 ppm, this being assigned to H2’ and H6’. 
The HSQC chemical shift map of 120e identified the equivalent carbons C3’/C5’ (δ 149.6 
ppm) as well as C2’/C6’ (δ 123.9 ppm). The quaternary C1’ was located at δ 144.9 ppm and 
the C3 was due to the downfield shift of the pyridyl substitution assigned to the 13C peak at δ 
122.8 ppm (Table 3-25). 
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Figure 3-29 2D HSQC contour plot of 3-(3’-pyridyl)-cytisine 119e [CDCl3, 500 MHz (
1H NMR); 125 
MHz (13C NMR)] 
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3.3.3.5.5 3-(Quinolin-8’-yl)-cytisine 121e 
 
The 1H and 13C signals of the cytisine moiety in 121e were assigned with the aid of previous 
findings (i.e. assignments of 117e – 120e, Table 3-24 and 3-25). The assignment of the 
quinoline moiety was facilitated by comparison of experimental and literature data for the 
unsubstituted quinoline286 and verified with information obtained from the COSY map (Figure 
3-30). The most deshielded signal at δ 8.86 ppm was identified as H7’ and this provided a 
starting point for the assignment of the remaining quinoline protons. A cross-peak between 
H7’ and a doublet of doublet at δ 8.15 ppm approved this “dd” to be H5’.  The H7’ proton also 
displayed a cross peak to the doublet of doublet at δ 7.35 ppm (4J = 4.1 Hz) and it was 
therefore assigned to H6’. The correlation between H5’ and H6’ was observed as 3J = 8.2 Hz.  
The triplet at δ 7.56 ppm (3J = 7.3 Hz) was attributed to H3’. This signal showed cross-peaks 
to the two “dd” signals located at δ 7.78 and 7.85 ppm,  which were identified as H4’ and H2’, 
respectively. 
The one-bond 1H-13C correlations detected in the HSQC spectrum allowed assignments of 
13C signals to the carbons linked to protons (Figure 3-31). The quaternary carbons C4’a (δ 
128.6 ppm) and C8’a (δ 146.5 ppm) were identified with regard to the literature data of the 
corresponding carbons in the unsubstituted quinoline (δ 128.0 and 148.1 ppm, 
respectively)286 The two remaining signals were assigned to carbons C1’ (δ 139.6 ppm) and 
C3 (δ 136.5 ppm) on the basis of calculated chemical shifts and chemical shifts of 
unsubstituted C1’ (δ 129.2 ppm) in quinoline and C3 (δ 116.8 ppm) in cytisine 27. However, 
the unambiguous differentiation of these two carbons would have required further NMR 
experiments, such as a 2D HMBC correlation map. 
 
3.3.3.5.6 3- and 5-(1-Methyl-1H-pyrazol-4’-yl)-cytisine 122e & 
126e 
 
The assignment of the 1H and 13C chemical shifts of the cytisine moieties in 122e and 126e 
(Tables 3-24, 3-25 and 3-26) was consequently achieved following those of 3- and 5-
(hetero)aryl substituted analogues (e.g. 93e, 103e, 119e or 125e).   
Two singlets shifted most downfield at δ 8.29 / 7.80 ppm in the 1H spectrum of 122e and at δ 
7.38 / 7.26 ppm in the spectrum of the 5-analogue 126e were assigned to H5’ and H2’ of the 
1-methyl-1H-pyrazol-4’-yl moiety. The HSQC spectrum located four methine carbons at δ 
136.8/139.1 ppm (C2’) and δ 129.9/129.1 ppm (C5’) for 122e and 126e, respectively. 
 
128Cytisine: NMR spectroscopy of novel ligands  
 
 
Figure 3-30 2D COSY contour plot of 3-(quinolin-8’-yl)-cytisine 121e (CDCl3, 500 MHz) 
 
Interestingly, the substitution of position 3 with 1-methyl-1H-pyrazol-4’-yl led to a significant 
upfield shift (∆ δ 6.4 ppm) of the 13C signal of C4. Upfield shift of C4 has been observed 
when position 5 was substituted with both aryl and heteroaryl moiety, but never with the 3-
substitution. The ∆ δ is remarkable as well, since the 5-substitution caused a shift of no more 
than 3.4 ppm. 
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Figure 3-31 2D HSQC contour plot of 3-(quinolin-8’-yl)-cytisine 121e [CDCl3, 500 MHz (
1H NMR); 
125 MHz (13C NMR)] 
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3.3.3.6 Disubstituted Analogues of Cytisine 
 
The 1H and 13C signals assignment of the disubstituted cytisine derivatives, 5-bromo-3-
phenyl-cytisine 128e and 5-bromo-3-(3’-pyridyl)-cytisine 129e, is listed in the Table 3-27 and 
it was easily completed with the aid of previous assignments, especially those of 3-
phenylcytisine 93e and 3-(3’-pyridyl)-cytisine 119e.  
The position of the substituents could be proved with the analysis of all previously gathered 
information. For example, in the structure of 128e the proton H2’ was located at δ 7.65 ppm, 
which compares well with the chemical shift of H2’ in 93e (δ 7.69 ppm). Thus, both signals 
were deshielded by the adjacent carbonyl group. Furthermore, the 13C chemical shift of C5 (δ 
98.8 ppm) compared to the chemical shift of the unsubstituted C5 in 93e (δ 104.9 ppm) gave 
an additivity increment of -6.1 ppm that compares well to the literature value of bromine’s 
SCS (-5.4 ppm)286.  
Similarly, the 1H chemical shifts of the pyridyl moiety in 129e were found to correlate greatly 
with the chemical shifts of the corresponding protons in 119e. The carbon C5 was located in 
129e at δ 98.7 ppm, which represented an upfield shift of -6.3 ppm when compared to the 
13C chemical shift of the unsubstituted C5 in 119e (δ 105.0 ppm).  
Due to the substitution of position 5, the H8 protons of both derivatives 128e and 129e 
appeared as two separated broad doublets with vicinal coupling of 2J = 12.9 Hz (128e) and 
13.2 Hz (129e). The signals of H11 and H13 were also separated doublets each with the 
mutual coupling of 2J = 12.3 Hz (for 128e) and 2J = 12.0 Hz (for 129e). 
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Table 3-27  1H and 13C chemical shifts of disubstituted derivatives of cytisine 128e and 129e 
[CDCl3; 500 MHz (
1H NMR); 125 MHz (13C NMR)] 
   
NH
N
O
X
Br
1'
2
3
45
67
8
9 10
11
13 2' 3'
4'
5'6'
X = C    128e
X = N    129e
 
 
 
3-Ph-5-Br-cyt  
128e 
δ [ppm] 
3-(3’pyridyl)-5-Br-
cyt 129e 
δ [ppm] 
 
3-Ph-5-Br-cyt 
128e 
δ [ppm] 
3-(3’-pyridyl)-5-Br-
cyt 129e 
δ [ppm] 
H3 --- --- C2 161.2 161.0 
H4 7.60 7.67 C3 128.6 125.3 
H5 --- --- C4 140.4 140.6 
H7 3.36 3.42 C5 98.8 98.7 
H8A 1.98 2.02 C6 147.0 149.1 
H8B 1.94 1.97 C7 34.9 35.0 
H9 2.34 2.39 C8 26.4 26.4 
H10α 3.96 4.00 C9 27.6 27.5 
H10β 4.13 4.16 C10 50.3 50.4 
H11A 3.08 3.12 C11 51.3 51.4 
H11B 2.99 3.03 C13 52.7 52.7 
H13A 3.18 3.25 C1’ 136.0 131.9 
H13B 2.96 2.98 C2’ 128.6 148.8 
H2’ 7.65 8.81 C3’ 128.1 N 
H3’ 7.37 N C4’ 127.8 148.3 
H4’ 7.30 8.55 C5’ 128.1 122.9 
H5’ 7.37 7.33 C6’ 128.6 136.1 
H6’ 7.65 8.13    
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3.4 In Vitro Pharmacology of Novel nAChR Ligands based 
on Cytisine 
 
In order to evaluate the impact of the substituents at positions 3 or 5 on the binding affinity of 
cytisine 27, all novel ligands were investigated in radioligand binding studies at several 
nAChR subtypes. 
For determination of α4β2* affinity, rat brain membranes and [3H]epibatidine were employed. 
Ki values for inhibition of [3H]MLA binding (α7* binding site) was measured also in rat brain 
membranes. Affinity for the ganglionic α3β4* nACh receptor was determined in assays 
performed with calf adrenals and the radioligand [3H]epibatidine. Torpedo californica 
electroplax provided tissues rich of (α1)2β1γδ receptor and the binding studies were 
completed with [3H]epibatidine.  
The receptor subtypes are designated with an asterix, following the IUPHAR 
recommendation to indicate the receptor subtype with an asterix, if a native tissue is used, 
where the definite subtype composition is not exactly known.  
The radioligand binding studies were performed by Aliaa Abdelrahman (research group of 
Dr. D. Gündisch). 
 
3.4.1 Structure-Activity Relationship of 3-Phenyl Analogues 
3.4.1.1 Results of the Radioligand Binding Studies  
 
α4β2* nAChRs (Table 3-28) 
Cytisine 27 possesses picomolar affinity for α4β2* nAChR (Ki = 0.122 nM). The introduction 
of a phenyl moiety into position 3 reduced the affinity of the parent alkaloid more than 1000-
fold (Ki = 128 nM for 93e). The bulkier m-biphenyl substituent (100e) showed the same effect 
(Ki = 200 nM).  
Meta-substitution of the phenyl moiety exerted various effects on α4β2* binding, but none of 
the 3-arylated cytisine ligands exhibited higher binding to α4β2* nAChR than the parent 
alkaloid 27. The affinity of 94e – 100e was found to be influenced by both steric and 
electrostatic effects produced by substituents in the meta-position of the phenyl ring. While a 
substitution of the meta-position with bulky electron withdrawing chlorine resulted in an 
approximately 1630-times less potent ligand 98e (Ki = 199 nM), the small electron 
withdrawing fluorine (compound 99e) in the same position caused only 45-fold decrease of 
the affinity (Ki = 5.7 nM) compared to cytisine 27. Strong electron withdrawing trifluoromethyl  
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Table 3-28 Binding affinity values (Ki) for 3-aryl derivatives of cytisine 93e – 100e at α4β2*, α7*, 
α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]b 
α3β4* 
[3H]epi 
calf adrenals 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
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Ki [nM]a 
NH
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N
O
 
 
93e 
 
128 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O NO2
 
 
94e 
 
23 
 
> 10,000 
 
> 2,000 
 
> 10,000 
NH
N
O CH3
 
 
95e 
 
28 
 
> 10,000 
 
>10,000 
 
> 10,000 
NH
N
O CF3
 
 
96e 
 
8.3 
 
> 10,000 
 
3,700 
 
> 10,000 
NH
N
O OCF3
 
 
97e 
 
67 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O Cl
 
 
98e 
 
199 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O F
 
 
99e 
 
5.7 
 
> 10,000 
 
1,200 
 
> 10,000 
NH
N
O Ph
 
 
100e 
 
200 
 
> 10,000 
 
>10,000 
 
> 10,000 
 
a) values are the mean from at least n = 3 to 5 independent assays 
b) preliminary results 
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group has the same impact on the binding affinity and the compound 96e shows nearly the 
same Ki value (Ki = 8.3 nM). Substitution of the phenyl ring with larger electron withdrawing 
nitro (compound 94e) and trifluoromethoxy (compound 97e) groups resulted in less potent 
ligands (Ki = 23 and 67 nM, respectively), when compared to compounds 96e and 99e.  
The role of the electron withdrawing properties is obvious from the binding affinities of 3-(m-
tolyl)-cytisine 95e (Ki = 28 nM) and the corresponding trifluoromethyl analogue 96e (Ki = 8.3 
nM). The size of the methyl and the trifluoromethyl moiety is nearly identical, but the methyl 
group as an electron donating substituent led to a 3-fold decrease in affinity compared to 
substitution with trifluoromethyl, which possesses strong electron withdrawing properties. 
α7* nAChR (Table 3-28) 
The binding affinity of cytisine 27 to α7* nAChR (Ki = 250 nM) was decreased via introduction 
of m-substituted phenyl moieties into position 3. The ligands 93e – 100e displayed Ki values 
> 10,000 nM. 
α3β4* nAChR (Table 3-28) 
The introduction of a phenyl moiety into position 3 decreased the cytisine’s 27 binding to the 
ganglionic nACh receptors (Ki = 19 nM). The ligands 93e – 100e displayed Ki > 1,200 nM, 
whereas the ligands featuring an electron withdrawing group, i.e. 3-(3’-trifluoromethylphenyl)-
cytisine 96e (Ki = 3,700 nM) and 3-(3’-fluorophenyl)-cytisine 99e (Ki = 1,200 nM) displaced 
[3H]epibatidine from the α3β4* binding sites in calf adrenals with highest affinities. Thus, the 
most potent α4β2* ligands possess the highest affinity for α3β4* nACh receptor.  
 
(α1)2β1γδ nAChR (Table 3-28) 
Cytisine 27 binds to the (α1)2β1γδ subtype with Ki = 1,300 nM. Substitution of the position 3 
in the cytisine backbone with various meta-substituted phenyl moieties (93e – 100e) resulted 
in Ki values >10,000 nM. 
 
3.4.1.2 Discussion 
 
According to the Sheridan model of the nicotinic pharmacophore108, cytisine 27 binds to the 
nAChR via two “bridges” – the bispidine nitrogen is responsible for pi-cation interaction and 
the pyridone oxygen (acting as hydrogen bond acceptor – HBA) builds hydrogen bonds with 
amino acids of the receptor’s binding domain.  
Previous SAR studies revealed that a substitution of the cytisine’s secondary amine caused 
dramatic loss of α4β2* affinity118,122,123, but halogenation of the α-position to the carbonyl 
group (position 3) improved the binding affinity and the 3-bromo analogue 40 displayed the 
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highest affinity (Ki = 0.010 nM).
118,183 These resuIts suggested, that next to the carbonyl 
oxygen accepting the hydrogen bond there is a region that accommodates the halogen 
substitution, but it was difficult to state how bulk-tolerant this region is.  
The results presented herein reveal that the introduction of a bulky aryl moiety into the 
position 3 of cytisine 27 decreases the affinity of this highly α4β2* potent ligand (Ki = 0.122 
nM). 3-Phenyl-cytisine 93e and 3-(m-biphenyl)-cytisine 100e displayed more than 1000-fold 
lower affinity (Ki = 128 and 200 nM, respectively) than the parent alkaloid 27. On the other 
hand, the addition of electron withdrawing fluoro, trifluoromethyl or nitro group to the phenyl 
moiety led to ligands 99e, 96e and 94e which showed higher affinity (Ki = 5.7 – 23 nM) than 
the parent 3-phenyl-cytisine 93e (Ki = 128 nM).  
Binding affinities of “all-carbon” analogues of cytisine 57 (Figure 3-32) support this 
hypothesis, since increasing the size of the substituents in the position that parallels the 
position 3 in cytisine 27 diminished affinity (e.g. Ki > 500 nM for phenyl analogue 57j, Figure 
3-32).185 However, the results presented by Coe et al185 also showed that while the 
introduction of an amino moiety (electron donating group) did not improve the affinity (Ki > 
500 nM for 57m), the introduction of an electron withdrawing substituent (e.g. trifluoromethyl 
57k or methoxy 57l) increased the binding to α4β2 nAChR subtype (Ki = 200 and 370 nM, 
respectively) (Figure 3-32).  
 
NH
R
57a   R = H                  Ki = 34 nM   (hα4β2, HEK293 cells)
57j    R = Ph                Ki > 500 nM (hα4β2, HEK293 cells)
57l    R =4-PhOMe      Ki = 370 nM (hα4β2, HEK293 cells)
57k   R =4-PhCF3        Ki = 200 nM (hα4β2, HEK293 cells)
57m  R =3-PhNH2       Ki  > 500 nM (hα4β2, HEK293 cells)
 
Figure 3-32 Binding affinities of 3-aryl substituted “all-carbon” derivatives of cytisine 57 [Ref.185]  
 
Thus, the position 3 of the cytisine backbone seems to possess dimensional limits, however 
the substituent’s volume itself is not the crucial factor for the α4β2 affinity. Increasing the size 
of the substituent via an addition of an electron-withdrawing group (e.g. phenyl 93e → 
trifluoromethylphenyl 96e) leads to an improvement of the binding affinity (e.g. Ki = 128 nM  
→ Ki = 8.3 nM).  
Another example is the comparison of the binding affinities of nitro analogues 94e, 57f and 
58 (Figure 3-33).  A nitro group directly bound to the cytisine backbone results in only 3-times 
lower affinity than cytisine 27 (Ki = 0.122 nM) and 3-nitrocytisine 58 retains picomolar Ki 
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value (Ki = 0.42 nM).
183 Introducing a phenyl ring between the cytisine and the nitro moiety 
further decreases the α4β2* affinity (Ki = 23 nM for 94e). The nitro group directly bound to the 
“all-carbon” cytisine scaffold provides ligands 57f with low nanomolar binding affinity, even if 
the HBA carbonyl group is missing.185  
 
NH
N
O NO2
NH
N
O
NO2
NH
NO2
                    58
Ki = 0.42 nM (α4β2, rat brain)
                      57f
Ki = 4.9 nM (α4β2, HEK293 cells)
                 94e
Ki = 23 nM (α4β2, rat brain)  
Figure 3-33 Structures and Ki values of nitro derivatives of cytisine [Ref. 183, 185]  
 
 
These collective findings suggest that small electron-withdrawing groups in the position 3 of 
the cytisine 27 core play an important role in the α4β2* receptor recognition.   
The introduction of phenyl moiety into position 3 led to cytisine derivative 93e with 
dramatically decreased affinity (Ki > 10,000 nM) for α3β4* nACh receptor compared to the 
lead 27 (Ki = 19 nM). An electron withdrawing substitution (CF3 and F) in the meta-position of 
phenyl moiety provided ligands 96e and 99e with micromolar α3β4* affinity (Ki = 1,200 – 
3,700 nM), whereas ligands with other meta-substituents (i.e. CH3, OCF3, Ph, Cl) showed 
lower inhibition of [3H]epibatidine binding in calf adrenals preparation (Ki > 10,000 nM). Thus, 
the bulk tolerating region next to the carbonyl group seems to be more limited for the α3β4* 
than for α4β2* affinity.  
The substitution of position 3 with aryl moieties was found to be detrimental for α7* and 
(α1)2β1γδ affinity as all ligands in the series under consideration showed lower inhibition of 
[3H]MLA and [3H]epibatidine binding in rat brain membranes and crude membrane fraction of 
Torpedo californica electroplax (Ki > 10,000 nM). 
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3.4.2 Structure-Activity Relationship of 5-Phenyl Analogues  
3.4.2.1 Results of the Radioligand Binding Studies 
 
α4β2* nAChR (Table 3-29) 
The introduction of a phenyl moiety into the position 5 of the cytisine 27 (Ki = 0.122 nM) 
decreased the binding affinity (Ki = 45 nM for 103e). The introduction of m-substituted phenyl 
moieties resulted in analogues with various α4β2* affinities. Both electron donating (CH3 in 
105e) and electron withdrawing (CF3 and OCF3 in 106e and 107e, respectively) substituents 
modified the affinity of 5-phenyl-cytisine 103e (Ki = 45 nM) very slightly (Ki = 23 – 55 nM). 
Surprisingly, the Ki value of 300 nM makes the 5-(3’-fluoro-phenyl) analogue 109e the less 
potent ligand in the series of 5-aryl derivatives. The biphenyl analogue 110e displayed affinity 
of Ki = 190 nM.  The introduction of m-nitrophenyl moiety into position 5 resulted in a ligand 
104e that displaced [3H]epibatidine from the rat brain with a high affinity (Ki = 3.7 nM). 
 
α7* nAChR (Table 3-29) 
Cytisine 27 binds to the α7* nACh receptor with Ki = 250 nM. Substitution of the position 5 in 
the cytisine backbone with various meta-substituted phenyl moieties (compounds 103e – 
110e) resulted in Ki values > 10,000 nM. 
 
α3β4* nAChR (Table 3-29) 
All 5-arylated cytisine analogues 103e – 110e possessed Ki > 10,000 nM, with an exception 
of 104e. The 5-(3’-nitrophenyl) derivative 104e inhibited [3H]epibatidine binding in calf 
adrenals with a Ki value of 481 nM. 
 
(α1)2β1γδ nAChR (Table 3-29) 
All compounds in the series of 5-phenyl cytisine analogues 103e – 110e displayed Ki > 
10,000 nM when tested in radioligand binding assays employing a crude membrane fraction 
of Torpedo californica electroplax  
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Table 3-29 Binding affinity values (Ki) for 5-aryl derivatives of cytisine 103e – 110e at α4β2*, α7*, 
α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]b 
α3β4* 
[3H]epi 
calf adrenals 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
NH
N
O
 
 
  27 
 
0.122 
 
250 
 
19  
 
1,300 
NH
N
O
 
 
103e 
 
45 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
O2N
 
 
104e 
 
3.7 
 
> 10,000 
 
481 
 
> 10,000 
NH
N
O
CH3
 
 
105e 
 
24 
 
> 10,000 
 
>10,000 
 
> 10,000 
NH
N
O
F3C
 
 
106e 
 
55 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
F3CO
 
 
107e 
 
23 
 
> 10,000 
 
> 10,000 
 
> 10,000 
Continued on page 139 
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Continued from page 138 
NH
N
O
Cl
 
 
108e 
170b > 10,000 > 10,000 > 10,000 
NH
N
O
F
 
 
109e 
 
300 
 
> 10,000 
 
> 2,000 
 
> 10,000 
NH
N
O
Ph
 
 
110e 
 
190 
 
> 10,000 
 
>10,000 
 
> 10,000 
 
a) values are the mean from at least n = 3 to 5 independent assays 
b) preliminary results 
  
3.4.2.2 Discussion 
 
Previous studies118,183 with 5-halogenated cytisine derivatives suggested that the position 5 is 
more bulk-tolerant than the position 3 but does not favour substituents with high 
electronegativity. Results presented herein confirm the bulk-tolerating properties of position 
5. The introduction of a phenyl moiety into the position 5 of cytisine 27 caused reduction of 
binding affinity, but the 5-phenyl-cytisine 103e (Ki = 45 nM) was 3-times more potent than its 
corresponding 3-phenyl analogue 93e (Ki = 128 nM). The derivative 110e possessing 3-
biphenyl moiety in the position 5 shows binding affinity (Ki = 190 nM) very similar to that of 
the corresponding 3-substituted analogue 100e (Ki = 200 nM). Thus, the 3- and 5-substituted 
counterparts seem to become equipotent with the increasing size of the substituents.  
The second hypothesis regarding the negative impact of the high electronegativity was 
confirmed with the ligand 109e that possesses fluorine in the meta-position of the phenyl 
moiety and shows the lowest affinity (Ki = 300 nM) in the series of 5-arylated cytisine 
analogues 103e – 110e. Thus, although the high electronegativity and electron withdrawing 
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effect is preferred for position 3, the same effect in position 5 is detrimental for α4β2* affinity.  
Substituents such as methyl (entry 105e), trifluoromethyl (entry 106e) or trifluoromethoxy 
(entry 107e) do not significantly alter the α4β2* binding affinity (Ki = 23 – 55 nM) when 
compared to 5-phenyl-cytisine 93e (Ki = 45 nM). 
5-(3’-Nitro-phenyl) analogue 104e exhibits the highest affinity in the series under 
consideration (Ki = 3.7 nM) and represents an 18-fold increase of the affinity in comparison to 
5-nitro-cytisine 59 (Ki = 65.6 nM)
183. It could be hypothesised that 104e binds to α4β2* nACh 
receptor in a new fashion. The pi-cation interaction between the basic nitrogen and electron 
rich aromatic acid residues of the binding domain remains, but the HBA function in the ligand 
104e is presented not by the carbonyl oxygen, but by the oxygen in the nitro group. The low 
nanomolar affinity of 5-nitro “all-carbon” analogue of cytisine 57h supports the presumption 
of the new binding mode, since the compound 57h, although missing the “conventional” HBA 
functionality (pyridone’s oxygen in cytisine 27), is able to inhibit [3H]nicotine binding in cells 
expressing α4β2* nAChRs (Ki = 14 nM).
185  Figure 3-34 illustrates a very simplified version of 
the new binding mode. In order to follow and prove this theory, one needs to synthesise and 
evaluate ligands bearing nitro group at various distances from bispidine’s nitrogen and avoid 
of any other HBA functionality.  
 
N
+
N
OH
H
α4β2 binding domain
N
O
N
+H
H
N
+ OO
α4β2 binding domain
N
+H
H
N
+
O
O
α4β2 binding domain
        27
Ki = 0.122 nM
        104e
   Ki = 3.7 nM
        57h
   Ki = 14 nM
A B C
 
Figure 3-34 Binding mode of cytisine 27 (A). A simplified version of the proposed new binding 
mode for the nitro analogues 104e and 57h (B and C). [Ki values for 57h from Ref. 
185] 
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3.4.3 Structure-Activity Relationship of Heterocyclic 
Analogues  
3.4.3.1 Results of the Radioligand Binding Studies  
3.4.3.1.1 3-Heterocyclic Cytisine Analogues  
 
α4β2* nAChR (Table 3-30) 
The introduction of various heteroaromatic moieties into position 3 resulted in compounds 
that inhibited [3H]epibatidine binding in rat brain membrane preparations (Table 5-3). 
Compound 117e, substituted with the 5’-indolyl moiety, had the lowest affinity (Ki = 853 nM) 
not only in the series under consideration but also among all novel cytisine derivatives. The 
introduction of the 3’-pyridyl and 4’-pyridyl residues into position 3 led to highly potent ligands 
119e and 120e (Ki = 0.91 and 3.9 nM, respectively). The compound 122e, substituted with a 
4’-(1-methyl-1H-pyrazole) moiety showed Ki value of 0.177 nM and thus is the analogue with 
highest α4β2* affinity. The addition of bulkier 3,4-methylenedioxyphenyl and quinolin-8-yl 
moieties led to analogues 118e and 121e with similar affinity (Ki = 110 and 95 nM, 
respectively). 
α7* nAChR (Table 3-30) 
The 3-heteroaryl cytisine derivatives 117e – 122e showed Ki values > 10,000 nM. 
 
α3β4* nAChR (Table 3-30) 
In the α3β4* binding assays, the 3-heteroaryl derivatives of cytisine 117e – 122e exhibit 
diverse structure-affinity patterns. The 3-(N-methyl-1H-pyrazol-4’-yl)-cytisine 122e possesses 
affinity (Ki = 33 nM) comparable to the affinity of the parent alkaloid 27 (Ki = 19 nM), whereas 
the 3-(3’-pyridyl) and 3-(4’-pyridyl) analogues 119e and 120e possess 3- and 11-fold lower 
affinity than cytisine 27 (Ki = 119 and 436 nM, respectively). The remaining 3-heteroaryl 
cytisine derivatives 117e, 118e and 121e show Ki > 10,000 nM. 
 
(α1)2β1γδ nAChR (Table 3-30) 
Substitution of the position 3 in cytisine 27 with heteroaryl moieties led to ligands 117e – 
122e with decreased affinity for muscle nACh receptor (Ki > 5,000 nM). 
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Table 3-30 Binding affinity values (Ki) for 3-heteroaryl derivatives of cytisine 117e – 122e at 
α4β2*, α7*, α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]b 
α3β4* 
[3H]epi 
calf adrenals 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
NH
N
O
 
 
  27 
 
0.122 
 
250 
 
19  
 
1,300 
NH
N
O
NH
 
 
117e 
 
853 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
O
O
 
 
118e 
 
110 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
N
 
 
119e 
 
0.91 
 
> 10,000 
 
119 
 
> 10,000 
NH
N
O
N
 
 
120e 
 
3.9 
 
> 10,000 
 
436 
 
> 10,000 
NH
N
O N
 
 
121e 
 
95 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
N
N
CH3
 
 
122e 
 
0.177 
 
> 10,000 
 
33 
 
> 5,000 
 
a) values are the mean from at least n = 3 to 5 independent assays 
b) preliminary results 
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3.4.3.1.2 5-Heterocyclic Cytisine Analogues 
 
α4β2* nAChR (Table 3-31) 
Four cytisine analogues 122e – 126e bearing heterocyclic substituent in position 5 exhibited 
binding affinities for the α4β2* subtype in the low nanomolar range (Ki = 2.2 – 96 nM). The N-
methyl-1H-pyrazole cytisine analogue 126e had the highest affinity (Ki = 2.2 nM) whereas the 
3’,4’-methylenedioxyphenyl analogue 124e showed the lowest affinity (Ki = 96 nM) of these 
four derivatives.  5-(5’-indolyl)- and 5-(3’-pyridyl) derivatives 123e and 125e displayed similar 
binding affinities (Ki = 20.4 and 10.9 nM, respectively). 
 
α7* nAChR (Table 3-31) 
All compounds in the series of 5-heteroaryl cytisine analogues 123e – 126e showed Ki > 
10,000 nM when tested in radioligand binding assays employing rat brain membranes and 
[3H]MLA. 
α3β4* nAChR (Table 3-31) 
The addition of a heterocyclic moiety into position 5 provided ligands 123e – 126e with 
various affinity for the α3β4* receptor. Two analogues, namely 125e (Ki = 4,300 nM) and 
126e (Ki = 656 nM) inhibited the [
3H]epibatidine binding in the calf adrenals preparation 
stronger than another two analogues 123e and 124e (Ki > 10,000 nM). 
 
(α1)2β1γδ nAChRs (Table 3-31) 
Cytisine derivatives 123e – 126e bearing heteroaryl moiety in position 5 exhibit Ki > 10,000 
nM when evaluated in radioligand binding assays employing [3H]epibatidine and Torpedo 
californica electroplax. 
 
3.4.3.2 Discussion 
 
The trend observed with bulkier substituents in the series of aryl substituted analogues 93e – 
100e and 103e – 110e has been confirmed also in the series of heterocyclic derivatives 117e 
– 126e. The increasing bulkiness of the substituent (i.e. 5’-indolyl, quinolin-8’-yl and 3’,4’-
methylenedioxyphenyl) hinders the interaction with α4β2* receptor and the ligands 117e, 
118e, 121e and 124e displayed lower affinities (Ki = 95 – 853 nM) than the parent alkaloid 27 
(Ki = 0.122 nM). The similar affinity of isomeric 3’,4’-methylenedioxyphenyl derivatives 118e 
and 124e (Ki = 110 and 96 nM) resembles the pattern observed with biphenyl derivatives 
100e and 110e  (Ki = 200 and 190 nM, respectively), i.e. with the increasing size of the 
substituent the isomeric ligands become equipotent. 
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Table 3-31 Binding affinity values (Ki) for 5-heteroaryl derivatives of cytisine 123e – 126e at 
α4β2*, α7*, α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]b 
α3β4* 
[3H]epi 
calf adrenals 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
NH
N
O
 
 
  27 
 
0.122 
 
250 
 
19  
 
1,300 
NH
N
O
NH
 
 
123e 
 
20.4 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
O O
 
 
124e 
 
96 
 
> 10,000 
 
> 10,000 
 
> 10,000 
NH
N
O
N
 
 
125e 
 
10.9 
 
> 10,000 
 
4,300 
 
> 10,000 
NH
N
O
N
N
CH3  
 
126e 
 
2.2 
 
> 10,000 
 
656 
 
> 10,000 
 
a) values are the mean from at least n = 3 to 5 independent assays 
b) preliminary results 
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The introduction of a smaller N-bearing heterocycle instead of the indolic or the quinolinic 
moiety into the position 3 resulted in compounds with affinities in the picomolar range. The 
compounds 119e (3’-pyridyl analogue) and 122e (N-methyl-1H-pyrazol-4’-yl analogue) 
turned out to be the most potent ligands in the series under consideration (Ki = 0.91 and 
0.177 nM, respectively), whereas the affinity of 122e compares well with the lead alkaloid 27 
(Ki = 0.122 nM). Incorporation of the 3’-pyridyl and N-methyl-1H-pyrazol-4’-yl moieties into 
the position 5 resulted in 12-fold reduction of affinity compared to their 3-substituted 
counterparts. However, the 5-substituted analogues 125e and 126e retain low nanomolar 
affinity (Ki = 10.9 and 2.2 nM, respectively). 
Substitution or replacement of 3’-pyridyl moiety decreased the α4β2* binding affinity. 4-
Pyridyl residue in the position 3 resulted in a compound 120e with 4-fold reduced affinity (Ki = 
3.9 nM) when compared to 3’-pyridyl analogue 119e, indicating the importance of nitrogen’s 
position to the pharmacophoric elements. Fluorine substitution of the 3’-pyridyl moiety also  
had a negative impact on the affinity towards α4β2 nAChR (Ki = 24 nM for (3-(2-fluoropyridin-
5-yl)-cytisine).125 
Comparison of the structure-activity patterns for α4β2* nAChR with respect to aryl and 
heteroaryl substitution in the position 3 indicates that the two series have the same structural 
requirements for the size of the substituent but different requirements when the position 3 
bears smaller moiety. By increasing the size of the substituent the binding affinity diminishes, 
regardless of the (hetero)aryl character of the substituent. However, the incorporation of 
small heteroaryl moieties into the cytisine molecule is accepted much better than the 
introduction of differently substituted phenyl moieties. 
The introduction of different substituents into the position 5 influenced the α4β2* binding 
affinity in a different, less destructive manner. Herein, the bulk tolerating region also 
possesses dimensional limits but the substitution in general reduced the binding affinity to a 
smaller degree. The high binding affinity of 5-(5’-indolyl)-cytisine 123e to the rat brain 
[3H]epibatidine binding sites (Ki = 20.4 nM) supports this hypothesis, as the corresponding 3-
isomer 117e showed a 40-fold lower affinity (Ki = 853 nM).  Additionally, one can not exclude, 
that the introduction of different substituents (e.g. 3-nitrophenyl, indol) leads to a new binding 
mode between the ligands and the α4β2* nACh receptor. Oxygen of the nitro group or indolic 
nitrogen could overtake or support (via HBA and/or pi-pi interaction) the role of the so far 
recognised pharmacophoric elements of cytisine 27.  
3-(N-Methyl-1H-pyrazol-4’-yl)-cytisine 122e with Ki = 33 nM has been identified as the most 
α3β4* potent ligand in this series. The 3’- and 4’-pyridyl moieties in position 3 resulted in a 
decrease of the α3β4*affinity (Ki = 119 and 436 nM for 119e and 120e, respectively). The 
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introduction of bulkier heterocyclic cores such as 5’-indolyl; 3’,4’-methylenedioxyphenyl or 8’-
quinolinyl caused more significant reduction of the α3β4* affinity (Ki > 10,000 nM). 
Position 5 seems to be even less bulk-tolerating, as 5-(3’-pyridyl)-cytisine 125e (Ki = 4,300 
nM) possesses a 36-fold lower affinity compared to the 3-counterpart 119e (Ki = 119 nM). 
Similarly, N-methyl-1H-pyrazol-4’-yl in position 5 resulted in ligand 126e with a 20-fold 
reduced affinity (Ki = 656 nM) compared to the 3-isomer 122e (Ki = 33 nM).  
Although the ligands with highest α4β2* affinity showed also the highest binding to α3β4* 
nAChR, the cytisine’s 27 selectivity (Ki (α4β2*)/Ki (α3β4*) ≈ 155) for the brain binding sites 
may be improved with the heteroaryl substitution of position 5. The 5-(5’-indolyl)-cytisine 
123e with a ratio of Ki (α4β2*)/Ki (α3β4*) ≈ 490 was identified as the most α4β2* selective 
ligand. Another two 5-heteroaryl derivatives of cytisine, namely 5-(3’-pyridyl) and 5-(N-
methyl-1H-pyrazol-4’-yl) analogues 125e and 126e also showed prevalence for the central 
[3H]epibatidine bindings sides over the peripheral α3β4* subtype (Ki (α4β2*)/Ki (α3β4*) ≈ 394 
and 298, respectively).  
 
3.4.4 Structure-Activity Relationship of Disubstituted 
Analogues 
3.4.4.1 Results of the Radioligand Binding Studies 
α4β2* nAChR (Table 3-32) 
5-Bromo-3-phenyl-cytisine 128e and 5-bromo-3-(3’-pyridyl)-cytisine 129e displaced 
[3H]epibatidine from rat brain membranes with similar affinities (Ki = 131 and 92 nM, 
respectively). Hence, the disubstitution of cytisine scaffold resulted in 1073- and 754-fold 
reduction of α4β2* affinity compared to the parent alkaloid 27 (Ki = 0.122 nM).  
α7* nAChR (Table 3-32) 
The cytisine analogues 128e – 129e displayed Ki > 10,000 nM when tested in radioligand 
binding assays employing rat brain membranes and [3H]MLA.  
α3β4* nAChR (Table 3-32) 
Cytisine derivatives 128e – 129e featuring two-fold substitution on the pyridone moiety 
exhibited for the α3β4* nAChRs Ki values > 2,000 nM . 
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Table 3-32 Binding affinity values (Ki) for disubstituted derivatives of cytisine 128e and 129e at 
α4β2*, α7*, α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]b 
α3β4* 
[3H]epi 
calf adrenals 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
NH
N
O
 
 
  27 
 
0.122 
 
250 
 
19  
 
1,300 
NH
N
O
Br  
 
128e 
 
131 
 
> 10,000 
 
> 5,000 
 
> 10,000 
NH
N
O
Br
N
 
 
129e 
 
92 
 
> 10,000 
 
> 2,000 
 
> 10,000 
 
a) values are the mean from at least n = 3 to 5 independent assays 
b) preliminary results 
 
(α1)2β1γδ nAChR (Table 3-32) 
Disubstitution of cytisine’s positions 3 and 5 resulted in a dramatic reduction of binding 
affinity to muscle nAChRs (Ki > 10,000 nM for both ligands 128e and 129e). 
 
3.4.4.2 Discussion 
 
5-Bromo-3-phenyl analogue 128e (Ki = 131 nM) retains the binding affinity of 3-phenyl-
cytisine 93e (Ki = 128 nM) but comparing compound 128e to the 5-bromo analogue 43 (Ki = 
0.308 nM)118 its affinity is 425-times decreased. This undoubtedly supports the previous 
finding about negative impact of 3-phenyl substitution on the receptor recognition. The 
moderate nanomolar affinity of 5-bromo-3-(3’-pyridyl)-cytisine 129e (Ki = 92 nM) was 
somehow expected from the results obtained from dihalogenated analogues, where the 
enhancing effect of 3-halogenation counterbalanced only partially with the deleterious effect 
of 5-halogenation.118,147,148 The dihalogenated analogues of cytisine possess lower affinities 
(Ki = 0.52 – 10.8 nM) than the monosubstituted analogues.
118 The disubstituted analogue 
119e displaced [3H]epibatidine from rat brain [3H]epibatidine binding sites with a 100-fold 
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lower affinity than the 3-(3’-pyridyl) analogue 119e (Ki = 0.91 nM) and with a 300-fold 
reduced binding affinity compared to 5-bromo-cytisine 43 (Ki = 0.308 nM)
118. 
 
3.5 Summary of Structure-Activity Relationships 
 
SAR for α4β2* nAChR 
 
• position 3 possesses bulk-tolerance limit since a substitution with the phenyl moiety 
decreased the binding affinity 
• the combination of steric and electrostatic properties is crucial for the binding affinity 
• the affinity within the 3-aryl analogues improved with the introduction of small electron 
withdrawing groups into the meta-position of the phenyl ring  
• introduction of 3-pyridyl and N-methyl-1H-pyrazol-4-yl moieties into position 3 yielded 
the most potent ligands in the series under consideration 
• substitution of position 3 with bulkier heterocyclic moieties not tolerated 
• substitution of position 5 significantly improves the subtype selectivity 
• introduction of 5-indolyl moiety into position 5 yielded the most selective ligand  
N
O
R
N
H
O
ON
N
N
N
N
CH
3
N
H O
O
N
N
N
CH3
R
R = H, CH3, OCF3, CF3
R = NO2
R = F, Ph
R = H, Cl, Ph
Ki = 1 - 10 nM
Ki = 10 - 100 nM
NH
Ki = 100 - 1000 nM
Ki = 0.122 - 1 nM
R = NO2, CH3, OCF3
R = F, CF3
5-Br-3-(3'-pyridyl)
5-Br-3-Ph
increased α4β2 selectivity  
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SAR for α3β4* nAChR 
• (hetero)aryl substitution of the position 3 reduces the binding affinity 
• within the 3-arylated analogues only the analogues with electron-withdrawing groups 
in the meta-position exhibited affinity in lower micromolar range 
• introduction of the N-methyl-1H-pyrazol-4-yl moiety into position 3 yielded the most 
potent ligand 
• position 5 does not accomodate bulkier substitution and 5-arylated analogues have 
better α4β2* selectivity profile than their 3-counterparts 
 
N
O
R
N
H
O
O
N
N
N
N
N
CH
3
R
NH
R = NO2
R = F 
R = H, CH3, OCF3,
        Ph, CF3
N
O
O
N
N
CH3
N
H
Ki = 100 - 1,000 nM
Ki = 1,000 - 10,000 nM
Ki > 10,000 nM
Ki = 19 - 100 nM
R = CH3, OCF3
           H, Cl, Ph
R = F, CF3, NO2
5-Br-3-(3'-pyridyl)
5-Br-3-Ph
 
 
 
 
 
 
SAR for α7* and (α1)2β1γδ nAChRs 
 
All modification on the cytisine scaffold led to significant decrease of the ligand’s binding 
affinities to the central α7* and neuromuscular (α1)2β1γδ nAChRs (Ki > 10,000 nM). 
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4 Project II: Development of Novel nAChR Ligands based 
on Choline 
 
4.1 Choline as a Lead Compound 
  
Choline 4, a precursor and a metabolite of acetylcholine 1, possesses micromolar affinity 
towards α4β2 nAChR (Ki = 112 µM) and is an effective α7 agonist even if it presents very low 
affinity for the α7 nACh receptor (Ki = 2,380 µM).
52  
Choline 4 has been shown to possess cytoprotective properties53 and a series of choline 
derivatives has been evaluated as neuroprotective agents. Jonnala et al53 reported that 
although choline 4 exhibited only about 40% of the full cytoprotective effect of nicotine 10, its 
pyrrolidine derivative 132 (Figure 4-1) showed a markedly improved potency and efficacy, 
thus the authors suggested that the choline structure may serve as a template for the 
development of novel agents with both α7-nicotinic agonist activity and potential 
neuroprotective ability. The same group synthesized several choline derivatives and 
identified JAY 2-21-29 (Figure 4-1) as the most effective analogue with potent cytoprotective 
action.290 
Simsek and co-workers showed that several 3-pyridyl ether analogues (e.g. 133, Figure 4-1) 
of choline displayed nanomolar affinities for [3H]nicotine sensitive binding sites and 
nociceptive properties.291 Similar analogues of choline, where the amine function is 
incorporated in a cyclic carbon skeleton are one of the most potent ligands for α4β2 nAChRs 
(e.g. A-85380 15).74a 
The structure of choline 4 can be found in a variety of compounds displaying multifarious 
pharmacological effects, for example in drugs with antihistaminic and analgesic properties 
like diphenhydramine 134 and nefopam 135, which even display affinities in micromolar 
range for neuronal nAChRs.292 Aryl ether analogues of choline are known as inhibitors of 
amine oxidase293 and are also described as compounds with antibacterial, cholesterol 
lowering, and germicidal properties.294 Mono- and poly-substituted pyridyl ether analogues of 
choline were patented for the use as pesticides.295  
Nevertheless, the structure of choline has attracted limited interest as a lead compound in 
the search for nAChR ligands and it was rationale to revisit this structure as a lead for 
development of novel nAChR ligands.  
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             Nefopam 135           
Ki = 23,000 nM (α7, rat brain)
Ki = 8,000 nM (α4β2, rat brain)
             A-85380 15
Ki =  0.05 nM (α4β2, rat brain)
Ki = 100 nM (α7, rat brain)
                133
Ki = 0.5 nM (α4β2, rat brain)
            choline 3
Ki = 112 µM (α4β2, rat brain)
Ki = 2.38 mM (α7, rat brain)
     pyrrolidinecholine 132
       JAY 2-21-29
      Diphenhydramine 134           
Ki = 4,800 nM (α7, rat brain)
Ki = 5,920 nM (α4β2, rat brain)
  
 
Figure 4-1 Structure and binding affinities of choline 3 and of compounds containing choline 
moiety (highlighted in blue) [Ref. 52, 53, 74a, 290 – 292]
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4.2 Syntheses of novel nAChR Ligands based on Choline 
4.2.1 Introduction 
 
The introduction of an amide moiety into the structure of phenyl ether of choline yielded a 
carbamate 5 with high affinity and subtype selectivity for α7 nAChR. In order to evaluate the 
structure 5 and obtain information about structural requirements and limitations for nAChR 
affinity, a library of phenylcarbamate analogues was synthesized.  
Cabamates are synthesized in various ways. Alkyl halides may be converted to carbamates 
by treatment with a secondary amine and K2CO3 under phase transfer conditions (Scheme 4-
1/A).296 When chloroformates ROCOCl are treated with primary amines, carbamates of type 
ROCONHR’ are obtained. An example of this reaction is the use of benzyl chloroformate to 
protect the amino group of amino acid and peptides. The PhCH2OCO group is called the 
carbobenzoxy group (abbreviated as Cbz) (Scheme 4-1/B).193 
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Scheme 4-1 Synthetic routes to carbamate derivatives [Ref. 193, 296 – 300] 
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Carbamates can be obtained from primary and secondary amines, if these react with CO, O2 
and an alcohol R’OH in the presence of a catalyst (Scheme 4-1/C) 297 or by treatment of 
nitroso and nitro compounds with CO, R’OH, Pd(OAc)2 and Cu(OAc)2 (Scheme 4-1/D).
298 
Cyanogen chloride reacts with alcohols in the presence of an acid catalyst such as dry HCl 
or AlCl3 to give carbamates (Scheme 4-1/E).
299  
Substituted carbamates are prepared when isocyanates are treated with alcohols (Scheme 
4-1/F).300 This is an excellent reaction, of wide scope and gives good yields. Isothiocyanates 
similarly give thiocarbamates RNHCSOR’, though they react slower than the corresponding 
isocyanates. The mechanism of this reaction is poorly understood, though the oxygen of the 
alcohol is certainly attacking the carbon of the isocyanate.193 The addition of ROH to 
isocyanates can also be catalysed by metalic compounds301 or by light302.  
 
4.2.2 Method/Results 
 
The synthesis of the phenylcarbamate derivatives was carried out according to the Method F 
(Scheme 4-2). Equimolar amounts of amino alcohols and the appropriate phenylisocyanates 
were stirred for 1.5 – 4 hours under argon atmosphere. The reaction was carried out in 
toluene at 50°C, as reflux temperature was found to reduce yields and increased the 
formation of the byproducts. The solvent was evaporated and the resulting oily residue was 
purified by flash chromatography on a small amount of silica gel eluting with 
dichlormethane/methanol mixture. The products were obtained as yellow oils that crystallised 
on standing (28% – 97%). 
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Scheme 4-2 Syntheses of carbamate analogues 136 – 141 
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The reaction had to be carried out in a water-free solvent (i.e. dry toluene) under argon 
atmosphere in order to avoid the decomposition of the isocyanate reactant.303  Isocyanates 
are hydrolysed in the presence of water to primary amines and this reaction is catalysed by 
acids or bases.193 This may explain why the addition of triethylamine was found to have 
negative impact on the yields of the syntheses. The primary amine then reacts with 
isocyanate to give substituted urea derivatives as side-products. Scheme 4-3 shows an 
unwanted synthesis of 1,3-di-m-tolyl-urea 142 from m-tolylisocyanate 143 in the presence of 
water. The side-product 142 (M = 240.3 g/mol) crystallised in toluene, thus was easily 
isolated by filtration and identified via mass spectroscopy ([M+H]+ = 240.2). Interestingly, m-
tolylisocyanate always led to the production of side products, whereas this side reaction was 
not observed when 3-bromopenylisocyanate was employed. Therefore, the yields of methyl 
analogues 136, 138 and 140 were significantly lower (28% – 42%) than the yields of the 
bromo analogues 137, 139 and 141 (75% – 97%). 
 
CH3NH2
N
H
N
H
O
CH3CH3
NH2CH3 NCO CH3
+
NCO CH3
143
+H2O
142  
Scheme 4-3 Synthesis of the side-product 1,3-di-m-tolyl-urea 142 
 
Compounds 144 and 145 were prepared by the Suzuki coupling reaction under microwave 
irradiation (Scheme 4-4). Microwave irradiation (60 – 100 W) and standard Suzuki conditions 
allowed addition of the phenyl and styryl moieties to the phenyl ring of 141 in less than 10 
minutes. The reaction mixture was allowed to cool to room temperature and the solvent 
evaporated under pressure. The oily residue was purified by column chromatography with 
the dichloromethane/methanol mixture and crystallised from the mixture of diethyl 
ether/petroleum ether. The coupling products were obtained as yellow crystalline powders 
(22% – 39%).   
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Scheme 4-4 Suzuki cross-coupling reaction under microwave accelerated conditions as a key step   
in the syntheses of the biaryls 144 and 145 
 
4.2.3 Discussion 
 
The syntheses of the carbamate derivatives 136 – 141 were carried out under argon 
atmosphere and in dry solvents. The addition of triethylamine, which is used for the 
preparation of carbamate derivatives304, did not positively influence the yield of the desired 
products 136 – 141. Reflux temperature led to the reduction of yields and increased the 
production of byproducts, e.g. 142.  
The azabicyclic carbamate derivative 141, also claimed as a α7 nAChR ligand in a patent of 
Astra Laboratories304, was used as a reactant for synthesis of the phenyl and styryl 
analogues 144 and 145. The combination of Suzuki cross-coupling protocol191 with 
microwave dielectric heating229,230 allowed synthesis of the coupling products 144 and 145 in 
10 min (22% – 39%).  
The low yields are results of several impacts and it has to be pointed out that the Suzuki 
protocol for addition of the phenyl or styryl moieties to the compound 141 was not optimized, 
since the reactions yielded sufficient amount of the products 144 and 145 for the biological 
evaluation. The following should be taken into consideration for the improvement of the 
reaction’s outcome; firstly, the carbamate bond might be instable for the Suzuki protocol 
under microwave accelerated conditions, although the microwave irradiation (up to 100 W) 
itself did not hydrolyse the carbamate bond employing DME as used in the Suzuki reaction. 
The boronic acids are in general weak acids (pKa = 8.6 for phenylboronic acid) and have not 
been reported to be able to cleave the carbamate bond. However, the combination of a 
boronic acid and microwave irradiation led to the formation of unwanted byproducts. Low 
yields of biaryl coupling product could be caused by the hydrolysis of the carbamate bond.  
Secondly, the applied microwave energy (60 – 100 W) probably led to the decomposition of 
the catalytic system. Optimization of the experimental protocol for the Suzuki cross-coupling 
reaction on the cytisine skeleton revealed that the energy of no more than 50 W should be 
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applied in the cross-coupling reactions employing Pd-catalyst (e.g. Pd(PPh3)4). Thus, using 
lower microwave energy could lead to higher yields.   
However, the protocol developed in our hands yielded the biphenyl carbamate coupling 
product 144 in a very fast and simpler way compared to the method described by Naito et 
al.305 or Astra Laboratories304. In their work, the biphenyl derivative 144 was synthesized 
using the biphenyl isocyanate, which was obtained by the addition of diphenylphosphoryl 
azide (DPPA) to the biphenyl-3-carboxylic acid (Figure 4-5/A)305 or by the addition of 
phosgene to 3-aminobiphenyl (Figure 4-5/B)304. The styryl analogue 145 is a novel nAChR 
ligand.   
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Scheme 4-5 Synthesis of 144 via different routes described by Naito et al. (A) and Astra 
Laboratories (B) [Ref. 304, 305] 
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4.3 In Vitro Pharmacology of Novel nAChR Ligands based on 
          Choline 
 
Compounds 136 – 141 and 144 – 145 were evaluated for their abilities to compete for 
[3H]epibatidine and [3MLA] binding sites in rat forebrain (α4β2*, α7*), pig adrenals (α3β4*) 
and Torpedo californica electroplax membrane fractions ((α1)2β1γδ).  
The receptor subtypes are designated with an asterix, following the IUPHAR 
recommendation to indicate the receptor subtype with an asterix, if native tissue is used, 
where the definite subtype composition is not exactly known.  
The radioligand binding studies were performed by Cristina Tilotta (research group of Dr. D. 
Gündisch). 
 
4.3.1 Results of the Radioligand Binding Assays 
Cyclization of the quaternary amine into a rigid azacyclic structure (N-methyl-pyrrolidine, N-
methyl-piperidine and quinuclidine) and subsequent m-substitution provided nAChR ligands 
with various binding profiles (Table 4-1 and 4-2). 
α4β2* and α7* nAChR 
N-Methylpyrrolidine- and N-methylpiperidine analogues 136 – 139 showed micromolar 
affinity for α7* (Ki = 10.8 – 31.8 µM) and nanomolar affinity for α4β2* nAChRs (Ki = 175 – 
1,248 nM). The α4β2* binding affinity of the unsubstituted N-methylpyrrolidine carbamate 146 
(Ki = 1,100 nM) remained unchanged with the methylation of the phenyl ring (Ki = 1,248 nM 
for 136) but was improved with a bromo substitution (Ki = 526 nM for 137). Whereas the 
unsubstituted N-methylpiperidino derivative 147 did not displace [3H]epibatidine from rat 
brain membrane preparations, the brominated analogue 139 showed micromolar affinity (Ki = 
3,770 nM) and the methyl analogue 138 nanomolar affinity (Ki = 175 nM) with a prevalence 
for the α4β2* nAChR (Ki(α4β2) / Ki(α7) ≈ 181). 
The quinuclidine analogue 149 like the phenylcarbamate 5 exhibited remarkable affinity for 
α7* (Ki = 44 and 39 nM, respectively) versus α4β2* (Ki = 3,084 and 835 nM). The substitution 
of the phenyl moiety, especially with bulky aryl residues reduced the affinity for α7* (Ki = 273 
– 1,135 nM), which can be strongly observed in the styryl analogue 145 (Ki = 6,100 nM). 
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Table 4-1 Binding affinity values (Ki) for phenylcarbamate derivatives of choline at α4β2*, α7*, 
α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]a 
α3β4* 
[3H]epi 
pig adrenal 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
O
N
+CH3
CH3
CH3
Br
 
4§ 22.3 196 135 697 
Br
O
N
+CH3
CH3
CH3
N
H
O
 
5§ 835 38.9 2,200 > 20,000 
O N
H
O
N
CH3
 
146§ 1,100 5,853 2,582 > 20,000 
O N
H
O
N
CH3
CH3
 
136 1,248 14,108 6,000 n.d. 
O N
H
O
N
CH3
Br
 
137 526 10,810 6,146 n.d. 
O N
H
O
N
CH3
 
147§ > 20,000 15,000 6,100 > 20,000 
O N
H
O
CH3
N
CH3
 
138 175 31,800 14,392 > 20,000 
O N
H
O
Br
N
CH3
 
139 3,770 27,000 6,357 n.d. 
§) synthesized by Matthias Ändra (research group of Dr. D. Gündisch) 
a) values are the mean from at least n = 3 to 5 independent assays 
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Table 4-2 Binding affinity values (Ki) for quinuclidine phenylcarbamate derivatives at α4β2*, α7*, 
α3β4* and (α1)2β1γδ nACh receptor subtypes 
 
Structure 
 
No. 
α4β2* 
[3H]epi 
rat brain 
Ki [nM]a 
α7* 
[3H]MLA 
rat brain 
Ki [nM]a 
α3β4* 
[3H]epi 
pig adrenal 
Ki [nM]a 
(α1)2β1γδ 
[3H]epi 
Torp. calif. 
electroplax 
Ki [nM]a 
N
OH
 
148 5,924 7,761 14,604 n.d. 
N
O N
H
O
 
149§ 3,084 44 1,627 > 20,000 
N
O N
H
O
Br
 
141 2,988 273 715 n.d. 
N
O N
H
O
CH3
 
142 2,695 321 1,478 n.d. 
N
O N
H
O  
144 7,772 1,135 1,448 n.d. 
N
O N
H
O  
145 5,350 6,100 5,976 n.d. 
§) synthesized by Matthias Ändra (research group of Dr. D. Gündisch) 
a) values are the mean from at least n = 3 to 5 independent assays 
 
α3β4* nAChR 
The phenylcarbamate derivatives 136 – 141 and 144 – 145 were also investigated for their 
affinities towards the α3β4* subtype and with an exception of 141 (Ki = 715 nM) all analogues 
showed Ki values in the micromolar range (Ki = 1,448 – 14,392 nM). Compared with the 
pyrrolidine and piperidine series a higher affinity for α3β4* is observed in the series of the 
quinuclidine derivatives.  
(α1)2β1γδ nAChR 
Several analogues were tested for their affinity for the (α1)2β1γδ nAChR and the evaluated 
derivatives showed low binding to the muscle type nAChR (Ki > 20,000 nM). 
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4.3.2 Discussion 
 
The phenylether of choline 4 was transformed into a α7 nAChR selective compound with 
nanomolar affinity when converting it into the corresponding carbamate analogue.55,292 
Cyclization of the quaternary nitrogen provided nAChR ligands with an interesting 
pharmacological profile. 
Methyl-pyrrolidine and methyl-piperidine derivatives showed Ki values in the higher 
nanomolar and lower micromolar range for α4β2* and lower affinity for α7* subtype. The 
subtype selectivity profile of the analogues 136 – 139 (α4β2* > α3β4* > α7*) is consistent 
with the affinity rank order of most nAChR ligands. Cyclization of the quaternary nitrogen into 
a quinuclidine core provided ligand 149 with a high α7* affinity (Ki = 44 nM). Methylation or 
bromination of the phenyl moiety in 149 decreased the α7* affinity (Ki = 273 – 321 nM), as 
did the introduction of bulkier phenyl or styryl moieties (Ki = 1,135 – 6,100 nM) 
3-Quinuclidinole 148, which can be considered as a rigid choline derivative was also tested 
for the ability to recognise various nAChR subtypes and it displayed Ki values in the 
micromolar range for α4β2* (Ki = 5,924 nM) and α7* (Ki = 7,761 nM) nAChRs, suggesting 
that the spatial distance between the nitrogen and oxygen in the structure of 3-quinuclidinole 
148 is compatible with the pharmacophore elements.  
In summary, carbamates bearing pyrrolidine (136-137) or piperidine (138-139) moiety have 
been shown to possess lower affinity for α7* nAChR than the analogues in the quinuclidine 
series (140 – 141 and 144 – 145), although the same structural elements are present (a 
protonable basic nitrogen, a carbamate moiety and a pi-electron system). Furthermore, in 
contrast to the quinuclidine analogues, the pyrrolidine and piperidine analogues exhibited 
higher affinities for α4β2* nAChR. Thus, the quinuclidine core linked via a carbamate bond to 
the pi-electron system provides a template for high affinity ligands with α7-subtype selectivity. 
Similar results were obtained with the exploration of the quinuclidine scaffold, which has 
become popular for construction of ligands, especially for the interaction with the α7 receptor 
subtype.306 However, the carbamate moiety as a link between the pharmacophoric elements 
does not show a predisposition for an α7-selective ligand. When in combination with other 
azacyclic cores, such as N-methylpyrrolidine or N-methylpiperidine, it provides ligands with 
prevalance for α4β2 nAChRs.  
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5 Summary 
 
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channel receptors composed 
of five polypeptide subunits. There are many different nAChR subtypes constructed from a 
variety of different subunit combinations, resulting into diverse roles of nAChRs in the central 
and peripheral nervous system. The CNS nicotinic mechanism is known to be involved in a 
normal human cognitive and behavioural functioning and the nAChRs have been implicated 
with a number of human pathologies (e.g. Alzheimer’s or Parkinson’s disease, schizophrenia, 
addiction or depression). Ongoing investigation of the molecular structure, function and 
distribution of nAChR has opened up a new era for the potential clinical application of nAChR 
drugs in the treatment of a various CNS disorders. Moreover, one cannot forget that 
activation of neuronal nAChRs produces antinociception in a variety of preclinical pain 
models. This activity suggests that compounds targeting neuronal nAChRs may represent a 
new class of analgesic agents.  
For this to be achieved, new nAChR ligands are being synthesized and tested for their 
activity in order to get more information about the structure requirements for an interaction 
with various nAChR subtypes. The new findings might provide important information 
regarding the selectivity. This will be of importance, since the in vivo profile of the hitherto 
existing agents tested in clinical trials is mostly accompanied by side effects. 
The presented Ph.D. thesis was focused on synthesis and biological evaluation of novel 
nicotinic acetylcholine receptor ligands based on cytisine 27 (Project I, main project) and 
choline 3 (Project II).  
 
Project I: Development of Novel nAChRs Ligands based on Cytisine 
The quinolizidine alkaloid cytisine 27 has been recognised as nAChR partial agonist with 
selectivity and subnanomolar affinity for α4β2 nAChR (Ki = 0.122 nM). The knowledge of the 
structure-activity relationship for this lead compound is very limited, due to the emerging 
trend of pharmaceutical companies to minimise the amount of biological data in the patent 
literature. Hardly anything is known about the impact of a bulkier substituent in position 3 
and/or 5 on the cytisine affinity. Therefore, a library of 3- and/or 5-(hetero)aryl analogues of 
cytisine was synthesized and evaluated for the affinity towards several nAChR subtypes. 
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Chemistry 
• Numerous isolation experiments were carried out and the total amount of 
approximately 15 g of cytisine 27 (0.11% – 0.48% yields with regard to the amount of 
the plant material) was isolated from natural sources (Laburnum anagyroides and 
watereri, Fabaceae). In order to improve purity of the isolated alkaloid 27, preparative 
HPLC was used instead of crystallization. 
• The intermediates 3-bromo-, 5-bromo- and 3,5-dibromo-N-tBOC-cytisine 81 – 83 
were synthesized like previously reported, however, the isomers were separated and 
purified with preparative HPLC and obtained in high purity. The column 
chromatography purification, performed according to the published procedures, was 
ineffective (difficult separation of the isomers, low yields). 
• The key step of the new synthetic route was palladium-mediated Suzuki cross-
coupling of either N-protected 3- or 5-bromocytisine 81 or 82 with different aryl- and 
heteroarylboronic acids under microwave-accelerated conditions. 
N
N
O
X
Y
tBOC
R B
OH
OH
N
N
O
R
tBOC
N
N
O
R
tBOC
81 or 82
R = (hetero)aryl81 X = Br, Y = H
82 X = H, Y = Br
+
  93 - 100  R = m-substituted phenyl
117 - 122  R = heteroaryl
103 - 110  R = m-substituted phenyl
123 - 126  R = heteroaryl
Pd(PPh3)4, base
      DME/H2O
30 W, 80°C
30 - 90 min
Pd(PPh3)4, base
      DME/H2O
30 W, 80°C
30 - 90 min
 
• Microwave heating has demonstrated clear advantages over the conventional heating 
procedures (faster reactions, higher yields, less side products) and allowed 
incorporation of (hetero)aryl moieties into position 3 or 5 in 30-90 minutes. 
• The purification of the coupling products was efficiently performed with preparative 
high performance liquid chromatography. 
• Selective Suzuki cross-coupling reaction was carried out with 3,5-dibromo-N-
tBOCcytisine 83. Employing carefully selected condition allowed coupling reaction 
only in position 3, while the bromine in position 5 was not attacked. In this way 
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obtained 3-phenyl-5-bromo- and 3-(3’-pyridyl)-5-bromo analogues 128 and 129 are 
novel disubstituted cytisine derivatives.   
• The N-tBOC protecting group was quantitatively hydrolysed in an aqueous solution of 
the compound employing the microwave dielectric heating.  This fast, efficient and 
clean (no reagents, water as a solvent) cleavage of the tBOC protecting group via 
microwave-mediated thermal fission of carbon dioxide and isobutene has not been 
described so far. 
N
N
O
tBOC
R2
R1
NH
N
O
R1
R2
       H2O, 150 W, 30 min
           "thermal fission"
CO2
CH3
CH2
CH3
++
 
 
• Detailed 1D and 2D NMR studies of cytisine 27 were performed and the 1H (in green) 
and 13C (in blue) chemical shifts of the cytisine were unambiguously assigned. 
NH
N
O
7.05
6.17
5.77
2.691.70
2.08 3.85/3.63
2.73 - 2.83
115.7
138.1104.2
150.734.925.6
27.0 49.1
52.3
162.8
53.3
2.73 - 2.83
 
 
• Detailed 1D and 2D NMR studies of 3-phenyl and 5-phenyl cytisine derivatives 93e 
and 103e afforded identification of “diagnostical tools”, which are very useful for 
differentiation of the 3- and 5-isomers.  
C6
C7
NH
N
O
H
H
H
H
H
d, δ 1.92 ppm
d, δ 1.84 ppm
δ 7.19 ppm
   upfield shift 
compared to cyt
3JH3/H4 = 9.5 Hz
NH
N
O H
H H
H
H
3-phenyl-cytisine 93e 5-phenyl-cytisine 103e
δ 7.69 ppm
3JH4/H5 = 7.2 Hz
s, δ 1.96 ppm
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In total, three known (93e, 99e and 103e) and twenty five novel pyridone-modified analogues 
of cytisine featuring a (hetero)aryl substituent in the position 3 or 5 were synthesized. The 
known ligands were re-synthesized in a new improved synthetic route (Suzuki reaction 
instead of Stille reaction) and in order to gain information about their pharmacological 
behaviour. 
N
N
N
HO
O
N
N
CH3 N
NH
N
O
3
5
R
R = H, NO2, CH3, CF3, OCF3, Cl, F, Ph
Substituents introduced into the position 3 or 5 of cytisine
 
 
Pharmacology 
All nAChRs ligands have been tested in radioligand binding studies for their affinity 
towards α4β2*, α7*, α3β4* and (α1)2β1γδ nAChR subtypes in order to understand what 
structure elements contribute to the subtype selectivity. The affinities of novel ligands are 
always compared to the affinity of the lead compound, i.e. cytisine 27 (Ki = 0.122 nM). 
• The introduction of m-substituted phenyl moieties into position 3 decreased the 
affinity for the α4β2* nACh receptor (Ki = 5.7 – 200 nM), whereas the degree of the 
affinity reduction depended on the nature of the meta-substituent (F < CF3 < NO2 ≈ 
CH3 < OCF3 < H < Cl < Ph). The results suggest that small electron-withdrawing 
groups on the phenyl moiety are preferred. 
• The α4β2* affinities of 5-aryl derivatives were decreased (Ki = 3.7 – 300 nM), 
however the meta-substitution of the phenyl ring influenced the α4β2* binding affinity 
in a different manner when compared to the corresponding series of 3-arylated 
analogues (NO2 < OCF3 ≈ CH3 < H < CF3 < Ph < F).  
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• The introduction of heterocyclic moieties into the position 3 of cytisine resulted in a 
ligand with a lowest α4β2* affinity (5-(5’-indolyl)-cytisine 123e, Ki = 853 nM) as well as 
in ligands with two highest α4β2* affinities (119e and 122e) 
NH
N
O
N
NH
N
O
N
N
CH3
     119e
Ki = 0.91 nM
      122e
Ki = 0.177 nM  
• Ligand 122e shows the highest affinity also for α3β4* nAChR (Ki = 33 nM)  
but retains subtype selectivity for α4β2* subtype (α4β2*/α3β4*/α7*/(α1)2β1γδ = 1 : 186 
: > 55,000 : 28,000). 
• The substitution of position 5 significantly improves the subtype selectivity since the 
α3β4* nAChR seems to possess smaller dimensional limit for the position 5 than the 
α4β2* receptor subtype. 5-Aryl and heteroaryl analogues of cytisine show better 
selectivity profile than their 3-counterparts.   
• The introduction of 5-indolyl moiety into position 5 yielded the most selective ligand 
123e (α4β2*/α3β4*/α7*/(α1)2β1γδ = 1 : 490 : >490 : 490). 
• The high binding data for 5-(3’-nitrophenyl)-cytisine 104e (Ki = 3.7 nM) and 5-(5’-
indol)-cytisine 113e (Ki = 20.4 nM) suggest the posibility of new binding mode 
between these ligands and the α4β2* nACh receptor (e.g. additional pi-pi interaction 
between the ligand and the receptor). 
• All 3-and 5- substituted cytisine derivatives showed low affinity for the α7* and 
(α1)2β1γδ nAChR subtype (Ki > 10,000 nM). 
• Disubstitution of the cytisine skeleton in positions 3 and 5 led to ligands 128e and 
129e with decreased affinity for the nAChR subtypes tested (α4β2*, α7*, α3β4* and 
muscle type).   
 
The putative hydrophobic region next to the HBA functionality of cytisine (carbonyl group) is 
indeed not bulk-tolerant, but rather the electrostatic than the steric properties of the aryl 
moiety ultimately influence the α4β2* affinity, i.e. 3-trifluoromethyl-phenyl analogues displays 
higher affinity than the 3-phenyl analogue. Thus, for the prediction of the binding affinities for 
cytisine derivatives one always has to consider the combination of substituent’s steric and 
electrostatic characteristics. The combined findings suggest that small electron-withdrawing 
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groups are preferred for the position 3. The introduction of a smaller N-bearing heterocycle 
into the position 3 resulted in compounds with affinities in picomolar range.  
The position 5 is more bulk-tolerant than the position 3 with regard to the α4β2* affinity, but 
less bulk-tolerant for the α4β3* affinity. Additionally, the position 5 does not favour 
substituents with high electronegativity. These results allow development of α4β2*-selective 
ligands via appropriate substitution of the position 5 (e.g. with bulky indole moiety). 
NH
N
O
electrostatic properties of the substituent 
          more influential than the size
smaller N-bearing heterocycles preferred
new binding bridge via
 5-substitution possible
bulk-limited position
substitution with (hetero)aryl moieties 
improves the subtype selectivity
3
5
 
These results provide valuable information regarding the requirements of the α4β2 nAChR 
subtype for a cytisine-derived ligand with high affinity and selectivity and greatly extend the 
knowledge of SAR for cytisine as a lead compound.  
 
Project II: Development of Novel nAChRs Ligands based on Choline 
The vast majority of the nAChR ligands are compounds selective for α4β2 subtype. Only 
limited amount of synthetic α7 agents, next to the naturally occurring toxins with high α7 
affinity, have been reported in the literature, e.g. GTS-21 13 and AR-R17779 26.  
Choline 3, a precursor and a metabolite of acetylcholine 1, possesses micromolar affinity for 
α4β2 receptor (Ki = 112 µM) and is an effective agonist of α7 nAChRs even if it presents very 
low affinity for this subtype (Ki = 2,380 µM). However, despite its pharmacological profile and 
cytoprotective properties, the structure of choline 3 has attracted limited interest as lead 
compound in the search for nAChR ligands. Therefore, it was rationale to revisiting this 
structure as a lead for development of novel nAChRs ligands.  
Addition of amide moiety into a phenylether of choline 4 (potent ganglion stimulant) resulted 
into a phenylcarbamate derivative 5, that exhibited nanomolar α7-affinity combined with high 
selectivity for this receptor subtype. In order to explore the requirements of the α7 nACh 
receptor for a selective and potent ligand and answer the question whether a carbamate 
bond between nAChR pharmacophoric elements always results into an α7-selective ligand, a 
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library of phenylcarbamate analogues was synthesized. In the target phenylcarbamate 
derivatives, the quaternary nitrogen was incorporated into various azacyclic systems (N-
methylpyrrolidine, N-methylpiperidine and quinuclidine) with the intention to improve BBB 
permeability. Additional substitution at the phenyl moiety should give deeper insight into the 
structure-activity relationship.  
Chemistry 
• The target phenylcarbamates were synthesized via the addition of corresponding 
azacyclic alcohol to the m-substituted phenylisocyanate. 
NCO X
R
O N
H
O
X
R
OH
N
CH3
N
CH3
N
+
  50°C
1.5 - 4 h
toluene
136   X = CH3 
137   X = Br
R = 
138   X = CH3 
139   X = Br
140   X = CH3 
141   X = Br
 
 
• In order to avoid hydrolyses of the isocyanates, the reactions were carried out under 
argon atmosphere in dry solvent (toluene).  
• The biaryl analogues 144 and 145 were successfully synthesized by employing the 
Suzuki protocol. Microwave dielectric heating was used instead of the conventional 
heating and allowed the addition of the phenyl and styryl moieties to the quinuclidine 
derivative 141 in 10 min. 
N
O N
H
O
Br
N
O N
H
O
R
B
OHR
OH
Pd(PPh3)4,Na2CO3
60 - 100 W
120°C, 10 min
144   R = phenyl
145   R = styryl
141
 
Pharmacology 
• Incorporation of the quaternary nitrogen into a pyrrolidine skeleton decreased the α7* 
binding while enhancing the α4β2* binding. The ligand’s affinity to the [3H]epibatidine 
binding sites in rat brain membranes is supported by meta-substitution of the phenyl 
moiety with bromine.  
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• Expansion of the pyrrolidine ring to piperidine leads to a notable reduction of the 
affinity for α4β2* and loss of the affinity for α7* nAChR subtype.  
• Quinuclidinole analogues exhibit remarkable selectivity for α7* receptor over α4β2* 
nAChR. Substitution in the position 3 of the phenyl moiety caused a reduction of 
binding affinity with the rank-order H < Br ≈ CH3 < Ph < styryl.  
The carbamates bearing pyrrolidine 136 – 137 or piperidine 138 – 139 moiety had been 
shown to possess a prevalance for the α4β2* nAChR subtype while the corresponding 
analogues in the quinuclidine series 140 – 141 revealed a higher binding to the α7* 
subtype.  Thus, the carbamate bond as a link between the protonable nitrogen and pi-
electron system does not necessarily provide an α7-selective ligand. The 3-quinuclidinole 
core seems to possess favourite distance between the oxygen and nitrogen and in 
combination with carbamate moiety and pi-electron system it provides a template for 
development of selective and potent α7 ligands. 
 
N
O N
H
O
N
N
N
CH3
N
CH3
carbamate link not related to the subtype selectivity
     quinuclidine core
preferred for α7 affinity=
N-methyl-pyrrolidine core
preferred for α4β2 affinity
N-methyl-piperidine core
preferred for α4β2 affinity
m-substitution improves α4β2 affinity
but reduces α7 affinity
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Concluding Remarks  
It has been long accepted that targeting nAChRs represent a pathway for the treatment of 
various CNS-related and non CNS-related disorders (e.g. Alzheimer’s and Parkinson’s 
disease, schizophrenia, depression, inflammation, pain). Advances in medicinal chemistry, 
molecular biology and behavioural pharmacology have resulted in a better understanding of 
the role of nAChRs in the pathological processes as well as in a development of various 
structurally different nicotinic ligands, whereas several agents have entered clinical trials.  
The presented thesis was focused on development of novel nAChR ligands based on 
cytisine and choline. The synthesized compounds enrich the nAChR pharmacopoeia and the 
collective findings of biological evaluation greatly extend the knowledge of structure-activity 
relationship for the leads cytisine and choline. 
It has been shown that bulky aryl substituents attached to the cytisine skeleton decrease the 
affinity of the lead to the α4β2 nACh receptor, while smaller nitrogen bearing heteroaryls in 
the position 3 afford ligands with picomolar affinity. Substitution of the position 5 in cytisine 
leads to an improved selectivity for central nicotinic receptor over nAChRs in the peripheral 
nervous system and this makes the 5-substituted analogues very interesting. Since the 
partial agonist behaviour of cytisine provides pharmacological profile required for the 
treatment of smoking cessation, it is almost essential in the future to test the activities of 
these ligands. Cytisine has been recently evaluated as an antidepressive drug and several 
novel derivatives presented herein are currently under investigation in a depression test 
system at Yale University in New Haven, USA.  
Carbamates bearing N-methyl-pyrrolidine or N-methyl-piperidine moiety have been shown to 
possess lower affinity for α7* nAChR than their analogues in the quinuclidine series, although 
the same structural elements are present (a protonable basic nitrogen, a carbamate moiety 
and a pi-electron system). However, the carbamate bond as a link between a quinuclidine 
core and the pi-electron system provides a template for high affinity ligands with α7-subtype 
selectivity, whereas replacement of the quinuclidine moiety by other azacyclic cores, such as 
N-methylpyrrolidine or N-methylpiperidine, provides ligands with prevalance for α4β2 
nAChRs. Since the carbamate bond is easily hydrolyzed and does not show a predisposition 
for a α7-selective ligand, it might be replaced by e.g. an amide bond. A library of compounds, 
in which various azacyclic cores are linked to a pi-electron system via an amide bond, would 
offer new and interesting nAChRs ligands.  
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6 Experimental Procedures 
 
6.1 General Information  
 
Ultraturrax Homogenization 
The homogenization was completed with ULTRA-TURRAX T50 DPX homogenizator 
(Janke&Kunkel, IKA Labortechnik, Germany). 
 
Microwave 
Microwave irradiation was carried out using the CEM-Discover microwave synthesis system 
(CEM GmbH, Kamp-Lintfort, Germany). 
 
Solid Phase Extraction 
SPE was performed on Solid Phase Extraction BAKERBOND speTM Columns (KMF 
Laborchemie Handels GmbH, St. Augustin, Germany). 
 
High Performance Liquid Chromatography 
The chromatographic system consisted of WellChrom Pump K-120 (Knauer GmbH, 
Germany), Injection & Switching Valves (Knauer GmbH, Germany), Preparative HPLC-Pump 
K-1800 (Knauer GmbH, Germany), Fast scanning Spectro-Photometer K-2600 (Knauer 
GmbH, Germany) and Electric Valve Drive (Knauer GmbH, Germany). The column used was 
Eurospher 100 C 18, 10 µm, 250 mm × 20 mm (ID) from Knauer GmbH, Germany. The 
mobile phase was a mixture of MeOH (HPLC Grade Methanol, Merck KgaA, Darmstadt, 
Germany) and deionised H2O. The flow rate of the mobile phase was 20 mL/min and the 
input of 10 mL was used. The chromatograms were scanned at 254 nm and collected to 
reaction flasks.  
 
Lyophilization 
Lyophilization of water was carried out using the Alpha 1-4 LSC (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany). 
 
Column Chromatography 
Column chromatography was carried out on Merck silica gel 60 (70 – 230 mesh). The 
solvents were evaporated with Vacuubrand CVC 2 rotary evaporator (Vacuubrand GmbH & 
Co KG, Wertheim, Germany). 
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NMR Spectroscopy 
1H- and 13C-NMR spectra (1D and 2D) were measured at 500 MHz and 125 MHz on a Bruker 
“Avance 500” spectrometer at the Institute for Pharmaceutical Chemistry, Poppelsdorf, 
University of Bonn. CDCl3 was used as a solvent and the chemical shift of the remaining 
protons of the deuterated solvent served as internal standard: δ 1H 7.24 ppm, δ 13C 77 ppm. 
The assignment was done with the aid of 2D NMR chemical shift maps (COSY, HSQC, 
HMBC) as well as with the aid of substituent chemical shifts. The coupling constants are 
given in Hertz (Hz) and the chemical shifts in part per million (ppm). The signal multiplicities 
are given as follows: s = singlet, d = doublet, t = triplet, q = quartet, sex = sextet, m = 
multiplet, br = broad, ovl = overlapping, p = pseudo. 
 
Mass Spectroscopy 
The mass spectra (EI with high resolution) were measured on an “MS-50 A.E.I.” or “MAT 95 
XL, Thermoquest” at the Kekulé Institute for Organic Chemistry and Biochemistry, Endenich, 
University of Bonn.  
 
InfraRed Spectroscopy  
Infrared spectra were determined on Perkin-Elmer 1600 Series FTIR (Perkin-Elmer, 
Wellesley, MA, USA) spectrophotometer at the Institute for Pharmaceutical Chemistry, 
Poppelsdorf, University of Bonn. 
  
Elemental microanalysis 
Elemental microanalyses were performed on a VarioEL apparatus (Elemetar 
AnalysenSysteme, GmbH, Hanau, Germany) at the Institute for Pharmaceutical Chemistry, 
Endenich, University of Bonn. 
 
Melting Point 
Melting points were determined on a Büchi B-545 melting point apparatus and are 
uncorrected. For some derivatives the melting point was not determined due to the little 
amount of the product. 
 
Thin Layer Chromatography 
The purity of the compounds was checked on TLC chromatography (Kieselgel 60 F254, 
Merck, Darmstadt, Germany) using CH2Cl2/MeOH/EDMA 99:1:1 v/v/v as a mobile phase.  
For the reverse phase TLC the RP-18 F254s plates (Merck, Darmstadt, Germany) and a 
mixture MeOH/H20 80:20 v/v were utilised. 
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Chemical substances 
Commercially obtained chemical substances (purity > 97%) were directly used in the 
chemical reactions. Commercially obtained solvents with the purity <97% were purified via 
destillation. The boronic acids were obtained from Acros Organics (provided by KMF 
Laborchemie Handels GmbH, Sankt Augustin, Germany) or Aldrich-Sigma Chemie GmbH, 
Taufkirchen, Germany in 95% – 98% purity.  
 
Numbering 
The alternative numbering used in the thesis for the name and assignment of the 1H and 13C 
NMR chemical shifts is not consistent with the IUPAC numbering. The IUPAC name of each 
compound is listed at the end of the spectroscopic characterisation. 
 
NH
N
O
3
7
2
4
5
6 1
8
9
1011
11a
IUPAC numbering
IUPAC name: 1,2,3,4,5,6-Hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
NH
N
O
12
1
2
3
6
78
9 10
11
13
45
N
N
H
O
alternative numbering
trivial name: cytisine 27 another often used figure of cytisine 27
 
Intermediates 
N-tBOC-cytisine 76, 3-bromo-N-tBOC-cytisine 81, 5-bromo-N-tBOC-cytisine 82 and 3,5-
dibromo-N-tBOC-cytisine 83 were synthesized as previously desribed124 and were used in 
following synthetic steps. 
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6.2 Cytisine 27 
NH
N
O
2
3
45
6
78
9 10
11
13
 
 
The seeds of Laburnum anagyroides and Laburnum watereri were collected each year in the 
Köln-Bonn area in the months September-October. The plant material was air-dried at least 
for 3 months and ground to a powder consistence.  
The plant material was extracted with CH2Cl2/MeOH/aq.NH3 through homogenization by 
Ultra-turrax for 8 hours (Table 6-1). The evaporated solvent were replaced, exactly the same 
amounts of each solvent were added to the homogenate during the extraction. The 
homogenate was centrifuged (2,000 × min, 40 min) and the supernatant collected. The dark 
green solution was concentrated under reduced pressure to the final volume of 500 mL and 
extracted with 1M HCl (3 × 100 mL). The aqueous acid solution was rendered alkaline with 
26% NH4OH (pH 11-12) and the free base extracted with CH2Cl2 (10 × 100 mL). The organic 
layers were collected and the solvent evaporated in vacuo. The dark green/brownish residue 
was chromatographed on silica gel column with CHCl3/MeOH 6:1 v/v. The alkaloid 27 was 
recrystallised from perchlorethylene or directly used in the next step (N-tBOC-cytisine 76, 
Method B).   
 
 
Table 6-1 Experimental conditions for the extraction of cytisine 27 
Extraction 
No. 
Amount of the 
plant material 
Solvents* 
CH2Cl2     MeOH     aq.NH3 
Cytisine 
27 
Yields 
1 350 g (seeds only) 500 mL       140 mL      60 mL 0.95 g 0.27% 
2 600 g (seeds only) 840 mL       240 mL      90 mL 2.90 g 0.48% 
3 1,000 g 2.5 L            1 L         250 mL 1.15 g 0.11% 
4 1,000 g 2.5 L            1 L         250 mL 1.83 g 0.18% 
5 500 mg 1.3 L        500 mL      125 mL 0.64 g 0.13% 
6 1,000 g 2.5 L            1 L         250 mL 1.36 g 0.14% 
* The same amount of solvents added through the 8 hours of homogenization. 
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M.p.: 155-156 °C 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.05 (dd, 3J = 9.1 Hz, 3J = 6.9 Hz, 1 H, H4); 6.17 (d, 3J = 
9.1 Hz, 1 H, H3); 5.77 (d, 3J = 6.9 Hz, 1 H, H5); 3.77 (d, 2J = 15.4 Hz, 1 H, H10β); 3.57 (dd, 
2J = 6.6 Hz, 3J = 15.7 Hz, 1 H, H10α); 2.70 – 2.75 (m, 4 H, H11+H13); 2.62 (s br, 1 H, H7); 
2.03 (s br, 1 H, H9); 1.65 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.8 (C=O, C2); 150.7 (C6); 138.1 (C4); 115.7 (C3); 
104.2 (C5); 53.3 (C13); 52.3 (C11); 49.1 (C10); 34.9 (C7); 27.0 (C9); 25.6 (C8)  
 
1H NMR (500 MHz, CD3OD) δ [ppm] 7.49 (dd, 3J = 9.1 Hz, 3J = 6.9 Hz, 1 H, H4); 6.44 (dd, 3J 
= 9.1 Hz, 4J = 1.6 Hz, 1 H, H3); 6.30 (dd, 3J = 6.9 Hz, 4J = 1.6 Hz, 1 H, H5); 4.09 (d, 2J = 15.5 
Hz, 1 H, H10α); 3.92 (dd, 2J = 6.6 Hz, 3J = 15.5 Hz, 1 H, H10β); 2.99 – 3.11 (m, 5 H, 
H11+H13+H7); 2.39 (s br, 1 H, H9); 2.04 (d, 2J = 12.9 Hz, 1 H, H8A); 1.98 (d,
 2J = 12.9 Hz 1 
H, H8B) 
 
13C NMR (125 MHz, CD3OD)  δ [ppm] 165.8 (C=O, C2); 153.3 (C6); 141.3 (C4); 117.0 (C3); 
108.0 (C5); 54.4 (C13); 53.4 (C11); 51.3 (C10); 36.6 (C7); 29.0 (C9); 26.9 (C8) 
 
IUPAC   1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one 
 
 
6.3 Synthesis of Intermediates 
6.3.1 N-tBOC-cytisine 76 
N
N
O
O
O
CH3
CH3
CH3
2
3
45
6
78
9 10
11
13
 
Method A 
Cytisine 27 (500 mg, 2.63 mmol), di-t-butyldicarbonate (688 mg, 3.15 mmol, 1.2 eq) and 
Na2CO3 (334 mg, 3.15 mmol, 1.2 eq) were stirred in 25 mL CH2Cl2 and 6 mL H2O at 60°C for 
2 hours. The reaction mixture was allowed to cool to room temperature and 10 mL of 
concentrated NaCl solution was added. The organic layer was dried over Mg2SO4 and the 
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solvent evaporated. The product was recrystallised from petroleum ether and obtained as off-
white crystalline powder (590 mg – 690 mg, 77% – 90%).  
 
Method B  
The dark brownish oily residue obtained from column chromatography in the isolation step 
was dissolved in 50 mL of CH2Cl2. Di-t-butyldicarbonate (2 g, 9.0 mmol), Na2CO3 (954 mg, 
9.0 mmol) and 10 mL H2O were added. The reaction mixture was stirred at 60°C. The 
reaction was monitored by TLC (CH2Cl2/MeOH 9:1 v/v) and reagents (di-t-butyldicarbonate, 
Na2CO3) were added until the cytisine spot disappeared. The mixture was allowed to cool to 
room temperature, washed with 30 mL of concentrated NaCl solution and the organic layer 
evaporated under reduced pressure. The yellow residue was dissolved in 150 mL of 
MeOH/H2O 60:40 v/v and the product was purified with HPLC. 
 
HPLC Method 
Mobile phase:    0 – 10’ MeOH/H2O 60:40 v/v 
10’ – 15’ gradient to 100% MeOH 
15’ – 25’ 100% MeOH 
Input: 10 mL 
Flow rate: 20 mL/min 
Run time: 25 min 
Detection: UV at λ = 254 nm 
Retention time: tr(N-tBOC-cytisine) = 6.9 min 
 
The collected aqueous layer were concentrated under reduced pressure and dried via 
lyophilization for at least 24 hours. N-tBOC-cytisine 76 was obtained as white crystalline 
powder and was directly used in the bromination step. The yields are calculated over the 
whole isolation/protection procedure and are listed in the Table 6-2.  
 
Table 6-2 Amount of cytisine 27 calculated from the amount of N-tBOC-cytisine 76. Yields 
calculated as the ratio of cytisine 27 quantity to the amount of plant material (1,000 g) 
 
Extraction 
No. 
Amount of 
the plant 
material 
Solvents* 
CH2Cl2      MeOH      aq.NH3 
N-tBOC-cytisine 
76 
Cytisine 
27 
Yields 
7 1,000 g 2.5 L            1 L         250 mL 1.80 g ~ 1.18 g 0.12% 
8 1,000 g 2.5 L            1 L         250 mL 1.76 g ~ 1.15 g 0.11% 
9 1,000 g 2.5 L            1 L         250 mL 2.70 g ~ 1.77 g 0.17% 
10 1,000 g 2.5 L            1 L         250 mL 2.30 g ~ 1.51 g 0.15% 
11 1,000 g 2.5 L            1 L         250 mL 2.06 g ~ 1.35 g 0.13% 
* The same amount of solvents added through the 8 hours of homogenization. 
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1H NMR (500 MHz, CDCl3) δ [ppm] 7.24 (dd, 3J = 9.1 Hz, 3J = 6.3 Hz, 1 H, H4); 6.41 (d, 3J = 
9.1 Hz, 1 H, H3); 6.03 (s br, 1 H, H5); 4.14 (d, 2J = 15.4 Hz, 1 H, H10β); 4.00 – 4.19 (m ovl., 2 
H, H13); 3.79 (dd, 2J = 6.6 Hz, 3J = 15.7 Hz, 1 H, H10α); 2.94 – 3.05 (m, 3 H, H7+H11); 2.38 
(s br, 1 H, H9); 1.93 (d, 1 H, H8A); 1.87 (d, 1 H, H8B); 1.30 (s, 9 H, tBOC-group) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.4 (C=O, C2); 154.5 (C=O; tBOC); 148.7 (C6); 138.9 
(C4); 117.1 (C3); 105.8 (C5); 80.3 (C(CH3), tBOC); 51.6 (C13); 50.5 (C11); 48.9 (C10); 34.8 
(C7); 28.0 (C(CH3), tBOC); 27.5 (C9); 26.1 (C8) 
 
IUPAC   8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-
carboxylic acid tert-butyl ester 
 
6.3.2 3-Bromo-N-tBOC-cytisine 81 and 5-Bromo-N-tBOC-cytisine 
82 
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N-tBOC-cytisine 76 (1 g, 3.44 mmol) and N-bromosuccinimide (613 mg, 3.44 mmol, 1 eq) 
were stirred in 30 mL CH2Cl2 at 60°C for 2 hours. The reaction mixture was allowed to cool to 
room temperature and the solvent evaporated in vacuo. The oily residue was dissolved in 
150 mL of MeOH/H2O 60:40 v/v and the isomers were separated and purified with HPLC. 
 
HPLC method 
Mobile phase: MeOH/H2O 60:40 v/v 
Input: 10 mL 
Flow rate: 20 mL/min 
Run time: 20 min 
Detection: UV at λ = 254 nm 
Retention time:  tr (3-Br-N-tBOC-cyt)     =   8.85 min 
tr (5-Br-N-tBOC-cyt)  = 11.55 min 
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The collected aqueous layers were concentrated under reduced pressure and products dried 
via lyophilization for at least 24 hours. The products were obtained as white crystalline 
powders in 38.0% – 51.9% (81) and 28.1% – 42.2% (82) yields (Table 6-3). 
 
 
Table 6-3 Yields of 3-bromo and 5-bromo-N-tBOC-cytisine isomers 81 and 82 
 
Experiment 
No. 
3-Br-N-tBOC-
cytisine  81 
Yields 
5-Br-N-tBOC-
cytisine  82 
Yields 
1 540 mg 43.0% 422 mg 33.6% 
2 543 mg 43.2% 353 mg 28.1% 
3 652 mg 51.9% 384 mg 30.6% 
4 646 mg 51.4% 530 mg 42.2% 
5 477 mg 38.0% 460 mg 36.6% 
6 507 mg 40.4% 286 mg 22.8% 
7 517 mg 41.2% 395 mg 31.5% 
8 504 mg 40.1% 354 mg 28.2% 
 
 
3-Bromo-N-tBOC-cytisine 81 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.64 (d, 3J = 7.6 Hz, 1 H, H4); 5.96 (s br, 1 H, H5); 4.23 
(d, 2J = 15.8 Hz, 1 H, H10β); 4.06 – 4.35 (m ovl., 2 H, H13); 3.85 (dd, 2J = 6.3 Hz, 3J = 15.5 
Hz, 1 H, H10α); 2.99 – 3.06 (m, 3 H, H7 + H11); 2.40 (s br, 1 H, H9); 1.94 (t, 2J = 13.2 Hz, 2 
H, H8); 1.30 (s, 9 H, tBOC) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 159.4 (C=O, C2); 154.4 (C=O, tBOC); 148.5 (C6); 140.8 
(C4); 112.5 (C3); 105.7 (C5); 80.6 (C(CH3), tBOC); 51.4 (C13); 50.2 (C11); 49.2 (C10); 34.7 
(C7); 28.0 (C(CH3), tBOC); 27.4 (C9); 26.0 (C8) 
 
IUPAC   9-bromo-8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine- 
3-carboxylic acid tert-butyl ester 
 
 
5-Bromo-N-tBOC-cytisine 82 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.42 (d, 3J = 9.8 Hz, 1 H, H4); 6.38 (d, 3J = 9.5 Hz, 1 H, 
H3); 4.36 (s br, 2 H, H13); 4.16 (d, 2J = 15.5 Hz, 1 H, H10β); 3.82 (dd, 3J = 6.0 Hz, 2J = 15.5 
Hz, 1 H, H10α); 3.42 (s br, 1 H, H7); 2.90 – 3.06 (m, 2 H, H11); 2.40 (s br, 1 H, H9); 1.97 (s, 
2 H, H8); 1.29 (s, 9 H, tBOC) 
178Experimental Procedures 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.3 (C=O, C2); 154.4 (C=O, tBOC); 145.9 (C6); 
142.4 (C4); 118.2 (C3); 99.3 (C5); 80.5 (C(CH3), tBOC); 50.2 (C13); 48.9 (C11); 47.2 (C10); 
34.2 (C7); 28.0 (C(CH3), tBOC); 27.4 (C9); 26.3 (C8) 
 
IUPAC 11-bromo-8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine- 
3-carboxylic acid tert-butyl ester  
 
6.3.3 3,5-Dibromo-N-tBOC-cytisine 83 
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N-tBOC-cytisine 76 (600 mg, 2.0 mmol) and N-bromosuccinimide (700 mg, 4.0 mmol, 2 eq) 
were stirred in 25 mL CH2Cl2 at 60°C for 2 hours. The reaction mixture was allowed to cool to 
room temperature and the solvent evaporated in vacuo. The oily residue was dissolved in 
100 mL of MeOH/H2O 60:40 v/v and the product was separated and purified with HPLC. 
 
HPLC method 
Mobile phase: isocratic MeOH/H2O 60:40 v/v 
Input: 10 mL 
Flow rate: 20 mL/min 
Run time: 25 min 
Detection: UV at λ = 254 nm 
Retention time: tr (3,5-diBr-N-tBOC-cyt)     =   16.9 min 
 
The collected aqueous layers were concentrated under reduced pressure and the product 
dried via lyophilization for at least 24 hours. The product was obtained as white crystalline 
powder (376 mg, 42%). 
 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.83 (s, 1 H, H4); 4.33 (s br, 2 H, H13); 4.22 (d, 2J = 
15.8 Hz, 1 H, H10β); 3.85 (dd, 3J = 7.0 Hz, 2J = 16.1 Hz, 1 H, H10α); 3.39 (s br, 1 H, H7); 
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2.87 – 3.10 (m, 2 H, H11); 2.39 (s br, 1 H, H9); 1.99 (t, 2J = 14.1 Hz, 2 H, H8); 1.29 (s, 9 H, 
tBOC) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 158.6 (C=O, C2); 154.2 (C=O, tBOC); 145.5 (C6); 
143.8 (C4); 113.2 (C3); 98.3 (C5); 80.7 (C(CH3), tBOC); 51.4 (C13); 48.9 (C11); 47.9 (C10); 
34.2 (C7); 28.0 (C(CH3), tBOC); 27.3 (C9); 26.2 (C8) 
 
IUPAC   9,11-dibromo-8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5] 
diazocine-3-carboxylic acid tert-butyl ester 
 
6.4 Synthesis of Novel nAChR Ligands Based on Cytisine 
 
6.4.1 General Procedures 
Suzuki cross-coupling reaction 
The appropriate bromo-N-tBOC-cytisine isomer (81 - 83, 0.27 mmol), boronic acid or ester 
(0.41 mmol; 1.5 eq), base (0.6 mmol, 2.2 eq), DME (3 mL) or DMF (3 mL) and H2O (1 mL) 
were placed in a 10-mL microwave glass tube. The solution was washed with argon for 10 
min. After the addition of Pd(PPh3)4 (0.027 mmol, 0.1 eq) the reaction vessel was sealed with 
a septum and placed into the microwave cavity. Microwave irradiation of 30 W was used, the 
temperature being ramped from room temperature to 80°C. Once 80°C was reached, the 
reaction mixture was held for 30 or 60 min. Then the mixture was allowed to cool to room 
temperature, the reaction vessel was opened and the solvent evaporated under pressure. 
The brown residue was extracted on SPE C-18 column eluting with mixture MeOH/H2O 
70:30 or 60:40 v/v. The aqueous solution was concentrated in vacuo and the tBOC-protected 
product was purified by HPLC.  
 
HPLC method 
The ratios of MeOH/H2O 80:20 (v/v), 70:30 (v/v), 60:40 (v/v), 55:45 (v/v), 50:50 (v/v) were 
used for 25 min. In the following 5 min gradient to 100% MeOH was run and the system was 
washed with MeOH for 15 min. The flow rate of the mobile phase was 20 mL/min and the 
input of 10 mL was used. The chromatograms were scanned at 254 nm and collected to 
reaction flasks. The retention time given for each compound is the retention time of the N-
tBOC-protected analogue. The fraction containing the desired product was concentrated in 
vacuo using a rotary evaporator. 
 
 
 
180Experimental Procedures 
 
Deprotection - Method A 
To the concentrated aqueous solution (approximately 15 mL) of the tBOC-protected product 
was added 1M HCl (15 mL) and the mixture was stirred at reflux for 24 hours. The reaction 
mixture was allowed to cool to room temperature and NaHCO3 was added. Free base was 
extracted with CHCl3, the organic solvent was evaporated and the desired product dried in 
vacuo. 
Deprotection - Method B 
The concentrated aqueous solution of the tBOC-protected product (approximately 70 mL) 
was put into a 80-mL microwave glass tube, sealed and placed into a microwave cavity. 
Microwave irradiation of 150 W was used, the temperature being ramped from room 
temperature to 150°C. Once 150°C was reached, the reaction mixture was held for 30 min. 
Then the mixture was allowed to cool to room temperature, the reaction vessel was opened 
and the solvent evaporated by lyophilization for at least 24 hours. 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), phenylboronic acid (50 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method B. The final 
product obtained as white crystalline powder (42 mg, 0.15 mmol, 58.4%). 
 
M.p.: 139.8 – 140.6 °C 
HPLC: tr = 16.73 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.69 (dt, 4J = 1.3 Hz, 3J = 7.2 Hz, 2 H, H2’ + H6’); 7.46 
(d, 3J = 7.2 Hz, 1 H, H4), 7.38 (t, 3J = 7.2 Hz, 2 H, H3’ + H5’); 7.29 (tt, 4J = 1.3 Hz, 3J = 7.2 
Hz, 1 H, H4’), 6.09 (d, 3J = 7.2 Hz, 1 H, H5); 4.19 (d, 2J = 15.5 Hz, 1 H, H10β); 3.96 (dd, 2J = 
6.3 Hz, 3J = 15.5 Hz, 1 H, H10α); 3.03 (d, 2J = 12.3 Hz, 1 H, H11A); 3.07 (dd, 
3J = 2.2 Hz, 2J = 
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12.3 Hz, 1 H, H13A); 3.02 (d br, 
2J = 12.3 Hz, 2 H, H11B + H13B); 2.91 (s br, 1 H, H7); 2.34 (s 
br, 1 H, H9); 1.96 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.1 (C=O, C2); 150.3 (C6); 137.4 (C4); 137.0 (C1’); 
128.6 (C2’ + C6’); 128.0 (C3’ + C5’); 127.4 (C3); 127.2 (C4’); 105.0 (C5); 54.0 (C13); 53.0 
(C11); 50.2 (C10); 35.7 (C7); 27.9 (C9); 26.3 (C8)  
 
MS (EI) m/z  266.2 (100), 223.1 (65), 210.1 (20), 185.1 (25), 167.1 (10), 149.1 (10), 133.1 
(10), 115.1 (10), 97.1 (10) 
 
HRMS for C17H18N2O   calc. 266.1419 
found 266.1426 
 
IUPAC   9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
 
6.4.3 3-(3’-Nitro-phenyl)-cytisine 94e    
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-nitrophenylboronic acid (68 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method A. The 
final product obtained as yellow crystalline powder (70 mg, 0.22 mmol, 83%). 
 
M.p.: 209.3 – 209.8 °C  
HPLC: tr = 17.18 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.53 (t, 4J = 1.9 Hz, 1 H, H2’); 8.10 – 8.13  (m, ovl., 2 H, 
H4’ + H6’); 7.54 (d, 3J = 7.3 Hz, 1 H, H4); 7.52 (t, 3J = 8.0 Hz, 1 H, H5’); 6.13 (d, 3J = 7.3 Hz, 
1 H, H5); 4.17 (d, 2J = 15.7 Hz, 1 H, H10β); 3.95 (dd, 3J = 6.6 Hz, 2J = 15.7 Hz, 1 H, H10α); 
2.98 – 3.14 (m, 4 H, H11 + H13); 2.95 (s br, 1 H, H7); 2.38 (s br, 1 H, H9); 1.97 (s, 2 H, H8); 
1.87 (s br, NH) 
182Experimental Procedures 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.7 (C=O); 152.0 (C6); 148.2 (C3’); 139.0 (C1’); 
137.6 (C4); 134.7 (C6’); 128.9 (C5’); 124.7 (C3); 123.3 (C2’); 121.9 (C4’); 105.0 (C5); 53.8 
(C13); 52.9 (C11); 50.3 (C10); 35.7 (C7); 27.7 (C9); 26.1 (C8) 
 
MS (EI) m/z  311.2 (90), 268.1 (100), 255.1 (20), 230.1 (15), 82.1 (25), 44.0 (10) 
 
HRMS for C17H17N3O3  calc. 311.1269 
found 311.1267  
 
IUPAC   9-(3-nitro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), m-tolylboronic acid (55 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 65:35 v/v. Deprotection by Method A. The final 
product obtained as off-white crystalline powder (49 mg, 0.16 mmol, 65%). 
 
M.p.: n.d. 
HPLC: tr = 16.27 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.52 (s br, 1 H, H2’); 7.43  (d, 3J = 7.3 Hz, 2 H, H4 + 
H6’); 7.26 (t, 3J = 7.3 Hz, 1 H, H5’); 7.09 (d, 3J = 7.3 Hz, 1 H, H4’); 6.06 (d, 3J = 7.0 Hz, 1 H, 
H5);  4.18 (d, 2J = 15.6 Hz, 1 H, H10β); 3.94 (dd, 3J = 6.6 Hz, 2J = 15.6 Hz, 1 H, H10α), 2.91 
(s br, 1 H, H7); 3.00 – 3.11 (m, 4 H, H11 + H13); 2.35 (s, 3 H, CH3); 2.34 (s, 1 H, H9); 1.97 
(s, 2 H, H8) 
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13C NMR (125 MHz, CDCl3) δ [ppm] 162.2 (C=O); 150.0 (C6); 137.5 (C1’); 137.3 (C3’); 
137.0 (C4); 129.3 (C2’); 128.1 (C4’); 128.0 (C5’); 127.6 (C3); 125.7 (C6’); 105.0 (C5); 53.9 
(C13); 52.8 (C11); 50.1 (C10); 35.6 (C7); 27.8 (C9); 26.3 (C8); 21.5 (CH3) 
 
MS (EI) m/z  280.2 (80), 237.1 (100), 224.1 (25), 199.1 (20), 82.1 (10), 44.0 (40) 
 
HRMS for C18H20N2O  calc. 280.1576 
found 280.1579  
 
IUPAC    9-m-tolyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-trifluoromethylphenylboronic acid (77 mg, 0.41 mmol), 
Na2CO3 (64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction 
time was 30 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was 
used. The HPLC separation was completed with MeOH/H2O 65:35 v/v. Deprotection by 
Method A. The final product obtained as off-white crystalline powder (47 mg, 0.14 mmol, 
52%). 
 
M.p.: 140.9 – 143.0 °C 
HPLC: tr = 19.28 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.95 (s, 1 H, H2’); 7.91  (d, 3J = 7.8 Hz, 1 H, H6’); 7.52 
(d, 3J = 7.8 Hz, 1 H, H4’); 7.49 (d, 3J = 7.0 Hz, 1 H, H4); 7.47 (t, 3J = 7.8 Hz, 1 H, H5’);  6.11 
(d, 3J = 7.0 Hz, 1 H, H5); 4.16 (d, 2J = 15.6 Hz, 1 H, H10β); 3.95 (dd, 3J = 6.3 Hz, 2J = 15.6 
Hz, 1 H, H10α); 2.99 – 3.13 (m, 4 H, H11 + H13); 2.94 (s br, 1 H, H7); 2.35 (s br, 1 H, H9); 
1.96 (s, 2 H, H8) 
 
184Experimental Procedures 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.9 (C=O, C2); 151.4 (C6); 138.1 (C1’); 137.4 (C4); 
131.9 (C6’); 130.4 (q, 2JC,F = 31.7 Hz, C3’); 128.4 (C5’); 125.8 (C3); 125.3 (q, 
3JC,F = 3.7 Hz, 
C4’); 123.8 (q, 3JC,F = 3.7 Hz, C2’); 123.2 (q, 
1JC,F = 272.5 Hz, CF3), 104.9 (C5); 54.0 (C13); 
53.0 (C11); 50.3 (C10); 35.7 (C7); 27.8 (C9); 26.2 (C8) 
 
MS (EI) m/z  334.2 (85), 291.1 (100), 270.0 (25), 253.1 (35), 82.1 (30), 44.0 (90) 
 
HRMS for C18H17F3N2O  calc. 334.1293 
found 334.1294 
 
IUPAC   9-(3-trifluoromethyl-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]-
diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-trifluoromethoxyphenylboronic acid (62 mg, 0.41 mmol), 
Na2CO3 (64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction 
time was 30 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was 
used. The HPLC separation was completed with MeOH/H2O 65:35 v/v. Deprotection by 
Method A. The final product obtained as off-white crystalline powder (61 mg, 0.17 mmol, 
64%). 
 
M.p.: n.d.  
HPLC: tr = 21.28 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.63 (ddd, 4J = 1.3 Hz, 4J = 1.6 Hz, 3J = 8.0 Hz, 1 H, 
H6’); 7.58 (s br, 1 H, H2’); 7.45 (d, 3J = 7.3 Hz, 1 H, H4); 7.38 (t, 3J = 8.0 Hz, 1 H, H5’); 7.11 
(dquint, 4J = 1.3 Hz, 3J = 8.0 Hz, 1 H, H4’); 6.07 (d, 3J = 7.3 Hz, 1 H, H5); 4.17 (d, 2J = 15.5 
Hz, 1 H, H10β); 3.93 (dd, 3J = 6.6 Hz, 2J = 15.5 Hz, 1 H, H10α); 2.95 – 3.12 (m, 4 H, H11 + 
H13); 2.91 (s br, 1 H, H7); 2.35 (s br, 1 H, H9); 1.95 (s br, 2 H, H8) 
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13C NMR (125 MHz, CDCl3) δ [ppm] 161.8 (C=O, C2); 151.1 (C6); 149.0 (q, 3JC,F = 1.5 Hz, 
C3’); 139.3 (C1’); 137.3 (C4); 129.2 (C5’); 126.9 (C6’); 125.6 (C3); 121.5 (q, 1JC,F = 257.0 Hz, 
CF3); 121.1 (C4’); 119.5 (C2’); 105.0 (C5); 53.7 (C13); 52.8 (C11); 50.2 (C10); 35.6 (C7); 
27.7 (C9); 26.1 (C8) 
 
MS (EI) m/z  350.2 (100), 307.1 (100), 294.1 (20), 269.1 (30), 82.0 (20), 44.0 (50) 
 
HRMS for C18H17F3N2O2  calc. 350.1242 
found 350.1244 
 
IUPAC   9-(3-trifluoromethoxy-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a] 
diazocin-8-one 
 
6.4.7 3-(3’-Chloro-phenyl)-cytisine 98e  
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-chlorophenylboronic acid (63 mg, 0.41 mmol), Na2CO3 
(64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 
30 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 65:45 v/v. Deprotection by Method B. The 
final product obtained as white crystalline powder (38 mg, 0.13 mmol, 47%). 
 
M.p.: 190.6 – 190.9 °C 
HPLC: tr = 20.39 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.69 (t, 4J = 1.6 Hz, 1 H, H2’);  7.58 (dt, 4J = 1.6 Hz, 3J = 
7.9 Hz, 1 H, H4’); 7.44 (d, 3J = 7.3 Hz, 1 H, H4);  7.29 (t, 3J = 7.9 Hz, 1 H, H5’); 7.23 (dd, 4J = 
1.6 Hz, 3J = 7.9 Hz, 1 H, H6’); 6.08 (d, 3J = 7.3 Hz, 1 H, H5); 4.16 (d, 2J = 15.6 Hz, 1 H, 
H10β); 3.94 (dd, 3J = 6.0 Hz, 2J = 15.6 Hz, 1 H, H10α); 3.11 (d, 2J = 12.0 Hz, 1 H, H11A); 3.06 
(dd, 3J = 2.2 Hz, 2J = 12.0 Hz, 1 H, H13A); 3.00 (d, 
2J = 12.0 Hz, 2 H, H11B + H13B); 2.92 (s 
br, 1 H, H7); 2.35 (s br, 1 H, H9); 1.96 (s br, 2 H, H8)  
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13C NMR (125 MHz, CDCl3) δ [ppm] 161.8 (C=O, C2); 151.0 (C6); 139.1 (C1’); 137.3 (C4); 
133.9 (C3’); 129.2 (C5’); 128.6 (C2’); 127.2 (C4’); 126.7 (C6’); 125.9 (C3); 105.0 (C5); 53.9 
(C13); 53.0 (C11); 50.2 (C10); 35.7 (C7); 27.8 (C9); 26.2 (C8) 
 
MS (EI) m/z  300.1 (100), 257.1 (95), 244.0 (30), 219.0 (40), 192.1 (5), 150.0 (10), 82.1 
(10), 68.1 (5) 
 
HRMS for C17H17ClN2O  calc. 300.1029 
found 300.1025 
 
IUPAC  9-(3-chloro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8- 
one 
 
6.4.8 3-(3’-Fluoro-phenyl)-cytisine 99e   
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-fluorophenylboronic acid (56 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 65:35 v/v. Deprotection by Method A. The 
final product obtained as off-white crystalline powder (35 mg, 0.12 mmol, 46%). 
 
M.p.: 138.9 – 140.0 °C 
HPLC: tr = 13.7 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.45 (d, 3J = 7.2 Hz, 1 H, H4); 7.43 (d br, 3J = 8.2 Hz, 2 
H, H2’ + H6’); 7.32  (dt, 4J = 6.3 Hz, 3J = 8.5 Hz, 1 H, H5’); 6.96 (tdd, 4J = 0.9 Hz, 4J = 2.5 Hz, 
3J = 8.5 Hz, 1 H, H4’); 6.08 (d, 3J = 7.2 Hz, 1 H, H5); 4.17 (d, 2J = 15.6 Hz, 1 H, H10β); 3.93 
(dd, 3J = 6.0 Hz, 2J = 15.6 Hz, 1 H, H10α); 3.12 (d, 2J = 12.0 Hz, 1 H, H11A); 3.06 (dd, 
3J = 
2.2 Hz, 2J = 12.0 Hz, 1 H, H13A); 3.01 (d, 
2J = 12.0 Hz, 1 H, H11B); 2.98 (d, 
2J = 13.0 Hz, 1 H, 
H13B); 2.92 (s br, 1 H, H7); 2.36 (s br, 1 H, H9); 2.26 (s br, NH); 1.96 (s br, 2 H, H8) 
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13C NMR (125 MHz, CDCl3) δ [pm] 163.6 (d, 1JC,F = 244.1 Hz, C3’); 161.9 (C=O, C2); 150.7 
(C6); 139.4 (d, 3JC,F = 8.2 Hz, C1’); 137.3 (C4); 129.4 (d, 
3JC,F = 8.5 Hz, C5’); 126.0 (d, 
4JC,F = 
2.3 Hz, C3); 124.1 (d, 4JC,F = 2.7 Hz, C6’); 115.6 (d, 
2JC,F = 22.4 Hz, C4’); 114.1 (d, 
2JC,F = 
21.2 Hz, C2’); 105.0 (C5); 53.6 (C13); 52.7 (C11); 50.1 (C10); 35.5 (C7); 27.7 (C9); 26.1 (C8) 
 
MS (EI) m/z  284.2 (100), 241.2 (100), 228.1 (30), 203.1 (40), 149.1 (25), 82.1 (20), 44.0 
(50)  
 
HRMS for C17H17FN2O  calc. 284.1325 
found 284.1324 
 
IUPAC    9-(3-fluoro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-
one 
 
6.4.9 3-(Biphenyl-3’-yl)-cytisine 100e     
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The Suzuki reaction was performed according to the general method with 3-bromo-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-biphenylboronic acid (80 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification mixture of MeOH/H2O 80:20 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 65:35 v/v for 15 min, then a gradient to the final 
mixture of MeOH/H2O 80:20 v/v was run for 15 min. Deprotection by Method A. The final 
product obtained as off-white crystalline powder (33 mg, 0.1 mmol, 36%).  
 
M.p.: 95.2 – 97 °C 
HPLC: tr = 27.29 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.91 (t, 4J = 1.6 Hz, 1 H, H2’); 7.69 (ddd, 4J = 1.3 Hz, 4J = 
1.6 Hz, 3J = 8.0 Hz, 1 H, H6’); 7.62 (dt, 4J = 1.3 Hz, 3J = 8.2 Hz, 2 H, H2’’ + H6’’); 7.51 (d, 3J = 
7.3 Hz, 1 H, H4; dd, ovl., 1 H, H4’); 7.44 (d, 3J = 8.0 Hz, 1 H, H5’); 7.40 (tt, 4J = 1.9 Hz, 3J = 
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7.0 Hz, 2 H, H3’’ + H5’’); 7.31 (tt, 4J = 1.3 Hz, 3J = 7.0 Hz, 1 H, H4’); 6.09 (d, 3J = 7.3 Hz, 1 H, 
H5); 4.19 (d, 2J = 15.6 Hz, 1 H, H10β); 3.97 (dd, 3J = 5.7 Hz, 2J = 15.6 Hz, 1 H, H10α); 3.00 – 
3.13 (m, 4 H, H11 + H13); 2.93 (s br, 1 H, H7); 2.35 (s br, 1 H, H9); 1.97 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.1 (C=O, C2), 150.4 (C6), 141.4 (C3’), 141.0 (C1’’), 
137.6 (C4), 137.8 (C1’), 129.1 (C3), 128.5*, 128.1*, 127.8*, 127.4*, 127.1*, 126.8*, 126.6*, 
125.5*, 105.3 (C5), 53.9 (C13), 53.0 (C11), 50.2 (C10), 35.3 (C7), 27.5 (C9), 26.3 (C8) 
 
MS (EI) m/z 342.2 (100), 299.2 (65), 262.1 (60), 183.1 (35), 108.0 (10) 
 
HRMS for C23H22N2O  calc. 342.1732 
found 342.1734  
 
IUPAC   9-biphenyl-3-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), phenylboronic acid (50 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 60 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method B. The final 
product obtained as white crystalline powder (28 mg, 0.1 mmol, 39%). 
 
M.p.: 91 °C 
HPLC: tr = 17.32 min 
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1H NMR (500 MHz, CDCl3) δ [ppm] 7.37 (tt, 4J = 1.3 Hz, 3J = 7.3, 2 H, H3’ + H5’); 7.31 (tt, 4J 
= 1.6 Hz, 3J = 7.3 Hz, 1 H, H4’); 7.21 (d, 3J = 9.5 Hz, 1 H, H4); 7.18 (tt, 4J = 1.6 Hz, 3J = 7.3 
Hz, 2 H, H2’ + H6’); 6.49 (d, 3J = 9.5 Hz, 1 H, H3), 4.19 (d, 2J = 15.6 Hz, 1 H, H10β); 3.95 
(dd, 3J = 6.9 Hz, 2J = 15.6 Hz; 1 H, H10α); 3.12 (d, 2J = 12.0 Hz, 1 H, H11A); 3.04 (s br, 1 H, 
H7); 2.92 (d, 2J = 12.0 Hz, 1 H, H11B); 2.81 (d, 
2J = 12.0 Hz, 1 H, H13A); 2.69 (dd, 
3J = 2.5 
Hz, 2J = 12.0 Hz, 1 H, H13B), 2.30 (s br, 1 H, H9); 1.92 (d, 
2J = 13.0 Hz, 1 H, H8A); 1.84 (d, 
2J 
= 13.0 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.1 (C=O); 147.5 (C6); 141.4 (C4); 138.5 (C1’); 129.8 
(C2’ + C6’); 128.6 (C3’ + C5’); 127.4 (C4’); 119.3 (C5); 116.1 (C3); 53.0 (C13); 52.2 (C11); 
50.4 (C10); 31.6 (C7); 27.4 (C9); 26.4 (C8) 
 
MS (EI) m/z  266.2 (100), 223.1 (100), 210.1 (30), 185.1 (20), 167.1 (10), 149.1 (10), 133.1 
(10), 82.1 (10) 
 
HRMS for C17H18N2O  calc. 266.1419 
found 266.1416 
 
IUPAC    11-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-nitrophenylboronic acid (68 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method A. The 
final product obtained as yellow crystalline powder (52 mg, 0.17 mmol, 62%). 
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M.p.: 175.6 – 177.2 °C 
HPLC: tr = 16.7 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.19 – 8.21 (m, 1 H, H4’); 8.09 – 8.11  (m, 1 H, H2’); 
7.55 – 7.60 (m, 2 H, H5’ + H6’); 7.18 (d, 3J = 9.3 Hz, 1 H, H4); 6.52 (d, 3J = 9.3 Hz, 1 H, H3); 
4.19 (d, 2J = 15.5 Hz, 1 H, H10β); 3.96 (dd, 2J = 6.6 Hz, 3J = 15.5 Hz, 1 H, H10α); 3.10 (d, 2J 
= 9.1 Hz, 1 H, H11A); 2.93 (s br, 2 H, H7 + H11B); 2.74 (d br, 
2J = 9.1 Hz, 2 H, H13); 2.35 (s 
br, 1 H, H9); 1.94 (s br, 1 H, H8A); 1.87 (s br, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.0 (C=O, C2); 148.4 (C3’); 148.1 (C6); 141.0 (C4); 
140.0 (C1’); 135.5 (C6’); 129.2 (C5’); 124.2 (C2’); 121.9 (C4’); 117.2 (C5); 116.3 (C3); 52.9 
(C13); 52.0 (C11); 50.5 (C10); 32.1 (C7); 27.7 (C9); 26.3 (C8) 
 
MS (EI) m/z 311.2 (65), 268.1 (100), 255.1 (20), 230.1 (15), 183.1 (10), 167.1 (10), 149.1 
(10), 82.1 (15), 68.1 (10) 
 
HRMS for C17H17N3O3  calc. 311.1270 
found 311.1269 
 
IUPAC  11-(3-nitro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
 
 
6.4.12 5-(3’-Methyl-phenyl)-cytisine 105e  
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), m-tolylboronic acid (55 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
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separation was completed with MeOH/H2O 65:35 v/v. Deprotection by Method A. The final 
product obtained as off-white crystalline powder (44 mg, 0.16 mmol, 58%). 
 
M.p.: n.d. 
HPLC: tr = 16.17 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.25 (t, 3J = 7.5 Hz, 1 H, H5’); 7.19 (d, 3J = 9.2 Hz, 1 H, 
H4); 7.12 (d br, 3J = 7.5 Hz, 1 H, H4’); 6.99 (d br, 3J = 7.5 Hz, 1 H, H6’; s br, ovl., 1 H, H2’); 
6.47 (d, 3J = 9.2 Hz, 1 H, H3); 4.19 (d, 2J = 15.5 Hz, 1 H, H10β); 3.93 (ddd, 4J = 0.9 Hz, 3J = 
6.9 Hz, 2J = 15.5 Hz, 1 H, H10α); 3.07 (s br, 1 H, H7); 3.04 (d, 2J = 12.3 Hz, H11A); 2.91 (d, 
2J = 12.3 Hz, 1 H, H11B); 2.81 (d, 
2J = 12.3 Hz, 1 H, H13A); 2.68 (dd, 
3J = 2.5 Hz, 2J = 12.3 
Hz, 1 H, H13B); 2.35 (s, 3 H, CH3); 2.29 (s br, 1 H, H9); 1.92 (d br, 
2J = 13.0 Hz, 1 H, H8A); 
1.83 (d br, 2J = 13.0 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.1 (C=O, C2); 147.4 (C6); 141.4 (C4); 138.4 (C1’); 
138.3 (C3’); 130.4 (C2’); 128.4 (C5’); 128.1 (C4’); 126.8 (C6’); 119.5 (C5);  116.0 (C3); 53.0 
(C13); 52.2 (C11); 50.4 (C10); 31.6 (C7); 27.4 (C9); 26.4 (C8); 21.4 (CH3) 
 
MS (EI) m/z  280.2 (80), 237.1 (100), 224.1 (25), 199.1 (20), 82.1 (10), 44.0 (30) 
 
HRMS for C18H20N2O  calc. 280.1576 
found 280.1577 
 
IUPAC   11-m-tolyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
 
6.4.13 5-(3’-Trifluoromethyl-phenyl)-cytisine 106e  
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-trifluoromethylphenylboronic acid (77 mg, 0.41 mmol), 
Na2CO3 (64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction 
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time was 30 min. For the SPE purification mixture of MeOH/H2O 70:30 v/v (100 mL) was 
used. The HPLC separation was completed with MeOH/H2O 65:35 v/v. Deprotection by 
Method A. The final product obtained as off-white crystalline powder (58 mg, 0.17 mmol, 
64%). 
 
M.p.: 155.2 – 157.0 °C 
HPLC: tr = 17.05 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.58 (d, 3J = 7.9 Hz, 1 H, H6’); 7.50  (t, 3J = 7.9 Hz, 1 H, 
H5’); 7.46 (s, 1 H, H2’); 7.39 (d, 3J = 7.9 Hz, 1 H, H4’); 7.17 (d, 3J = 9.2 Hz, 1 H, H4), 6.49 (d, 
3J = 9.2 Hz, 1 H, H3); 4.18 (d, 2J = 15.7 Hz, 1 H, H10β); 3.94 (dd, 3J = 6.0 Hz, 2J = 15.7 Hz, 1 
H, H10α); 3.06 (d, 2J = 12.3 Hz, 1 H, H11A); 2.93 (s br, 1 H, H7); 2.90 (d, 
2J = 12.3 Hz, 1 H, 
H11B); 2.75 (d, 
2J = 12.3 Hz, 1 H, H13A); 2.69 (dd, 
3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, H13B); 2.31 
(s br, 1 H, H9); 1.93 (d br, 2J = 12.9 Hz, 1 H, H8A), 1.82 (d br, 
2J = 12.9 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.0 (C=O, C2); 148.0 (C6); 140.8 (C4); 139.3 (C1’); 
133.2 (C6’); 130.9 (q, 2JC,F = 32.2 Hz, C3’); 129.2 (C5’); 126.5 (q, 
3JC,F = 3.7 Hz, C2’); 124.9 
(q, 1JC,F = 272.5 Hz, CF3), 124.3 (q, 
3JC,F = 3.7 Hz; C4’); 117.6 (C5); 116.4 (C3); 53.0 (C13); 
52.1 (C11); 50.5 (C10); 31.7 (C7); 27.3 (C9); 26.3 (C8) 
 
MS (EI) m/z  334.2 (80), 291.1 (100), 253.1 (20), 196.1 (5), 183.1 (5), 167.1 (10), 149.1 
(10), 97.1 (5), 82.1 (10) 
 
HRMS for C18H17F3N2O  calc. 334.1293 
found 334.1295  
 
IUPAC 11-(3-trifluoromethyl-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-
a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 5-bromo-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-trifluoromethoxyphenylboronic acid (62 mg, 0.41 mmol), 
K3PO4 (60 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time 
was 60 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. 
The HPLC separation was done with MeOH/H2O 65:35 v/v. Deprotection by Method B. The 
final product obtained as off-white crystalline powder (26 mg, 0.07 mmol, 27%).  
 
M.p.: n.d. 
HPLC: tr = 21.12 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.41 (t, 3J = 8.0 Hz, 1 H, H5’); 7.20 (ddd, 4J = 1.3 Hz, 4J 
= 2.5 Hz, 3J = 8.0 Hz, 1 H, H4’); 7.19 (d, 3J = 9.2 Hz, 1 H, H4); 7.15 (dt, 4J = 1.3 Hz, 3J = 8.0 
Hz, 1 H, H6’); 7.08 (d, 4J = 2.5 Hz, 1 H, H2’); 6.50 (d, 3J = 9.2 Hz, 1 H, H5); 4.26 (d, 2J = 15.7 
Hz, 1 H, H10β); 3.95 (dd, 3J = 6.9 Hz, 2J = 15.7 H, 1 H, H10α); 3.39 (d, 2J = 12.3 Hz, 1 H, 
H11A); 3.11 (s br, 1 H, H7); 3.07 (d, 
2J = 12.3 Hz, 1 H, H11B); 2.92 (d, 
2J = 12.3 Hz, 1 H, 
H13A); 2.82 (dd, 
3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, H13B); 2.46 (s br, 1 H, H9);  1.91 (s br, 2 H, 
H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.2 (C=O, C2), 149.3 (q, 3J = 1.5 Hz, C3’), 148.3 
(C6), 140.0 (C1’), 141.1 (C4), 130.2 (C5’), 128.2 (C6’), 122.3 (C4’), 120.0 (C2’), 119.4 (q, J = 
257.6 Hz, CF3), 117.0 (C3), 116.4 (C5), 51.2 (C13), 50.4 (C11), 49.8 (C10), 30.5 (C7), 26.4 
(C9), 25.5 (C8) 
 
MS (EI) m/z  350.2 (60), 307.1 (100), 294.1 (25), 269.1 (20), 82.0 (30), 44.0 (50) 
 
HRMS for C18H17F3N2O2  calc. 350.1242 
found 350.1252 
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IUPAC    11-(3-trifluoromethoxy-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-
a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-chlorophenylboronic acid (63 mg, 0.41 mmol), K3PO4 (60 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 60 
min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was done with MeOH/H2O 65:45 v/v. Additional flash chromatography on 
silica gel done with CH2Cl2/MeOH/EDMA 99:1:1 v/v/v and the purification was completed with 
HPLC (MeOH/H2O 65:35 v/v for 25 min). Deprotection by Method B. The final product 
obtained as white crystalline powder (18 mg, 0.06 mmol, 22%). 
 
M.p.: 80.6 – 81 °C 
HPLC: 20.52 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.32 (m, ovl., 2 H, H2’ + H4’);  7.21 (t, 3J = 8.3 Hz, 1 H, 
H5’); 7.17 (d, 3J = 9.2 Hz, 1 H, H4); 7.09 (dd, 4J = 1.6 Hz; 3J = 8.3 Hz, 1 H, H6’); 6.49 (d, 3J = 
9.2 Hz, 1 H, H3); 4.21 (d, 2J = 15.6 Hz, 1 H, H10β); 3.95 (dd, 3J = 6.1 Hz, 2J = 15.6 Hz, 1 H, 
H10α); 3.17 (d, 2J = 12.6 Hz, 1 H, H11A); 3.04 (s br, 1 H, H7); 2.95 (d, 
2J = 12.6 Hz, 1 H, 
H13A); 2.81 (dd, 
3J = 2.2 Hz, 2J = 12.6 Hz, 1 H, H13B); 2.73 (d, 
2J = 12.6 Hz, 1 H, H11B); 2.34 
(s br, 1 H, H9); 1.93 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) not available due to the small amount of the sample 
 
MS (EI) m/z  300.1 (100), 257.1 (95), 244.0 (30), 219.0 (40), 192.1 (5), 150.0 (10), 82.1 
(10), 68.1 (5)  
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HRMS for C17H17ClN2O  calc. 300.1029 
found 300.1025 
 
IUPAC  11-(3-chloro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-
one 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-fluorophenylboronic acid (56 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. HPLC 
separation was completed with MeOH/H2O 65:35 v/v. Deprotection by Method A. The final 
product obtained as off-white crystalline powder (62 mg, 0.22 mmol, 81%).  
 
M.p.: n.d. 
HPLC: tr = 12.32 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.32 (td, 4J = 6.0 Hz, 3J = 7.9 Hz, 1 H, H5’); 7.16 (d, 3J = 
9.2 Hz, 1 H, H4); 7.01 (tdd, 4J = 0.9 Hz, 4J = 2.5 Hz, 3J = 8.5 Hz, 1 H, H4’); 6.96 (dt, 4J = 1.4 
Hz, 3J = 7.9 Hz, 1 H, H6’); 6.90 (dt, 4J = 1.4 Hz, 3J = 7.9 Hz, 1 H, H2’); 6.47 (d, 3J = 9.2 Hz, 1 
H, H3); 4.17 (d, 2J = 15.7 Hz, 1 H, H10β); 3.92 (dd, 3J = 6.8 Hz, 2J = 15.7 Hz, 1 H, H10α); 
3.03 (d, 2J = 11.3 Hz, 1 H, H11A); 3.07 (s br, 1 H, H7), 2.93 (s br, 1 H, H11B); 2.79 (d br, 
2J = 
11.0 Hz, 1 H, H13B); 2.71 (d br, 
2J = 11.0 Hz, 1 H, H13B); 2.31 (s br, 1 H, H9); 1.91 (s br, 2 H, 
H8A + NH); 1.84 (d br, 
2J = 12.6 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.6 (1JC,F = 247.6 Hz; C3’); 163.0 (C=O, C2); 147.6 
(C6); 140.9 (C4); 140.6 (3JC,F = 7.7 Hz, C1’); 130.1 (
3JC,F = 8.5 Hz, C5’); 125.6 (
4JC,F = 2.8 Hz, 
196Experimental Procedures 
 
C6’); 118.0 (4JC,F = 1.7 Hz, C5); 116.8 (
2JC,F = 21.0 Hz, C2’); 116.2 (C3), 114.4 (
2JC,F = 21.0 
Hz, C4’); 52.8 (C13); 52.1 (C11); 50.4 (C10), 31.6 (C7); 27.3 (C9); 26.2 (C8) 
 
MS (EI) m/z  284.1 (95), 241.0 (100), 228.0 (30), 203.0 (20), 149.0 (20), 133.0 (15), 82.1 
(10), 57.1 (10) 
 
 HRMS for C17H17FN2O  calc. 284.1325 
found 284.1334 
 
IUPAC  11-(3-fluoro-phenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-
one 
 
6.4.17 5-(Biphenyl-3’-yl)-cytisine 110e    
NH
N
O
1 '
2
3
45
67
8
9 1 0
1 1
1 3
2 '
3 '
4 ' 5 '
6 '
1 ''
2 ''3 ''
4 ''
5 '' 6 ''
 
 
The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-biphenylboronic acid (80 mg, 0.41 mmol), Na2CO3 (64 
mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 
min. For the SPE purification, a mixture of MeOH/H2O 80:20 v/v (100 mL) was used. The 
HPLC separation was done with MeOH/H2O 65:35 v/v for 15 min, subsequently a gradient to 
the final mixture of MeOH/H2O 80:20 v/v was run for 15 min. Deprotection by Method A. The 
final product obtained as off-white crystalline powder (58 mg, 0.17 mmol, 62%). 
 
 M.p.: 168.5 – 169.8 °C 
HPLC: tr = 27.65 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.55 – 7.58 (m, 3 H, H2’+H2’’+H6’’); 7.41 – 7.46  (m, 4 
H, H3’’+H5’’+H5’+H6’); 7.35 (tt, 4J = 1.6 Hz, 3J = 7.6 Hz, 1 H, H4’’); 7.26 (d, 3J = 9.1 Hz, 1 H, 
H4); 7.17 (dt, 4J = 1.6 Hz, 3J = 7.6 Hz, 1 H, H4’); 6.51 (d, 3J = 9.1 Hz, 1 H, H3); 4.22 (d, 2J = 
15.4 Hz, 1 H, H10β); 3.96 (dd, 
3J = 6.6 Hz, 2J = 15.4 Hz, 1 H, H10α); 3.09 (s, 1 H, H7); 3.07 
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(d, 2J = 12.3 Hz, 1 H, H11A); 2.91 (d, 
2J = 12.3 Hz, 1 H, H11B); 2.85 (d, 
2J = 12.3 Hz, 1 H, 
H13A); 2.72 (dd, 
3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, H13B), 2.30 (s, 1 H, H9); 1.94 (d br, 
2J = 12.9 
Hz, 1 H, H8A); 1.84 (d br, 
2J = 12.9 Hz, 1 H, H8B); 1.23 (br s, 1 H, NH) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.1 (C=O); 147.7 (C6); 141.6 (C1’’); 141.3 (C4); 
140.6 (C3’); 139.0 (C1’); 129.1∗; 128.6*; 128.9*; 128.6*; 128.5*; 127.1*; 127.6*; 126.1*; 119.1 
(C5); 116.1 (C3);  53.0 (C13); 52.3 (C11); 50.5 (C10); 31.4 (C7); 27.4 (C9); 26.4 (C8) 
 
MS (EI) m/z  342.2 (100), 299.2 (90), 262.1 (50), 201.20 (20), 183.1 (30), 170.1 (20), 149.0 
(20) 
 
HRMS for C23H22N2O  calc. 342.1732 
found 342.1734 
 
IUPAC   11-biphenyl-3-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 5-indolylboronic acid (65 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 60:40 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method B. The final 
product obtained as yellowish crystalline powder (31 mg, 0.1 mmol, 37%). 
  
M.p.: 139.0 – 141.1 °C 
HPLC: tr = 16.12 min 
 
                                                 
∗ the assignment of the biphenyl moiety could not be completed 
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1H NMR (500 MHz, CDCl3) δ [ppm] 8.28 (s br, 1 H, indolic NH); 7.92 (s br, 1 H, H2’); 7.52 
(dd, 4J = 1.6 Hz, 3J = 8.5 Hz, 1 H, H7’); 7.47 (d, 3J = 7.0 Hz, 1 H, H4); 7.38 (d, 3J = 8.5 Hz, 1 
H, H6’); 7.16 (pseudo t, 3J = 2.8 Hz, 1 H, H4’); 6.54 (tt, 4J = 0.9 Hz, 3J = 2.2 Hz, 1 H, H3’); 
6.06 (d, 3J = 7.0 Hz, 1 H, H5); 4.22 (d, 2J = 15.6 Hz, 1 H, H10β); 3.96 (dd, 3J = 6.3 Hz, 2J = 
15.6 Hz, 1 H, H10α); 3.12 (d, 2J = 12.6 Hz, 1 H, H11A); 3.00 – 3.06 (m, 3 H, H11B + H13); 
2.89 (s br, 1 H, H7); 2.34 (s br, 1 H, H9); 1.96 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.6 (C=O); 148.9 (C6); 136.7 (C4); 135.3 (C5a); 129.1 
(C1’); 128.9 (C3); 127.8 (C2a); 124.3 (C4’); 123.2 (C7’); 120.9 (C2’); 110.5 (C6’); 105.1 (C5); 
103.0 (C3’); 53.8 (C13); 52.9 (C11); 50.1 (C10); 35.6 (C7); 27.9 (C9); 26.4 (C8) 
 
MS (EI) m/z  305.2 (100), 261.1 (70), 249.2 (20), 233.2 (20), 44.0 (10) 
HRMS for C19H19N3O  calc. 305.1528 
found 305.1531 
 
IUPAC   9-(1H-Indol-5-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3,4-methylenedioxyphenylboronic acid (68 mg, 0.41 mmol), 
Na2CO3 (64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction 
time was 30 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was 
used. The HPLC separation was completed with MeOH/H2O 60:40 v/v. Deprotection by 
Method B. The final product obtained as off-white crystalline powder (30 mg, 0.1 mmol, 
36%). 
 
M.p.: 259.1 – 261.6 °C 
HPLC: tr = 18.99 min 
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1H NMR (500 MHz, CDCl3) δ [ppm] 7.38 (d, 3J = 7.3 Hz, 1 H, H4); 7.26 (d, 4J = 1.6 Hz, 1 H, 
H2’); 7.12 (dd, 4J = 1.6 Hz, 3J = 8.2, 1 H, H6’); 6.81 (d, 3J = 8.2 Hz, 1 H, H5’); 6.05 (d, 3J = 7.3 
Hz, 1 H, H5); 5.94 (s, 2 H, CH2); 4.16 (d, 
2J = 15.7 Hz, 1 H, H10β); 3.93 (dd, 3J = 6.6 Hz, 2J = 
15.7 Hz, 1 H, H10α); 3.11 (d, 2J = 12.0 Hz, 1 H, H11A); 3.06 (dd, 
3J = 2.2 Hz, 2J = 12.0 Hz, 1 
H, H13A); 3.00 (d br; 
2J = 12.0 Hz, 2 H, H11B + H13B); 2.90 (s br, 1 H, H7); 2.34 (s br, 1 H, 
H9); 1.95 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.1 (C=O, C2); 149.9 (C6); 147.3 (C3’); 146.8 (C4’); 
136.4 (C4); 131.4 (C1’); 127.1 (C3); 122.1 (C6’); 109.4 (C2’); 108.0 (C5’); 104.9 (C5); 100.9 
(CH2); 54.0 (C13); 53.0 (C11); 50.2 (C10); 35.7 (C7); 27.9 (C9); 26.4 (C8) 
 
MS (EI) m/z 310.1 (100), 267.0 (70), 254.0 (20), 229.0 (25), 180.0 (5), 155.0 (10), 140.0 
(10) 
 
HRMS for C18H18N2O3  calc. 310.1317 
found 310.1324 
 
IUPAC  9-(benzo[1,3]dioxol-5-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-
8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 3-pyridineboronic acid (49 mg, 0.41 mmol), K3PO4 (126 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 60 min. 
For the SPE purification, a mixture of MeOH/H2O 60:40 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 50:50 v/v. Deprotection by Method B. The final 
product obtained as yellow crystalline powder (48 mg, 0.18 mmol, 66%).  
 
M.p.: 79.8 – 81.6 °C 
HPLC: tr = 16.05 min 
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1H NMR (500 MHz, CDCl3) δ [ppm] 8.78 (d, 4J = 1.6 Hz, 1 H, H2’); 8.49 (dd, 4J = 1.6 Hz, 3J 
= 4.7 Hz, 1 H, H4’); 8.16 (ddd, 4J = 1.6 Hz, 4J = 2.2 Hz, 3J = 7.9 Hz, 1 H, H6’); 7.49 (d, 3J = 
7.3 Hz, 1 H, H4); 7.29 (ddd, 5J = 0.9 Hz, 3J = 4.7 Hz, 3J = 7.9 Hz, 1 H, H5’); 6.11 (d, 3J = 7.3 
Hz, 1 H, H5); 4.16 (d, 2J = 15.6 Hz, 1 H, H10β); 3.94 (dd, 3J = 6.9 Hz, 2J = 15.6 Hz, 1 H, 
H10α); 3.11 (d, 2J = 12.0 Hz, 1 H, H11A); 3.06 (dd, 
3J = 2.2 Hz, 2J = 12.0 Hz, 1 H, H13A); 2.99 
– 3.03 (m, 2 H, H 11B + H13B); 2.95 (s br, 1 H, H7); 2.36 (s br, 1 H, H9); 1.96 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.9 (C=O, C2); 151.5 (C6); 149.1 (C2’); 148.2 (C4’); 
137.2 (C4); 136.1 (C6’); 133.2 (C1’); 123.9 (C3); 122.8 (C5’); 105.0 (C5); 53.9 (C13); 53.0 
(C11); 50.3 (C10); 35.7 (C7); 27.8 (C9); 26.2 (C8) 
 
MS (EI) m/z  267.1 (100), 223.1 (100), 211.1 (20), 186.1 (25), 82.1 (5) 
 
HRMS for C16H17N3O   calc. 267.1371 
found 267.1376 
 
IUPAC   9-pyridin-3-yl -1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 4-pyridineboronic acid (49 mg, 0.41 mmol), K3PO4 (126 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 90 min. 
For the SPE purification, a mixture of MeOH/H2O 60:40 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 50:50 v/v. Deprotection by Method B. The final 
product obtained as yellow crystalline powder (45 mg, 0.17 mmol, 62%).  
 
M.p.: n.d. 
HPLC: tr = 17.8 min 
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1H NMR (500 MHz, CDCl3) δ [ppm] 8.57 (dd, 4J = 1.6 Hz, 3J = 6.1 Hz, 2 H, H3’ + H5’); 7.67 
(dd, 4J = 1.6 Hz, 3J = 6.1 Hz, 2 H, H2’ + H6’); 7.57 (d, 3J = 7.4, 1 H, H4); 6.13 (d, 3J = 7.4 Hz, 
1 H, H5); 4.16 (d, 2J = 15.8 Hz, 1 H, H10β); 3.95 (dd, 3J = 6.6 Hz, 2J = 15.8 Hz, 1 H, H10α); 
3.11 (dd, 3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, H11A); 3.07 (dd, 
3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, 
H13A); 3.04 (d, 
2J = 12.3 Hz, 1 H, H13B);  3.00 (ddd, 
4J = 1.2 Hz, 3J = 2.5 Hz, 2J = 12.3 Hz, 1 
H, H11B); 2.94 (s br, 1 H, H7), 2.36 (s br, 1 H, H9), 1.96 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.5 (C=O, C2); 152.6 (C6); 149.6 (C3’ + C5’); 144.9 
(C1’); 137.8 (C4); 123.9 (C2’ + C6’); 122.8 (C3); 104.9 (C5); 53.9 (C13), 53.0 (C11), 50.3 
(C10), 35.8 (C7), 27.8 (C9), 26.2 (C8) 
 
MS (EI) m/z  267.1 (100), 223.1 (100), 211.1 (25), 186.1 (40), 149.1 (10), 133.6 (10), 117.1 
(10), 82.1 (10) 
 
HRMS for C16H17N3O  calc. 267.1371 
found 267.1379 
 
IUPAC   9-pyridin-4-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (50 mg, 0.13 mmol), 8-quinolineboronic acid (35 mg, 0.2 mmol), K3PO4 (60 mg, 
0.3 mmol), Pd(PPh3)4 (15 mg, 0.013 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method B. The final 
product obtained as off-white crystalline powder (37 mg, 0.12 mmol, 44%).  
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M.p.: 207.1 – 209.7 °C 
HPLC: tr = 18.43 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.86 (dd, 4J = 1.9 Hz, 3J = 4.1 Hz, 1 H, H7’);  8.15 (dd, 4J 
= 1.9 Hz, 3J = 8.2 Hz, 1 H, H5’); 7.85 (dd, 4J = 1.3 Hz, 3J = 7.3 Hz, 1 H, H2’);  7.78 (dd, 4J = 
1.3 Hz, 3J = 7.3 Hz, 1 H, H4’); 7.58 (d, 3J = 7.3 Hz, 1 H, H4); 7.56 (t, 3J = 7.3 Hz, 1 H, H3’); 
7.35 (dd, 3J = 4.1 Hz, 3J = 8.2 Hz, 1 H, H6’); 6.16 (d, 3J = 7.3 Hz, 1 H, H5); 4.21 (d, 2J = 15.7 
Hz, 1 H, H10β); 3.96 (dd, 3J = 6.3 Hz, 2J = 15.7 Hz, 1 H, H10α); 3.13 (d, 2J = 12.3 Hz, 1 H, 
H13A); 3.08 (s br, 2 H, H11); 3.02 (d, 
2J = 12.3 Hz, 1 H, H13B); 2.95 (s br, 1 H, H7); 2.33 (s 
br, 1 H, H9), 1.96 (t, 2J = 13.2 Hz, 2 H, H8), 1.83 (br s, NH) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 162.5 (C=O, C2); 150.4 (C6); 149.9 (C7’); 146.5 (C8’a); 
139.8 (C4); 139.6 (C1’); 136.5 (C3); 136.4 (C5’); 131.0 (C2’); 128.6 (C4’a); 127.7 (C4’); 126.2 
(C3’); 120.8 (C6’); 104.8 (C5); 53.9 (C13); 53.0 (C11); 50.1 (C10); 35.8 (C7); 27.9 (C9); 26.4 
(C8) 
 
MS (EI) m/z  317.2 (100), 273.1 (50), 261.1 (40), 245.1 (20), 231.1 (10), 167.1 (15) 
 
HRMS for C20H19N3O  calc. 317.1528 
found 317.1532 
 
IUPAC   9-quinolin-8-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 3-bromo-N-tBOC-
cytisine 81 (100 mg, 0.27 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-pyrazole (84 mg, 0.41 mmol), K3PO4 (126 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 
mmol), DME and H2O. The reaction time was 30 min. For the SPE purification, a mixture of 
MeOH/H2O 60:40 v/v (100 mL) was used. The HPLC separation was completed with 
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MeOH/H2O 50:50 v/v. Deprotection by Method B. The final product obtained as yellow 
crystalline powder (51 mg, 0.19 mmol, 70%).  
 
M.p.: 113.4 °C 
HPLC: tr = 15.32 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.29 (s, 1 H, H5’); 7.80 (s, 1 H, H2’); 7.56 (d, 3J = 7.3 
Hz, 1 H, H4); 6.05 (d, 3J = 7.3 Hz, 1 H, H5); 4.18 (d, 2J = 15.7 Hz, 1 H, H10β); 3.94 (dd, 3J = 
6.6 Hz, 2J = 15.7 Hz, 1 H, H10α); 3.90 (s, 3 H, CH3); 3.09 (d, 
2J = 12.0 Hz, 1 H, H11A); 3.03 
(dd, 3J = 2.2 Hz, 2J = 12.0 Hz, 1 H, H13A); 2.99 (d, 
2J = 12.0 Hz, 1 H, H13B); 2.96 (d, 
2J = 12.0 
Hz, 1 H, H11B); 2.90 (s br, 1 H, H7), 2.33 (s br, 1 H, H9), 1.94 (s br, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.2 (C=O, C2); 148.0 (C6); 136.8 (C2’); 132.4 (C4); 
129.9 (C5’); 119.8 (C3); 117.8 (C1’); 105.1 (C5); 53.9 (C13); 52.9 (C11); 50.1 (C10); 38.9 
(CH3); 35.5 (C7); 27.9 (C9); 26.4 (C8) 
 
MS (EI) m/z  270.1 (100), 227.1 (60), 214.1 (10), 189.1 (20), 135.1 (5), 82.1 (5) 
 
HRMS for C15H18N4O  calc. 270.1481 
found 270.1480 
 
IUPAC   9-(1-Methyl-1H-pyrazol-4-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-
a]diazocin-8-one 
 
204Experimental Procedures 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 5-indolylboronic acid (65 mg, 0.41 mmol), Na2CO3 (64 mg, 
0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 30 min. 
For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The HPLC 
separation was completed with MeOH/H2O 60:40 v/v. Deprotection by Method B. The final 
product obtained as yellowish crystalline powder (21 mg, 0.07 mmol, 26%). 
 
M.p.: 176.5 – 177.5 °C 
HPLC: tr = 15.55 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.53 (s br, 1 H, 5’-NH); 7.44 (t, 4J = 0.9 Hz, 1 H, H2’); 
7.39 (dt, 4J = 0.9 Hz, 3J = 7.0 Hz, 1 H, H7’); 7.28 (d, 3J = 9.1 Hz, 1 H, H4); 7.26 (t, 3J = 2.8 
Hz, 1 H, H4’); 6.98 (dd, 3J = 1.6 Hz, 3J = 7.0 Hz, 1 H, H6’); 6.53 (tt, 4J = 0.9 Hz, 3J = 2.8 Hz, 1 
H, H3’); 6.49 (d, 3J = 9.1 Hz, 1 H, H3); 4.23 (d, 2J = 15.7 Hz, 1 H, H10β); 3.97 (dd, 3J = 6.9 
Hz, 2J = 15.7 Hz, 1 H, H10α); 3.14 (s br, 1 H, H7); 3.08 (d, 2J = 12.3 Hz, 1 H, H11A); 2.93 (d, 
2J = 12.3 Hz, 1 H, H11B); 2.87 (d, 
2J = 12.3 Hz, 1 H, H13A); 2.64 (dd, 
3J = 2.5 Hz, 2J = 12.3 
Hz, 1 H, H13B); 2.30 (s br, 1 H, H9); 1.93 (d br, 
2J = 12.7 Hz, 1 H, H8A); 1.81 (d br, 
2J = 12.7 
Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.2 (C=O, C2); 147.6 (C6); 142.2 (C4); 135.0 (C5’a); 
129.8 (C1’); 128.0 (C2’a); 125.1 (C4’); 123.9 (C7’); 121.7 (C2’); 120.5 (C5); 115.7 (C3); 111.1 
(C6’); 102.6 (C3’); 52.9 (C13); 52.2 (C11); 50.4 (C10); 31.6 (C7); 27.4 (C9); 26.4 (C8) 
 
MS (EI) m/z  305.1 (100), 262.1 (70), 249.1 (25), 235.0 (20), 221.0 (15), 206.1 (10), 154.1 
(10) 
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HRMS for C19H19N3O  calc. 305.1528 
found 305.1533 
 
IUPAC   11-(1H-indol-5-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
 
 
6.4.25 5-(3’,4’-Methylenedioxy-phenyl)-cytisine 124e 
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The Suzuki reaction performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3,4-methylenedioxyphenylboronic acid (68 mg, 0.41 mmol), 
Ba(OH)2*8H2O (185 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The 
reaction time was 60 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 
mL) was used. The HPLC separation was completed with MeOH/H2O 60:40 v/v. 
Deprotection by Method B. The final product obtained as off-white crystalline powder (21 mg, 
0.07 mmol, 25%). 
 
M.p.: 94.5 – 96.5 °C 
HPLC: tr = 18.68 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.17 (d, 3J = 9.3 Hz, 1 H, H4); 6.80 (d, 3J = 7.9 Hz, 1 H, 
H5’); 6.65 (d, 4J = 1.8 Hz, 1 H, H2’); 6.63 (dd, 4J = 1.8 Hz, 3J = 7.9 Hz, 1 H, H6’); 6.45 (d, 3J = 
9.3 Hz, 1 H, H3); 5.97 (s, 2 H, CH2); 4.18 (d, 
2J = 15.7 Hz, 1 H, H10β); 3.93 (dd, 3J = 6.6 Hz, 
2J = 15.7 Hz, 1 H, H10α); 3.08 (d, 2J = 12.0 Hz, 1 H, H11A; s br, ovl., 1 H, H7); 2.92 (d, 
2J = 
12.0 Hz, 1 H, H11B); 2.82 (d, 
2J = 12.0 Hz, 1 H, H13A); 2.72 (dd, 
3J = 2.2 Hz, 2J = 12.0 Hz, 1 
H, H13B); 2.30 (s br, 1 H, H9); 1.95 (d br, 
2J = 12.9 Hz, 1 H, H8A); 1.84 (d br, 
2J = 12.9 Hz, 1 
H, H8B) 
 
206Experimental Procedures 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.1 (C=O, C2); 147.8 (C6); 147.7 (C3’); 146.9 (C4’); 
141.5 (C4); 132.0 (C1’); 123.1 (C6’); 118.8 (C5); 116.0 (C3); 110.2 (C2’); 108.4 (C5’); 101.2 
(CH2), 52.9 (C13); 52.1 (C11); 50.4 (C10); 31.6 (C7); 27.4 (C9); 26.4 (C8) 
 
MS (EI) m/z  310.1 (100), 267.0 (70), 254.0 (20), 229.0 (25), 155.0 (10), 82.0 (10) 
 
HRMS for C18H18N2O3  calc. 310.1317 
found 310.1318 
 
IUPAC 11-(benzo[1,3]dioxol-5-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-
a]diazocin-8-one 
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 3-pyridineboronic acid (49 mg, 0.41 mmol), Ba(OH)2*8H2O 
(185 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DMF and H2O. The reaction time was 
90 min. For the SPE purification, a mixture of MeOH/H2O 60:40 v/v (100 mL) was used. The 
HPLC separation was competed with MeOH/H2O 50:50 v/v. Deprotection by Method B. The 
final product obtained as yellow crystalline powder (23 mg, 0.09 mmol, 32%).  
 
M.p.: 70.4 – 72.0 °C 
HPLC: tr = 14.52 min 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.58 (dd, 4J = 1.6 Hz, 3J = 5.0 Hz, 1 H, H4’); 8.49 (d, 4J 
= 1.9 Hz, 1 H, H2’); 7.55 (dt, 4J = 1.9 Hz, 3J = 7.9 Hz, 1 H, H6’); 7.33 (ddd, 5J = 0.6 Hz, 3J = 
5.0 Hz, 3J = 7.9 Hz, 1 H, H5’); 7.18 (d, 3J = 9.2 Hz, 1 H, H4); 6.52 (d, 3J = 9.2 Hz, 1 H, H3); 
4.21 (d, 2J = 15.6 Hz, 1 H, H10β); 3.95 (dd, 3J = 6.6 Hz, 2J = 15.6 Hz, 1 H, H10α); 3.14 (d, 2J 
= 12.0 Hz, 1 H, H11A); 2.97 (s br, 1 H, H7); 2.93 (d, 
2J = 12.0 Hz, 1 H, H11B); 2.79 (d, 
2J = 
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12.0 Hz, 1 H, H13A); 2.71 (dd, 
3J = 2.5 Hz, 2J = 12.0 Hz, 1 H, H13B); 2.35 (s br, 1 H, H9), 1.94 
(d, 2J = 13.0 Hz, 1 H, H8A), 1.86 (d, 
2J = 13.0 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.0 (C=O, C2); 150.5 (C6); 148.8 (C2’); 148.1 (C6); 
141.0 (C4); 137.2 (C6’); 134.3 (C1’); 123.5 (C5’); 116.7 (C3); 115.3 (C5), 52.7 (C13); 51.8 
(C11); 50.4 (C10); 31.6 (C7); 27.2 (C9); 26.2 (C8) 
 
MS (EI) m/z 267.1 (100), 224.1 (95), 211.1 (20), 186.1 (15), 156.1 (10), 82.0 (5) 
 
HRMS for C16H17N3O  calc. 267.1371 
found 267.1377  
 
IUPAC   11-pyridin-3-yl -1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-one 
 
 
6.4.27 5-(1-Methyl-1H-pyrazol-4’-yl)-cytisine 126e  
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The Suzuki reaction was performed according to the general method with 5-bromo-N-tBOC-
cytisine 82 (100 mg, 0.27 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-pyrazole (84 mg, 0.41 mmol), Ba(OH)2*8H2O (185 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 
0.027 mmol), DME and H2O. The reaction time was 60 min. For the SPE purification, a 
mixture of MeOH/H2O 60:40 (100 mL) was used. The HPLC separation was completed with 
MeOH/H2O 50:50 v/v. Deprotection by Method B. The final product obtained as yellow 
crystalline powder (14 mg, 0.05 mmol, 19%).  
 
M.p.: n.d. 
HPLC: tr = 12.65 min 
 
208Experimental Procedures 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 7.38 (s, 1 H, H5’); 7.26 (s, 1 H, H2’); 7.22 (d, 3J = 9.1 
Hz, 1 H, H4); 6.46 (d, 3J = 9.1 Hz, 1 H, H3); 4.17 (d, 2J = 15.7 Hz, 1 H, H10β); 3.95 (dd, 3J = 
6.9 Hz, 2J = 15.7 Hz, 1 H, H10α); 3.91 (s, 3 H, CH3); 3.13 (s br, 1 H, H7); 3.08 (d, 
2J =12.3 
Hz, 1 H, H11A); 2.98 (d, 
2J = 12.3 Hz, 1 H, H11B); 2.93 (d, 
2J = 12.3 Hz, 1 H, H13A); 2.87 (dd, 
3J = 2.5 Hz, 2J = 12.3 Hz, 1 H, H13B); 2.31 (s, 1 H, H9); 1.88 (s, 2 H, H8) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 163.1 (C=O, C2); 148.2 (C6); 142.0 (C4); 139.1 (C2’); 
129.1 (C5’); 118.5 (C1’); 116.3 (C3); 109.4 (C5); 52.9 (C13); 52.4 (C11); 50.4 (C10); 39.1 
(CH3); 31.8 (C7); 27.3 (C9); 26.3 (C8)  
 
MS (EI) m/z  270.1 (100), 227.1 (68), 214.1 (25), 200.1 (15), 189.1 (30), 146.0 (20), 119.1 
(10), 82.0 (10) 
 
HRMS for C15H18N4O  calc. 270.1481 
found 270.1482  
 
IUPAC  11-(1-methyl-1H-pyrazol-4-yl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-
a]diazocin-8-one 
 
 
6.4.28 5-Bromo-3-phenyl-cytisine 128e    
NH
N
O
Br
1'
2
3
45
67
8
9 10
11
13 2' 3'
4'
5'6'
 
The Suzuki reaction was performed according to the general method with 3,5-dibromo-N-
tBOC-cytisine 83 (121 mg, 0.27 mmol), 3-phenylboronic acid (50 mg, 0.41 mmol), Na2CO3 
(64 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 
30 min. For the SPE purification, a mixture of MeOH/H2O 80:20 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 70:30 v/v. Deprotection by Method A. The 
final product obtained as off-white crystalline powder (38 mg, 0.11 mmol, 33%). 
 
M.p.: 126.1 – 127.0 °C 
HPLC: tr = 25.23 min 
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1H NMR (500 MHz, CDCl3) δ [ppm] 7.65 (d, 3J = 7.2 Hz, 2 H, H2’+H4’); 7.60 (s, 1 H, H4); 
7.37 (t, 3J = 7.2 Hz, 2 H, H3’ + H5’); 7.30 (tt, 4J = 1.3 Hz, 3J = 7.2 Hz, 1 H, H4’); 4.13 (d, 2J = 
15.5 Hz, 1 H, H10β); 3.96 (dd, 3J = 6.6 Hz, 2J = 15.5 Hz, 1 H, H10α); 3.36 (s br, 1 H, H7); 
3.18 (d, 2J = 12.3 Hz, 1 H, H13A); 3.08 (d, 
2J =12.3 Hz, 1 H, H11A); 2.99 (d, 
2J = 12.3 Hz, 1 H, 
H11B); 2.96 (d, 
2J = 12.3 Hz, 1 H, H13B); 2.34 (s br, 1 H, H9); 1.98 (d br, 
2J = 12.9 Hz, 1 H, 
H8A); 1.94 (d br, 
2J = 12.9 Hz, 1 H, H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.2 (C=O, C2); 147.0 (C6); 140.4 (C4); 136.0 (C1’); 
128.6 (C3); 128.6 (C2’ + C6’); 128.1 (C3’ + C5’); 127.8 (C4’); 98.8 (C5); 52.7 (C13); 51.3 
(C11); 50.3 (C10); 34.9 (C7); 27.6 (C9); 26.4 (C8) 
 
MS (EI) m/z  344.1 (100), 302.0 (80), 277.1 (20), 263.0 (40), 162.1 (40), 82.1 (20), 57.1 (10) 
 
HRMS for C17H17BrN2O  calc. 344.0524 
found 344.0529 
 
IUPAC  11-bromo-9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-8-
one 
 
6.4.29 5-Bromo-3-(pyridin-3’-yl)-cytisine 129e   
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The Suzuki reaction was performed according to the general method with 3,5-dibromo-N-
tBOC-cytisine 83 (121 mg, 0.27 mmol), 3-pyridineboronic acid (49 mg, 0.41 mmol), K3PO4 
(60 mg, 0.6 mmol), Pd(PPh3)4 (30 mg, 0.027 mmol), DME and H2O. The reaction time was 
60 min. For the SPE purification, a mixture of MeOH/H2O 70:30 v/v (100 mL) was used. The 
HPLC separation was completed with MeOH/H2O 70:30 v/v. Deprotection by Method B. The 
final product obtained as yellow crystalline powder (39 mg, 0.11 mmol, 41%).  
 
M.p.: 87.6 – 92.3 °C 
HPLC: tr = 26.98 min 
 
210Experimental Procedures 
 
1H NMR (500 MHz, CDCl3) δ [ppm] 8.81 (d, 4J = 1.6 Hz, 1 H, H2’); 8.55 (dd, 4J = 2.0 Hz, 3J = 
5.1 Hz, 1 H, H4’); 8.13 (dt, 4J = 2.0 Hz, 3J = 8.0 Hz, 1 H, H6’); 7.67 (s, 1 H, H4);  7.33 (dd, 3J 
= 5.1 Hz, 3J =8.0 Hz, 1 H, H5’); 4.16 (d, 2J = 15.8 Hz, 1 H, H10β); 4.00 (dd, 3J = 6.6 Hz, 2J = 
15.8 Hz, 1 H, H10α); 3.42 (s br, 1 H, H7); 3.25 (d, 2J = 12.0 Hz, 1 H, H13A); 3.12 (d, 
2J =12.0 
Hz, 1 H, H11A); 3.03 (d, 
2J = 12.0 Hz, 1 H, H11B); 2.98 (dd, 
3J = 2.2 Hz, 2J = 12.0 Hz, 1 H, 
H13B); 2.39 (s br, 1 H, H9); 2.02 (d br, 
2J = 13.2 Hz, 1 H, H8A); 1.96 (d br, 
2J = 13.2 Hz, 1 H, 
H8B) 
 
13C NMR (125 MHz, CDCl3) δ [ppm] 161.0 (C=O, C2); 149.1 (C6); 148.8 (C2’); 148.3 (C4’); 
140.6 (C4); 136.1 (C6’); 131.9 (C1’); 125.3 (C3); 122.9 (C5’); 98.7 (C5); 52.7 (C13); 51.4 
(C11); 50.4 (C10); 35.0 (C7); 27.5 (C9); 26.4 (C8) 
 
MS (EI) m/z  347.0/345.0 (90), 303.0 (100), 289.0 (20), 264.0 (40), 223.1 (10), 194.1 (10), 
168.1 (5), 82.0 (10) 
 
HRMS for C16H16BrN3O  calc. 345.0477 
found 345.0475 
 
IUPAC 11-bromo-9-pyridin-3-yl-1,2,3,4,5,6-hexahydro-1,5-methano-pyridino[1,2-a]diazocin-
8-one 
 
 
 
6.5 Synthesis of Novel nAChR Ligands Based on Choline 
 
6.5.1 General Procedure for the Synthesis of 
Phenylcarbamates 
 
Equimolar amounts of the amino alcohol and appropriate phenylisocyanate were stirred in 
toluene (10 mL) under argon atmosphere at 50 °C for 1.5 – 4 hours. The solvent was 
evaporated and the resulting oily residue was purified by flash chromatography on a small 
amount of silica gel (max. 50 mg) eluting with CH2Cl2/MeOH (95:5). 
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6.5.2 (3-Methyl-phenyl)-carbamic (S)-(-)-1-methyl-pyrrolidin-2-yl-
methyl ester 136 
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The synthesis was performed according to the general method with (S)-(-)-1-methyl-2-
pyrrolidinylmethanol (0.24 mL, 2 mmol) and m-tolylisocyanate (0.26 mL, 2 mmol). The final 
product was obtained as a colourless oil (206 mg, 0.83 mmol, 42%). 
 
M.p.: 62.1-62.3 °C 
[α]D
20 + 1.3295° (c 0.02, MeOH) 
IR (KBr): 1565, 1710, 2799, 2855, 3053 cm-1 
 
1H NMR (500 MHz, CDCl3) δ 7.21 (s, 1 H, H2’); 7.11 – 7.17 (m, 2 H, H5’ + H6’); 6.84 (d, 3J 
= 6.9 Hz, 1 H, H4’); 6.67 (s, 1 H, NH); 4.22 (dd, 3J = 4.4 Hz, 2J = 11.0 Hz, 1 H, CH2A); 4.05 
(dd, 3J = 4.7 Hz, 2J = 11.4 Hz, 1 H, CH2B); 3.08 (dt, 
3J = 1.9 Hz, 3J = 8.2 Hz, 1 H, H2); 2.43 – 
2.48 (m, 1 H, H5A); 2.40 (s, 3 H, CH3); 2.30 (s, 3 H, N-CH3); 2.20 – 2.26 (dt, 
3J = 7.6 Hz, 3J = 
9.5 Hz, 1 H, H5B);  1.88 – 1.93 (m, 1 H, H4A); 1.64 – 1.81 (m, 3 H, H3 + H4B) 
 
13C NMR (125 MHz, CDCl3)   δ 153.5 (C=O); 139.0 (C1’); 137.8 (C3’); 128.8 (C5’); 124.2 
(C4’); 119.2 (C2’); 115.6 (C6’); 66.0 (CH2); 64.2 (C2); 57.5 (C5); 41.2 (N-CH3); 27.9 (C3); 
22.7 (C4); 21.5 (CH3) 
 
MS (EI) m/z  248.1 (20) [M], 97 (20), 84 (100) 
 
Anal. calcd. for C14H20N2O2  (248.33) C, 67.71; H, 8.05;  N, 11.28 
     Found  C, 67.21; H, 8.12;  N, 10.65  
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6.5.3 (3-Bromo-phenyl)-carbamic (S)-(-)-1-methyl-pyrrolidin-2-yl-
methyl ester 137 
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The synthesis was performed according to the general method with (S)-(-)-1-methyl-2-
pyrrolidinylmethanol (0.24 mL, 2 mmol) and m-bromophenylisocyanate (0.25 mL, 2 mmol). 
The final product was obtained as a colourless oil, which crystallised on standing (610 mg, 
1.94 mmol, 97%).  
 
M.p.: 49.0 – 49.6 °C 
IR (KBr): 2942, 2857, 1714, 1596 cm-1 
[α]D
20 + 1.3295° (c 0.02, MeOH) 
 
1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1 H, H2’); 7.23 (s br, 1 H, H6’); 7.10 – 7.16 (m, 2 H, 
H4’ + H5’); 6.78 (br s, 1 H, NH); 4.22 (dd, J = 4.4 Hz, J = 11.0 Hz, 1 H, CH2A); 4.10 (dd, J = 
4.4 Hz, J = 11.0 Hz, 1 H, CH2B); 3.07 (dt, J = 1.9 Hz, J = 7.9 Hz, 1 H, H2); 2.42 – 2.47 (m, 1 
H, H5A); 2.39 (s, 3 H, N-CH3); 2.20 – 2.25 (dt, J = 7.3 Hz, J = 9.5 Hz, 1 H, H5B); 1.82 – 1.93 
(m, 1 H, H4A); 1.63 – 1.82 (m, 3 H, H3 + H4B) 
 
13C NMR (125 MHz, CDCl3) δ 153.2 (C=O); 139.2 (C1’); 130.3 (C5’); 126.3 (C4’); 122.7 
(C3’); 121.4 (C2’); 117.0 /C6’); 66.3 (CH2); 64.1 (C2); 57.5 (C5); 41.1 (CH3); 27.8 (C3); 22.7 
(C4) 
 
MS (EI) m/z  312.1 (20) [M-H+], 198.9 (10), 97 (20), 84.0 (100) 
 
Anal. calc. for C13H17BrN2O2  (313.202) C, 49.85; H, 5.47; N, 8.94 
  Found C, 49.01; H, 5.57; N, 8.54 
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6.5.4 (3-Methyl-phenyl)-carbamic 1-methyl-piperidin-2-yl-methyl 
ester 138 
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The synthesis was performed according to the general method with 2-hydroxymethyl-N-
methylpiperidine (0.26 mL, 2 mmol) and m-tolylisocyanate (0.26 mL, 2 mmol). The final 
product was obtained as a yellowish oil, which crystallised on standing (210 mg, 0.6 mmol, 
30%).  
M.p.: 73.5 – 75.5 °C 
IR (KBr): 2937, 2852, 2803, 1732 cm-1 
 
1H NMR (500 MHz, CDCl3) δ 7.23 (s, 1 H, H2’); 7.15 – 7.19 (m, 2 H, H5’ + H6’); 6.87 (d, 3J = 
6.9 Hz, 1 H, H4’); 6.81 (s, 1 H, NH); 4.25 (dd, 3J = 4.1 Hz, 2J = 11.7 Hz, 1 H, CH2A); 4.23 (dd, 
3J = 3.2 Hz, 2J = 11.7 Hz, 1 H, CH2B); 2.88 – 2.93 (m, 1 H, H2); 2.34 (s, 3 H, N-CH3); 2.32 (s, 
3 H, CH3); 2.08 – 2.13  (m, 2 H, H6); 1.75 – 1.82 (m, 1 H, H3A); 1.50 – 1.69 (m, 4 H, H4 + 
H5); 1.24 – 1.34 (m, 1 H, H3B)  
 
13C NMR (125 MHz, CDCl3) δ 153.6 (C=O); 139.0 (C1’); 137.8 (C3’); 128.9 (C5’); 124.2 (C4’); 
119.1 (C2’); 115.6 (C6’); 66.2 (CH2); 62.9 (C2); 57.4 (C6); 43.2 (N-CH3); 29.2 (C3); 25.8 (C5); 
24.2 (C4); 21.5 (CH3)  
 
MS (EI) m/z  262.2 (38) [M], 134 (10), 98.1 (100), 77 (10) 
 
Anal. calcd. for C15H22N2O2  (262.353) C, 68.67; H, 8.45; N, 10.67   
 Found  C, 68.78; H: 8.47; N, 10.13 
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6.5.5 (3-Bromo-phenyl)-carbamic 1-methyl-piperidin-2-yl-methyl 
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The synthesis was performed according to the general method with 2-hydroxymethyl-N-
methylpiperidine (0.26 mL, 2 mmol) and m-bromophenylisocyanate (0.25 mL, 2 mmol). The 
final product was obtained as yellowish oil, which crystallised on standing (555.2 mg, 1.7 
mmol, 85%). 
M.p.: 67.3 – 68.1 °C 
IR (KBr): 2936, 2856, 2794, 1729, 1705, 1533 cm-1  
 
1H NMR (500 MHz, CDCl3) δ 7.66 (s, 1 H, H2’); 7.26 (d, 3J = 7.8 Hz, 1 H, H6’); 7.12 – 7.20 
(m, 2 H, H4’ + H5’); 7.04 (s, 1 H, NH); 4.28 (dd, 3J = 3.8 Hz, 2J = 11.7 Hz, 1 H, CH2A); 4.20 
(dd, 3J = 3.2 Hz, J = 11.7 Hz, 1 H, CH2B); 2.91 (d, 
3J = 11.7 Hz, 1 H, H2);  2.35 (s, 3 H, N-
CH3); 2.06 – 2.12 (m, 2 H, H6); 1.76 – 1.80 (m, 1 H, H3A); 1.51 – 1.68 (m, 4 H, H4 + H5); 
1.25 – 1.35 (m, 1 H, H3B) 
 
13C NMR (125 MHz, CDCl3)  δ 153.2 (C=O); 139.3 (C1’); 130.2 (C5’); 126.3 (C4’); 122.7 
(C3’); 121.3 (C2’); 116.9 (C6’); 66.3 (CH2); 62.8 (C2); 57.3 (C6); 43.0 (N-CH3); 29.1 (C6); 
25.6 (C5); 24.1 (C4) 
 
MS (EI) m/z   326.1 (10) [M+], 196.9 (10), 98 (100) 
 
Anal. calcd. for  C14H19Br N2O2 (327.218) C, 51.39; H, 5.85; N, 8.56 
        Found C, 50.81; H, 6.00; N, 8.12   
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6.5.6 m-Tolyl-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester 140 
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The synthesis was performed according to the general method with 3-quinuclidinole (254 mg, 
2 mmol) and m-tolylisocyanate (0.26 mL, 2 mmol). The resulting oily residue was purified by 
column chromatography eluting with CH2Cl2/MeOH (90:10→90:50 v/v) and crystallised from 
diethyl ether. The final product was obtained as white crystalline powder (150 mg, 0.57 
mmol, 28%).  
 
M.p.: 150.1 – 150.4 °C 
IR (KBr): 2938, 2866, 2780, 1710, 1598, 1559 cm-1 
 
1H NMR (500 MHz, CDCl3) δ 7.29 (s, 1 H, H2’); 7.26 (d, 3J = 8.2 Hz, 1 H, H6’); 7.18 (t, 3J = 
7.6 Hz, 1 H, H5’); 6.88 (d, 3J = 7.6 Hz, 1 H, H4’); 4.84 – 4.85 (m, 1 H, H3A); 3.34 (qui, J = 1.7 
Hz, 1 H, H3B); 3.25 (ddd, J = 2.4 Hz, J = 8.4 Hz, J = 14.7 Hz, 1 H, H2); 2.77 – 2.95 (m, 5 H, 
H2 + H6 +H8); 2.34 (s, 3 H, CH3); 2.10 – 2.14 (m, 1 H, H4); 1.98 – 2.06 (m, 1 H, H5 or H7); 
1.78 – 1.85 (m, 1 H, H5 or H7); 1.66 – 1.72 (m, 1 H, H5 or H7); 1.52 – 1.58 (m, 1 H, H5 or 
H7)  
 
13C NMR (125 MHz, CDCl3): δ 156.0 (C=O); 140.3 (C1’); 140.0 (C3’); 130.0 (C5’); 125.1 
(C4’); 120.8 (C2’); 117.3 (C6’); 72.5 (C3); 56.4 (C2); 48.3 (C8); 47.3 (C6); 26.8 (C4); 25.1 
(C7); 21.9 (C5); 20.4 (CH3)  
 
MS (EI) m/z   260.2 (25) [M], 147.1 (10), 134.0 (32), 122.0 (40), 105.0 (100), 82 (18), 77 (25)  
 
Anal. calcd. for C15H20N2O2  (260.34) C, 68.20;  H, 7.74; N, 10.76   
Found  C, 68.37;  H, 7.72; N, 10.98 
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6.5.7 3-Bromo-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester 
141 
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The synthesis was performed according to the general method with 3-quinuclidinole (254 mg, 
2 mmol) and 3-bromophenylisocyanate (0.25 mL, 2 mmol). The oily residue was crystallised 
from diethyl ether to yield the final product as white crystals (488 mg, 1.5 mmol, 75%).  
 
M.p.: 162.2 – 162.4 °C 
IR (KBr): 3163, 2943, 2866, 1722, 1595 cm-1 
 
1H NMR (500 MHz, CDCl3 + TMS) δ 7.65 (s, 1 H, H2’); 7.26 (s, 1 H, H6’); 7.13 – 7.20 (m, 2 
H, H4’ + H5’); 7.08 (s, 1 H, NH); 4.80 – 4.91 (m, 1 H, H3); 3.27 (ddd, J = 1.9 Hz, J = 8.4 Hz, J 
= 14.5 Hz, 1 H, H2A); 2.73 – 2.96 (m, 5 H, H2B + H6 + H8); 2.09 – 2.18 (s, 1 H, H4); 1.81 – 
1.87 (m, 1 H, H5 or H7); 1.68 – 1.75 (m, 1 H, H5 or H7); 1.55 – 1.61 (m, 1 H, H5 or H7); 1.40 
– 1.46 (m, 1 H, H5 or H7) 
 
13C NMR (125 MHz, CDCl3 + TMS) δ 153.1 (C=O); 139.4 (C1’); 130.3 (C5’); 126.3 (C4’); 
122.8 (C3’); 121.6 (C2’); 117.0 (C6’); 72.5 (C3); 55.4 (C2); 47.3 (C8); 46.5 (C6); 25.4 (C4); 
24.5 (C7); 19.5 (C5) 
 
MS (EI) m/z   324.1 (40) [M-H+], 126.1 (100), 109.0 (28), 82.0 (22) 
 
Anal. calc. for C14H17BrN2O2  (325.21) C, 51.70; H, 5.27; N, 8.61  
  Found C, 51.05; H, 5.22; N: 8.60 
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6.5.8 Biphenyl-3-yl-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl 
ester 144 
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3-Bromo-carbamic acid 1-aza-bicyclo-[2.2.2]oct-3-yl ester 141 (325 mg, 1 mmol), 
phenylboronic acid (244 mg, 2 mmol), tetrakis-(triphenylphosphin)-palladium(0) (58 mg, 0.05 
mmol), Na2CO3 (233 mg, 2.2 mmol), toluene (5 mL) and a magnetic stir bar were placed in a 
10-mL microwave glass tube. The vessel was sealed with a septum and placed into the 
microwave cavity. Enhanced microwave irradiation of 100 W was used, the temperature 
being ramped from room temperature to 120°C. Once 120°C was reached, the reaction 
mixture was held for 20 min. Then, the mixture was allowed to cool to room temperature, the 
reaction vessel was opened and the solvent was evaporated under pressure. The oily 
residue was purified by column chromatography on silica gel eluting with CH2Cl2/MeOH 
(80:20). The final product was crystallised from the mixture of diethyl ether/petroleum ether 
and obtained as a yellow crystalline powder (37.7 mg, 0.11 mmol, 22.7%).  
 
M.p.: 201 – 202 °C 
IR (KBr) 3189, 2934, 2868, 1716 cm-1 
 
1H NMR (500 MHz, DMSO-d6)   δ 9.66 (s, 1 H,  NH); 7.79 (s, 1 H, H2’); 7.58 (dt, 
4J = 1.4 Hz,  
3J = 7.1 Hz, 2 H, H2’’+H6’’); 7.43 – 7.47 (m, 3 H, H6’+H3’’+H5’’); 7.36 (tt, 4J = 1.4 Hz, 3J = 7.1 
Hz, 1 H, H4’’); 7.35 (t, 3J = 7.7 Hz, 1 H, H5’); 7.25 (dt, 4J = 1.5 Hz, 3J = 8.2 Hz, 1 H, H4’); 4.68 
– 4.71 (m, 1 H, H3); 3.15 (ddd, J = 1.8 Hz, J = 7.9 Hz, J = 14.5 Hz, 1 H, H2A); 2.57 – 2.72 (m, 
5 H, H2B + H6 + H8); 1.98 (sx, J = 3.2 Hz, 1 H, H4); 1.78 – 1.83 (m, 1 H, H5 or H7); 1.59 – 
1.65 (m, 1 H, H5 or H7); 1.47 – 1.54 (m, 1 H, H5 or H7), 1.33 – 1.39 (m, 1 H, H5 or H7) 
 
13C NMR (125 MHz, DMSO-d6)   δ 153.6 (C=O); 140.9 (C3’); 140.4 (C1’); 139.9 (C1’’); 129.4 
C5’); 129.1 (C3’’ + C5’); 127.6 (C4’’); 126.7 (C2’’ + C6’’), 120.9 (C4’); 117.4 (C2’); 116.6 
(C6’); 71.4 (C3); 55.3 (C2); 47.1 (C8); 46.1 (C6); 25.4 (C4); 24.4 (C7); 19.3 (C5) 
 
MS (EI) m/z   322.2 (10) [M+] 
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Anal. calcd. for C20H22N2O2 (322.41): C, 74.50; H, 6.88; N, 8.69.  
Found:  C, 74.28; H, 6.48; N, 8.15. 
 
 
6.5.9 3-(Styryl)-phenyl]carbamic acid 1-aza-bicyclo-[2.2.2]oct-3-yl 
ester 145 
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3-Bromo-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester 141 (325 mg, 1mmol), styrylboronic 
acid (300 mg, 2mmol), tetrakis-(triphenylphosphin)-palladium(0) (115.5 mg, 0.1 mmol), 
Na2CO3 (233 mg, 2.2mmol), toluene (5mL) and a magnetic stir bar were placed in a 10-mL 
microwave glass tube. The vessel was sealed with a septum and placed into the microwave 
cavity. Microwave irradiation of 60 W was used, the temperature being ramped from room 
temperature to 120 °C. Once 120 °C was reached, the reaction mixture was held for 10 min. 
Then the mixture was allowed to cool to room temperature, the reaction vessel was opened 
and the solvent was evaporated under pressure. The oily residue was purified by column 
chromatography on silica gel eluting with CH2Cl2/MeOH (90:10). The final product was 
crystallised from the mixture of diethyl ether/petroleum ether and obtained as a yellow 
crystalline powder (101.1 mg, 0.2 mmol, 39%). 
 
M.p.: 174 – 175 °C 
IR (KBr): 3021, 2945, 2771, 2661, 2589, 1728, 1589, 1547, 1224, 960 cm-1 
 
1H NMR (500 MHz, DMSO-d6)  δ 9.81 (s, 1 H, NH); 7.70 (s, 1 H, H2’); 7.59 (d, 
3J = 7.1 Hz, 2 
H, H2’’ + H6’’); 7.44 (d, J = 7.3 Hz, 1 H, H6’); 7.37 (t, 3J = 7.4 Hz, 3 H, H3’’ + H5’’ + H5’); 7.26 
– 7.29 (m, 2 H, H4’ + H4’’); 7.20 (d, 3J = 16.6 Hz, 1 H, -CH=); 7.13 (d, 3J = 16.6 Hz, 1 H,-
CH=); 4.93 – 5.00 (m, 1 H, H3); 3.68 (ddd, J = 2.1 Hz, J = 8.4 Hz, J = 13.7 Hz, 1 H, H2A); 
3.15 – 3.25 (m, 5 H, H2B + H6 + H8); 2.28 (sx, J = 2.9 Hz, 1 H, H4); 1.73 – 1.91 (m, 4 H, H5 
+ H7) 
 
13C NMR (125 MHz, DMSO-d6)  δ 153.0 (C=O); 139.3 (C1’); 137.7 (C3’); 136.9 (C1’’); 129.2, 
128.8 (C3’’ + C5’’); 128.7 (-CH=); 128.5 (C5’); 127.9 (C4’’); 126.7 (C2’’ + C6’’); 121.2 (C4’); 
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118.03 (C6’); 116.5 (C2’); 67.6 (C3); 53.1 (C2); 45.9 (C8); 45.1 (C6); 24.0 (C4); 20.2 (C7); 
16.9 (C5) 
MS (EI) m/z  348.2 (100) [M+] 
Anal. calcd. for C22H24N2O2 (348.45): C, 75.83; H, 6.94; N, 8.04 
    Found  C, 75.68; H, 6.96; N, 8.23 
 
 
 
 
6.6 In Vitro Evaluation of Novel nAChRs Ligands 
6.6.1 General Information 
 
Instruments 
 
Filter:    Whatman GF/B, Brandell, Gaithersburg, MD, USA 
Harvester:   Brandell M48, M24, Gaithersburg, MD, USA 
Homogenizator:  RW 16 basic, IKA Labortechnik, Germany 
Liquid Scintillation Counter: Tricarb 2900 TR, canberra packard/Perkin Elmer, Dreieich, 
Germany 
pH Meter: WTW, pH – 197, with pH-Electrode SenTix41, IKA 
Labortechnik, Germany 
Photometer: Beckman DU, 530 Life Science, Germany 
Pipettes: Eppendorf research and Eppendorf Multipipette plus 
Ultraturrax: T25 basic, IKA Labortechnik, Germany 
Vortex: MS2, Minishaker, IKA Labortechnik, Germany 
Centrifuge:  Beckman AvantiTM, J-20 XP, Beckman Coulter, USA 
 
Chemicals 
Calcium Chloride Dihydrate (CaCl2)  C 3306, Sigma-Aldrich Chemie GmbH,  
München, Germany 
Dimethylsulfoxide (DMSO)   Merck KG, Darmstadt, Germany 
Ethanol p.a.      Merck KG, Darmstadt, Germany 
N-[2-Hydroxyethyl]piperazine- 
N’[2-ethansulfonic] acid (HEPES) H 3375, Sigma-Aldrich Chemie GmbH,  
München, Germany 
Magnesium Chloride Hexahydrate (MgCl2) M 2670, Sigma-Aldrich Chemie GmbH,  
München, Germany 
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Methyllycaconitine Citrate (MLA)  M 168, Sigma-Aldrich Chemie GmbH,  
München, Germany 
Natrium Chloride (NaCl)   S 7653, Sigma-Aldrich Chemie GmbH,  
München, Germany 
(S)-(-)-Nicotine Hydrogentartrate  N 5260, Sigma-Aldrich Chemie GmbH,  
München, Germany 
Potassium Chloride (KCl)   P 9541, Sigma-Aldrich Chemie GmbH,  
München, Germany 
D-(+)-Saccharose  84097, Fluka Biochemika, Sigma-Aldrich Chemie 
GmbH, Taufkirchen, Germany 
Tris[Hydroxymethyl]aminomethane   T 1503, Sigma-Aldrich Chemie GmbH,  
                    (TRIS base) München, Germany 
Tris[Hydroxymethyl]aminomethane  T 3253, Sigma-Aldrich Chemie GmbH,  
Hydrochlorid (TRIS*HCl)  München, Germany 
Water Elga Pure Lab ultra   ELGA, Ransbach-Baumbach, Germany 
Ultima GoldTM     Perkin Elmer and Analytical Science, MA, USA 
 is a mixture of: Ethoxylated Alkylphenol 10% – 20% 
    Bis(2-ethylhexyl) hydrogen phosphate 10% – 20% 
    Docusate Sodium ≤ 2.5% 
    Triethyl Phosphate ≤ 2.5% 
    Diisopropyl Naphtalene Isomers 60% – 80% 
    2,5 – Diphenyloxazole ≤ 2.5% 
    1,4 – Bis(4-methyl-alpha-styryl) benzene ≤ 2.5% 
    
Radioligands 
(±)-[3H]Epibatidine ([3H]Epi)  Perkin Elmer Life Sciences Products, 
(S.A.: 33.3 – 66.6 Ci/mmol)   Köln, Germany 
[3H]Methyllycaconitine ([3H]MLA)  TOCRIS Cookson Ltd., Avonmouth, Bristol, 
     (S.A.: 20 Ci/mmol) England 
 
Tissues 
frozen Torpedo californica Electroplax Marinus Inc., Long Beach, CA, USA 
frozen Sprague-Dawley rat brains Pel-Freez Biologicals, rogers, AR, USA 
Calf adrenals local slaughterhouse, Köln, Germany 
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Buffer Solutions 
HSS-Buffer (HEPES Salt Solution, incubation assay buffer, buffer for membrane preparation) 
   15.0 nM HEPES 
 120.0 nM NaCl 
    5.4 mM KCl 
    0.8 mM MgCl2*6H2O 
    1.8 mM CaCl2*2H2O 
 adjusted with concentrated NaOH-solution to pH 7.4 
 
TRIS-Buffer (rinse buffer) 
 42.0 mM TRIS*HCl 
    8.0 mM TRIS-Base 
 
Saccharose/TRIS-Buffer (for membrane preparation) 
    320.0 mM D-(+)-Saccharose 
      25.0 mM TRIS*HCl 
 
 
6.6.2 Membrane Preparation 
 
Preparation of rat brains 
 
Frozen rat brains were thawed slowly before the preparation of the P2 rat brain membrane 
fraction (30 – 60 min on ice, afterwards at room temperature). A single cut just behind the 
inferior colliculi was done to exclude the cerebellum and medulla. After the determination of 
the wet weight (1.32 g on average), the brains were pressed into a pulp using a syringe and 
homogenised in saccharose buffer with a glass teflon homogenizator (Potter, 10 seconds). 
The tissue was then centrifuged (1,000 × g, 20 min, 4°C), the supernatant (S1) aspirated with 
a Pasteur pipette and stored on ice. The P1 pellet was re-suspended in saccharose buffer 
and the centrifugation was repeated. The supernatant S1’ was collected and added to the 
supernatant S1. The combined supernatants were centrifuged (25,000 × g, 20 min, 4°C), the 
supernatant S2 was removed and the pellet P2 collected and diluted with HSS-buffer. The 
buffer volume added was calculated on the basis of the wet weight in a ratio 1:2.  
The final pellet was stored in aliquots at -80°C. On the day of the experiment, the P2 
membrane fraction was thawed, diluted with HSS-buffer (30-fold volume), homogenised and 
centrifuged (35,000 × g, 10 min, 4°C). The collected pellet was suspended in HSS-buffer and 
used in the radioligand binding experiments. 
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Preparation of calf adrenals 
Frozen calf adrenals (-80°C) were placed on ice for 30 – 60 min and allowed to thaw slowly 
before they were cut into small pieces. After determination of the wet weight (4-6 g), the 
tissue was homogenised in HSS-buffer (Ultraturrax at 750 rpm). The homogenate was 
centrifuged (30,000 × g, 10 min, 4°C), the pellets collected and washed. This procedure was 
repeated five times. The buffer volume used to re-suspend the pellets was calculated on the 
basis of the wet weight in a ratio 1:6.5.  
The prepared tissues were stored in aliquots at -80°C. One hour before the experiments the 
tissues were slowly thawed, homogenised in HSS-buffer and centrifuged (25,000 × g, 20 
min, 4°C). The pellets were re-suspended in fresh HSS-buffer and used for radioligand 
binding assays. 
Preparation of Torpedo californica electroplax 
 
Frozen samples of Torpedo californica electric organ (-80°C) were placed on ice for 30 – 60 
min and allowed to thaw slowly before the membrane preparation. The tissue was 
homogenised in an ice-cold HSS-buffer (Ultraturrax at 750 rpm) and centrifuged (30,000 × g, 
10 min, 4°C). The pellets were collected, washed four times with HSS-buffer through re-
homogenization and centrifugation at the same settings. The remaining pellets were 
collected, re-suspended in HSS and stored in aliquots at -80°C. 
One hour before the experiments the tissues were slowly thawed, homogenised in HSS-
buffer and centrifuged (25,000 × g, 20 min, 4°C). The pellets were re-suspended in fresh 
HSS-buffer and used for radioligand binding assays. 
 
6.6.3 Radioligand Binding Studies 
 
 
Competition assay using (±)-[3H]epibatidine ([3H]Epi) and rat brain P2-fraction 
(α4β2* nAChR) 
A dilution row of 6 – 9 concentrations of the test compound was prepared. Each assay 
sample, with a total volume of 500 µL contained 100 µL of the membrane protein (60µg), 
100 µL of  (±)-[3H]epibatidine (0.5 nM), 100 µL of HSS-buffer and 200 µL of the test 
compound. Non-specific binding was determined in the presence of 300 µM (-)-nicotine 
tartrate salt. The samples were homogenised and incubated for 90 min at 22°C. The 
incubation was terminated by vacuum filtration through glass fibre filters pre-soaked in 1% 
poly(ethyleneimine). The filter were rinsed three times with TRIS-buffer, punched out and 
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transferred into 4 mL scintillation vials. The scintillation vials were filled with scintillation 
cocktail (2 mL) and the radioactivity was measured using a liquid scintillation counter.    
Assays were carried out in duplicate, triplicates or quadruplicates. 
 
Competition assay using [3H]methyllycaconitine ([3H]MLA) and rat brain P2-fraction 
(α7* nAChR) 
 
A dilution row of 6 – 9 concentrations of the test compound was prepared. Each assay 
sample, with a total volume of 250 µL contained 50 µL of the test compound, 100 µL of 
[3H]MLA and 100 µL of the P2-membrane protein fraction (60 – 70 µg). Non-specific binding 
was determined in the presence of 1 µM MLA. The samples were homogenised and 
incubated for 120 min at 22°C. The incubation was terminated by vacuum filtration through 
glass fibre filters pre-soaked in 1% poly(ethyleneimine). The filters were rinsed three times 
with TRIS-buffer, punched out and transferred into 4 mL scintillation vials. The scintillation 
vials were filled with scintillation cocktail (2 mL) and the radioactivity was measured using a 
liquid scintillation counter.    
Assays were carried out in duplicates, triplicates or quadruplicates. 
 
Competition assay using (±)-[3H]epibatidine ([3H]Epi) and calf adrenals membrane fraction 
(α3β4* nAChR) 
 
A dilution row of 6 – 9 concentrations of the test compound was prepared. Each assay 
sample, with a total volume of 500 µL contained 200 µL of the test compound, 100 µL of (±)-
[3H]epibatidine, 100 µL of the calf adrenal membrane protein fraction (60 – 70 µg) and 100 
µM of HSS-buffer. Non-specific binding was determined in the presence of 300 µM (-)-
nicotine tartrate salt. The samples were homogenised and incubated for 90 min at 22°C. The 
incubation was terminated by vacuum filtration through glass fibre filters pre-soaked in 1% 
poly(ethyleneimine). The filters were rinsed three times with TRIS-buffer, punched out and 
transferred into 4 mL scintillation vials. The scintillation vials were filled with scintillation 
cocktail (2 mL) and the radioactivity was measured using a liquid scintillation counter.    
Assays were carried out in duplicates, triplicates or quadruplicates 
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Competition assay using (±)-[3H]epibatidine ([3H]Epi) and Torpedo californica electroplax 
((α1)2β1γδ nAChR) 
 
A dilution row of 6 – 9 concentrations of the test compound was prepared. Each assay 
sample, with a total volume of 500 µL contained 200 µL of the test compound, 100 µL of (±)-
[3H]epibatidine and 100 µL of the Torpedo californica electroplax fraction (60 – 70 µg). Non-
specific binding was determined in the presence of 300 µM (-)-nicotine tartrate salt. The 
samples were homogenised and incubated for 90 min at 22°C. The incubation was 
terminated by vacuum filtration through glass fibre filters pre-soaked in 1% 
poly(ethyleneimine). The filters were rinsed three times with TRIS-buffer, punched out and 
transferred into 4 mL scintillation vials. The scintillation vials were filled with scintillation 
cocktail (2 mL) and the radioactivity was measured using a liquid scintillation counter.    
Assays were carried out in duplicates, triplicate or quadruplicates. 
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7 Abreviations 
 
ACh   acetylcholine  
AChBP  acetylcholine binding protein 
AD   Alzheimer’s disease 
ADNFLE  Autosomal Dominant Nocturnal Frontal Lobe Epilepsy 
BBB   blood-brain barrier  
9-BBN   9-borabicyclo[3.3.1]nonane 
α-Bgt    α -Bungarotoxin  
tBOC   tert-butoxycarbonyl  
br   broad 
CDCl3   deuterated chloroform 
CD3OD  deuterated methanol 
CNS   Central Nervous System 
COSY   Correlated Spectroscopy 
d   doublet 
dba   dibenzylideneacetone 
DEPT   Distortionless Enhancement by Polarization Transfer 
DHβE    dihydro-β-erythroidine  
DMA   N,N-dimethylacetamide 
DME   1,2-dimethoxyethane 
DMF   dimethylformamide 
DMCC   N,N-dimethylcarbamoylcholine 
DMSO   dimethylsulfoxide   
DMPP   N,N-dimethylphenylpiperazine 
DPPA   diphenylphosphoryl azide 
dppf   1,1’-bis(diphenylphosphino)ferrocene  
GABAA   γ-aminobutyric acid receptor type A 
GHz   gigahertz 
GTS-21   3-(2,4-dimethoxybenzylidene)-anabaseine  
h    hour(s) 
HBA   hydrogen bond acceptor 
HBD   hydrogen bond donor 
[3H]α-Bgt   tritium labelled α-bungarotoxin  
(±)-[3H]Epi   tritium labelled (±)-epibatidine  
[3H]MLA  tritium labelled methyllycaconitine  
HEK    human embryonic kidney cells  
HMBC   Heteronuclear Multiple Bond Correlation 
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HMPA   hexamethylphosphoric triamide 
HPLC   High Performance Liquid Chromatography 
HRMS   High Resolution Mass Spectroscopy 
HSQC   Heteronuclear Single Quantum Coherence 
5-HT   5-hydroxytryptamine (serotonine) 
Hz    Hertz  
INADEQUATE Incredible Natural Abundance Double Quantum Transfer Experiment 
IR    infrared spectrum/spectroscopy 
J   coupling constant  
Kd    dissociation constant  
Ki    inhibition constant 
LSC    liquid scintillation counter 
M   molar  
m    multiplet 
mAChR  muscarinic acetylcholine receptor 
MAOS   Microwave-Assisted Organic Synthesis 
MCC   N-methylcarbamoylcholine  
Me    Methyl-  
MeCN   acetonitrile 
MeOH   methanole  
mg    milligram 
min    minutes 
MLA    methyllycaconitine  
mM   milimolar 
mmol    millimol  
µM   micromolar 
M.p.    Melting point  
MS    mass spectroscopy  
n    number of experiments 
nAChR  nicotinic acetylcholine receptor 
NBS   N-bromosuccinimide 
nM   nanomolar 
NMP   N-methylpyrrolidinone 
NMR   Nuclear Magnetic Resonance 
ovl.   overlapping 
PET   Positron Emission Tomography 
PD   Parkinson’s Disease 
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pM   picomolar 
RP   reverse phase 
q    quartet 
s    singlet  
SAR   structure-activity relationship  
SCS   substituent-induced chemical shift 
SEM    standard error of the mean  
sex   sextet 
SFD   single-frequency decoupling   
SH-SY5Y   human neuroblastoma cell line  
SN   nuclephilic substitution 
SPE   solid phase extraction 
t    triplet 
TBAB   tetrabutylammonium bromide 
Tf   triflate 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
UV   ultraviolet spectroscopy 
VMAT-2  vesicular monoamine transporter-2 
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in the Cologne night scene anymore, but we definitely are the funniest bunch of people in Cologne – 
Antonio A. – our founder and his missus Nicole, Célia – the loudest member and always a great 
company, Sergio C. – the most peaceful member who somehow managed to get into a trouble with 
Ordnungsamt , Rosa (pronounced Rousa) – einfach eine tolle Freundin, und Antonio C. and of 
course, Pedro Pinto – always together – whenever I saw you or heard you, I felt happy – Andrea (tio 
Baresi, ueu ueu bum bum bum casino casino) thanks for driving us around and being always helpful, 
Sergio G. – you were the highlight of every party! – Jean-Marc (“put the pizza in the oven….”) – great 
person in his special way, and Ana – disappearing for months but luckily always coming back  – 
Andreas – you were the only German who managed with us more than one night and Sofia, “big-
stuff-Samba-queen”!  You guys are great and my only regret is that we didn’t meet each other sooner, 
but both the fun & friendship made up for the lost time. I miss you already. 
A special Thanks for our oldest “German” friend Sebastian, not only for looking after my flowers when 
we were on holidays, but for being such a nice person and bringing the warm Argentinean soul to 
Köln. Sebastian, gracias por la amistad y todo…..nos vemos, seguramente 
Danke, Danke schön goes to my Brazilian dancing group, to which I became addictive over the years. 
I could not miss out on anything, the great dancing classes, the organised chaos we produced every 
time when planning things, the absolutely amazing trip to Hamburg and Lindenthal, but most of all the 
friendship that kept us together, is one of the most beautiful things that ever happened to me. Ihr 
meine Lieben – Beatriz, Julie, Ingrid, Elena, Christina, Marivaldo und Delsinho (the best dancer 
ever!) – ihr seid meine Familie in Köln und seitdem ich euch habe, fühle ich mich in Kölle zu Hause 
und glücklich.  Ich liebe euch… 
And finally, Ďakujem to my wonderful parents, for their endless love, care, support, freedom and 
coping so great with the distance that is between us. Maminka, tatík – ďakujem vám za všetku lásku a 
pochopenie počas celého štúdia. Gracias to my wonderful parents-in-law for being such a wonderful 
parents-in-law, for their love and nice time together. I am happy that I married into such a nice family… 
Four years ago the life got beautiful, my deepest thanks to the one responsible. 
